Quality of care in rheumatology. Translating evidence into practice by Lesuis, N.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/160313
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Uitnodiging
Voor het bijwonen van de 
openbare verdediging van 
mijn proefschrift:
Quality of care in 
rheumatology 
translating evidence 
into practice
 
Op maandag 3 oktober 2016 
om 16.30 uur 
in de Aula Major van de 
Radboud Universiteit 
Nijmegen,  
Comeniuslaan 2 te Nijmegen
Receptie ter plaatse na afloop 
van de promotie.
Paranimfen:
Chantal Bouman & Lieke Tweehuysen 
promotienienke2016@gmail.com
Het proefschrift is ook digitaal
in te zien via:
http://issuu.com/gildeprintdrukkerijen/
docs/proefschrift_lesuis/1
Nienke Lesuis
Pinksterbloemstraat 45
6832 BG Arnhem
n.lesuis@maartenskliniek.nl
Nienke Lesuis
Quality of care
in rheumatology
Translating evidence
into practice
Q
uality of care in rheum
atology
Translating evidence into practice
N
ienke Lesuis
Nienke Lesuis
Quality of car
in rheumatology
Translat ng evidence
into practice
Q
uality of care in rheum
atology
Translating evidence into practice
N
ienke Lesuis
Nienke Lesuis
Quality of care
in rheumatology
Translating evidence
into practice
Q
uality of care in rheum
atology
Translating evidence into practice
N
ienke Lesuis Nienke Lesuis
Quality of care
in rheum tology
Translating evidence
into practice
Q
uality of care in rheum
atology
Translating evidence into practice
N
ienke Lesuis
Nienke Lesuis
uality of care
in rheu atology
Translating evidence
into practice
Q
uality of care in rheum
atology
Translating evidence into practice
N
ienke Lesuis

Quality of care in rheumatology 
Translating evidence into practice
Nienke Lesuis
Colofon
ISBN: 978-90-9029850-4
Lay-out and printing: Nicole Nijhuis (Gildeprint, Enschede)
Cover illustration: Aikaterini Chatzidionysiou
Cover design: Ruben Janssen (Burorub grafisch ontwerp & illustratie, Nijmegen)
Publication of this thesis was financially supported by the Sint Maartenskliniek and the 
Radboud University Nijmegen, the Netherlands.
Quality of care in rheumatology 
Translating evidence into practice
Proefschrift
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken, 
volgens het besluit van het college van decanen in het openbaar te verdedigen op 
maandag 3 oktober 2016, om 16.30 uur precies.
door
Nienke Lesuis
geboren op 21 september 1986
te Oosterhout (Noord-Brabant)
Promotoren: Prof. dr. M.E.J.L. Hulscher 
 Prof. dr. R.F. van Vollenhoven (Karolinska Instituut, Zweden)
Copromotor:  Dr. A.A. den Broeder (Sint Maartenskliniek)
Manuscriptcommissie: Prof. dr. J.W.A. Smit
 Prof. dr. T.P.M. Vliet-Vlieland (Leids Universitair Medisch Centrum)
 Prof. dr. P. Verschueren (Universitair Ziekenhuis Leuven, België)
     
CONTENTS
General introduction  7
Theme 1: Use of diagnostic laboratory tests in rheumatic diseases
Chapter 1 Introduction to theme 1 17
Chapter 2 Choosing Wisely in daily practice: an intervention study on  27
 Antinuclear Antibody testing by rheumatologists. (Including a Letter
 to the Editor and Author reply regarding this manuscript)
Chapter 3 Choosing Wisely in daily practice: a mixed methods study on  67
 determinants of Antinuclear Antibody testing by rheumatologists
Chapter 4 Dutch Society for Rheumatology - Choosing Wisely 89
Chapter 5 The value of routine creatine kinase and thyroid stimulating  95
 hormone testing in patients with suspected fibromyalgia: 
 a cross-sectional study 
Chapter 6  The effects of an educational meeting and subsequent computer  105
 reminders on the ordering of laboratory tests by rheumatologists: 
 an interrupted time series analysis 
Theme 2: Guideline adherence in the treatment of rheumatoid arthritis
Chapter 7 Introduction to theme 2 119
Chapter 8 Practice what you preach? An exploratory multilevel study on  147
 rheumatoid arthritis guideline adherence by rheumatologists
Chapter 9 Rheumatologists’ guideline adherence in rheumatoid arthritis:  169
 a randomized controlled study on electronic decision support, 
 education and feedback
Chapter 10 Implementation of protocolized tight control and biological  203
 dose optimization in daily clinical practice: results of a pilot study
Chapter 11 Summary and general discussion 
 11.1 Summary 229
 11.2 General discussion 235
Chapter 12  Nederlandse samenvatting 257
List of publications (including earlier theses of the Sint Maartenskliniek) 269
 Curriculum Vitae 277
Dankwoord 279

 GENERAL INTRODUCTION
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
8  |  General introduction
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
General introduction  |  9
PROLOGUE
This thesis deals with quality of care in rheumatology, focussing on the potential gap between 
evidence and daily practice of two important aspects of daily care in rheumatology: the 
use of laboratory tests in the diagnostic process of rheumatic diseases and adherence of 
rheumatologists to optimal care recommendations in the treatment of rheumatoid arthritis 
(RA). The behaviour of rheumatologists will be the central focus of both themes and 
this introduction will deal with the general background of this thesis whereas a specific 
introduction to both themes will be provided before the start of each theme.
WHAT IS OPTIMAL QUALITY OF CARE?
Quality of care in itself is a rather abstract term, but more practical descriptions do exist. 
One of the most used descriptions, developed around 1980 by Donabedian, distinguishes 
structures, processes and outcomes of care1. The structure of care describes aspects of the 
setting in which care is delivered, such as the number of rheumatologists or the presence 
of a treatment protocol. Next, the process of care describes the actions of the health care 
professionals, for example, whether the protocol is followed. Finally, the outcome reflects 
the effect of the given care in terms of mortality, morbidity and health status. It is believed 
that more desirable outcomes are obtained if the structure of care provides the opportunity 
to deliver the most optimal care processes.
Around 1990, the Institute of Medicine (IOM) defined quality of care as ‘the degree to 
which health services for individuals and populations increase the likelihood of desired 
health outcomes and are consistent with current professional knowledge’2. This definition 
incorporates two different aspects of quality of care: are current standards of care adhered 
to by health professionals and does this improve patients outcomes. The last aspect is 
also the domain of clinical trials, for example testing the effect of new drugs on clinically 
important outcomes. This means that standards of care continually change as trials 
provide new insights on the best care that should be provided to patients. The next step, 
professionals adhering to standards of care, will be the focus of this thesis.
In addition to the definition of quality of care, the IOM also formulated six criteria that 
pertain to quality of care. Care should be i) safe; ii) effective; iii) patient-centred; iv) 
timely; v) efficient; and vi) equitable2. In recent years ‘transparency’ and ‘verifiability’ are 
often used as additional criteria of quality of care and in its most recent quality of care 
statement the Dutch Rheumatology associations has incorporated all seven criteria3. 
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10  |  General introduction
IS QUALITY OF DAILY CARE CURRENTLY OPTIMAL?
The literature on the two themes of this thesis suggests that rheumatologists’ behaviour 
regarding test ordering and guideline adherence is not yet optimal4;5. With regard to 
diagnostic tests, clinicians in general often order too many tests (test overuse)4, whereas 
recommendations for all kinds of diseases are often not applied (non-adherence to 
guidelines)6. Although not extensively studied within rheumatology, existing studies on 
this topic suggest the same pattern5;7-9. This implies that also in rheumatology a gap exists 
between evidence and daily practice, and therefore the first question this thesis aims to 
answer is ‘do rheumatologists provide evidence-based care in daily practice?’. 
HOW CAN WE IMPROVE QUALITY OF DAILY CARE?
If a gap between evidence and practice exists, the next step would be to bridge this gap by 
finding effective interventions to close this gap. Before commenting on different effective 
interventions, it is first important to realize what factors influence test ordering behaviour 
and guideline adherence of physicians as this information is needed to develop effective 
intervention strategies10;11. This subject has been extensively studied outside rheumatology, 
leading to different checklists, frameworks and taxonomies. With regard to guideline 
adherence, these different studies have been summarized in a systematic review by Flottorp 
et al, providing a comprehensive checklist of 54 determinants in seven domains (guideline 
factors; health professional factors; patient factors; professional interactions; incentives 
and recourses; capacity for organizational change; social, political and legal factors)12. For 
test ordering behaviour a similar review exists, classifying determinants into five categories 
(diagnostic, therapeutic and prognostic, patient-related, doctor-related, and policy and 
organization-related factors)13. 
These kind of checklists can be used when planning an intervention in order to choose the 
one that best fits with the specific local situation11. Many different types of interventions 
exist and a useful overview is provided by the Effective Practice and Organization of 
Care (EPOC) group. This Cochrane review group is specialized in undertaking reviews on 
all types of interventions that aim to improve health professional practice. According to 
their taxonomy 19 different types of interventions targeted at healthcare workers can be 
recognized14. Of those interventions, education, audit and feedback, and reminders are 
much used interventions to improve care. According to the different EPOC reviews on those 
three types of interventions, they result in a small to moderate improvement of the desired 
behaviour15-18. Interventions specifically tailored to the local situation have also been subject 
of a EPOC review concluding that they are more effective than non-tailored interventions11.
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All in all, test ordering behaviour and guideline adherence of physicians can be influenced 
by a large array of factors and many different types of interventions exist to improve quality 
of care. Unfortunately, these types of studies are scarce within rheumatology despite 
evidence that quality of care in rheumatology is not always optimal. Therefore, the second 
and third question of these thesis are ‘what factors influence whether evidence-based care 
is provided?’ and ‘how can the provision of evidence-based care be improved?’ respectively.
AIM AND OUTLINE OF THIS THESIS
In summary, this thesis aims to describe current quality of care with regard to laboratory 
test use and RA guideline adherence of rheumatologists, also aiming to explore underlying 
determinants and assess the effectiveness of different interventions to further improve 
quality of rheumatologic care.
These aims are incorporated in the two themes of this thesis: theme 1 comprises the 
chapters 1 to 6 and will describe overuse of different laboratory tests commonly used by 
rheumatologists and possible interventions to counter this overuse. The chapters 7 to 10 
form the second theme and they describe current guideline adherence in RA and potential 
methods to enhance uptake of guidelines in daily practice. Both themes start with a separate 
introduction of the topics (chapter 1 and chapter 7), also including a more specific outline 
of the content of these chapters.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
12  |  General introduction
REFERENCES
 (1)  Donabedian A. The quality of care. How can it be assessed? JAMA 1988; 260(12):1743-1748.
 (2)  Committee of quality of health care in America. Crossing the quality chasm: a new health 
system for the 21st century. National Academy press 2001. Available at http://www.nap.edu/
read/10027/chapter/1#xix
 (3)  Den Broeder AA. Memo strategie kwaliteitsbeleid Nederlandse Vereniging van Reumatologie 
2014. 
 (4)  Zhi M, Ding EL, Theisen-Toupal J, Whelan J, Arnaout R. The landscape of inappropriate 
laboratory testing: a 15-year meta-analysis. PLoS One 2013; 8(11):e78962.
 (5)  MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, Brook RH et al. Quality of care for 
patients with rheumatoid arthritis. JAMA 2000; 284(8):984-992.
 (6)  McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A et al. The quality of health 
care delivered to adults in the United States. N Engl J Med 2003; 348(26):2635-2645.
 (7)  Kiely P, Williams R, Walsh D, Young A. Contemporary patterns of care and disease activity 
outcome in early rheumatoid arthritis: the ERAN cohort. Rheumatology (Oxford) 2009; 48(1):57-
60.
 (8)  Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y et al. Prescribing practices 
in a US cohort of rheumatoid arthritis patients before and after publication of the American 
College of Rheumatology treatment recommendations. Arthritis Rheum 2012; 64(3):630-638.
 (9)  Benhamou M, Rincheval N, Roy C, Foltz V, Rozenberg S, Sibilia J et al. The gap between 
practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early 
rheumatoid arthritis: results from the ESPOIR cohort. J Rheumatol 2009; 36(5):934-942.
 (10)  Morgan DJ, Brownlee S, Leppin AL, Kressin N, Dhruva SS, Levin L et al. Setting a research agenda 
for medical overuse. BMJ 2015; 351:h4534.
 (11)  Baker R, Camosso-Stefinovic J, Gillies C, Shaw EJ, Cheater F, Flottorp S et al. Tailored 
interventions to address determinants of practice. Cochrane Database Syst Rev 2015; 
4:CD005470.
 (12)  Flottorp SA, Oxman AD, Krause J, Musila NR, Wensing M, Godycki-Cwirko M et al. A checklist 
for identifying determinants of practice: a systematic review and synthesis of frameworks and 
taxonomies of factors that prevent or enable improvements in healthcare professional practice. 
Implement Sci 2013; 8:35.
 (13)  Whiting P, Toerien M, de S, I, Sterne JA, Dieppe P, Egger M et al. A review identifies and classifies 
reasons for ordering diagnostic tests. J Clin Epidemiol 2007; 60(10):981-989.
 (14)  Effective Practice and Organisation of Care (EPOC). EPOC Taxonomy 2015. Oslo: Norwegian 
Knowledge Centre for the Health Services. Available at: http://epoc.cochrane.org/epoc-
taxonomy
 (15)  Ivers N, Jamtvedt G, Flottorp S, Young JM, Odgaard-Jensen J, French SD et al. Audit and 
feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst 
Rev 2012; 6:CD000259.
 (16)  Shojania KG, Jennings A, Mayhew A, Ramsay CR, Eccles MP, Grimshaw J. The effects of on-
screen, point of care computer reminders on processes and outcomes of care. Cochrane 
Database Syst Rev 2009;(3):CD001096.
 (17)  Forsetlund L, Bjorndal A, Rashidian A, Jamtvedt G, O’Brien MA, Wolf F et al. Continuing 
education meetings and workshops: effects on professional practice and health care outcomes. 
Cochrane Database Syst Rev 2009;(2):CD003030.
 (18)  O’Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J, Kristoffersen DT et al. 
Educational outreach visits: effects on professional practice and health care outcomes. 
Cochrane Database Syst Rev 2007;(4):CD000409.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
General introduction  |  13

Theme 1
Use of diagnostic laboratory tests in rheumatic diseases

1
INTRODUCTION TO THEME 1 
Use of diagnostic laboratory tests in rheumatic diseases
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1
WHAT IS OPTIMAL DIAGNOSTIC TEST USE? 
The use of laboratory tests during the diagnostic process of patients with rheumatic 
complaints is common practice among rheumatologists and physicians in general. Often the 
tests used are perceived as ‘perfect’ and its results seen as ‘the truth’. Unfortunately, this 
is often not the case and the diagnostic value of a laboratory test depends on many factors. 
To begin with, the test should be of good technical quality and be able to discriminate 
between healthy and sick individuals, or between clinically important outcomes. This is 
often expressed as the sensitivity and specificity of a test. The sensitivity of a test is the 
percentage of individuals with a certain disease, having a positive test result; whereas 
the specificity is the percentage of individuals without the disease, having a negative test 
result. A perfect test would have a sensitivity and specificity of 100%, but no such tests 
exist. Thus false-negative (negative test when individual has a disease) and false-positive 
(positive test in healthy individual) will inevitably occur.
Besides no test having a 100% sensitivity and specificity, there is another problem with 
these test characteristics: they do no tell what a physician needs to know. Sensitivity and 
specificity assume that it is already known if an individual has a disease or not. But for 
a physician seeing a patient, the question is the other way around: does the positive or 
negative test in my patient means that he has or has not the disease? Exactly this question 
can be answered by calculating the predictive value of a test. In contrast to the sensitivity 
and specificity, the positive and negative predictive value (PPV and NPV respectively) take 
into account the pre-test probability of the disease in question. The pre-test probability on 
disease is an estimation of the chance for an individual person to have the disease, based 
on information gathered before performing the test. For healthy individuals the pre-test 
probability is similar to the prevalence of the disease in the general population, whereas 
disease-specific symptoms can increase this chance.
The effect of pre-test probability on the interpretation of lab results is illustrated in table 1. 
In this table two scenarios are described, using anti-CCP testing (sensitivity and specificity of 
90%) for rheumatoid arthritis (RA) as an example. As can be seen in table 1, the PPV differs 
between the scenarios (90% in scenario 1 and only 32% in scenario 2). As the sensitivity and 
specificity in both scenarios are similar, the differences are caused by the differences in pre-
test probability on RA between the scenarios (50% and 5% in scenario 1 and 2 respectively).
This principle is known as Bayes Theorem and provides a mathematical framework 
for analyzing how diagnostic probability is influenced by pretest probability, the test 
characteristics (sensitivity/specificity), and the outcomes of the test. Bayes theorem has 
important clinical consequences. In an optimal situation (scenario 2), a physician can trust 
the laboratory result to give a fairly definitive answer on the question ‘has my patient RA?’. 
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Table 1: Influence of pre-test probabilities of disease on the diagnostic value of a test
Scenario 1 (pre-test probability on rheumatoid arthritis = 50%)
RA present RA absent
Test positive 450 50 500
Test negative 50 450 500
500 500 1000
Positive predictive value 450 / 500 = 90%
Negative predictive value 450 / 500 = 90%
Scenario 2 (pre-test probability on rheumatoid arthritis = 5%)
RA present RA absent 
Test positive 45 95 140
Test negative 5 855 860
50 950 1000
Positive predictive value 45 / 140 = 32%
Negative predictive value 855 / 860 = 99%
However, in the more realistic situation (scenario 1) the physician can still not answer this 
question as the chance on RA in his patient is only 32% if the test result is positive. 
In addition to the positive and negative predictive value, a good laboratory test should 
also have additional value. This means that the chance on disease after the test (PPV) has 
to be substantially higher or lower than the chance on disease before the test (pre-test 
probability). This is the case in both scenarios of the RA example, although the absolute 
PPV of 32% in scenario 2 still limits the actual diagnostic value. The criterion of additional 
value also implies that diagnostic testing in scenarios with a very high or very low pre-test 
probability on disease is not useful as the pre- and post-test probabilities will be similar. In 
general it is recognized that diagnostic tests have the most optimal PPV and NPV if the pre-
test probability on disease lies between 30 and 60%1.
Finally, a good laboratory tests also needs to have consequences for treatment or prognosis 
and needs to be cost-effective. A test which is followed by the same decision regardless of 
the test result is essentially a wasted test. Often this has to do with a too high or low pre-
test probability on disease, leading to no or not enough additional value of the test to have 
consequences for treatment or prognosis. 
All in all it can be concluded that perfect diagnostic laboratory tests do not exist and that 
physicians need to take into account the uncertainty associated with the use of these tests. 
This is a huge challenge for many physicians that will be described next.
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1
IS THE USE OF DIAGNOSTIC LABORATORY TESTS IN DAILY PRACTICE 
CURRENTLY OPTIMAL?
That correct use of diagnostic laboratory tests constitutes a challenge for many physicians 
is reflected in studies on inappropriate use of laboratory tests. In the most recent meta-
analysis on this topic it was found that around 20% of the laboratory tests can be classified as 
overutilization2. Keeping the previous example on RA in mind, overuse will mimic the second 
scenario (low pre-test probability) leading to a higher rate of false-positives. Furthermore, 
inappropriate testing leads to higher costs and a higher patient burden due to uncertainty 
and additional testing, making this a real and significant problem in medicine. 
Assuming that rheumatologists are not very different from other medical specialists with 
regard to the use of diagnostic laboratory tests, overutilization of laboratory testing will 
probably also present in rheumatology care. Although no review on the use of the full 
range of laboratory tests in rheumatology is available, some studies on specific laboratory 
use in rheumatology are present. Those mainly focus on anti-CCP testing or immunologic 
laboratory tests such as Antinuclear Antibodies (ANA)3-5. Especially the latter test has 
gained extra attention within rheumatology in recent years, confirming that ANA testing 
is commonly overused by rheumatologists7-11. The Choosing Wisely campaign, launched in 
2012 by the ABIM foundation (Advancing Medical Professionalism to Improve Health Care; 
United States of America), seems to have had a large role in this6. This campaign aims to 
‘advance a national dialogue on avoiding wasteful or unnecessary medical tests, treatments 
and procedures’ by publishing top five lists of ‘things that physicians and patients should 
question’ (www.choosingwisely.org). As a result, such a list was published in 2013 by the 
American College of Rheumatology (ACR), including ANA testing as ‘a thing to question’6. 
However, rheumatologists use far more laboratory tests than ANA alone and for those tests 
much less is known about their use in daily practice, although it is likely that overuse is also 
present for those tests seeing the evidence from other specialties.
WHAT FACTORS INFLUENCE DIAGNOSTIC LABORATORY TEST ORDERING IN 
DAILY PRACTICE?
As ordering diagnostic test is such an integral part of healthcare, many studies have tried to 
identify determinants that influence the use of laboratory tests. A review from 2007 groups 
these determinants into diagnostic, therapeutic and prognostic, patient, physician and 
policy-related factors12. A second review focussing on physician-related determinants only, 
divided these determinants into modifiable and non-modifiable factors. In this last review 
practice location, practice setting, age, gender and specialisation of the physician were 
identified as non-modifiable determinants. Determinants such as physician experience and 
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knowledge were found to be modifiable determinants13. Despite these reviews, the exact 
relation between determinants and laboratory testing often remains unclear as different 
studies have different results. For example, a higher physician age can both lead to fewer 
or more laboratory tests ordered12. Unfortunately, determinant studies on laboratory test 
overuse in rheumatology are virtually non-existent, so insight is needed in the relation 
between potential determinants and laboratory testing by rheumatologists. 
HOW CAN DIAGNOSTIC LABORATORY TEST USE IN DAILY PRACTICE BE 
IMPROVED?
Many different studies have tried to decrease laboratory test overuse by performing 
different types of interventions. The most recent systematic review on this topic classifies 
these interventions into educational interventions, audit and feedback, system-based 
interventions such as Clinical Decision Support Systems (CDSS), and incentive or penalty 
interventions14. Almost 30% of the interventions were multifaceted with educational, audit 
and feedback, and a system-based intervention being the most frequently performed 
combination of interventions. This review observed a large variation in the effectiveness 
of interventions, with effects on laboratory test use ranging between 99.7% reduction to 
a 27.7% increase in test volume. When looking at the separate intervention categories, 
educational interventions had the highest median relative reduction in test volume (34.5%, 
interquartile range (IQR) 16.5% to 49.0%). Audit and feedback or system-based interventions 
had similar median relative reduction rates (22%, IQR 8.6% to 34.6% and 22.2%, IQR 3.6% to 
68.3% respectively), while incentive or penalty interventions only gave a relative reduction 
of 5.8%. Finally, it seemed that multifaceted interventions were more effective than single-
component interventions with relative reductions of 32.7% and 21.4% respectively. Based on 
these results this review concludes that all type of interventions can reduce laboratory test 
ordering, but the effect range is large and much heterogeneity between studies is present14. 
Not many intervention studies to decrease laboratory test use within rheumatology exist. A 
few intervention studies on ANA overuse have been performed, all introducing some kind of 
clinical guideline or algorithm to prevent second line testing if the ANA result is negative. 
These studies reported positive effects – i.e. a decrease in the number of second line tests 
- whereas specificity of the tests increased15-17. 
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1
OUTLINE OF THEME 1: USE OF DIAGNOSTIC LABORATORY TESTS IN 
RHEUMATIC DISEASES
As described in this chapter, studies on diagnostic laboratory test overuse amongst 
rheumatologists are still lacking although initiatives to counter overuse, such as the 
Choosing Wisely campaign, are employed. In order to provide more insight into this topic, 
the first part of this thesis will describe laboratory test overuse, explore determinants of 
this overuse and assess the effectiveness of different interventions to counter overuse. 
Chapter 2 and 3 both focus on Antinuclear Antibody (ANA) testing as this is a commonly 
used test by rheumatologists despite the limited place it should have within rheumatology. 
In Chapter 2 we describe the results of a simple intervention (education and feedback) on 
the ANA use by rheumatologists in three different hospitals in the Netherlands. Chapter 3 
is a continuation of the previous chapter, now exploring various determinants of ANA use by 
rheumatologist. This is done using both a quantitative (questionnaire study on the influence 
of personality, thinking styles, cognitive bias and numeracy) and a qualitative approach 
(focus group meeting with rheumatologists). 
In chapter 4 a non-peer reviewed article is presented, describing the Dutch version of 
the Choosing Wisely campaign for rheumatology. As part of the Choosing Wisely campaign 
the American College of Rheumatology published a list of ‘five things that physicians and 
patients should question’ and this example was followed in 2014 by the Dutch Society of 
Rheumatology. The final Dutch top 5 list and its development are described in this chapter.
Chapter 5 provides a closer look on two other commonly used tests in rheumatology: creatine 
kinase (CK) and thyroid stimulating hormone (TSH). Both tests are often recommended in 
the diagnostic workup of fibromyalgia (FMS), but hardly any underlying evidence for these 
recommendations exists. Therefore we assessed the prevalence of abnormal CK and TSH, 
and the prevalence of related diagnoses in a cohort of patients with suspected FMS.
The final chapter, chapter 6, describes the effects of an intervention aimed at reducing use 
of diagnostic laboratory tests. Similar to CK and TSH testing, the evidence for widespread 
use of complement, cryoglobuline, gammaglobuline and M protein testing in rheumatology 
is scarce. To discourage the use of these tests, an automatic reminder was incorporated in 
the electronic health record, reminding the rheumatologist of the limited evidence for the 
use of these tests if they ordered one. Using routine laboratory tests such as C-reactive 
protein as a control group, the effect of this reminder is assessed. 
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ABSTRACT
Objective
To assess the effect of a simple intervention on Anti-Nuclear Antibody (ANA) test overuse 
by rheumatologists.
Methods
This was an explorative, pragmatic before and after controlled implementation study 
among rheumatologists working at three rheumatology departments of secondary and 
tertiary care centers in the Netherlands. The intervention was given in all study centers 
separately and combined education with feedback. 
Six outcome measures describe the intervention effects: the ANA/new patient ratio 
(APR), difference with the target APR, percentage of positive ANA tests, percentage of 
repeated ANA testing, percentage of ANA associated diseases and APR variation between 
rheumatologists. 
Outcomes were compared between the pre- and post-intervention period (both 12 
months) using (multilevel) logistic regression or F-testing. Results are reported together 
for center 1 and 2, and separately for center 3 because ANA tests could not be linked to 
an individual rheumatologist in center 3.
Results
The APR decreased from 0.37 to 0.11 after the intervention in center 1 and 2 (odds ratio 
(OR) 0.19, 95%-confidence interval (95%-CI) 0.17 to 0.22, p-value <0.001) and from 0.45 
to 0.30 in center 3 (OR 0.53, 95% CI 0.45 to 0.62, p <0.001). The percentage of repeated 
ANA requests in all centers and the APR variation center 1 and 2 decreased significantly. 
Only in center 3 the percentage of ANA associated diseases increased significantly. 
Conclusion
A simple intervention resulted in a relevant and significant decrease in the numbers of 
ANA tests requested by rheumatologists, together with an improvement on three other 
outcome measures. 
Trial registration number (ClinicalTrials.gov): NCT02409251
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SIGNIFICANCE AND INNOVATIONS
- Overuse of laboratory testing is a widespread problem in medicine with an 
estimated 21% of laboratory tests being requested inappropriately
- Overuse of tests leads to an increase in health care costs and increased numbers 
of false positive results, causing unnecessary anxiety in both patients and doctors.
- The American College of Rheumatology recently named Anti-Nuclear Antibody (ANA) 
testing as one of the ‘top five things to avoid’ in the Choosing Wisely campaign 
- A relatively simple intervention, teaching rheumatologists’ how to correctly use 
ANA testing, can lead to a sizable reduction in the number of ANA requests 
INTRODUCTION
The number of laboratory tests performed has steadily risen over the past years and it is 
estimated that 21% of laboratory tests are requested inappropriately.(1) This is a real and 
significant problem in medicine, as inappropriate testing leads to a higher patient burden 
due to uncertainty and additional testing, higher false-positive rates and higher costs.(1) 
In recent years this problem has gained more attention and the internationally expanding 
Choosing Wisely campaign is a good example of the effort taken to decrease overuse.(2) 
As part of the Choosing Wisely campaign the American College of Rheumatology (ACR) 
published a list of ‘five things that physicians and patients should question’. The first item 
on this list is: ‘do not test Anti-Nuclear Antibody (ANA) sub-serologies without a positive ANA 
and clinical suspicion of immune-mediated disease’.(3) 
ANA testing is often used as a screening test for various rheumatic diseases. However, a 
large review on this subject concluded that the false-positive rate associated with ANA 
testing severely limits its usefulness as a screening test. ANA testing can be useful in 
case of a reasonable clinical suspicion on Systemic Lupus Erythematosus (SLE), Systemic 
Sclerosis (SSc), polymyositis (PM), dermatomyositis (DM), Mixed Connective Tissue Disorder 
(MCTD) and Sjögren Syndrome (SS).(4,5) Despite this advice, several publications that have 
described ANA and/or ANA sub serology use in clinical practice conclude that these tests are 
frequently overused.(6-11) 
Combining current literature and the Choosing Wisely advice we argue that in order to 
avoid ‘broad testing of auto antibodies’ (3) one should first decrease ANA testing itself. For 
this reason we developed an intervention to improve ANA test requests, thus decreasing 
ANA overuse. This paper describes the effects of this intervention on ANA requests done by 
rheumatologists.
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MATERIAL AND METHODS
Study design and participants
An explorative, pragmatic, before- and after-controlled implementation study on ANA 
overuse was performed among rheumatologists working at the outpatient clinic departments 
of different hospitals in the Netherlands. The rheumatologists of seven rheumatology 
departments of secondary and tertiary care centers were approached and asked to 
participate in this study. If a center decided to participate, all rheumatologists working 
at this center at study start were eligible for participation. Rheumatologists in training 
(trainees) were not eligible for participation as they often work only for a short period of 
time in the same hospital, leading to incomplete data. Furthermore, we could never be 
sure if the decision to order an ANA test was their own decision as trainees work under the 
supervision of a rheumatologist. Rheumatologists not giving their consent or not working the 
full pre- and post-intervention period as a rheumatologist at a participating hospital were 
excluded. Consent from all rheumatologists was sought at the moment of introduction of 
the study during regular staff meetings. 
Although the intervention was aimed at rheumatologists, patient data were needed to 
assess the intervention effects. Therefore, all patients with an ANA test requested by a 
participating rheumatologist during the study period were included. Patients with an ANA 
test requested during a clinical admission were excluded.  
The pre- and post-intervention period both lasted 12 months, with the time needed to 
prepare the intervention included in the pre-intervention period (see also ‘statistical 
analysis and reporting of results’).
When reporting this study, the Standards for Quality Improvement Reporting Excellence 
(SQUIRE) guidelines were followed.(12)
Intervention
The intervention was an improved version of an intervention used before in one of the study 
centers to optimize requesting of Magnetic Resonance Imaging scans of the sacroiliac joints.
(13)
The intervention in this study consisted of a one-hour group session, combining an educational 
meeting with feedback (14), and was given separately in all participating centers. Six months 
after the intervention, a one-hour booster session was held. During both sessions, feedback 
on ANA testing was provided, followed by background information on ANA testing, a short 
recommendation on when to request an ANA test – or not - in daily practice and a target 
ANA/new patient ratio (APR) to reach after the intervention. The target APR was calculated 
by doubling the number of patients with an ANA-associated diagnosis in the pre-intervention 
period and dividing this by the number of new patients seen in the pre-intervention period. 
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This calculation follows Bayes theorem which assumes that a test performs optimally when 
the pre-test probability on disease is approximately 50% (see also ‘outcome measures’ for 
an explanation of Bayes theorem).
Both the intervention and the booster session were planned during regular meeting hours, 
in order to make it easy for rheumatologists to attend. Attendance was monitored during 
the sessions, and rheumatologists not present received an email with alternative times on 
which the session was held again. Although rheumatologists in training could not participate 
in this study, they were allowed to attend the intervention and booster session as part of 
their rheumatology training. All sessions were given by a resident of rheumatology (NL), 
with additional support from an experienced rheumatologist and epidemiologist (AdB). 
A complete description of the intervention and the PowerPoint slides used during the 
intervention can be found in appendices 1 and 2 respectively. 
Outcome measures 
The diagnostic value of a test in clinical practice depends primarily on the difference 
between pre- and post-test probabilities, the latter being expressed as the positive or 
negative predictive value of a test (PPV and NPV respectively). In contrast to the sensitivity 
and specificity of a test, the PPV and NPV are highly influenced by the pre-test probability 
of the disease. This application of  ‘Bayes theorem’ results in a low diagnostic value of a 
test in case of a low pre-test probability of the disease of interest, even if the sensitivity 
and specificity are high (see appendix 3 for more a more elaborate explanation including 
example calculations).(15) 
When applying Bayes theorem to clinical practice, overuse of a test is essentially 
characterized by suboptimal patient selection by the requesting physician. This results in a 
too low pre-test probability and consequently a low diagnostic value of the test. To estimate 
the pre-test probability for all individual patients intensive chart review would be needed. 
As this was deemed to labor intensive, we defined the following six, readily available, 
outcome measures that are all closely related to pre-test probability on disease: the ANA/
new patient ratio (APR), the difference with the target APR, percentage of positive ANAs, 
percentage of repeated ANA testing within one year, percentage of ANA associated diseases 
and APR variation between rheumatologists (table 1). All these outcomes were measured on 
clinic level, but for the latter outcome an extra step was needed. In order to assess variation 
between rheumatologists, we first calculated the APR for all single rheumatologists in one 
center which was followed by calculating the mean APR out of these individual APRs. The 
standard deviation around this mean APR on clinic level was then used as the outcome 
measure to assess variation between rheumatologists. As a result the mean APR will differ 
slightly from the APR described as the first outcome measure.
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Table 1: outcome measures 
Outcome 
measure
Calculation Expected situation before 
the intervention (overuse)
Expected change after the 
intervention (less overuse)
APR (ratio) Number of ANA tests 
requested divided by the 
number of new patients 
seen at the rheumatology 
outpatient clinic
High in comparison with the 
population at risk
Decrease (only ANA testing 
in the population at risk 
due to improved patient 
selection)
Difference with 
the target APR* 
(%)
Absolute difference 
between the actual and 
target APR divided by the 
target APR
High in comparison with the 
population at risk (i.e. an 
actual APR well above the 
target APR)
Decrease (only ANA testing 
in the population at risk 
due to improved patient 
selection)
Positive ANA 
tests (%)‡
Number of ANA tests with 
a positive result divided 
by the total number of 
ANA tests
Few positive tests, the 
percentage of positive 
ANA tests will approach 
the percentage of positive 
ANA tests in the healthy 
population 
Increase (only ANA testing 
in the population at risk 
due to improved patient 
selection)
Repeated ANA 
testing within 
one year (%)Ξ
Number of patients with 
more than one ANA test 
done divided by the total 
number of patients with 
an ANA test done
High in comparison to the 
population at risk. Repeated 
ANA testing without a 
change in clinical picture 
is not recommended as the 
pre-test probability will be 
very high or low (4;6)
Decrease (repeated ANA 
testing only in those 
with a change in clinical 
picture, i.e. improved 
patient selection)
ANA associated 
diseases (%)
Number of patients with a 
diagnosis of SLE, SSc, PM/
DM, MCTD or SS divided 
by the total number of 
patients
Few patients with an 
associated diagnosis, the 
percentage of associated 
diagnosis will approach the 
incidence in the normal 
population
Increase (only ANA testing 
in the population at risk 
due to improved patient 
selection)
APR variation 
between 
rheumatologists
Standard deviation around 
the mean APR
Variation between 
rheumatologists that cannot 
be explained by case mix 
differences  
Decrease (more similar 
behavior between 
rheumatologists)
APR: ANA/patient ratio, ANA: Anti-Nuclear Antibody, SLE: systemic lupus erythematosus, SSc: systemic 
sclerosis, PM/DM: polymyositis/dermatomyositis, MCTD: mixed connective tissue disease, SS: Sjögren’s 
syndrome. *Due to the differences in the number of patients with an ANA-associated diagnosis between 
the centers, the target differed between the centers and therefore this outcome will be reported for 
all centers separately. ‡Tests results reported as ‘weakly positive’ are regarded as negative. ΞAs we had 
no access to laboratory databases outside the participating centers, only repeated testing within one 
center could be assessed.
Study time frame
The study started in February 2012 with asking seven different hospitals to participate. In 
the hospitals that decided to participate, the study started between March and October 
2012. The intervention in those hospitals took place consecutively between June 2012 and 
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June 2013, the booster session taking place six months thereafter from November 2012 to 
January 2014 (figure 1). 
Figure 1: study time frame per participating center
Data sources
In order to assess the outcome measures, data were obtained from two different sources. 
First, laboratory databases from the participating hospitals were used to retrieve ANA data. 
These included the number of ANA tests performed, test results, test dates, gender and 
age of the patient in whom the ANA was tested, and the name of the rheumatologist who 
requested the ANA. However, this last variable proved not to be reliable in all participating 
centers due to organizational issues. Therefore, outcome measures requiring these data 
(APR variation) were omitted for those centers. 
Secondly, information on patient diagnosis and number of new patients seen was obtained 
from administrative hospital databases. After combining both datasets locally, patient data 
were analyzed anonymously. 
All patient data were retrieved from the relevant sources on three time points. Firstly, data 
on the twelve month period before study start was obtained from a participating center 
directly after the rheumatologists decided to participate (study start). This data was used 
to prepare the feedback provided to the rheumatologists during the intervention. Secondly, 
two months before the booster session data was collected to prepare the feedback on first 
three months of the post-intervention period. Thirdly, the final data on the full study period 
(24 months; pre- and post-intervention) to assess and analyze the outcome measures was 
obtained twelve months after the intervention (end of study). This means that both pre- and 
post-intervention data were obtained retrospectively. 
Characteristics of the rheumatologist study population, including demographic (age, gender) 
and practice (work experience, patient contact, PhD) data were collected at study start.
Ethical approval
This study was presented to the local medical ethical board (Commissie Mensgebonden 
Onderzoek [CMO]), but according to Dutch Act on Medical Research Involving Human 
Subjects, this study did not need ethical approval (CMO reference number 2015-1653). 
All participating hospitals approved the study, and all participating rheumatologist gave 
consent. In addition, it was made clear to all participating rheumatologists that they could 
stop with this study at any time without providing a reason. 
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All patient data (consisting of only age, sex, ANA testing result, and administrative diagnosis) 
were retrieved within the hospital by matching two datasets locally, after which the data 
was anonymized. As this data cannot be traced back to an individual patient (no name, 
initials or other identifying information), no written informed consent was needed from the 
patients according to Dutch Data Protection Act. The study was registered at ClinicalTrials.
gov (NCT02409251).
Statistical analysis & reporting of results
All analyses were done using STATA version 13. Depending on the type of variable descriptive 
statistics are presented as percentages with the accompanying absolute numbers or as 
means with standard deviations. All outcome measures, except for the difference with the 
target APR, were compared between the pre- and post-intervention period. The exception 
for the target APR was made because the difference between the actual and target APR 
was expressed as a percentage of the target APR (table 1). This made testing for statistical 
significance between the pre- and post-intervention difference difficult. Therefore we chose 
to deviate from the study protocol and only describe the results of this outcome measure 
without further statistical testing.
Because the intervention took place on rheumatologist level and some outcomes were 
measured at patient level, four out of six outcomes (APR, % positive ANA tests, % repeated 
ANA requests and % ANA associated diseases) had to be analyzed using mixed model multilevel 
logistic regression. However, in one center the ANA tests could not reliably be attributed to 
individual rheumatologists. This made it impossible to perform multilevel logistic regression 
analyses including the data from this center. Therefore it was decided to analyze (using 
logistic regression) and report those four outcome measures separately for this center. All 
results from the (multilevel) regression analyses are reported as odds ratios (OR) with the 
corresponding 95% confidence interval (95% CI) and p-value.
For the remaining outcome measure (practice variation) another analysis technique was 
chosen. Practice variation was defined as the standard deviation around the mean APR 
(based on the APR of individual rheumatologists). Testing of its statistical significance was 
done using the F-test (two-sided, α = 0.05).  All analyses were done on an intention-to-treat 
basis.
As mentioned before, the time needed to prepare the intervention was included in the pre-
intervention period. During this preparation period the participating rheumatologists knew 
about the study, but the intervention was yet to come (see figure 1). As we did not know if 
this knowledge could already influence requesting behavior of the rheumatologists, a post-
hoc sensitivity analysis was done with and without the preparation period included in the 
pre-intervention period. 
A second post-hoc sensitivity analysis was done in order to assess whether the effects in the 
post-intervention period were different before and after the booster session.
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RESULTS
Setting & participants
Of the seven hospitals approached, three decided to participate (43%). These included 
one general (center 1), one specialized (center 2) and one academic center (center 3).  A 
total of 30 rheumatologists worked at these centers and 29 of them could be included (see 
figure 2). With 316 rheumatologists registered in the Netherlands, almost 10% of the total 
population of rheumatologists was included in this study.
One of rheumatologists in center 3 was lost to follow-up after the intervention due to a 
change of jobs. Attendance at the intervention and booster session was high, with only 
two rheumatologists from center 3 not attending the sessions for unknown reasons despite 
repeated invitations for an alternative time. In table 2 the baseline characteristics of the 
three participating centers and their rheumatologists are given. 
Figure 2: study flow chart
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Table 2: characteristics of the study population 
Centre 1 Centre 2 Centre 3
Type of center (hospital) General 
hospital
Specialized 
hospital
University 
hospital
Included rheumatologists, no 6 14 9
Demographic and practice characteristics of included rheumatologists’
Age, mean ±SD years 40.2 ± 4.3 48.8 ± 9.8 46.8 ± 8.5
Females, % (no./total no.) 83.3 (5/6) 43.0 (6/14) 66.7 (6/9)
Work experience as a rheumatologist, mean ±SD years 4.7 ± 2.7 12.2 ± 10.3 12.3 ± 7.3
Patient contact per week, mean ±SD no 60.8 ± 9.3 58.9 ± 17.0 49.7 ± 16.2
Completed or ongoing PhD, % (no./total no.) 33.3 (2/6) 71.4 (10/14) 77.9 (7/9)
Intervention effect on the ANA tests requested
The intervention resulted in a significant decrease of the APR in all centers, with the APR 
decreasing from 0.37 to 0.11 (OR 0.19 95% CI 0.17 to 0.22) in center 1 and 2; and from 
0.45 to 0.30 (OR 0.53, 95% CI 0.45 to 0.62) in center 3. Also significant improvement was 
seen in the percentage of repeated ANA requests in all centers, the percentage of ANA 
associated diagnosis in center 3 and APR variation between rheumatologists in center 1 and 
2. The percentage of positive ANA tests did not increase in any of the centers. Before the 
intervention all centers had an APR well above the target APR (absolute difference between 
+200% and +850% of the target APR). After the intervention the difference had decreased 
(+83% to +175%), but none of the centers reached the target APR. All results are described in 
table 3 and the APR variation between rheumatologists, including the target APR, is further 
illustrated in figure 3. 
As mentioned in the methods section, two post-hoc sensitivity analyses were performed. No 
differences were observed compared to the primary analyses, except for the percentage of 
repeated ANA requests being lower in the post-intervention period after the booster session 
compared to the period before this session (1.7% versus 9.8%; OR 0.15, 95% CI 0.04 to 0.68). 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Intervention on ANA overuse  |  37
2
Ta
bl
e 
3:
 p
re
- 
an
d 
po
st
-i
nt
er
ve
nt
io
n 
re
su
lt
s 
on
 t
he
 s
ix
 o
ut
co
m
e 
m
ea
su
re
s
Pr
e-
in
te
rv
en
ti
on
Po
st
-i
nt
er
ve
nt
io
n
O
R 
(9
5%
 C
I)
P-
va
lu
e
AP
R 
(n
o.
/t
ot
al
 n
o.
)
Ce
nt
er
 1
 a
nd
 2
Ce
nt
er
 3
0.
37
 (
18
99
/5
15
0)
0.
45
 (
61
9/
13
64
)
0.
11
 (
47
5/
42
04
)
0.
30
 (
34
1/
11
21
)
0.
19
 (
0.
17
 t
o 
0.
22
)
0.
53
 (
0.
45
 t
o 
0.
62
)
<0
.0
1Ξ
<0
.0
1†
Di
ff
er
en
ce
 w
it
h 
ta
rg
et
 A
PR
, 
% 
(9
5%
 C
I)
Ce
nt
er
 1
 (
ta
rg
et
 A
PR
: 
0.
04
)
Ce
nt
er
 2
 (
ta
rg
et
 A
PR
: 
0.
06
)
Ce
nt
er
 3
 (
ta
rg
et
 A
PR
: 
0.
15
)
+8
50
% 
(7
75
 t
o 
90
0%
)
+5
17
% 
(4
83
 t
o 
55
0%
)
+2
00
% 
(1
80
 t
o 
22
0%
)
+1
75
% 
(1
50
 t
o 
25
0%
)
+8
3%
 (
67
 t
o 
11
7%
)
+1
00
% 
(8
0 
to
 1
20
%)
n/
a
n/
a
n/
a
n/
a
n/
a
n/
a
Po
si
ti
ve
 A
N
A 
te
st
s,
 %
 (
no
./
to
ta
l n
o.
) 
Ce
nt
er
 1
 a
nd
 2
Ce
nt
er
 3
24
.6
 (
46
6/
18
96
)
37
.0
 (
22
8/
61
6)
24
.4
 (
11
5/
47
1)
37
.7
 (
12
7/
33
7)
1.
05
 (
0.
82
 t
o 
1.
36
)
1.
03
 (
0.
78
 t
o 
1.
35
)
0.
69
Ξ
0.
84
†
Re
pe
at
ed
 A
N
A 
re
qu
es
ts
, 
% 
(n
o.
/t
ot
al
 n
o.
) C
en
te
r 
1 
an
d 
2
Ce
nt
er
 3
6.
9 
(1
22
/1
76
7)
9.
0 
(5
0/
55
4)
1.
3 
(6
/4
69
)
3.
7 
(1
2/
32
7)
0.
15
 (
0.
07
 t
o 
0.
35
)
0.
38
 (
0.
20
 t
o 
0.
73
)
<0
.0
1Ξ
<0
.0
1†
AN
A 
as
so
ci
at
ed
 d
ia
gn
os
is
, 
% 
(n
o.
/t
ot
al
 n
o.
) 
Ce
nt
er
 1
 a
nd
 2
Ce
nt
er
 3
6.
8 
(1
27
/1
87
0)
17
.1
 (
10
5/
61
4)
8.
2 
(3
8/
46
2)
25
.2
 (
78
/3
09
)
1.
38
 (
0.
93
 t
o 
2.
03
)
1.
63
 (
1.
17
 t
o 
2.
28
)
0.
11
Ξ
<0
.0
1†
AP
R 
va
ri
at
io
n 
be
tw
ee
n 
rh
eu
m
at
ol
og
is
ts
* 
(m
ea
n 
AP
R)
Ce
nt
er
 1
 a
nd
 2
Ce
nt
er
 3
0.
20
 (
0.
37
)
n/
a
0.
08
 (
0.
12
)
n/
a
n/
a
n/
a
<0
.0
1Δ
n/
a
O
R:
 o
dd
s 
ra
ti
o,
 9
5%
 C
I:
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
. 
*D
ue
 t
o 
th
e 
qu
al
it
y 
of
 t
he
 d
at
a 
th
is
 c
ou
ld
 o
nl
y 
be
 a
ss
es
se
d 
fo
r 
ce
nt
er
 1
 a
nd
 2
. 
Ξ M
ix
ed
 m
od
el
 m
ul
ti
le
ve
l 
lo
gi
st
ic
 r
eg
re
ss
io
n.
 † L
og
is
ti
c 
re
gr
es
si
on
. 
Δ F
-t
es
t,
 t
w
o-
si
de
d.
  
Si
gn
ifi
ca
nt
 v
al
ue
s 
ar
e 
in
 b
ol
d.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
38  |  Chapter 2
Figure 3: APR of individual rheumatologists in center 1 and 2
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DISCUSSION
To our knowledge this is the first study attempting implementation of the ANA advice from 
the Choosing Wisely campaign by trying to improve rheumatologists’ requesting behavior 
with a relative simple intervention. Our study shows a significant and relevant decrease 
in the numbers of ANA tests requested by rheumatologists in the post-intervention period. 
This effect was accompanied by improvement on three other outcomes on appropriate ANA 
testing (less repeated ANA requests, more ANA associated diagnosis and less APR variation 
between rheumatologists). As not all outcome measured changed, it seems that ANA 
requesting behavior has improved, but is not yet optimal. 
Strengths & limitations
Besides being one of the first studies on this topic, the main strengths of this study are 
the inclusion of three different types of hospitals, the relatively large number of included 
rheumatologists, the use of a simple intervention, the adequate follow-up duration, and 
the inclusion of outcome measures based on the theoretical framework of Bayes theorem. 
These measures have the additional advantage of being easy to retrieve from hospital 
databases, thereby aiding future replication of our results and further implementation in 
clinical practice. 
However, this study has some limitations. Firstly, in center 3, ANA tests could not be reliable 
attributed to a single rheumatologist within this center. As a result, no individualized 
feedback could be provided during the intervention and non-included health care providers 
(such as residents) could not be excluded from the dataset. This probably resulted in the 
lower intervention effects seen in center 3. Nevertheless, also in center 3 we found a 
significant and relevant intervention effect. Secondly, we only studied patients where 
an ANA test had been ordered, so we are unable to comment on the decision that was 
made in many other patients not to request an ANA test. The literature suggests there is 
considerable overuse of ANA testing rather than underuse, and therefore we chose to focus 
on the patients where such overuse could be present (i.e. where ANA testing had been 
done). Furthermore, assessing whether not requesting an ANA test was correct would call 
for very labor intensive chart review making this less feasible. 
Thirdly, participation of hospitals was on a voluntary basis, making our conclusion about 
the intervention effects only generalizable to centers willing to participate in this kind of 
implementation projects. Also, within the included centers participation was voluntary and 
some selection bias could have occurred with the drop out of one rheumatologist in center 
3. Again this bias would be small and lead to more conservative estimates.
Lastly, due to our study design we are not able to infer a definite causal relation between 
our intervention and the results afterwards because other events in the same time period 
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might have attributed to the observed results. However, we are not aware of any events 
during the study that could have influenced rheumatologists’ ANA requesting behavior with 
this magnitude. The only exception could be the blinding of the rheumatologists, as they 
only did know about the study just before the intervention and not during the full study 
period. However, sensitivity analysis yielded no difference between including or excluding 
this period in the pre-intervention period.
Relation to other studies 
As mentioned in the introduction, several groups have studied ANA overuse; however, we 
are only aware of two other intervention studies. In these studies, a diagnostic algorithm 
was implemented; according to the algorithm ANA sub serology was not done by the 
laboratory if the ANA was negative, even if both tests were requested simultaneously by 
the physician.(16;17) This led to a decrease in ANA (sub serology) testing in both studies. 
Notably, this diagnostic algorithm was already in use in all study centers for several years; 
despite this algorithm overuse was still present.
With regard to the effects observed in this study, we were surprised by the extend of APR 
decrease, especially since intervention effects in other studies on overuse of diagnostic 
tests are not often as large as ours.(18-20) A reason for the observed effect, especially in 
center 1 and 2, could be the presence of the second author (AdB) during the interventions. 
He is probably seen as the informal leader of the rheumatology department of both center 1 
and  2 and he has played a crucial role in the close collaboration that exists between these 
two centers, which is known to aid implementation.(21) 
Unfortunately, we can only compare two outcome measures, other than the APR, with other 
studies. These two studies have yielded similar results to our pre-intervention results with 
regard to repeated ANA testing and ANA-associated diagnoses. As this were not intervention 
studies, further comparison is not possible. Furthermore, it is noteworthy that not all 
measures in this study changed after the intervention. The percentage of positive ANA tests 
did not change in any of the centers, no center reached the target APR although they came 
closer, and only in center 3 the percentage of ANA associated diagnosis increased. These 
results may seem counterintuitive, especially the lack of increase in the percentage of 
ANA positive tests after the intervention. However, we think that this is (still) caused by 
suboptimal patient selection of the rheumatologists in combination with a relatively low 
specificity of the ANA test itself. Or in other words, although the extent of ANA overuse 
has decreased after the intervention, rheumatologists still request too many ANA tests and 
did not come close enough to the target APR to see an increase in the percentage of ANA 
positivity.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Intervention on ANA overuse  |  41
2
Practical implications & future research
Despite its limitations, we assume that our study accurately represents the beneficial effects 
of a simple intervention on ANA overuse in centers willing to change their behavior. Possible 
gains are less false-positive test results, less patient burden and less costs. Unfortunately, 
we were not able to perform a formal cost-analysis. However, if we assume that without 
the intervention the APR would have remained similar, around 1200 extra ANA tests would 
have been requested in the post-intervention period. As not only the costs from the ANA test 
itself (approximately 10 euro per test) are saved, but also costs from potential subsequent 
testing and treatment, it seems that savings gained with this simple and cheap intervention 
are substantial.
Despite our positive results and the possible gains, replication of our results would be 
warranted before this intervention is widely implemented. Given the fact that overuse is 
still present in the participating centers, improvements of our intervention could also be 
explored. 
Although both the Choosing Wisely advice and this study were aimed at rheumatologists, 
decreasing ANA overuse can also be relevant for other specialties such as internal medicine, 
neurology and primary care physicians. The latter could be especially important as the 
setting in which ANA tests are requested most (primary care versus secondary or tertiary 
care), might differ between countries. Furthermore, overuse of laboratory tests is not 
limited to ANA tests, making it worthwhile to apply the same type of intervention also to 
other tests. This might help many more physicians to avoid doing unnecessary tests and to 
choose even more wisely. 
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APPENDIX 1: COMPLETE DESCRIPTION OF THE INTERVENTION AND 
BOOSTER SESSION
Intervention
The intervention (an one hour, educational session) consisted of three parts, but started 
with a short introduction about the study and it was made clear to the rheumatologists that 
all results presented were strictly confidential and that in no way the information could be 
used outside the study (for example by the management of the centers). This was done in 
order to create a non-judgmental environment. 
In the first part of the intervention feedback on ANA requesting behavior over the last 
year was presented to the rheumatologists. The feedback started with information on the 
number of ANA tests, the results of the ANA tests requested, the number of repeated ANA 
tests within one year and the number of ANA associated diagnosis. All results were presented 
as percentages, except for the number of ANA tests requested. This was given as an absolute 
number, accompanied by the ANA/new patient ratio (number of ANA tests divided by the 
number of new patients; APR). In this way, the number of ANAs was put in perspective with 
the number of new patients. In addition, the variation in the APR between the individual 
rheumatologists and/or centers was discussed. 
The feedback was provided in three different ways. First, all outcomes from all participating 
centers were presented. This made it possible for the rheumatologists to compare their group 
performance with group level performance of their peers in the other participating hospitals. 
Secondly, a non-anonymous bar graph picturing the individual APR of all rheumatologists in 
one center was presented. Also, an anonymous bar graph picturing the same information 
of the rheumatologists in the other centers was given. Finally, all rheumatologists received 
an individual feedback report after the intervention. This report contained all results on 
individual level together with (non-)anonymous peer information as described above. 
Despite our efforts to provide a similar intervention to all participating hospitals, the 
feedback component differed slightly between the hospitals on two points due to 
organizational issues. When the intervention was given for the first time, data from the 
other participating hospitals was not yet available. Therefore, the rheumatologists in the 
first participating hospital (center 2) did not receive information about their peers in other 
hospitals. Furthermore, it was not possible to obtain data on the level of the individual 
rheumatologists in all participating centers. As a consequence, the rheumatologists in 
this hospital (center 3) received their feedback only on hospital level and information on 
variation between rheumatologists could not be provided.  
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The second part of the intervention consisted of general background information on 
different topics, all deemed relevant for correct use of ANA tests. We started with providing 
generic background on the relation between pre-test probability and diagnostic test results 
(also called Bayes theorem). This was done because literature suggests that physicians 
fail to apply knowledge about pre-test probability of a disease and test characteristics 
when deciding to request a particular test.[22] Bayes theorem was explained and further 
illustrated by calculating the positive and negative predictive values in a situation with 
overuse (pre-intervention data) and without overuse (hypothetical numbers reflecting an 
‘ideal’ situation).[15] An example of this calculation can be found in appendix 3. After this 
general background the focus was shifted back to the main topic and more information on 
ANA testing was given, including test characteristics and current literature on correct ANA 
use. The second part of the intervention ended with an introduction about the nature and 
effects of cognitive bias. This topic was included because other studies suggest that medical 
decisions, including requesting laboratory tests, can be influenced by cognitive bias.[22] 
Cognitive bias can be explained as a type of error in our thinking that occurs when we are 
processing and interpreting information around us. These errors are often a result of our 
attempt to simplify information processing, but this simplification can lead to inaccurate 
decisions. Many different types of cognitive biases are known, but during the intervention 
only four of them were described (confirmation bias, availability bias, primacy error and 
insensivity to sample size). These four were judged to be most important when deciding on 
requesting a laboratory test such as an ANA test.
The third and final part of the intervention consisted of two simple recommendations on 
how to apply the first two parts in daily practice. Firstly, a short guideline on when – not - to 
request an ANA test was given (see table 1). Secondly, in every center the rheumatologists 
were given a target APR to reach after the intervention. This target was calculated for all 
centers separately, using the same method and assuming that a test performs optimally 
when the pre-test probability on disease is around 50%. In order to create an indication 
of the number of patients needed to create a pre-test probability of 50%, the number of 
patients with an ANA-associated disease in the pre-intervention period was doubled. This 
number was then divided by the number of new patients seen in the pre-intervention period, 
as to calculate the APR. For example, if in the pre-intervention the numbers of newly seen 
patients, ANA tests and ANA associated diagnoses were 5000, 1000 and 50 respectively, the 
pre-test probability on disease would be 0.05% (50/1000) with an APR of 0.2 (1000/5000). 
The target after the intervention would be 100 ANA tests (50*2), giving an APR of 0.02 
(100/5000) and a pre-test probability of 50% (50/100). Again, to account for differences in 
number of patients, the target was given as the APR instead of the absolute number of ANA 
tests. 
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Table 1: recommendations and targets provided during the intervention
Guideline/target description
Short guideline 
on ANA use in 
daily practice
Only request an ANA test in case of a reasonable clinical suspicion on an ANA-
associated disease (SLE, SSc, PM/DM, SS or MCTD). Do not request an ANA test in 
the following situations:
- Patients with rheumatoid arthritis, fibromyalgia, Raynaud phenomenon 
without other complaints, undifferentiated arthralgia
- Patients recently tested for ANA positivity (<1 year)
- As an ‘yearly follow-up’
- At the start of TNF-blockers
- Patients already known to you with changing complaints but no reasonable 
suspicion on an ANA-associated disease
Target APR to 
reach after the 
intervention
Centre 1: 0.04
Centre 2: 0.06
Centre 3: 0.15
SLE: systemic lupus erythematosus, SSc: systemic sclerosis, PM/DM: polymyositis/dermatomyositis, SS: 
Sjögren’s syndrome, MCTD: mixed connective tissue disease.
Booster session
The booster session included the same components as the intervention, now using post-
intervention data from the first three months as feedback. 
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APPENDIX 2: POWERPOINT SLIDES USED DURING THE INTERVENTION AND 
BOOSTER SESSION
 Rheumatologists & Antinuclear 
Antibody testing: how to make them 
choose wisely?
An example of the presentation used during the intervention in three 
centres in the Netherlands 
Authors: Nienke Lesuis (resident of rheumatology; MD) and Alfons A den Broeder (rheumatologist-epidemiologist; MD, PhD) 
Sint Maartenskliniek, Nijmegen, the Netherlands
Content
• Introduction
• How are we doing now?
• Methods
• Results
• How can we choose more wisely?
• Background information on laboratory testing in general
• Background information on ANA testing
• Background information on cognitive bias
• In daily clinical practice…
• Take home message
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Introduction
Why Antinuclear Antibodies (ANA)?
• Laboratory tests are an important part of daily clinical practice and 
suboptimal use is common 
• Suboptimal use mainly leads to overuse of laboratory tests 
• Overuse can have important negative consequences 
• Increased number of false-positives, leading to:
• More overuse of other (laboratory) tests / unnecessary 
treatment
• Decreased quality of life (patients)
• Increased health care costs
Zhi et al. PLOS one november 2013; van Walraven et al. JAMA August 2012. 
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How are we doing now? - methods
General
Main goal: improving the quality of our health care
Study goal: to assess the effect of a simple training session and booster 
session on the ANA tests requested by rheumatologists. 
• Number of ANA requests & their results
• Patient characteristics & diagnosis
• Practice variation between rheumatologists
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How are we doing now? - results
Summary
• Too many ANA tests requested
• Numbers, results & diagnoses
• Too much practice variation
• Large differences between rheumatologists
How are we doing now? - results
Too many ANA tests requested: diagnoses
Top 3 diagnoses in the total population of patients in whom an ANA 
was requested 
1. Undifferentiated arthralgia/myalgia 30%
2. Fibromyalgia 11%
3. Rheumatoid arthritis 10%
ANA associated diseases: 5%
How are we doing now? - results
Pre-test probability of the disease: 50 / 1000 = 5.0%
Disease + Disease -
ANA + 45 95 140
ANA - 5 855 860
50 950 1000
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Rheumatologists & Antinuclear 
Antibody testing: how to make them 
choose wisely?
An example of the presentation used during the intervention in three 
centres in the Netherlands 
Authors: Nienke Lesuis (resident of rheumatology; MD) and Alfons A den Broeder (rheumatologist-epidemiologist; MD, PhD) 
Sint Maartenskliniek, Nijmegen, the Netherlands
Content
• Introduction
• How are we doing now?
• Methods
• Results
• How can we choose more wisely?
• Background information on laboratory testing in general
• Background information on ANA testing
• Background information on cognitive bias
• In daily clinical practice…
• Take home message
Content
• Introduction
• How are we doing now?
• Methods
• Results
• How can we choose more wisely?
• Background information on laboratory testing in general
• Background information on ANA testing
• Background information on cognitive bias
• In daily clinical practice…
• Take home message
Content
• Introduction
• How are we doing now?
• Methods
• Results
• How can we choose more wisely?
• Background information on laboratory testing in general
• Background information on ANA testing
• Background information on cognitive bias
• In daily clinical practice…
• Take home message
How are we doing now? - results
Summary
• Too many ANA tests requested
• Numbers, results & diagnoses
• Too much practice variation
• Large differences between rheumatologists
How are we doing now? - results
Summary
• Too many ANA tests requested
• Numbers, results & diagnoses
• Too much practice variation
• Large differences between rheumatologists
How are we doing now? - results
Too many ANA tests requested: numbers & results
Numbers
• 1000 ANAs in twelve months (1-1-2010 to 1-1-2011)
Results
• 86% negative
• 14% positive
How are we doing now? - results
Too many ANA tests requested: diagnoses
Top 3 diagnoses in the total population of patients in whom an ANA 
was requested 
1. Undifferentiated arthralgia/myalgia 30%
2. Fibromyalgia 11%
3. Rheumatoid arthritis 10%
ANA associated diseases: 5%
How are we doing now? - results
Disease + Disease -
ANA + 45 95 140
ANA - 5 855 860
50 950 1000
How are we doing now? - results
Pre-test probability of the disease: 50 / 1000 = 5.0%
Disease + Disease -
ANA + 45 95 140
ANA - 5 855 860
50 950 1000
How are we doing now? - results
Pre-test probability of the disease: 50 / 1000 = 5.0% 
Sensitivity: 45 / 50 = 90% Specificity: 855 / 950 = 90%
Disease + Disease -
ANA + 45 95 140
ANA - 5 855 860
50 950 1000
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How are we doing now? - results
Pre-test probability of the disease: 50 / 1000 = 5.0% 
Sensitivity: 45 / 50 = 90% Specificity: 855 / 950 = 90%
Disease + Disease -
ANA + 45 95 140
ANA - 5 855 860
50 950 1000
How are we doing now? - results
Pre-test probability of the disease: 50 / 1000 = 5.0% 
Sensitivity: 45 / 50 = 90% Specificity: 855 / 950 = 90%
PPV: 45 / 140 = 32% NPV: 855 / 860 = 99%
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Sensitivity: 45 / 50 = 90% Specificity: 855 / 950 = 90%
PPV: 45 / 140 = 32% NPV: 855 / 860 = 99%
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How are we doing now? - results
Pre-test probability of the disease: 50 / 1000 = 5.0% 
Sensitivity: 45 / 50 = 90% Specificity: 855 / 950 = 90%
PPV: 45 / 140 = 32% NPV: 855 / 860 = 99%
PPV & NPV depend on the population assessed (pre-test probability), 
sensitivity & specificity do not …
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How are we doing now? – results
(ideal situation)
Pre-test probability of the disease: 500 / 1000 = 50.0% 
Disease + Disease -
ANA + 500
ANA - 500
1000
How are we doing now? – results
(ideal situation)
Pre-test probability of the disease: 500 / 1000 = 50.0% 
Sensitivity: 90% Specificity: 90%
Disease + Disease -
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ANA - 500
1000
How are we doing now? – results
(ideal situation)
Pre-test probability of the disease: 500 / 1000 = 50.0% 
Sensitivity: 90% Specificity: 90%
Disease + Disease -
ANA + 450 50 500
ANA - 50 450 500
500 500 1000
How are we doing now? – results
(ideal situation)
Pre-test probability of the disease: 500 / 1000 = 50.0% 
Sensitivity: 90% Specificity: 90%
PPV: 450 / 500 = 90% NPV: 855 / 860 = 99%
Disease + Disease -
ANA + 450 50 500
ANA - 50 450 500
500 500 1000
How are we doing now? – results
(ideal situation)
Pre-test probability of the disease: 500 / 1000 = 50.0% 
Sensitivity: 90% Specificity: 90%
PPV: 450 / 500 = 90% NPV: 450 / 500 = 90%
Disease + Disease -
ANA + 450 50 500
ANA - 50 450 500
500 500 1000
How are we doing now? - results
Practice variation
• 1000 ANA requests by 7 rheumatologists in 12 months
• 900 unique patients (so, 100 repeated requests)
• 3200 new outpatient clinic patients seen in those 12 months
• ANA/new patient ratio (APR): 1000 / 3200 = 0.31
• Variation between rheumatologists:
• APR between 0.17 and 0.45 (standard deviation = 0.11)
 Patient: chance of getting an ANA test seems to be heavily dependent of 
your rheumatologist…
How are we doing now? - results
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• Background information on cognitive bias
• In daily clinical practice…
• Take home message
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How are we doing now? - results
Pre-test probability of the disease: 50 / 1000 = 5.0% 
Sensitivity: 45 / 50 = 90% Specificity: 855 / 950 = 90%
PPV: 45 / 140 = 32% NPV: 855 / 860 = 99%
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ANA - 5 855 860
50 950 1000
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Pre-test probability of the disease: 50 / 1000 = 5.0% 
Sensitivity: 45 / 50 = 90% Specificity: 855 / 950 = 90%
PPV: 45 / 140 = 32% NPV: 855 / 860 = 99%
PPV & NPV depend on the population assessed (pre-test probability), 
sensitivity & specificity do not …
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ANA - 50 450 500
500 500 1000
How are we doing now? - results
Summary
• Too many ANA tests requested
• Numbers, results & diagnoses
• Too much practice variation
• Large differences between rheumatologists
How are we doing now? - results
Practice variation
• 1000 ANA requests by 7 rheumatologists in 12 months
• 900 unique patients (so, 100 repeated requests)
• 3200 new outpatient clinic patients seen in those 12 months
• ANA/new patient ratio (APR): 1000 / 3200 = 0.31
• Variation between rheumatologists:
• APR between 0.17 and 0.45 (standard deviation = 0.11)
 Patient: chance of getting an ANA test seems to be heavily dependent of 
your rheumatologist…
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• Background information on laboratory testing in general
• Background information on ANA testing
• Background information on cognitive bias
• In daily clinical practice…
• Take home message
How can we choose more wisely? –
laboratory testing
Use of laboratory tests in general
• Positive likelyhood ratio (pLR) of 2-5: test is useful (↑ post-test probability)
• Negative likelyhood ratio (nLR) of 0.2-0.5: test is useful (↓post-test 
probability)
• Pre-test probability: combination of the clinical picture & prevalence of the 
disease
• Low pre-test probability & a good pLR post-test probability is still low. Don’t 
use the test.
• Moderate pre-test probability (± 50%) & a good pLR/nLR post-test 
probability will clearly in- or decrease. Use the test
• High pre-test probability & a good pLR test result will not make a 
difference. Don’t use the test.
Solomon et al. Arthritis & Rheumatism August 2002.
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How can we choose more wisely? –
ANA testing
ANA – test techniques & results
• Different techniques give different results
• Test characteristics depend on the disease of interest and control group 
used
• SLE: sens 93%   spec 57%    pLR 2,2     nLR 0,1
• Sjögren: sens 48%   spec 52%    pLR 0,99   nLR 1,01
• In general: sensitivity >> specificity
• Many false-positives
 ANA testing is only useful to exclude certain (rheumatic) diseases
Solomon et al. Arthritis & Rheumatism August 2002.
How can we choose more wisely? –
ANA testing
Test characteristics – positive results
• Healthy population
• 1:40 25-30%  (Own centre: 28%)
• 1:80 10-15%
• >1:160 5%
• Relatives
• >1:40 25-30%
 ANA testing is not useful as a screening test for rheumatic diseases
Solomon et al. Arthritis & Rheumatism August 2002.
How can we choose more wisely? –
Cognitive bias
Cognitive bias
• Errors in our thinking that occur when we are processing and interpreting 
information around us, leading to inaccurate decisions and wrong 
interpretations  irrationality
• Heuristics (shortcuts in decision making)
• Limited information processing capacity 
• Emotions
• …
• Unconscious & hard to recognize in your own thinking
• Influencing diagnostic & therapeutic decisions
Bornstein et al. Journal of Evaluation in Clinical Practice 2000.
How can we choose more wisely? –
Cognitive bias
Confirmation bias
• Selective collection and interpretation of evidence in order to confirm a 
hypotheses (‘cherry picking’)
• Being right feels better than being wrong…
• Severe sicca complaints, arthritis and a diagnosis of Sjögren’s
syndrome (diagnosed by a colleague somewhere else)  ANA to 
‘confirm’
How can we choose more wisely? –
Cognitive bias
Availability bias
• The tendency to overestimate the likelihood of events with greater 
"availability" in memory (influenced by how recent the memories are or 
how unusual or emotionally charged they may be)
• Your last patient was a young women with severe, newly diagnosed 
SLE  ANA in the next young women presenting with arthralgia
How can we choose more wisely? –
Cognitive bias
Primacy error/anchoring
• The tendency to rely too heavily, or "anchor," on one trait or piece of 
information when making decisions. Usually the first piece of information 
that we acquire (‘you never have a second chance for a first impression)
• Two groups of doctors were asked to estimate the probability on a 
pulmonary embolism, both groups were given a irrelevant percentage 
as ‘anchor’:
• Case description & low anchor (1%)  estimated probability of 
23% on pulmonary embolism
• Case description & high anchor (90%)  estimated probability of 
53% on pulmonary embolism
Brewer et al. Medical Decision Making March-April 2007.
How can we choose more wisely? –
Cognitive bias
Insensitivity to sample size
• The tendency to not take into account sample size and/or not take into 
account underlying prevalence of a disease
• Bilateral wrist pain in an older patient with hypothyroidism: carpal 
tunnel syndrome or osteoarthritis?
• Side effects seen in two patients generalising to all patients?
How can we choose more wisely? –
Cognitive bias
What should we do with cognitive bias?
• Know that these biases exist
“from unskilled & unaware to unskilled & aware”
• Protect yourself:
• Recognition of cognitive bias in your own thinking (difficult!)
• Adhere to guidelines (diagnostic, treatment)
For the interested reader: ‘Irrationality’ by David Sutherland and ‘Thinking, Fast and 
Slow’ by Daniel Kahneman
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Target: APR = 0.03
Mean: APR = 0.31
How many ANA tests should we do?
Take home message
• ANA testing is only useful in case of a reasonable suspicion on an ANA-
associated disease
• Always use clinical context when interpreting ANA test results
• Protect yourself against cognitive bias, use a guideline 
Rheumatologists & Antinuclear 
Antibody testing: how to make them 
choose wisely?
An example of the presentation used during the booster session in 
three centres in the Netherlands 
Authors: Nienke Lesuis (resident of rheumatology; MD) and Alfons A den Broeder (rheumatologist-epidemiologist; MD, PhD) 
Sint Maartenskliniek, Nijmegen, the Netherlands
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How can we choose more wisely? –
ANA testing
Test characteristics – positive results
• Healthy population
• 1:40 25-30%  (Own centre: 28%)
• 1:80 10-15%
• >1:160 5%
• Relatives
• >1:40 25-30%
 ANA testing is not useful as a screening test for rheumatic diseases
Solomon et al. Arthritis & Rheumatism August 2002.
How can we choose more wisely? –
Cognitive bias
Confirmation bias
• Selective collection and interpretation of evidence in order to confirm a 
hypotheses (‘cherry picking’)
• Being right feels better than being wrong…
• Severe sicca complaints, arthritis and a diagnosis of Sjögren’s
syndrome (diagnosed by a colleague somewhere else)  ANA to 
‘confirm’
How can we choose more wisely? –
Cognitive bias
Primacy error/anchoring
• The tendency to rely too heavily, or "anchor," on one trait or piece of 
information when making decisions. Usually the first piece of information 
that we acquire (‘you never have a second chance for a first impression)
• Two groups of doctors were asked to estimate the probability on a 
pulmonary embolism, both groups were given a irrelevant percentage 
as ‘anchor’:
• Case description & low anchor (1%)  estimated probability of 
23% on pulmonary embolism
• Case description & high anchor (90%)  estimated probability of 
53% on pulmonary embolism
Brewer et al. Medical Decision Making March-April 2007.
How can we choose more wisely? –
Cognitive bias
What should we do with cognitive bias?
• Know that these biases exist
“from unskilled & unaware to unskilled & aware”
• Protect yourself:
• Recognition of cognitive bias in your own thinking (difficult!)
• Adhere to guidelines (diagnostic, treatment)
For the interested reader: ‘Irrationality’ by David Sutherland and ‘Thinking, Fast and 
Slow’ by Daniel Kahneman
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In daily clinical practice
When should I use ANA testing?
• ANA in case of:
• A reasonable suspicion on an ANA-associated disease (systemic lupus 
erythematosus, systemic sclerosis, polymyositis/dermatomyositis, 
Sjögren’s syndrome, mixed connective tissue disease)
• No ANA in case of:
• RA, fibromyalgia, Raynaud without other complaints, arthralgia
• Recently (< 1 year) tested (in another centre)
• Yearly ‘follow-up’
• Start of TNF blockers
• Patient already known by you without a change in clinical picture
Solomon et al. Arthritis & Rheumatism August 2002.
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Take home message
• ANA testing is only useful in case of a reasonable suspicion on an ANA-
associated disease
• Always use clinical context when interpreting ANA test results
• Protect yourself against cognitive bias, use a guideline 
Rheumatologists & Antinuclear 
Antibody testing: how to make them 
choose wisely?
An example of the presentation used during the booster session in 
three centres in the Netherlands 
Authors: Nienke Lesuis (resident of rheumatology; MD) and Alfons A den Broeder (rheumatologist-epidemiologist; MD, PhD) 
Sint Maartenskliniek, Nijmegen, the Netherlands
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What was it all about?
General
Main goal: improving the quality of our health care
Study goal: to assess the effect of a simple training session and booster 
session on the ANA tests requested by rheumatologists
• Number of ANA requests & their results
• Patient characteristics & diagnosis
• Practice variation between rheumatologists
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Summary
• Decrease in the number of ANA tests requested
• Numbers, results & diagnoses
• Decrease in practice variation
• Smaller differences between rheumatologists
How are we doing now? - results
Decrease in ANA tests requested: numbers & results
Numbers
• 150 ANAs in four months (compared to 330 in the same period last 
year)
Results
• 85% negative
• 15% positive
How are we doing now? - results
Decrease in ANA tests requested: diagnoses
Top 3 diagnoses in the total population of patients in whom an ANA 
was requested [percentage in the pre-intervention period]
1. Undifferentiated arthralgia/myalgia 28% [30%]
2. Fibromyalgia 12% [11%]
3. Rheumatoid arthritis 10% [10%]
ANA associated diseases: 7% [5%]
How are we doing now? - results
Disease + Disease -
ANA + 10 14 24
ANA - 1 125 126
11 139 150
How are we doing now? - results
Pre-test probability of the disease: 11 / 150 = 7.0% 
Sensitivity: 10 / 11 = 90% Specificity: 125 / 139 = 90%
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ANA - 1 125 126
11 139 150
How are we doing now? - results
Pre-test probability of the disease: 11 / 150 = 7.0% 
Sensitivity: 10 / 11 = 90% Specificity: 125 / 139 = 90%
PPV: 10 / 24 = 42% NPV: 855 / 860 = 99%
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What was it all about?
General
Main goal: improving the quality of our health care
Study goal: to assess the effect of a simple training session and booster 
session on the ANA tests requested by rheumatologists
• Number of ANA requests & their results
• Patient characteristics & diagnosis
• Practice variation between rheumatologists
How are we doing now? - results
0
0,1
0,2
0,3
0,4
AP
R
ANA/patient-ratio (APR)
Intervention
How are we doing now? - results
Summary
• Decrease in the number of ANA tests requested
• Numbers, results & diagnoses
• Decrease in practice variation
• Smaller differences between rheumatologists
How are we doing now? - results
Decrease in ANA tests requested: numbers & results
Numbers
• 150 ANAs in four months (compared to 330 in the same period last 
year)
Results
• 85% negative
• 15% positive
How are we doing now? - results
Decrease in ANA tests requested: diagnoses
Top 3 diagnoses in the total population of patients in whom an ANA 
was requested [percentage in the pre-intervention period]
1. Undifferentiated arthralgia/myalgia 28% [30%]
2. Fibromyalgia 12% [11%]
3. Rheumatoid arthritis 10% [10%]
ANA associated diseases: 7% [5%]
How are we doing now? – results 
(pre-intervention)
Pre-test probability of the disease: 50 / 1000 = 5.0% 
Sensitivity: 45 / 50 = 90% Specificity: 855 / 950 = 90%
PPV: 45 / 140 = 32% NPV: 855 / 860 = 99%
Disease + Disease -
ANA + 45 95 140
ANA - 5 855 860
50 950 1000
How are we doing now? - results
Disease + Disease -
ANA + 10 14 24
ANA - 1 125 126
11 139 150
How are we doing now? - results
Pre-test probability of the disease: 11 / 150 = 7.0%
Disease + Disease -
ANA + 10 14 24
ANA - 1 125 126
11 139 150
How are we doing now? - results
Pre-test probability of the disease: 11 / 150 = 7.0% 
Sensitivity: 10 / 11 = 90% Specificity: 125 / 139 = 90%
Disease + Disease -
ANA + 10 14 24
ANA - 1 125 126
11 139 150
How are we doing now? - results
Pre-test probability of the disease: 11 / 150 = 7.0% 
Sensitivity: 10 / 11 = 90% Specificity: 125 / 139 = 90%
Disease + Disease -
ANA + 10 14 24
ANA - 1 125 126
11 139 150
How are we doing now? - results
Pre-test probability of the disease: 11 / 150 = 7.0% 
Sensitivity: 10 / 11 = 90% Specificity: 125 / 139 = 90%
PPV: 10 / 24 = 42% NPV: 855 / 860 = 99%
Disease + Disease -
ANA + 10 14 24
ANA - 1 125 126
11 139 150
How are we doing now? - results
Pre-test probability of the disease: 11 / 150 = 7.0% 
Sensitivity: 10 / 11 = 90% Specificity: 125 / 139 = 90%
PPV: 10 / 24 = 42% NPV: 125 / 126 = 99%
Disease + Disease -
ANA + 10 14 24
ANA - 1 125 126
11 139 150
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How are we doing now? - results
Pre-test probability of the disease: 11 / 150 = 7.0% 
Sensitivity: 10 / 11 = 90% Specificity: 125 / 139 = 90%
PPV: 10 / 24 = 42% NPV: 125 / 126 = 99%
Disease + Disease -
ANA + 10 14 24
ANA - 1 125 126
11 139 150
PPV & NPV depend on the population assessed (pre-test probability), sensitivity & 
specificity do not …
How are we doing now? - results
Summary
• Decrease in the number of ANA tests requested
• Numbers, results & diagnoses
• Decrease in practice variation
• Smaller differences between rheumatologists
How are we doing now? - results
Practice variation
• 150 ANA requests by 7 rheumatologists in 4 months
• 145 unique patients (so, 5 repeated requests)
• 1100 new outpatient clinic patients seen in those 4 months
• ANA/new patient ratio (APR): 150 / 1100 = 0.14
• Variation between rheumatologists:
• APR between 0.10 and 0.21 (standard deviation = 0.04)
 Patient: chance of getting an ANA test seems to be dependent of your 
rheumatologist… (but less than before the intervention)
How are we doing now? - results
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APR: Pre-intervention
(own centre only)
Mean APR Target APR
How are we doing now? - results
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APR: Post-intervention
(own centre only)
Mean APR Target APR
How are we doing now? - results
0
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How are we doing now? - results
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Variation in ANA test results
(own centre only)
Positive ANA Negative ANA
How are we doing now? - results
Summary
• Decrease in the number of ANA tests requested
• % positive ANA tests and diagnosis almost unchanged
• Practice variation decreased
• Target APR: approximately reached by some rheumatologists
Content
• Introduction
• How are we doing now?
• Methods
• Results
• How can we choose more wisely?
• Background information on ANA testing
• Background information on cognitive bias
• In daily clinical practice…
• Take home message
How can we choose more wisely? –
ANA testing
Test characteristics – positive results
• Healthy population
• 1:40 25-30%  (Own centre: 28%)
• 1:80 10-15%
• >1:160 5%
• Relatives
• >1:40 25-30%
 ANA testing is not useful as a screening test for rheumatic diseases
Solomon et al. Arthritis & Rheumatism August 2002.
How can we choose more wisely? –
Cognitive bias
Casus babies
A certain city is served by two hospitals. In the larger hospital 
45 babies are born each day, and in the smaller hospital about 
15 babies are born each day. For a period of one year, the two hospitals 
recorded the days on which more the 60% of the babies born were boys. At 
the end of the year, which hospital recorded more such days?
Larger hospital
Small hospital
About the same (i.e., within 5% of each other)
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Testing for phenylketonuria is very effective in identifying and preventing 
serious morbidity and mortality in newborns. The sensitivity is 99.9% and 
specificity is 99.9%. About one out of every 14.000 live births is afflicted. If 
an infant tests positive, the likelihood of disease is:
High
Moderate
Low
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
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How are we doing now? - results
Summary
• Decrease in the number of ANA tests requested
• Numbers, results & diagnoses
• Decrease in practice variation
• Smaller differences between rheumatologists
How are we doing now? - results
0
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APR: Pre-intervention
(own centre only)
Mean APR Target APR
How are we doing now? - results
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How are we doing now? - results
Summary
• Decrease in the number of ANA tests requested
• % positive ANA tests and diagnosis almost unchanged
• Practice variation decreased
• Target APR: approximately reached by some rheumatologists
Content
• Introduction
• How are we doing now?
• Methods
• Results
• How can we choose more wisely?
• Background information on ANA testing
• Background information on cognitive bias
• In daily clinical practice…
• Take home message
How can we choose more wisely? –
ANA testing
ANA – test techniques & results
• Different techniques give different results
• Test characteristics depend on the disease of interest and control group 
used
• SLE: sens 93%   spec 57%    pLR 2,2     nLR 0,1
• Sjögren: sens 48%   spec 52%    pLR 0,99   nLR 1,01
• In general: sensitivity >> specificity
• Many false-positives
 ANA testing is only useful to exclude certain (rheumatic) diseases
Solomon et al. Arthritis & Rheumatism August 2002.
How can we choose more wisely? –
ANA testing
Test characteristics – positive results
• Healthy population
• 1:40 25-30%  (Own centre: 28%)
• 1:80 10-15%
• >1:160 5%
• Relatives
• >1:40 25-30%
 ANA testing is not useful as a screening test for rheumatic diseases
Solomon et al. Arthritis & Rheumatism August 2002.
Content
• Introduction
• How are we doing now?
• Methods
• Results
• How can we choose more wisely?
• Background information on ANA testing
• Background information on cognitive bias
• In daily clinical practice…
• Take home message
How can we choose more wisely? –
Cognitive bias
Casus babies
A certain city is served by two hospitals. In the larger hospital 
45 babies are born each day, and in the smaller hospital about 
15 babies are born each day. For a period of one year, the two hospitals 
recorded the days on which more the 60% of the babies born were boys. At 
the end of the year, which hospital recorded more such days?
Larger hospital
Small hospital
About the same (i.e., within 5% of each other)
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
How can we choose more wisely? –
Cognitive bias
Casus babies
A certain city is served by two hospitals. In the larger hospital 
45 babies are born each day, and in the smaller hospital about 
15 babies are born each day. For a period of one year, the two hospitals recorded 
the days on which more the 60% of the babies born were boys. At the end of the 
year, which hospital recorded more such days?
Larger hospital
Small hospital
About the same (i.e., within 5% of each other)
Insensitivity to sample size: statistic variation increases as sample size decreases
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Testing for phenylketonuria is very effective in identifying and preventing 
serious morbidity and mortality in newborns. The sensitivity is 99.9% and 
specificity is 99.9%. About one out of every 14.000 live births is afflicted. If 
an infant tests positive, the likelihood of disease is:
High
Moderate
Low
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Testing for phenylketonuria is very effective in identifying and preventing 
serious morbidity and mortality in newborns. The sensitivity is 99.9% and 
specificity is 99.9%. About one out of every 14.000 live births is afflicted. If 
an infant tests positive, the likelihood of disease is:
High
Moderate
Low
The positive predictive value depends on your test population…
Calculate!
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
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How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Pre-test probability of the disease = incidence = 1 : 14000
Sensitivity = 99.9% Specificity = 99.9%
Disease + Disease -
Test +
Test -
How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Pre-test probability of the disease = incidence = 1 : 14000
Sensitivity = 99.9% Specificity = 99.9%
*Number of babies born in the Netherlands every year
Disease + Disease -
Test +
Test -
13 179987 180000*
How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Pre-test probability of the disease = incidence = 1 : 14000
Sensitivity = 99.9% Specificity = 99.9%
*Number of babies born in the Netherlands every year
Disease + Disease -
Test + 12.99
Test - 0.01
13 179987 180000*
How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Pre-test probability of the disease = incidence = 1 : 14000
Sensitivity = 99.9% Specificity = 99.9%
*Number of babies born in the Netherlands every year
Disease + Disease -
Test + 12.99 180 182.99
Test - 0.01 179807 179807.01
13 179987 180000*
How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Pre-test probability of the disease = incidence = 1 : 14000
Sensitivity = 99.9% Specificity = 99.9%
NPV = 179807 / 179807.01 = 100%
*Number of babies born in the Netherlands every year
Disease + Disease -
Test + 12.99 180 182.99
Test - 0.01 179807 179807.01
13 179987 180000*
How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Pre-test probability of the disease = incidence = 1 : 14000
Sensitivity = 99.9% Specificity = 99.9%
PPV = 12.99 / 182.99 = 7% NPV = 179807 / 179807.01 = 100%
*Number of babies born in the Netherlands every year
Disease + Disease -
Test + 12.99 180 182.99
Test - 0,01 179807 179807.01
13 179987 180000*
How can we choose more wisely? –
Cognitive bias
Casus atrial fibrillation
Coumadin or aspirin is indicated for embolus prophylaxis in patients with 
chronic atrial fibrillation (although coumadin is believed to be better). The 
last three patients you have treated with coumadin have developed 
complications secondary to the drug. You have never seen any complication 
related to aspirin. You are now seeing in referral a patient with atrial 
fibrillation who was sent to you for your recommendation regarding embolic 
prophylaxis. Which drug do you recommend?
Coumadin
Aspirin
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
How can we choose more wisely? –
Cognitive bias
Casus atrial fibrillation
Coumadin or aspirin is indicated for embolus prophylaxis in patients with 
chronic atrial fibrillation (although coumadin is believed to be better). The 
last three patients you have treated with coumadin have developed 
complications secondary to the drug. You have never seen any complication 
related to aspirin. You are now seeing in referral a patient with atrial 
fibrillation who was sent to you for your recommendation regarding embolic 
prophylaxis. Which drug do you recommend?
Coumadin
Aspirin
Availability bias:  the tendency to overestimate the likelihood of events with 
greater "availability" in memory
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
How can we choose more wisely? –
Cognitive bias
Casus boy or girl
You are a paediatrician. The last four patients you have seen in your office 
today have been girls. The next patient you are to see is more likely to be:
Girl
Equal change of being a boy or girl
Boy
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
How can we choose more wisely? –
Cognitive bias
What should we do with cognitive bias?
• Know that these biases exist
“from unskilled & unaware to unskilled & aware”
• Protect yourself:
• Recognition of cognitive bias in your own thinking (difficult!)
• Adhere to guidelines (diagnostic, treatment etc)
For fun: http://www.youtube.com/watch?v=3RsbmjNLQkc&feature=player_detailpage
For the interested reader: ‘Irrationality’ by David Sutherland and ‘Thinking, Fast and 
Slow’ by Daniel Kahneman
In daily clinical practice
When should I use ANA testing?
• ANA in case of:
• A reasonable suspicion on an ANA-associated disease (systemic lupus 
erythematosus, systemic sclerosis, polymyositis/dermatomyositis, 
Sjögren’s syndrome, mixed connective tissue disease)
• No ANA in case of:
• RA, fibromyalgia, Raynaud without other complaints, arthralgia
• Recently (< 1 year) tested (in another centre)
• Yearly ‘follow-up’
• Start of TNF blockers
• Patient already known by you without a change in clinical picture
Solomon et al. Arthritis & Rheumatism August 2002.
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How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Pre-test probability of the disease = incidence = 1 : 14000
Sensitivity = 99.9% Specificity = 99.9%
*Number of babies born in the Netherlands every year
Disease + Disease -
Test +
Test -
13 179987 180000*
How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Pre-test probability of the disease = incidence = 1 : 14000
Sensitivity = 99.9% Specificity = 99.9%
*Number of babies born in the Netherlands every year
Disease + Disease -
Test + 12.99 180 182.99
Test - 0.01 179807 179807.01
13 179987 180000*
How can we choose more wisely? –
Cognitive bias
Casus phenylketonuria
Pre-test probability of the disease = incidence = 1 : 14000
Sensitivity = 99.9% Specificity = 99.9%
PPV = 12.99 / 182.99 = 7% NPV = 179807 / 179807.01 = 100%
*Number of babies born in the Netherlands every year
Disease + Disease -
Test + 12.99 180 182.99
Test - 0,01 179807 179807.01
13 179987 180000*
How can we choose more wisely? –
Cognitive bias
Casus atrial fibrillation
Coumadin or aspirin is indicated for embolus prophylaxis in patients with 
chronic atrial fibrillation (although coumadin is believed to be better). The 
last three patients you have treated with coumadin have developed 
complications secondary to the drug. You have never seen any complication 
related to aspirin. You are now seeing in referral a patient with atrial 
fibrillation who was sent to you for your recommendation regarding embolic 
prophylaxis. Which drug do you recommend?
Coumadin
Aspirin
Availability bias:  the tendency to overestimate the likelihood of events with 
greater "availability" in memory
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
How can we choose more wisely? –
Cognitive bias
Casus boy or girl
You are a paediatrician. The last four patients you have seen in your office 
today have been girls. The next patient you are to see is more likely to be:
Girl
Equal change of being a boy or girl
Boy
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
How can we choose more wisely? –
Cognitive bias
Casus boy or girl
You are a paediatrician. The last four patients you have seen in your office 
today have been girls. The next patient you are to see is more likely to be:
Girl
Equal change of being a boy or girl
Boy
Gamblers fallacy: misconceptions of chance, chance is commonly but 
erroneously viewed as a self-correcting process. 
Inventory of Cognitive Bias in Medicine (Hershberger et al. Acad Med 1994)
How can we choose more wisely? –
Cognitive bias
What should we do with cognitive bias?
• Know that these biases exist
“from unskilled & unaware to unskilled & aware”
• Protect yourself:
• Recognition of cognitive bias in your own thinking (difficult!)
• Adhere to guidelines (diagnostic, treatment etc)
For fun: http://www.youtube.com/watch?v=3RsbmjNLQkc&feature=player_detailpage
For the interested reader: ‘Irrationality’ by David Sutherland and ‘Thinking, Fast and 
Slow’ by Daniel Kahneman
Content
• What was it all about?
• How are we doing now?
• Results
• How can we choose even more wisely?
• Background information on laboratory testing in general
• Background information on ANA testing
• Background information on cognitive bias
• In daily clinical practice…
• To be continued…
In daily clinical practice
When should I use ANA testing?
• ANA in case of:
• A reasonable suspicion on an ANA-associated disease (systemic lupus 
erythematosus, systemic sclerosis, polymyositis/dermatomyositis, 
Sjögren’s syndrome, mixed connective tissue disease)
• No ANA in case of:
• RA, fibromyalgia, Raynaud without other complaints, arthralgia
• Recently (< 1 year) tested (in another centre)
• Yearly ‘follow-up’
• Start of TNF blockers
• Patient already known by you without a change in clinical picture
Solomon et al. Arthritis & Rheumatism August 2002.
To be continued…
• Final post-intervention measurement  (12 months pre-intervention)
• Keep on doing less ANA tests!
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APPENDIX 3: BAYES THEOREM
Often the value of diagnostic tests is displayed as the sensitivity and specificity of the test, 
but the real value in clinical practice is highly influenced by the pre-test probability of the 
disease for which the test is requested. In contrast to the sensitivity and specificity, the 
positive and negative predictive value take into account the pre-test probability of the 
disease and are therefore more insightful when judging the clinical value of a test. This can 
be best illustrated with an example (see also table 1). A new test has been developed to 
diagnose Sjögren’s syndrome (SS) and has a sensitivity and specificity of both 90%. Due to 
this good test characteristics, this test is used to screen 1000 healthy people in a general 
hospital (pre-test probability of 5% on SS). Given these characteristics, 140 people will 
have a positive test, but only 45 of them have SS. This leads to a PPV of only 32% (45/140). 
In the same way the NPV can be calculated, which is 99% (855/860). In this situation, a 
rheumatologist can rule out SS in case of a negative test, but if a person tests positive, there 
is still uncertainty about the diagnosis. 
Because of these results, the hospital decides to be more selective when using this test, 
so now only people with complaints compatible with SS are tested (pre-test probability of 
50%). With the same number of people and the same test characteristics, a PPV of 90% and 
a NPV of 99% are found, giving much more certainty to the rheumatologist whether or not 
to diagnose SS. This discrepancy in the PPV between the two scenarios is caused by the 
much larger percentage of false-positive results compared to the true positives in the first 
setting (pre-test probability 5%), compared to the second setting (pre-test probability 50%). 
In general it is recognized that diagnostic tests have the most optimal PPV and NPV if the 
pre-test odds on disease lies between the 30 and 60%.
Table 1: 2 x 2 table for scenarios with different pre-test probabilities
Scenario 1 (pre-test probability on SS = 50%)
Sjögren’s syndrome present Sjögren’s syndrome absent
Test positive 450 50 500
Test negative 50 450 500
500 500 1000
Scenario 2 (pre-test probability on SS = 5%)
Sjögren’s syndrome present Sjögren’s syndrome absent 
Test positive 45 95 140
Test negative 5 855 860
50 950 1000
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Re: Lesuis et al. Choosing Wisely in daily practice: an intervention study on Antinuclear 
Antibody testing by rheumatologists.
Robert Ferrari
Dear Editor,
I commend Lesuis et al.[1] for taking a further step in the effort to effect change in how 
physician’s choose tests, in this case examining the often overused anti-nuclear antibody 
(ANA) test. Lesuis et al. showed that an educational intervention could reduce the number 
of ANA tests ordered by rheumatologists. The usefulness of this approach in other scenarios 
may be an issue, however. In Canada, for example, the Canadian Rheumatology Association 
(CRA) has developed a list of 5 tests, procedures, or therapies that have evidence indicating 
they may be not adding value and, in some instances, may be harmful.[2] Among the list 
of five items developed by the CRA for Choosing Wisely Canada is the following: “Don’t 
order anti-nuclear antibodies (ANA) as a screening test in patients without specific signs 
or symptoms of systemic lupus erythematosus (SLE) or another connective tissue disease 
(CTD).”[2] In a subsequent study of our membership (data unpublished), we found that 
more than 80% of rheumatologists surveyed were already following this approach. The 
problem in Canada appears not to be the rheumatologists.  In Alberta, Canada, for example 
approximately 60,000 ANA tests are done each year. For a population of 4 million in Alberta, 
this means, for example, that 1 in 65 Albertans have their ANA tested every year at a cost 
of 3 million dollars US annually, not including costs for additional physician visits, referrals, 
and investigations associated with a positive result. Local experience indicates that most 
of these tests are not ordered by specialists.[3] Rheumatologists in Canada routinely report 
receiving referrals based solely on a positive ANA. 
Although education could be an approach used with all physicians, disseminating that 
education widely may be a challenge. Another approach may instead be modifying the 
serology ordering form to encourage evidence-based ANA testing. Various classification 
criteria have been developed to increase the sensitivity and specificity of a test in terms 
of an SLE diagnosis. Although clinical diagnoses do not always meet classification criteria, 
the chances of a patient having a diagnosis of SLE meeting formally declared classification 
criteria are high (i.e., the criteria were developed by looking at patients with the diagnosis 
and those without). The Systemic Lupus Erythematosus Collaborating Clinics (SLICC) 
classification criteria consider not merely ANA positivity, but also serositis, oral ulcers, 
arthritis, photosensitivity, cytopenia, renal involvement, neurological disorders, and specific 
rashes.[4] Having at least four positives from these categories signifies a high likelihood of 
correctly classifying a patient as having SLE. Using this knowledge, one could develop a 
serology ordering form that asks the ordering physician to consider the following:
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ANA (Anti-Nuclear Antibody) test. At least two of the following criteria must be met for 
this test to be completed. 
- Lupus rash
- Oral ulcers
- Physician-observed swelling of two or more joints OR tender joints with morning 
stiffness
- Serositis, pleurits, or pericarditis
- Evidence of renal disease
- Evidence of neurologic disease
- Cytopenia
- Anti-phospholipid antibody positive
- Non-scarring alopecia
- Low complement levels
That is, of a patient does not have at least 2 of these criteria present, positive ANA testing 
will certainly not be helpful. It has recently been shown in an Alberta practice setting that 
using these a priori minimum criteria before ordering ANA tests can greatly reduce the 
number of tests ordered without missing important diagnoses.[3]  
1. Lesuis N, Hulscher ME, Piek E, Demirel H, van der Laan-Baalbergen N, Meek I, et 
al. Choosing Wisely in daily practice: an intervention study on Antinuclear Antibody 
testing by rheumatologists. Arthritis Care Res 2015 Sep 28. doi: 10.1002/acr.22725.
2. Chow SL, Thorne C, Bell MJ, Ferrari R, Bagheri Z, Boyd T, et al. Choosing Wisely 
Canada. Canadian Rheumatology Association: five things physicians and patients 
should question. J Rheumatol 2015;42:682-9.
3. Ferrari R. Evaluation of the Canadian Rheumatology Association Choosing Wisely 
recommendation concerning anti-nuclear antibody (ANA) testing. Clin Rheumatol 
2015;34:1551-6.
4. Petri M, Obai AM, Alarcón GS, Gordon C, Merril JT, Fortin PR, et al. Derivation and 
validation of the Systemic Lupus International Collaborating Clinics classification 
criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
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Comment on “Choosing Wisely in daily practice: an intervention study on Antinuclear 
Antibody testing by rheumatologists”: reply
Nienke Lesuis; Marlies EJL Hulscher; Ester Piek; Hatice Demirel; Nicole van der Laan-
Baalbergen; Inger Meek; Ronald F van Vollenhoven; Alfons A den Broeder
Dear editor,
We thank dr. Ferrari for his interest in and valuable comments on our recently published 
study on Antinuclear Antibody (ANA) overuse by rheumatologists. 
Firstly, dr. Ferrari notes that in Canada ANA overuse among rheumatologists seems not to 
be widespread as 80% of surveyed rheumatologists reports to follow the Canadian Choosing 
Wisely advice to only order an ANA test in case of specific signs and symptoms of systemic 
lupus erythematosus (SLE) or another connective tissue disease (CTD).[1] This seems to 
concern self-reported adherence to the Choosing Wisely advice, and we are not certain that 
the same results would be found if ANA test use in those rheumatologists would actually be 
measured. This because self-reported results have been proven before to overrate actual 
results [2]. Therefore, we think that ANA overuse might still be a problem among Canadian 
rheumatologists.
We agree with dr. Ferrari that ANA overuse might also be a major problem amongst general 
practitioners (GP), stressing the need for an intervention that is easy to implement in a 
primary care setting. Dr. Ferrari suggested to modify serology ordering forms by making it 
obligatory for ordering physicians to complete a list of clinical criteria and only if two or 
more of those criteria are present, the ANA test will be completed.[1] Although we support 
the general idea, this approach has some drawbacks. Firstly, the checklist focuses on SLE 
only, while ANA testing can also be useful in other CTDs such as systemic sclerosis or in 
other patient populations (for example autoimmune hepatitis).[3] For this reason we chose 
to include a more general comment in our educational meeting (‘do not use ANA testing 
without a reasonable suspicion on an ANA-associated disease’). Of note, we have tested the 
effect of computerized reminders in our ordering system, repeating the intervention advice 
every time a rheumatologist wanted to order an ANA test or another rarely indicated test in 
rheumatology such as complement levels. This resulted in a large decrease in the number 
of orders for those tests (manuscript in preparation). So, we agree with dr. Ferrari that the 
modification of ordering forms can be a very effective way of promoting evidence-based 
test ordering but the exact content of such modifications can be debated. In addition, to 
our opinion such a modification should always be combined with education as to explain the 
rationale of the planned modification to its users.
Finally, we want to comment on the implicit suggestion of dr. Ferrari that the proposed 
modification of order forms could also be used to reduce ANA overuse by GPs. Although this 
might be possible, we think that it could be argued that ANA testing has no place at all in 
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primary care. This because of the very low incidence of ANA associated diseases and the at 
best modest test characteristics of ANA testing, resulting in the need to refer a patient with 
relevant CTD complaints irrespective of the outcome of an ANA test. 
1. Ferrari R. Re: Lesuis et al. Choosing Wisely in daily practice: an intervention study on 
Antinuclear Antibody testing by rheumatologists. Arthritis Care Res (Hoboken) 2015.
2. Davis DA, Mazmanian PE, Fordis M et al. Accuracy of physician self-assessment compared 
with observed measures of competence. A systematic review. JAMA 2006;296(9):1094-
1102.
3. Solomon DH, Kavanaugh AJ, Schur PH et al. Evidence-based guidelines for the use of 
immunologic tests: Antinuclear Antibody testing. Arhritis Rheum 2002;47(4):434-44.
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Choosing Wisely in daily practice: a mixed methods study on 
determinants of Antinuclear Antibody testing by rheumatologists
Nienke Lesuis
Alfons A den Broeder
Ronald F van Vollenhoven
Johanna E Vriezekolk
Marlies EJL Hulscher
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ABSTRACT
Objectives 
To explore the relation between Antinuclear Antibody (ANA) overuse and rheumatologist-
related factors before and after an intervention aimed at reducing ANA overuse. 
Methods 
In this mixed methods study we performed surveys among rheumatologists (n=20) before 
and after the ANA intervention (education and feedback). We identified clinician-related 
determinants of ANA overuse (demographic characteristics, cognitive bias, numeracy, 
personality, thinking styles and knowledge) by multivariate analysis. Two focus group 
meetings with rheumatologists were held six months after the intervention to explore 
self-reported determinants. 
Results 
Questionnaires were completed by all rheumatologists and eight participated in the 
focus groups. Rheumatologist with more work experience and a less extravert personality 
ordered more ANA tests before the intervention (β 0.01, 95% confidence interval (95%-
CI) 0.003 to 0.02, p= 0.01; β -0.11, -0.21 to -0.01, p= 0.04 respectively; R2 47%). After 
the intervention, female rheumatologists changed less than their male colleagues with 
regard to the number of ordered ANA tests (β 0.15, 95%-CI 0.03 to 0.26, p= 0.02; R2 25%). 
During the focus groups seven themes were identified that influenced improvement in 
ANA overuse: determinants related to the intervention and study, individual health 
professionals, patients, professional interactions, incentives and resources, capacity 
for organizational change and, social, political and legal factors.
Conclusions 
We identified several determinants that together explained a sizable part of the 
variance observed in the ANA outcomes at baseline and in the change in ANA outcomes 
afterwards. Furthermore, the focus groups yielded additional factors suggesting a 
complex interplay of determinants influencing rheumatologists’ ANA ordering behavior.
Trial registration 
ClinicalTrials.gov, https://clinicaltrials.gov/ct2/home, NCT02409251
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INTRODUCTION
Approximately 20% of laboratory tests ordered by physicians are ordered inappropriately, 
leading to higher costs, higher false-positive rates and a higher patient burden.[1] In the 
past few years the internationally expanding Choosing Wisely campaign has resulted in 
the American and Canadian rheumatology associations having included a statement on 
Antinuclear Antibody (ANA) use in their Choosing Wisely lists.[2, 3] Furthermore, a research 
agenda on medical overuse was published and recommended to identify determinants 
of overuse.[4] Although ANA overuse has been described in several publications, its 
determinants are not yet known.[5-8]
We previously conducted a pragmatic implementation study aiming to decrease ANA overuse.
[9] Using the data of this study, we now explore the relationship between ANA overuse and 
potential physician-related determinants of this overuse. 
MATERIALS AND METHODS
Study design and participants
This was a mixed methods study, combing quantitative and qualitative methods. The 
study was embedded in a multicenter (n= 3), pragmatic, before-and after controlled 
implementation study assessing the effect of education and feedback on ANA overuse. The 
implementation study took place in the Netherlands and lasted 24 months (12 month pre- 
and post-intervention period).[9]
Rheumatologists working in one of the three participating hospitals (general, specialized 
and academic hospital) from the implementation study were eligible for participation in 
this study. Those working the full study period at a study hospital of whom individual data 
on ANA overuse was available could be included.
Outcome measures & data collection
ANA overuse 
To cover different aspects of ANA overuse the following four outcome measures were used: 
the ANA/patient ratio (APR; number of ANA tests ordered divided by the number of new 
patients seen at the rheumatology outpatient clinic), percentage of positive ANA tests, 
percentage of repeated ANA testing within one year and the percentage of ANA associated 
diseases (systemic lupus erythematosus, systemic sclerosis, polymyositis/dermatomyositis, 
mixed connective tissue disease or Sjögren’s syndrome). All outcome measures were 
calculated at rheumatologist level.
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The ANA outcomes calculated over the pre-intervention period were used to explore 
baseline associations with the determinants, whereas the difference between the pre- and 
post-intervention period outcomes (ANA outcome change scores) were used to analyze 
improvement in ANA use.
Determinants of ANA overuse 
The following potential determinants for ANA overuse were assessed: age, gender, PhD 
degree, years of work experience, cognitive bias, personality traits, thinking styles, 
numeracy and ANA knowledge (last five questionnaires further explained in supplement 1). 
These determinants were assessed at baseline using web-based questionnaires (invitation 
send between March and June 2012; reminder two weeks after the first invitation). 
In addition, questionnaires assessing modifiable determinants (cognitive bias, numeracy and 
ANA knowledge) were administered a second time, three months after the intervention. The 
difference between the baseline score and post-intervention score (determinant change 
score) was then used in the analyses with the ANA outcome change scores. 
Self-reported determinants of improvement in ANA overuse 
To explore self-reported determinants of improvement in ANA overuse we organized two 1.5 
hour focus group sessions in the largest study center (n= 14). Both meetings were planned 
after regular working hours, took place at the study hospital and were led by a female 
psychologist-researcher (JV, PhD). A minimum of 4 and maximum of 8 participants could 
participate in one session. The main question during the focus group was “why did you 
change your behavior after the intervention”. Both sessions were audiotaped and transcribed 
verbatim (see also supplement 2 for a more detailed methods description). 
Data analysis 
All analyses were performed using STATA 13.1. Descriptive statistics are presented as 
percentages with the accompanying absolute numbers, or as means with standard deviations.
Associations between ANA baseline or change outcomes and the determinants were 
analyzed using multiple linear regression. Results from these analyses are reported as 
regression coefficients (β) with the corresponding 95% confidence interval (95%-CI), p-value 
and explained variance (R2). Before these analyses, variance, floor/ceiling effects and co 
linearity were assessed, and all determinants were tested separately with linear regression 
(univariate analyses). 
The transcripts of the focus groups were analyzed by NL and JV using thematic content-
analysis. The results of the qualitative analysis were discussed with the other researchers 
(AdB, MH and RvV) and compared to existing frameworks on this subject (supplement 2) 
[10-12].
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Ethical approval
This study was presented to the local medical ethical board (CMO region Arnhem-Nijmegen) 
and this study was exempt from ethical approval (CMO number 2015-1653). All participating 
hospitals approved the study, and all participating rheumatologist gave consent. 
All patient data, needed to calculate ANA outcomes, were retrieved within the study 
hospitals by matching two datasets locally, after which data was anonymized and provided 
to the research group. The study was registered at ClinicalTrials.gov (NCT02409251).
RESULTS
Setting and participants 
All rheumatologists (n=29) working at the three study hospitals were eligible for participation. 
However, the nine rheumatologists from the university hospital had to be excluded because 
no data on individual ANA overuse was available. The remaining 20 rheumatologists 
completed all questionnaires on both time points (mean age 46.2 ± 9.3 years, 55% female, 
60% PhD degree or pursuing a PhD, mean working experience 9.9 ± 9.3 years). Eight of the 
rheumatologists from the specialized hospital participated in the focus groups. 
Table 1: Outcomes on ANA overuse and questionnaire scores
Pre-intervention 
(baseline; n = 20) 
Post-intervention 
(n = 20)
Change score  
(n = 20)
ANA overuse outcomes
ANA/new patient ratio 0.37 ± 0.19 0.12 ± 0.08 -0.25 ± 0.14
% positive ANA tests 25.7 ± 14.6 24.9 ± 16.9 -0.8 ± 16.2
% repeated ANA testing within 1 year 10.9 ± 10.4 1.3 ± 3.7 -9.5 ± 9.4
% ANA associated diseases* 7.1 ± 4.5 9.6 ± 10.2 2.5 ± 7.4
Questionnaire scores
Cognitive bias 13.0 ± 4.3 13.4 ± 3.9 0.4 ± 2.4
Numeracy** 6.6 ± 1.0 n/a n/a
ANA knowledge 3.3 ± 2.3 5.2 ± 1.5 1.9 ± 1.8
Personality 
Extraversion
Neuroticism
Openness to experience
Consciousness
Agreeableness
3.33 ± 0.72
2.80 ± 0.53
3.63 ± 0.50
3.67 ± 0.52
3.80 ± 0.31
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
Thinking styles 
Rational
Experiential
77. ± 8
64.6 ± 8.1
n/a
n/a
n/a
n/a
* Systemic lupus erythematosus, systemic sclerosis, polymyositis/dermatomyositis, mixed connective 
tissue disease or Sjögren’s syndrome. **This determinant was excluded from further analysis due to 
marked ceiling effects
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Results on ANA outcomes and determinants
In table 1 descriptive results on ANA outcomes and determinants are shown. 
In the multivariate regression analyses, three out of four ANA baseline outcome measures 
(APR, repeated ANA and ANA associated diagnosis) and all ANA change outcomes were 
associated with one or more baseline determinants (table 2). No associations between ANA 
change outcomes and determinant change scores (ANA knowledge and cognitive bias) were 
found.
Table 2: Multivariate associations between ANA outcomes and determinants 
ANA outcome β(95% CI) P-value
Associations between ANA baseline outcomes and baseline determinants
ANA/new patient ratio
Work experience, in years 0.01 (0.003 to 0.02) 0.01
Extraversion -0.11 (-0.21 to -0.01) 0.04
Explained variance (%) 47
% of ANA associated diagnoses
Work experience, in years 0.22 (0.03 to 0.42) 0.03
Extraversion 2.87 (0.38 to 5.35) 0.03
Explained variance (%) 39
% of repeated ANA tests
Female gender -10.2 (-18.92 to -1.53) 0.02
Explained variance (%) 25
Associations between ANA change outcomes and baseline determinants
ANA/patient ratio
Female gender 0.15 (0.03 to 0.26) 0.02
Explained variance (%) 25
% of positive ANA tests
Female gender
Explained variance (%)
-16.53 (-29.93 to -3.12)
23
0.02
% of ANA associated diagnoses
Extraversion 6.61 (2.72 to 10.49) <0.01
Agreeableness -15.05 (-23.99 to -6.10) <0.01
Explained variance (%) 47
% of repeated ANA tests
Female gender 10.33 (2.78 to 17.88) 0.01
Explained variance (%) 28
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During the focus group meetings seven major themes were identified as being of importance 
to ordering less ANA tests after the intervention. These themes related to 1) the intervention 
and study, 2) individual health professionals,3) patients, 4) professional interactions, 5) 
incentives and resources, 6) capacity for organizational change and 7) social, political and 
legal factors (table 3). A full explanation of all themes including quotes is provided in 
supplement 2. 
Table 3 Themes, subthemes and groups of self-reported determinants of improvement in ANA overuse 
as identified during the focus group meetings
Theme Subtheme Group Quote
1. Intervention & 
study factors
Study characteristics “What helped me 
enormously was actually 
the first talk, in which a 
few things that of course 
I already knew, became 
really clear. But that had 
simply drifted away.”
“An enthusiastic 
researche, that has a 
mutually encouraging 
effect. And then you’re 
more likely to adjust your 
behavior than when some 
idiot says: shouldn’t you 
be ordering fewer tests?”
Study participation
Quality of the 
intervention
Content of the 
intervention
Recommended 
behavior during the 
intervention
Feasibility
Research team Familiarity with the research 
team
Trust in the research team
Enthusiasm of the research 
team
2. Individual 
health 
professional 
factors
(Previous) clinical 
experience
“The fact that it’s 
in actually a useless 
screening instrument was 
an extra eye-opener.”
“The fact that someone 
says to you, ‘you don’t 
need to order those 
things’: what a relief…”
Knowledge & 
awareness
Awareness regarding the 
importance of clinical 
judgment and valid reasons to 
order a test
Awareness regarding own 
practice and its consequences
Awareness regarding false 
assumptions on test properties 
and previous behavior
Cognitions (including 
attitudes)
Agreement with the proposed 
problem and solution
Expected outcome
Professional pride & curiosity
Fear of uncertainty
Responsibility
Changing attitudes on ANA 
testing
Professional behavior Nature of the new behavior
Confidence in new behavior
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3. Patient factors Patient numbers -
4. Professional 
interactions
Team process Experience with peer to peer 
coaching
“I actually found it quite 
a challenge and so it’s 
become a bit of a game 
to order as few ANA tests 
as possible (…). After all, 
you want to be top of the 
class, don’t you.” 
Atmosphere
Willingness to change
Peer to peer contact
5. Incentives and 
resources
Financial incentives 
and disincentives
Healthcare costs -
Nonfinancial incentives 
and disincentives
Time constraints
Assistance for clinicians Electronic Health Record as 
barrier
Electronic Health Record as 
aid
6. Capacity for 
organizational 
change
Regulations, rules, 
policies
Department’s personnel policy
Department’s care policy “It’s actually the 
continuation of a trend 
that has been going on for 
years. That we’re simply 
taking decisions with 
respect to the diagnosis 
and treatment, based on 
evidence.”
Organizations’ research policy
7. Social, 
political and 
legal factors
Economic constraints 
on the health care 
budget
Healthcare costs “With all the commotion 
surrounding the cost of 
healthcare, I think we 
need to look critically at 
our ordering behavior, 
that’s part and parcel of 
it too.”
DISCUSSION
This study shows that baseline rheumatologist characteristics such as gender, work 
experience and personality were associated with the ANA outcomes before and a change 
in outcomes after the intervention. Furthermore, the focus groups yielded many additional 
potential explanations for the observed improvement in ANA overuse after the intervention.
The main strength of this study is the use of a mixed methods design, making it possible to 
capture more determinants of ANA overuse than with quantitative analysis alone. Conversely, 
as the study sample was relatively small and the focus groups took place in only one center, 
not all determinants might be captured and our results may not be generalizable to other 
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centers. However, many of the themes identified during the focus groups are also found in 
previous studies.[10-12]
Although studies on determinants of ANA overuse are scarce, two reviews summarize the 
reasons for diagnostic test ordering in general. The relation between female gender, work 
experience and test ordering has been observed before, but so far no consistent pattern has 
emerged. For example, more work experience was associated with a decrease, increase or 
no change in the number of tests ordered.[11, 12]
Also in our study determinants seemed not always to be consistently associated with ANA 
outcome measures. For example, at baseline more work experience was both associated 
with more ANA tests and more ANA associated diagnoses. However, if principles on optimal 
test use are applied one would expect more tests to lead to less related diagnoses (Bayes 
theorem). That our results are not following this principle, might be caused by two 
rheumatologists in our sample, who have many years of work experience and also preferably 
see patients with systemic auto-immune diseases. Finally, three out of the seven relations 
found, included personality: less extravert rheumatologists ordered more ANA tests; more 
extravert rheumatologists had more ANA associated diagnoses; and more extravert and less 
agreeable rheumatologists changed more after the intervention regarding ANA associated 
diagnoses. The first two associations are in accordance with each other and follow Bayes 
theorem. Still, the reasons behind these observations are hard to give, although the original 
descriptions of both extraversion (enthusiastic, assertive, confident) and agreeableness 
(altruistic, cooperative) seem to fit with the direction of the associations.[13] As we are 
aware of only one other study on this topic, observing the same association [14], this would 
be an interesting direction for further research.
In addition to the questionnaires, the focus groups yielded many possible determinants 
which could be grouped into seven themes, matching an existing framework on this subject.
[10] Interestingly, some of the themes yielded from the focus groups seemed contradictory 
to the determinants assessed with questionnaires. This inconsistency was most profound in 
the knowledge domain. Focus group participants stressed the importance of the knowledge 
that was refreshed by the intervention and the new awareness on different aspects of 
ANA testing. Although this seems to follow the increased scores on the ANA knowledge 
questionnaire after the intervention it did not translate into any association with ANA 
outcomes. This observation is also known from studies on guideline adherence.[11, 15] 
In summary, the baseline determinants work experience, personality and gender are 
associated with ANA overuse at baseline and improvement in ANA overuse after the 
intervention. The focus groups yielded many more potential determinants suggesting a 
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complex interplay of factors affecting ANA ordering behavior. Future research could focus 
on quantifying the relationship between the factors mentioned in the focus group and actual 
behavior. Furthermore, we hope that our results might help many more physicians to avoid 
doing unnecessary tests and to choose even more wisely. 
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SUPPLEMENT 2: METHODS AND RESULTS ON THE SELF-REPORTED 
DETERMINANTS OF IMPROVEMENT IN ANA OVERUSE
METHODS
To assess self-reported determinants of improvement in ANA overuse we organized focus 
group sessions. For pragmatic reasons, only in the largest center two 1.5 hour focus group 
meetings were held. Here, all 14 eligible rheumatologists received an invitation (email) 
explaining the purpose of the meeting. Both meetings were planned after regular working 
hours, took place at the study hospital and were led by a female psychologist-researcher 
(JV, PhD). A minimum of 4 and maximum of 8 participants could participate in one session.
Another female researcher (NL, MD) was present during the sessions to take field notes, 
but had no active role in the discussion. Both researchers worked at the study center and 
were known by the participating rheumatologists. No other people were present during the 
meetings except for the participants and the researchers.
During the focus group JV used an interview guide, which was prepared by NL, JV and AdB. 
Due to time constraints, pilot testing was not possible. The focus group started with a short 
introduction about its content, after which introductory questions were asked. This was 
followed by the main question “why did you change your behavior after the intervention, i.e. 
why are you now ordering less ANA tests compared to the period before the intervention”. 
Both sessions were audiotaped and transcribed verbatim. 
The transcripts of the focus groups were analyzed by NL and JV using thematic content-
analysis. Firstly, the transcripts were read by NL to identify text parts relevant to the 
identification of (sub) themes (open coding). Secondly, all these parts were separately 
double coded by two NL and JV (axial coding). Next, they compared codes and discrepancies 
between them were resolved by discussion. Thirdly, all codes were grouped into (sub) themes 
by NL and JV (selective coding). Finally, the results of the coding process were discussed 
with the other researchers (AdB, MH and RvV) and compared to existing frameworks on this 
subject [1-3], if necessary adaptations were made. 
RESULTS
During the focus group meetings seven major themes were identified as being of importance 
to ordering less ANA tests after the intervention. These themes related to 1) the intervention 
and study, 2) individual health professionals,3) patients, 4) professional interactions, 5) 
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incentives and resources, 6) capacity for organizational change and 7) social, political and 
legal factors (table 1). All these themes will be discussed below.
Theme 1: intervention and study factors. This theme comprised the subthemes study 
characteristics, study participation, quality of the intervention, content of the intervention, 
recommended behavior during the intervention and the research team. The majority of the 
codes were related to the content or quality of the intervention and the research team. 
For example, it was stressed by the participants that the content of the intervention was 
correct and refreshed existing knowledge, aiding their behavior change. 
“And of course you agree with the content, otherwise you wouldn’t do it…”
“What helped me enormously was actually the first talk, in which a few things that of 
course I already knew, became really clear. But that had simply drifted away.”
Participants mentioned that the enthusiasm of and trust in the research team, and the 
fact that the research team was known to the rheumatologists, were important factors for 
changing their ordering behavior. 
“An enthusiastic researcher, that has a mutually encouraging effect. And then you’re more 
likely to adjust your behavior than when some idiot says: shouldn’t you be ordering fewer 
tests?”
Theme 2: individual health professional factors. This theme comprised the subthemes 
clinical or previous clinical experience, knowledge & awareness, cognitions and professional 
behavior. Awareness was frequently mentioned as an important prerequisite for behavior 
change. Knowing or refreshment of existing knowledge on an ANA not being a perfect 
test was important for behavioral change, similar to being self-aware about own ordering 
behavior.
“The fact that it’s in actually a useless screening instrument was an extra eye-opener.”
Furthermore, participants indicated that their thoughts on ANA testing changed due to the 
intervention. Ordering less ANA tests was now seen as delivering high quality healthcare and 
not ordering an ANA test was being regarded as ‘cool’. Moreover, the rheumatologists felt 
relieved by the fact that it can also be okay not to order an ANA test.
“So in terms of content, you have a feeling that you’re now producing better work.”
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“I’ve been really good. In the past 3 months, I’ve only ordered one ANA…”
“The fact that someone says to you, ‘you don’t need to order those things’: what a relief…”
Finally, it was mentioned that participants broke their former routines and they felt 
confident with the new behavior.
Theme 3: patients. It was mentioned by one rheumatologist that after the intervention 
fewer patients with a possible ANA associated disease were seen at the study clinic, leading 
to less ANA orders. The other participants did not directly recognize this determinant and 
no other patient factors were mentioned.
Theme 4: professional interactions. All determinants in this theme related to team 
processes. For example, participants felt safe within the team, they were willing to change 
their behavior and they were triggered by the non-anonymous feedback given during the 
intervention leading to competition between participants. 
“I actually found it quite a challenge and so it’s become a bit of a game to order as few ANA 
tests as possible (…). After all, you want to be top of the class, don’t you.” 
Theme 5: incentives and resources. Financial (dis)incentives, nonfinancial (dis)incentives 
and assistance for clinicians were identified as subthemes. For example, potential cost 
savings by ordering less ANA tests, time constraints and the electronic health record system 
were referred to as influencing factors to change ordering behavior.
Theme 6: capacity for organizational change. Participants felt that the department had 
created a safe learning environment. In addition, the ANA study was regarded by the 
participants as fitting with existing policies on both hospital- and department level. 
“It’s actually the continuation of a trend that has been going on for years. That we’re 
simply taking decisions with respect to the diagnosis and treatment, based on evidence.”
Theme 7: social, political and legal issues. Within this theme participants only mentioned 
that societal concerns on (rising) healthcare costs influenced their behavior.
“With all the commotion surrounding the cost of healthcare, I think we need to look 
critically at our ordering behavior, that’s part and parcel of it too.”
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The Dutch Society for Rheumatology (NVR) has issued a top 5 list of wise choices as part 
of the ‘Choosing Wisely’ campaign in the Netherlands. This campaign has been set up by 
the Federation of Medical Specialists and the Netherlands Organization for Health Research 
and Development (ZonMw) and was inspired by the American ‘Choosing Wisely’ campaign. 
The aim of the campaign is to provide support for medical specialists and patients in taking 
decisions about appropriate care. One of the elements of the Choosing Wisely campaign 
is the formulation of ‘Wise Choices’ by the medical specialist organizations. This list of 
evidence-based recommendations is intended as a practical guide that will enable doctors 
and patients to decide together on the most appropriate care for the individual patient. 
Lists of wise choices have already been issued for various specialisms including internal 
medicine, neurosurgery, radiology, urology and orthopedics.
The NVR has now also prepared a list of five recommendations on patient-centered 
diagnostics and care. These recommendations were drafted by the NVR’s Quality Committee 
and assessed by the Council. In selecting the topics covered in the list, it was decided 
to focus on procedures that either occur frequently (measuring both ESR and CRP during 
follow-up of rheumatoid arthritis) or have a significant impact (doses of biological therapies 
that exceed the registered dose). The NVR hopes that this list will encourage its members 
to think about patient-centered care in rheumatology and that these five recommendations 
will be followed in daily practice so that patient-centered care will actually start to be 
delivered.
More information on the Choosing Wisely Netherlands campaign (including the publication 
of Wise Choices by the medical specialist organizations) is available at http://www.
kwaliteitskoepel.nl/verstandig-kiezen/. More information about the American Choosing 
Wisely campaign can be found at http://www.choosingwisely.org/ and http://www.
choosingwisely.org/societies/american-college-of-rheumatology/.
RECOMMENDATION 1
During the follow-up for patients with rheumatoid arthritis the preferred option is to 
request either a CRP test alone or an ESR test alone.
There is a high correlation between CRP and ESR, which means that there is no value in 
carrying out both tests at the same time in patients with rheumatoid arthritis (RA). Using 
the test characteristics (CRP has higher specificity than ESR), costs (ESR is cheaper than 
CRP) and other factors (CRP is less subject to influence by the age and sex of the patient), 
one of the tests can be excluded so that only either ESR or CRP is tested during the follow-
up of RA patients.
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Source: Crowson et al. Which measure of inflammation to use? A comparison of erythrocyte 
sedimentation rate and C-reactive protein measurements from randomized clinical trials 
of golimumab in rheumatoid arthritis. J Rheumatol 2009. Wolfe F. Comparative usefulness 
of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid 
arthritis. J Rheumatol 1997.
RECOMMENDATION 2
Prescribing doses of biological therapies that are higher than the registered dose is not 
appropriate.
Biological therapies, like other medications, are registered for a dose that has maximum 
effect at patient group level. Higher doses do little or nothing to increase effectiveness 
and are accompanied by an increase in side effects. In addition, such treatment is not cost-
effective. If a patient does not respond within 4 to 6 months of starting treatment, switch 
to a different anti-rheumatic therapy: this has a greater likelihood of producing a response 
than increasing the biological dose.
Source: Bongartz et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of 
serious infections and malignancies: systematic review and metaanalysis of rare harmful 
effects in randomized controlled trials. JAMA 2006. Pavelka et al. Increasing the infliximab 
dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm 
its efficacy. Ann Rheum Dis 2009.
RECOMMENDATION 3
Only request Lyme diagnostics if the patient has joint symptoms consistent with Lyme 
disease.
Joint symptoms with Lyme disease often present as asymmetrical monoarthritis or 
oligoarthritis, particularly of the knee. This means that Lyme diagnostics are only appropriate 
in rheumatology where patients have monoarthritis or oligoarthritis involving the knee 
and other causes have been excluded, or where patients have large joint monoarthritis 
or oligoarthritis and there are indications for Lyme borreliosis in the patient’s history (for 
example, a tick bite). Non-specific joint symptoms or tiredness in combination with a tick 
bite (or suspected bite) do not constitute indications for Lyme diagnostics.
Source: Dutch College of General Practitioners guideline for arthritis 2009 https://www.
nhg.org/standaarden/volledig/nhg-standaardartritis#note-5). Textbook on rheumatology 
and clinical immunology 2013.
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RECOMMENDATION 4
Only request an ANA test if history-taking and physical examination suggest a reasonable 
chance of an ANA-related disease.
25-30% of the healthy population has a positive ANA (low titer) and this high percentage of 
false positives means that ANA is not suitable as a screening test for rheumatic conditions. 
ANA testing only has value as part of the diagnostic process where a reasonable suspicion 
(based on history, physical examination and some additional tests) of an ANA-related disease 
exists. These relatively rare diseases (within the field of rheumatology) are: systemic lupus 
erythematosus, systemic sclerosis, polymyositis/dermatomyositis, mixed connective tissue 
disease and Sjögren’s syndrome.
Source: Solomon et al. Evidence-based guidelines for the use of immunologic tests: 
antinuclear antibody testing. Arthritis & Rheumatism 2002.
RECOMMENDATION 5
The preferred option is to prescribe a traditional NSAID such as ibuprofen, naproxen 
or diclofenac - if necessary in combination with PPI - rather than a selective NSAID 
(etoricoxib and celecoxib).
There is no difference in effectiveness at patient group level between traditional NSAIDs 
and selective NSAIDs. The risk of gastric complications is also equally high for users of 
traditional NSAIDs combined with a proton pump inhibitor as for users of a selective NSAID. 
The differences in other side effects are minimal. The cost of a coxib is significantly higher 
than for a traditional NSAID.
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ABSTRACT
Objectives
To examine the prevalence of abnormal creatine kinase (CK) and thyroid stimulating 
hormone (TSH) values and previously unknown myopathy or thyroid disease in patients 
with suspected fibromyalgia (FMS).
Methods
All adult patients with suspected FMS, referred to the study hospital between November 
2011 and April 2014 could participate. Patients with a history of myopathy or a previous 
diagnosis of thyroid disorder were excluded. Outcome measures were the percentages 
of abnormal CK and TSH values and the final diagnosis in those patients.
Results
373 patients were included in this study (94% female, mean age 42 years). 7.5% (95%-CI 
5.2% to 10.6%) of them had an abnormal CK according to the local reference values. 
Applying the European Federation of the Neurological Societies guideline this changed 
to 0.5% (95%-CI 0.2% to 1.9%). In none of these patients hyperCKemia related myopathy 
was diagnosed and the final diagnosis was FMS in 89% of the patients. 
3.5% (95%-CI 2.1% to 5.9%) of the patients had an elevated TSH and 1.4% (95-CI 0.6% 
to 3.1%) a lowered TSH, with one patient having an somewhat lowered Free Thyroid 
Hormone level. The final diagnosis was FMS in all these patients.
Conclusions
Abnormal CK and TSH values are rare in patients with suspected FMS, and do not result 
in an alternative diagnosis. Therefore, it seems that routine testing of CK and TSH levels 
in patients with suspected FMS referred to secondary care does not contribute to the 
diagnostic process.
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INTRODUCTION
Fibromyalgia syndrome (FMS) is a chronic pain syndrome mainly affecting women. The 
prevalence is around 2% and due to this high prevalence as well as its large impact on 
patients’ quality of life, FMS is a major health issue [1, 2]. In addition, due to disputes about 
aetiology, pathogenesis and classification, FMS still is a somewhat controversial disease [3, 
4]. 
FMS can be diagnosed using the preliminary 2010 American College of Rheumatology (ACR) 
diagnostic criteria. One of those criteria is the absence of another disease that causes the 
complaints [5]. Although not specifically included in these diagnostic criteria, numerous 
blood tests have been recommended as routine screening for patients with suspected FMS to 
exclude alternative diagnoses [6]. However, it is still unclear whether these tests contribute 
to the diagnostic process in patients with suspected FMS. 
Both creatine kinase (CK) and thyroid stimulating hormone (TSH) are frequently mentioned 
tests in the routine diagnostic work-up of FMS due to the presumed similarities between 
FMS and myopathies or hypothyroidism [4, 6-10]. However, the routine use of CK and TSH 
testing is, to our knowledge, not adequately supported by data. For example, there is no 
clear data to suggest that there is indeed a higher pre-test chance of myopathy or thyroid 
disease in patients with suspected FMS compared to the general population. Also, data is 
absent on the presumed increased chance of abnormal CK and TSH values in patients with 
suspected FMS compared to healthy controls. Finally, the added value of CK and TSH testing 
has not been assessed.
Our aim was therefore to explore the diagnostic value of CK and TSH testing in patients with 
suspected FMS. More specifically, we aimed to determine the prevalence of abnormal CK 
and TSH values and the prevalence of previously unknown myopathy or thyroid disease in 
patients with suspected FMS.
PATIENTS AND METHODS
Study design
This cross-sectional study is embedded in a study examining the prevalence of myotonic 
dystrophy type 2 among patients with suspected FMS. Details on the methods of the original 
study are described in a separate manuscript (under review). The methods relevant to our 
study will be described below.
The local ethical committee approved this study (CMO Nijmegen Arnhem: 3655109111) and 
all patients provided informed consent. 
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Setting and participants
All consecutive patients with suspected FMS referred to the outpatient clinic of the 
rheumatology department at the Sint Maartenskliniek (specialized hospital in rheumatology, 
orthopaedics and rehabilitation; the Netherlands) between November 2011 and April 2014 
were eligible for participation. Exclusion criteria were age <18 years, an established other 
diagnosis responsible for the pain and currently receiving Cognitive Behavioural Therapy (as 
participation in the original study might interfere with its goals). In addition, we applied an 
extra exclusion criterion in our current study: having an established diagnosis of myopathy 
or thyroid disorder. 
Outcome measures and data collection
Outcome measures were the percentage of patients with abnormal CK and TSH values and 
the final diagnosis in those patients. 
Baseline patient characteristics were retrieved from the patients’ charts (age, gender, 
medical history, final diagnosis, and if the patient was referred to the study centre as a 
second opinion). The latter characteristic was defined as the patient being seen in the last 
year by another secondary care specialist for the same complaints as presented during 
the first visit at the study centre. The final diagnosis (ICD-9 code) was determined by the 
treating rheumatologist using a protocolized diagnostic approach (history taking, physical 
examination, a neuromuscular questionnaire and the 2010 ACR FMS diagnostic criteria). 
Serum CK and TSH were determined in all patients at the clinical laboratory of the study 
centre. The reference values used in the study centre for a normal CK in men and women 
were <200 U/l and <170 U/l respectively. As there is debate on the reference values for 
CK, we also used the hyperCKemia values proposed by the European Federation of the 
Neurological Societies (EFNS).[11] According to this guideline hyperCKemia is present when 
CK ≥504 U/l for non-black men and ≥325 U/l for non-black women [11]. CK levels may vary 
within individuals (for example after physical exercise), therefore CK testing was repeated 
if the first test result was abnormal. A normal TSH was defined as a TSH between 0.4 and 4.0 
mE/l. Free Thyroid Hormone (FT4) was assessed when TSH was abnormal (reference values 
for normal FT4: 8 to 22 pmol/l). In case of abnormal TSH or FT4 values, no repeated testing 
was performed as TSH and FT4 values show no relevant day to day variation.[12] 
Data analysis
Statistical analysis was performed using STATA version 13.1. All outcome measures are given 
as percentages or means and include the 95%-confidence interval (95%-CI) or standard 
deviation (SD), as appropriate. A post-hoc sensitivity analysis was performed excluding 
patients seen as a second opinion.
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RESULTS
Setting and participants
All 398 patients included in the original study were considered for participation in this study. 
We had to exclude 23 patients because of known previous myopathy or thyroid disorder 
(figure 1). Due to missing data on CK and TSH values in 2 patients, 373 patients were 
included in the final analysis (mean age of 42 years ±11 years, 94% female). Of the patients 
with a final ICD-9 diagnosis of fibromyalgia, 92% fulfilled the ACR 2010 criteria (table 1). 
Figure 1 Study flowchart
Figure 1  Study flowchart 
 
 
Participation in original 
study  
(n = 398) 
Inclusion in final analyses 
(n = 373) 
 
Excluded 
� Previous diagnoses of thyroid 
disorder (n = 22) 
� Previous diagnosis of hyperCKemia 
related myopathy (n = 1) 
 Inclusion in this study  
(n = 375) 
Missing data on CK and/or TSH value 
(n = 2) 
  
•
•
Table 1 Characteristics of the patient population
Characteristics
Study population 
(n = 373)
Female sex, n(%) 354 (94%)
Mean age, years (range) 42 ± 11 (18 to 75)
Second opinion, n(%) 107 (29%)
Final clinical diagnosis, n(%)
Fibromyalgia 
Other*
358 (95%)
17 (5%)
*Other diagnosis were mono-arthritis; polyarthropathy or polyarthritis unspecified; ankylosing 
spondylitis/Bechterev’s syndrome; spondylosis; osteo-arthrosis; bursitis/enthesiopathy/synovitis; 
osteoporosis; arthropathy/arthralgia; hypermobility syndrome or Ehlers-Danlos syndrome and lumbago 
or neuralgia, neuritis or radiculitis, unspecified.
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Results of CK and TSH testing
The mean CK in our study population was 96 ± 50 U/L (range: 23 to 470 U/L) and the mean 
TSH was 1.8 ± 1.4 mE/L (range: 0.1 to 17.6mE/L). 
28 (7.5%; 95%-CI 5.2% to 10.6%) patients had an elevated CK according to the reference 
standard used at the study centre (range: 171 to 470 U/l). Using the EFNS reference standard, 
2 (0.5%; 95%-CI 0.2% to 1.9%) patients had an abnormal CK (357 and 470 U/l respectively). In 
both of these patients a repeated CK test was normal. No diagnosis of hyperCKemia related 
myopathy was given in any of the 28 patients with an abnormal CK, and their final diagnoses 
were fibromyalgia (n=25), osteoporosis (n=1), arthropathy/arthralgia (n=1) and ankylosing 
spondylitis (n=1).
18 patients had an abnormal TSH value, with 13 (3.5%; 95%-CI 2.1% to 5.9%) patients having 
an elevated TSH and 5 (1.4%; 95%-CI 0.6% to 3.1%) a lowered TSH. One patient with an 
elevated TSH had a slightly reduced FT4 (7.7 pmol/l). This was interpreted by the treating 
rheumatologist as subclinical hypothyroidism unrelated to the FMS complaints, and no 
further action was taken. The final diagnosis in all patients with abnormal TSH values was 
fibromyalgia.
A sensitivity analysis excluding all second opinion patients yielded similar results to the 
original analyses.
DISCUSSION
This study suggests that relevant abnormal CK and TSH values and a final diagnosis of 
underlying thyroid disease or hyperCKemia related myopathy are rare in patients with 
suspected FMS. Therefore, it seems that routine testing of CK and TSH in secondary care 
patients with suspected FMS does not contribute positively to the diagnostic process.
To our knowledge this is the first study assessing the diagnostic value of two commonly 
used test in suspected FMS. Some strong points of our study are the prospective design, the 
well-defined patient population and the relatively large sample size. However, this study 
has some limitations. Firstly, we were not able to compare the CK and TSH results against a 
gold standard. For example, muscle biopsies could have been taken to serve as the golden 
standard for myopathies. However, this was not deemed feasible in the context of our study. 
Instead, we used a combination of history taking, physical examination, a neuromuscular 
checklist and the ACR 2010 FMS criteria as, to our view, create a reasonable surrogate 
golden standard.
Secondly, there was a relatively high proportion of second opinion patients in our study, 
probably higher than in other rheumatology departments. However, the sensitivity analyses 
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with exclusion of 2nd opinion patients showed similar results. Therefore this does not seem 
to hamper the validity of our findings. 
Thirdly, patients may already have had their CK and TSH tested by the general practitioner. 
This could have caused a selection bias leading to underestimation of the prevalence of 
abnormal CK and TSH testing and associated diseases in our study. This because patients 
that were already diagnosed with thyroid disorder or hyperCKemia related myopathy would 
probably not have been referred to the rheumatologist for a FMS work-up. Although a valid 
concern, even if the majority of patients had received CK and TSH testing by the general 
practitioner this would not invalidate the generalisability of our results to other secondary 
care rheumatology departments. However, we would encourage the execution of a similar 
study in primary care.
In spite of widespread use of CK and TSH testing in suspected FMS and recommendations 
on this topic in some guidelines, our results do not contradict existing evidence. Although 
this may seem counterintuitive, this has to do with the earlier mentioned lack of data on 
CK and TSH testing in suspected FMS. Publications suggesting that routine CK or TSH testing 
is relevant in the diagnostic work-up of FMS [4, 6, 7] base this recommendation on the 
presumed similarity of symptoms between FMS and thyroid disease or myopathies. However, 
these recommendations are not based on prevalence data as provided in our study and also 
seem to ignore the very low prevalence of clinically relevant myopathies. 
Furthermore, for both CK and TSH studies on normal values in healthy controls are available. 
Regarding CK, the median value in healthy controls was 84 U/l and 122 U/l for women and 
men respectively [13]. With regard to TSH, the prevalence of abnormal TSH ranged from 
7.3% to 10.4% [14-16]. As our results come close to these results in the normal population, 
they support our conclusion of not using routine CK and TSH testing in suspected FMS 
patients. Based on these studies routine testing in suspected FMS patients would be just as 
irrational as routine testing in the whole general population.
Finally, with regard to CK testing there are some additional limitations. Several studies 
claim that CK in general is not a good test due to its low specificity. There is a wide variation 
in serum CK levels in the healthy population, dependent on physiological factors like sex, 
race and recent physical exercise [13, 17]. Therefore, the reference values for serum CK are 
subject to debate.[11] In our study the use of either strict or liberal reference values had a 
large impact on number of patients with abnormal values (28 versus 2 patients respectively), 
with the two highest CK values turning out to be false positives after repeated testing. 
Furthermore, elevated serum CK can reflect a muscular disorder but can also occur in other 
conditions such as hypothyroidism, drug use, alcoholism, muscle trauma, infections, and 
malignancies [18-20]. 
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In summary, it seems that routine CK and TSH testing did not contribute to the diagnostic 
process in any of the studied patients. Therefore, we recommend against the routine use of 
CK and TSH testing in patients with suspected FMS seen at a secondary care centre. However, 
elective testing in patients with signs and or symptoms suggestive of muscular or thyroid 
disease should still be done and be followed by appropriate diagnostic or therapeutic steps.
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ABSTRACT
Objectives
To examine the effects of an educational meeting and subsequent computer reminders 
on the number of ordered laboratory tests.
Methods
Using interrupted time series analysis we assessed whether trends in the number of 
laboratory tests ordered by rheumatologists between September 2012 and September 
2015 at the Sint Maartenskliniek (the Netherlands) changed following an educational 
meeting (September 2013) and introduction of computer reminders into the 
Computerized Physician Order Entry System (July 2014). The analyses were done for the 
set of tests on which both interventions had focussed (intervention tests; complement, 
cryoglobulins, immunoglobins, myeloma protein) and a set of control tests unrelated 
to the interventions (alanine transferase, anti-cyclic citrullinated peptide, C-reactive 
protein, creatine, haemoglobin, leukocytes, mean corpuscular volume, rheumatoid 
factor and thrombocytes).
Results
At study start 101 intervention tests and 7660 control tests were ordered per month by 
the rheumatologists. After the educational meeting both the level and trend of ordered 
intervention and control tests did not change significantly. After implementation of 
the reminders the level of ordered intervention tests decreased with 85.0 tests (95%-
CI -133.3 to -36.8, p <0.01), the level of control tests did not change following the 
introduction of reminders.
Conclusions
In summary, an educational meeting alone was not effective in decreasing the number 
of ordered intervention tests, but the combination with computer reminders did result 
in a large decrease of those tests. Therefore, we recommend using computer reminders 
additionally to education if reduction of inappropriate test use is aimed for.
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INTRODUCTION
Excessive use of diagnostic laboratory tests is a major problem in healthcare and has 
recently been recognized as an important field for research [1]. Not only does it constitute 
a waste of resources, it also results in an increased rate of false positives which may lead to 
further unnecessary testing, unnecessary treatment, and increased anxiety in both patients 
and physicians [1, 2]. Still, many clinicians order irrelevant laboratory tests despite the 
available information about unnecessary test utilization [2, 3]. 
A number of approaches have been used to reduce inappropriate testing using methods 
such as discouraging or not automatically fulfilling test orders, reducing availability of 
testing, giving feedback, raising awareness through education and the use of computer 
reminders [4]. Education, feedback and reminders are much used intervention strategies 
and although results differ between studies they have shown to be effective in different 
settings, including the reduction of unnecessary test orders [5-8]. 
A substantial proportion of diagnostic laboratory tests that were ordered at the rheumatology 
department of the study centre were tests that are not, or only very rarely, indicated for 
use in patients with a suspected rheumatic disease. This concerned the following tests: 
complement, cryoglobulins, immunoglobulins, myeloma protein (M protein) and Anti-
Nuclear Antibodies (ANA). These tests were all ordered relatively frequently, are expensive, 
and overuse could easily lead to false positives and associated over-treatment. Therefore, 
the aim of this study was to examine the effect of two interventions on the number of 
ordered tests. Of note, ANA testing has been subject to a specific intervention which results 
are described elsewhere and was therefore not included in this study [9].
METHODS
Study design and setting
This is a controlled trial, using an interrupted time series design, on the effect of 
an educational meeting and subsequent introduction of computer reminders on the 
number of diagnostic tests ordered by 26 clinicians (15 rheumatologists, 7 residents, 4 
physician assistants and nurse practitioners) from the rheumatology department at the 
Sint Maartenskliniek (specialized clinic for rheumatology, orthopaedics and rehabilitation 
medicine; the Netherlands). 
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As this was a quality improvement project performed by researchers working at the study 
centre, no formal ethical approval was needed. Furthermore, no informed consent of the 
patients was asked as no individual patient data were needed to assess the effectiveness of 
the interventions. 
Interventions
An educational meeting regarding the intervention tests (complement, cryoglobulins, 
immunoglobulins and M protein; table 1) took place in September 2013. This meeting consisted 
of a 1-hour educational meeting, presented by two experienced medical immunologists 
working at the external laboratory where the intervention tests were performed. During 
the meeting background information on the intervention tests was provided and the rare 
indications in daily rheumatology practice for these tests were explained. Clinicians were 
advised not to order test tests unless specific signs or symptoms were present. At the time 
of the educational meeting 26 clinicians (15 rheumatologists, 4 physician assistants and 7 
residents) were working at the rheumatology department, all were invited for the meeting. 
Table 1 Intervention and control tests used in this study 
Intervention tests Pop-up text
Complement 3 (C3) There is no indication within rheumatology for complement testing. One 
exception is C3 testing in the follow up of systemic lupus erythematosus 
to assess the risk of nephritis or neuro-psychiatric systemic lupus 
erythematosus although the evidence is limited. When clinical signs of 
complement deficiency disease are present, do not test for complement 
but refer to the internal medicine department.
Complement 4 (C4)
Cryoglobulins Cryoglobulins testing is only indicated in cutaneous vasculitis and/or 
mononeuritis, and when there are signs of hyperviscosity syndrome.
Immunoglobulin A (IgA) There is no indication within rheumatology for measurement of 
immunoglobulins. There is a limited association with the presence of a 
rheumatic disease, and abnormal results have no clinical consequences. 
Only in the analysis of recurring infections and when monitoring gamma 
globulin therapy, testing is recommended.
Immunoglobulin G (IgG)
Immunoglobulin M (IgM)
M protein There is no indication within rheumatology for assessment of 
monoclonal gammopathy. In case of a suspected haematologic 
malignancy referral to the haematology or internal medicine 
department is necessary, independent of a M protein result. Therefore, 
testing by rheumatologists is not needed
Control tests 
Alanine transaminase (ALT) Leukocytes
Anti-cyclic citrullinated 
peptide (anti-CCP)
Mean corpuscular volume (MCV)
C-reactive protein (CRP) Rheumatoid factor (RF)
Creatine Thrombocytes
Haemoglobin 
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In July 2014 computer reminders were incorporated into the Computerized Physician Order 
Entry system, which is linked to the Electronic Health Record (EHR) used at the study centre 
(EZIS 5.2, Chipsoft). The reminders functioned as follows: whenever a clinician tried to 
order one of the intervention tests a pop-up message appeared explaining in which specific 
rheumatology-related situation the test was indicated or not (table 1). If clinicians still 
wanted to order the test, a text field was shown asking the reason for ordering the test. 
The intervention tests could only be ordered if a reason was entered although there was 
no check whether the reason was valid. Both the educational meeting and the computer 
reminders were available for all clinicians ordering laboratory tests at the rheumatology 
department. The development of the reminders was a collaboration between the laboratory 
and rheumatology department. 
The content of each reminder was created by 3 rheumatologists, including an expert on 
systemic diseases and the coordinator of the laboratory.
Outcome measures and data collection
The primary outcome of this study was the number of intervention and control tests ordered 
by clinicians working at the study clinic. Data on the outcomes are measured at equally 
spaced (monthly) intervals over the study period (September 2012 to September 2015). The 
control tests were a set of simple routine tests at which no intervention was targeted (table 
1). These were included to control for time trends in clinicians’ ordering behaviour that 
were unrelated to the interventions. 
Secondary outcomes were the percentage of abnormal intervention test results and the 
percentage of valid reasons provided with the intervention test orders after implementation 
of the reminders, as judged by two experts. 
Data on the number of intervention and control tests ordered by included clinicians were 
collected retrospectively using the local laboratory database. Data was collected for 
the twelve months before any intervention (pre-intervention period; September 2012 to 
September 2013), 10 months after the educational meeting but before implementation of 
the computer reminders (post-intervention period 1; September 2013 to July 2014), and the 
14 months after computer reminders were implemented (post-intervention period 2; July 
2014 to September 2015).
Data analysis
Statistical analyses were performed using STATA version 13.1. Depending on the type of 
variable, descriptive statistics are presented as percentages with the accompanying 
absolute numbers or as means.
To assess the impact of the two interventions on the numbers of tests ordered segmented 
regression analysis of interrupted time series analysis (ITSA) was used. Using ITSA we were 
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able to detect whether or not our interventions had a significantly greater effect than any 
underlying secular trend [10]. The segmented linear regression models included two change 
points (education and reminders) in order to estimate changes in the level and trend of the 
number of ordered tests after the change points. Separate regression models were run for 
the intervention and control test data. Sensitivity analyses assessing the impact of possible 
autocorrelation between measurements of consecutive months were performed. Of note, 
due to the order of implementation of the interventions, the effect of education is relative 
to the pre-invention period and the estimated effect of reminders is the additional effect 
of reminders on top of the educational intervention. Results are reported as regression 
coefficients (level and trend) with the corresponding 95% confidence interval (95% CI) and 
p-value.
A chi square test was used to compare the number of abnormal results over the three 
periods. Outcomes were defined as statistical significant if p<0.05. 
RESULTS
23 out of the 26 clinicians attended the educational meeting (15 out of 15 rheumatologists, 
all 4 of the physician assistants and 4 out of 7 residents), which was received positively and 
discussed critically.
At the start of the pre-intervention period 101 intervention tests were ordered per month 
(level) and during the pre-intervention period the number of ordered intervention tests 
increased with 2.8 test per month (non-significant; trend). After the educational meeting 
the number of intervention tests ordered remained stable, with no significant changes in 
level or trend. After implementation of the reminders, the level of ordered intervention 
tests decreased significantly with 85.0 tests (95%-CI -133.3 to -36.8, p <0.01) although the 
difference in trend was non-significant (1.06, 95%-CI -6.2 to 8.3, p= 0.77). With regard to 
the control tests, 7660 tests were ordered at the start of the pre-intervention period. None 
of the two interventions resulted in a significant change in either the level or the trend of 
ordered control tests. The results are also graphically depicted in figure 1.
In the analysis of intervention and of control test, the autocorrelation function and the 
Durbin-Watson tests (up to order 10) showed little indication of autocorrelation between 
consecutive months. Sensitivity analyses modelling autocorrelation (up to order 10) were 
performed. These did not substantially improve fit and led to the same conclusion for the 
interventions.
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Figure 1 Number of intervention and control test orders per month
Similar to the numbers of intervention tests ordered, the percentage of abnormal test results 
did not change (pre-intervention period 17.7% and 17.4% after the educational meeting, p= 
0.83). Comparable results were obtained for the period following the reminders with the 
percentage of abnormal intervention test results being 18.4% (p= 0.73). 
Finally, all intervention tests ordered after the implementation of the reminders included 
a clearly worded reason. However, only 34% of those reasons were judged to be valid. In 
addition, this did not make any difference regarding the percentage of abnormal test results 
in this subgroup with18.8% being abnormal (p= 0.89). 
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DISCUSSION 
In this study we observed that an educational meeting alone was not effective, however 
addition of targeted computer reminders did give a substantial decrease in the number of 
orders for intervention tests while the number of control test orders did not change. 
The strengths of our study are the use of an interrupted time series design, the inclusion 
of control tests and the stepwise independent use of two different and relatively simple 
interventions. However, some limitations are also present. Firstly, the educational meeting 
and the implementation of computer reminders were available to all clinicians, meaning 
that after implementation we did not have a control group of intervention tests without 
being subject to the intervention. However, we did include a selection of routine laboratory 
tests as a control group to see whether a change in the number of intervention tests ordered 
could be caused by an overall change in test ordering behaviour. Secondly, when only looking 
at the intervention tests, we are not able to infer a definite causal relation between our 
intervention and the results afterwards because other events in the same time period might 
have attributed to the observed results. However, as no changes were observed in the 
number of ordered control tests after the implementation of the computer reminders, it is 
very unlikely that another event in the same time period caused the observed decrease in 
the number of intervention tests. Furthermore, the number of patients seen at the study 
clinic was relatively stable over the full study period (data not shown), excluding this as 
a reason for the observed results. Finally, a steady increase in the number of ordered 
intervention tests is visible near the end of the observation period. Although the difference 
in trend between the pre-intervention period and the period after intervention 2 was non-
significant, the increase may continue past the end of this study. Therefore we plan to 
replicate our analysis in the future to extend our current follow-up period.
The lack of effect from the educational meeting alone in our study corresponds with 
previous research suggesting that education is a necessary but on its own insufficient 
intervention to reduce test ordering. Strengthening this conclusion is the fact that nearly 
all of the departments clinicians (23 out of 26) attended the educational meeting, meaning 
that the lack of effect from the educational meeting is not likely to be a result of a lack of 
attendance. A factor that could explain the lack of effect from the educational meeting is 
that it was provided by two immunologists from another hospital. This may have reduced 
the acceptance as one of our previous studies regarding a similar intervention showed that a 
familiar intervention team was an important factor for clinicians in changing their ordering 
behaviour (manuscript under preparation). Furthermore, our study confirms previous 
observations that education has a stronger effect when combined with other interventions 
[4, 11]. In addition, the effect of the computer reminders corresponds to other studies. 
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These studies also found the reminders to be effective, although this usually concerned 
smaller effects than observed in our study [5]. 
Other than the combination between education and computer reminders, three other 
factors are likely to have contributed to the effect of reminders observed in our study. 
Firstly, previous studies have shown that reminders are more successful if they interrupt 
in the practitioner’s routine and are delivered at the time of decision making [12]. Both 
factors were incorporated with our reminder system, as reminders were shown directly after 
selecting one of the intervention tests in the CPOE system. Secondly, the intervention tests 
in this study were not ordered very frequently, even before any intervention. This means 
that the risk of pop-up fatigue, a weakness of computer reminders where overly frequent 
pop-ups get ignored after some time, was limited [11, 13]. However, pop-up fatigue may 
not have been completely avoided as the number of ordered intervention tests is slowly 
increasing again near the end of the study period. Thirdly, the pop-up text was created in 
collaboration by 3 of the department’s rheumatologists and a laboratory coordinator, which 
may have increased the acceptance of the pop-ups compared to a situation where someone 
from outside the clinic was responsible for the pop-ups.
In addition to the number of tests ordered, we also assessed the percentage of abnormal 
test results. One would expect that a reduction in the number of unnecessary tests would 
also increase the proportion of correctly ordered tests and therefore an increase in the 
percentage of abnormal results. Contrary to this, the percentage of abnormal test results 
did not change, which may seem counterintuitive. However, this can be explained by the 
observation that only 34% of the reasons provided with the intervention test orders were 
valid, making it likely that patient selection by clinicians is still suboptimal. This is further 
supported by the fact that the percentage of abnormal test results did not differ between 
the intervention tests ordered with a valid reason and those without one, which means that a 
higher percentage of correctly ordered tests would not necessarily increase the percentage 
of abnormal results. This lack of difference in the percentage of abnormal results could 
indicate that even for patients with a valid reason for testing the test may not be useful in 
the majority of patients. In other words, overuse of intervention tests by clinicians is still 
present, although to a lesser extent than before the interventions. 
In summary, the educational meeting alone was not effective in decreasing the number 
of ordered intervention tests, but the combination with computer reminders did result 
in a large decrease of those tests. Therefore, we recommend using computer reminders 
additionally to education if reduction of inappropriate test use is aimed for.
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ABSTRACT
While most rheumatology practices are characterized by strong commitment to quality 
of care and continuous improvement to limit disability and optimize quality of life for 
patients and their families, the actual step towards improvement is often difficult. 
This because there are still barriers to be addressed and facilitators to be captured 
before a satisfying and cost-effective practice management is installed. Therefore this 
review aims to assist practicing rheumatologists with quality improvement of their daily 
practice, focusing on care for rheumatoid arthritis (RA) patients. 
First we define quality of care as ‘the degree to which health services for individuals 
and populations increase the likelihood of desired health outcomes and are consistent 
with current professional knowledge’. Often quality is determined by the interplay 
between structure, processes and outcomes of care, which is also reflected in 
corresponding indicators to measure quality of care. Next, a brief overview is given 
of the current treatment strategies used in RA, focusing on the tight control strategy, 
since this strategy forms the basis of international treatment guidelines. Adherence to 
tight control strategies leads, also in daily practice, to better outcomes in patients with 
regard to disease control, functional status and work productivity. Despite evidence 
in favor of tight control strategies, adherence in daily practice is often challenging. 
Therefore, the next part of the review focuses on possible barriers and facilitators 
of adherence, and potential interventions to improve quality of care. Many different 
barriers and facilitators are known and targeting these can be effective in changing 
care, but these effects are rather small to moderate. With regard to RA, few studies 
have tried to improve care, such as a study aiming to increase the number of disease 
activity measures done by a combination of education and feedback. Two out of the 
three studies showed markedly positive effects of their interventions, suggesting that 
change is possible. Finally, a simple step-by-step plan is described, which could be used 
by rheumatologists in daily practice wanting to improve their RA patient care. 
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INTRODUCTION
Musculoskeletal disorders, such as gout, osteoarthritis and rheumatoid arthritis (RA) are 
considered to be among the most burdensome medical conditions (1). This has led to the 
execution of many randomized controlled trials (RCTs) that have provided evidence for the 
best therapeutic interventions for these diseases. Despite this constant stream of evidence 
based recommendations, the translation into daily practice is often suboptimal (1). 
While many practicing rheumatologists will agree that quality of care is an important 
aspect in rheumatology, the actual step to improve quality of care is often difficult, since 
rheumatologists do not know where and how to start, and there are no clear strategies 
available how to approach improvement of quality of care in their clinical practice. 
This review, with the goal of assisting practicing rheumatologists with their own quality 
improvement of care, aims to fill this gap. It starts with a brief general introduction on 
quality of care and how to measure this. Thereafter, the focus will shift to RA and we will 
discuss what optimal RA care is, how we can measure whether quality demands are met or 
not, and how this could be improved. In the latter part, two case descriptions of successful 
quality improvement projects in RA will be discussed. Finally, we will give practical 
recommendations to rheumatologists who want to further improve their own performance. 
A. WHAT IS QUALITY OF CARE AND HOW CAN YOU MEASURE IT?
Quality of care in itself is a rather abstract term, but more practical descriptions do exist. 
One of the most used descriptions, developed around 1980 by Donabedian, distinguishes 
structures, processes and outcomes of care (2). The structure of care describes aspects 
of the setting in which care is delivered, such as the number of rheumatologists or the 
presence of a treatment protocol. Next, the process of care describes the actions of the 
health care professionals, for example, whether the protocol is indeed followed. Finally, 
the outcome reflects the effect of the given care in terms of mortality, morbidity and health 
status. It is believed that more desirable outcomes are obtained if the structure of care 
provides the opportunity to deliver the most optimal care processes (fig 1). 
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Figure 1: the Donabedian Triad. Donabedian hypothesized that all elements are linked to each other 
(3)
Around 1990, the Institute of Medicine (IOM) defined quality of care as ‘the degree to which 
health 
services for individuals and populations increase the likelihood of desired health outcomes 
and are consistent with current professional knowledge.’ Furthermore the IOM formulated 
the following six criteria that pertain to quality of care; Care should be i) safe; ii) effective; 
iii) patient-centered; iv) timely; v) efficient; and vi) equitable (4),. When using these 
criteria it is important to take into account the different perspectives of the stakeholders 
(patients or health insurers, for example) (5).
Knowing how to describe quality of care is a prerequisite for its measurement. Often quality 
indicators are used to assess quality of care. A quality indicator is ‘a measurable element 
of practice performance for which there is evidence or consensus that it can be used to 
assess the quality, and hence change the quality of care provided’(6). Quality indicators are 
often grouped using the before mentioned quality definition by Donabedian, thus providing 
structure-, process- and outcome indicators. Outcome indicators reflect the result of the 
care that was provided by the healthcare provider, while process indicators reflect the 
actual care given to patients (‘what is done’). Structure indicators, on the other hand, 
describe organisational aspects (‘what is available’) (7). How these indicators are used 
within rheumatology will be described later in this review; we will now first describe what 
optimal care in RA is. 
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B. WHAT IS OPTIMAL RHEUMATOID ARTHRITIS CARE?
The treatment of RA has substantially improved during the last two decades. Until 1990 the 
use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) was limited, due to the belief that 
DMARDs were too toxic to use for a non-life threatening disease such as RA (8-10). Obviously, 
these assumptions changed and in the following decades the importance of DMARDs, both 
synthetic and biological, in the management of RA has become more obvious. This has 
resulted in treatment strategies such as a step-up approach and combination therapy, as 
well as treat-to-target strategies (8-10). 
Improvements in care for RA patients have not only been the result of an increase in the 
number of effective therapeutic options, but also because of broader insight into the course 
of the disease and its prognosis. For example, it became clear that active RA is associated 
with a high risk of cardiovascular morbidity and mortality. Furthermore, it was found that 
RA treatment should start as early as possible (in the so called ‘window of opportunity’) in 
order to prevent the occurrence of irreversible joint damage or at least to halt progression of 
the disease (11, 12) Other terminology used in this context is ‘hit hard, hit early’ (intensive 
treatment early in the disease course) and ‘tight control’. Although tight control is the 
mainstay of optimal clinical RA care, it is not the only part of good RA care. Shared care 
with specialized nurses or physician assistants, cardiovascular risk management and the 
management of comorbidities are some examples of other important aspects of RA care. As 
we cannot cover all these aspects and the tight control principle currently forms the basis 
of major treatment guidelines, we will now focus on this strategy (13, 14). 
Tight control, also called treat to target, can be defined as ‘frequent assessment of disease 
activity combined with an objective structured protocol to make treatment changes 
that maintain low disease activity or remission at an agreed target’ (15). Recently, an 
international task force provided an update of the 2010 treat to target recommendations 
(14). These recommendations describe a generic principle or strategy, not necessarily 
advocating a particular type of intervention, that should be adhered to in order to reach 
disease remission or low disease activity in RA patients. The four overarching principles and 
ten recommendations focus around shared decision making, the importance of setting a 
treatment target, measuring disease activity, changing treatment until the desired goal is 
reached and maintaining the treatment goal thereafter (14). 
Various studies have proven the effectiveness of the tight control regime, with the TICORA 
(Tight Control of Rheumatoid Arthritis) study being one of the first to show the beneficial 
effects of tight control. In the TICORA study, patients in the tight control group had a 
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significantly better disease outcome after 18 months as compared to the control group with 
regard to the EULAR good response criteria (82% vs 44%, p<0.0001) and the mean decrease 
in Disease Activity Score (DAS; -3.5 vs -1.5, p<0.0001) (11). 
After the TICORA study, several studies have replicated these findings and in 2010 a meta-
analysis on the effects of tight control was published. This meta-analysis concluded that 
patients treated according to tight control principles had significantly better DAS-28 
responses as compared to patients treated with usual care (mean difference = 0.59; p < 
0.001) (16). In addition, they also compared tight control with- and without protocolized 
treatment adjustments. These comparisons showed a beneficial effect of protocolized 
treatment adjustments, with the DAS-28 decreasing 0.66 points more (95% CI 0.72 to 1.11; 
P < 0.0001) if a specific treatment protocol was used. Also, an improvement in functionality 
and a decrease in joint damage was observed (16). 
Although tight control studies so far have focussed on reaching remission or low disease 
activity, secondary analyses have shown that lower disease activity is also associated with 
improved work productivity, less comorbidity and lower cardiovascular risk (17). This may 
imply that applying tight control in daily practice benefits RA patients with regard to disease 
control and important other aspects of their lives such as work. 
In summary, due to the complexity of RA and the increasing treatment arsenal, it can be 
difficult for rheumatologists to provide optimal RA care in all patients. However, it seems 
that using tight control based treatment strategies could assist rheumatologists in achieving 
low disease activity or remission in the majority of their patients, ensuring better clinical 
outcomes and promoting better work productivity, less comorbidity and lower cardiovascular 
risk (17).
C. HOW CAN WE MEASURE WHETHER OPTIMAL RHEUMATOID ARTHRITIS 
CARE IS PROVIDED?
As mentioned in the first section, quality of care can be assessed using predefined quality 
indicators for the structure, processes and outcomes of care (6,7). With regard to RA, a 
broadly accepted set of quality indicators is lacking. However, several groups around the 
world have made an attempt to develop sets of RA quality indicators. In the following 
paragraphs some of these indicator sets will be discussed. 
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Dutch researchers have described one of the first sets, designed to monitor RA disease 
course in the Dutch Rheumatoid Arthritis Monitoring (DREAM) cohort. This indicator set 
consists of 10 process-, 5 structure- and 3 outcome-indicators and is divided into different 
subcategories. These subcategories are: the measurement of disease activity, structural 
damage, functionality, follow-up frequency, intensification of pharmacological therapy, 
prerequisites for measuring disease activity and patients’ disease activity (for example the 
percentage of RA patients in remission one year after diagnosis) (18). 
Two other groups in Europe have also developed sets of quality indicators. Firstly, the 
National Health Service in England (NHS) has developed quality indicators for RA, along with 
indicators for other diseases, in order to standardize improvements in the delivery of primary 
care (19). Management of RA in primary care may include; checking for cardiovascular risk 
and blood pressure, checking the risk for osteoporosis and checking for signs of depression. 
During an annual meeting in primary care the effects of the disease upon a person’s life 
can be assessed, for example by monitoring the side-effects of medication or assessing the 
psychological situation of the patient. The NHS indicator sets reflects this care and comprises 
one structural-, one outcome-, and two process indicators, subdivided in two domains. The 
first domain is ‘records’(19). This domain documents whether the primary care physician 
establishes and maintains a register for patients of 16 years and older with RA. The second 
domain is ‘ongoing management’. In this domain, for example the documentation of the 
percentage of patient who had an annual face to face meeting with general practitioner in 
the preceding 12 months is documented (19). 
The second European indicator set is developed by the European Musculoskeletal Conditions 
Surveillance and Information Network (EUMUSC.NET) and contains 14 indicators (one 
outcome, two structural and 11 process indicators) (20). To our knowledge, the EUMUSC.NET 
has not divided these indicators in domains. Therefore, we decided to divide this extensive 
list of indicators into six domains, namely; organisation, screening, pharmacological 
treatment, non-pharmacological treatment, monitoring and outcome. These indicators 
are also stated in table 1, where they can be compared with the American College of 
Rheumatology (ACR) indicators. 
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In the United States, the Arthritis Foundation and the ACR have also developed sets of 
indicators The extensive set from the Arthritis Foundation comprises 27 process indicators 
and they can be divided in 17 domains being: time to referral, history and examination, 
regular follow up, radiographs of hand and feet, radiographs of cervical spine, DMARDs, folic 
acid with methotrexate (MTX), osteoporosis prophylaxis, use of glucocorticoids, exercise, 
assistive devices, surgery, baseline and follow-up studies, methotrexate transminitis 
(increases in aminotransferases), informing patients about risks (such as risks regarding 
the use of non-steroidal anti-inflammatory drugs (NSAIDs), DMARDs, glucocorticoids and 
narcotics), reproductive issues and finally vaccines (21).The set developed by the ACR 
includes five process indicators and one outcome indicator. We have grouped these indicators 
in the following domains; screening, pharmacological treatment and monitoring, as to our 
knowledge no domains were proposed by the research team. The indicators from this set are 
also stated in table 1 for illustrative purposes (22).
An international task force developed a set of 10 quality indicators, using the Measurement 
of Efficacy of Treatment in the Era of Outcome in Rheumatology (METEOR) database. This 
set consists of seven process indicators and three outcome indicators; time to diagnosis, 
antibodies and radiographic assessment, frequency of visits, disease activity assessment, 
functional status assessment, remission of disease activity (clinical remission), low disease 
activity, level of functional limitation, time to first DMARD and type of first DMARD (23). 
 
Finally, the Australian Rheumatoid Association has proposed a set of three process indicators. 
These indicators cover measurement of disease activity and co-morbidities (24). 
Looking at these seven sets, obviously the majority of these indicators include process 
measures. Of the 82 indicators, only 9 were outcome indicators, (18-24). The majority 
report the ‘number of times’ a certain outcome is measured (process), rather than the 
actual outcomes themselves. When thinking back to the triad suggested by Donabedian, 
which links process, structures and outcome of care to each other, an imbalance between 
the different types of indicators in the current sets is quite apparent (2, 7). Furthermore, the 
availability of many sets from which to choose may further jeopardise the implementation 
in daily practice. In conclusion, a better-balanced (more outcome, less process) and more 
widely accepted indicator set would be instrumental in achieving uniform measurement 
of RA care. In the meantime, a rheumatologist willing to measure the quality of his own 
practice should choose one of the available indicator sets which best reflects what one 
wants to measure.
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D. IS OPTIMAL CARE DELIVERED TO RHEUMATOID ARTHRITIS PATIENTS?
As described in this review, the use of tight control strategies is beneficial to RA patients 
and major treatment guidelines have embraced the tight control strategy (11, 13, 15). 
Unfortunately, the existence of these guidelines and the underlying evidence for their 
efficacy seems to be insufficient to ensure application of tight control in daily practice. This 
issue has been addressed by several studies, with rather underwhelming results. Here we 
will briefly summarize some of these studies. 
Benhamou et al, assessed the potential gap between daily practice and recommendations 
on first DMARD prescription in RA in the French multicenter ESPOIR cohort (25). This cohort 
included early RA patients between 2002 and 2005, and during this period two guidelines 
on DMARD treatment in early RA were introduced: the national guideline by the French 
Society of Rheumatologists (STPR guideline) and the international set of management 
recommendations by the European League Against Rheumatism (EULAR guideline). Benhamou 
et al observed that first DMARD prescriptions in early RA were performed according to STPR 
recommendations in 58% of the patients, while 54% of the prescriptions adhered to the 
EULAR guidelines. As both guidelines were presented at international conferences at the 
end of the ESPOIR inclusion period, the authors concluded that the potential gap between 
evidence and practice was substantial (25). 
Around the same time another European study assessed treatment patterns in early RA 
patients (ERAN cohort) (15). In this cohort 97% of the patients were prescribed a DMARD; 
however, median time between onset of the RA symptoms and DMARD prescription was 8 
months. Most often the first DMARD was prescribed as monotherapy (91%) and the addition 
of a second DMARD later in the treatment course was observed in 48%. Despite the high 
percentage of DMARD users, only 33% of the patients were in DAS-28 remission after three 
years (15).
Also in the United States the prescribing practices of rheumatologists were assessed. In 
contrast to the ESPOIR and ERAN cohort, this study also included biologic DMARD (bDMARD) 
prescriptions and compared adherence before- and after the publication of the ACR 
treatment recommendations (26). In this study, 43% of the MTX monotherapy users with 
moderate disease activity and poor prognosis received care according to the ACR guideline; 
in MTX monotherapy users with high disease activity this was 51%. In patients using multiple 
conventional synthetic DMARDs (csDMARDs), 43% and 51% of those with moderate or high 
disease activity respectively, received care consistent with the ACR guideline. Interestingly, 
the publication of the ACR guideline did not result in improved guideline adherence in 
patients with active disease (26).
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The results of these three studies may seem rather disappointing. However, a Dutch study 
on guideline adherence in the DREAM remission induction cohort yielded more positive 
results (27). In this early RA cohort, adherence to adequate monitoring of disease activity 
(DAS-28 assessed at least every 3 months) and a predefined treatment protocol was 
assessed. The researchers observed that adequate monitoring of disease activity took place 
in 88% of the visits and in 69% of the visits the rheumatologist adhered to the treatment 
recommendations. According to the authors these results point to the feasibility of using a 
tight control strategy in daily practice (27). 
Finally, in another study using data from the ESPOIR cohort it was observed that adherence 
to tight control strategies in daily practice may have real benefits for patients (28). It 
was found that early RA patients who were not treated according to the 2007 EULAR 
recommendations on early RA were at an increased risk of radiographic progression at 1 year 
and functional impairment at 2 years (odds ratio (OR) 1.98;1.08 to 3.62) and OR 2.36;1.17 to 
4.67 respectively) (28). In addition two studies presented at the 2014 ACR annual meeting 
concluded that RA disease control was better in patients in whom a tight control strategy 
was actively applied than in patients in whom this was not the case (29, 30).
Overseeing the literature described in this section, we can conclude that application of a 
tight control strategy in daily practice is feasible, but general adherence is not yet optimal 
(14, 24-29). In addition we saw that suboptimal adherence may have negative consequences 
for patients with regard to disease control, radiographic progression and functional status.
E. HOW CAN YOU IMPROVE RHEUMATOID ARTHRITIS CARE?
We have learned from various studies described in the previous section that optimal RA 
care is not always delivered to patients. The main question now is: how can we improve RA 
care? In order to answer this question we will look to the field of implementation science, 
an area specifically focusing on bridging the gap between evidence and clinical practice. 
First we will describe which factors can influence the successful uptake of evidence by 
physicians (also called ‘barriers and facilitators’ to implementation). Thereafter, potential 
interventions to change clinical practice are described.
Factors influencing adherence to evidence-based recommendations
Many studies have made an attempt to understand barriers and facilitators associated with 
implementing change and consequently different checklists, frameworks and taxonomies 
have been developed. In 2013 a systematic review by Flottorp et al was published, describing 
the development of a comprehensive checklist (TICD checklist), integrating previous 
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checklists, frameworks and taxonomies (31). In this review ‘barriers and facilitators to 
implementation’ are called ‘determinants of practice’, and the developed checklist consists 
of 54 of such determinants. The determinants are subdivided in seven domains, namely: 
guideline factors; health professional factors; patient factors; professional interactions; 
incentives and recourses; capacity for organizational change; social, political and legal 
factors (table 2). According to the authors this checklist can be used as a screening tool 
to identify determinants that need further investigation before a particular change can be 
implemented. The underlying idea is that this can facilitate the development and evaluation 
of interventions tailored to specific determinants (31). This hypothesis will be discussed 
further when potential interventions to change practice are described.
Table 2: Overview of the domains and determinants of the TICD checklist
Subdomain Determinant
Domain 1: Guideline factors
Recommendation Quality of evidence supporting the recommendation
Strength of recommendation
Clarity
Cultural appropriateness
Accessibility of the recommendation
Source of the recommendation
Consistency with other guidelines
Recommended clinical intervention Feasibility
Accessibility of the intervention
Recommended behavior Compatibility
Effort
Trialability
Observability
Domain 2: Individual health professional factors
Knowledge and skills Domain knowledge
Awareness and familiarity with the recommendation
Knowledge about own practice
Skills needed to adhere
Cognitions (including attitudes) Agreement with the recommendation
Attitudes towards guidelines in general
Expected outcome
Intention and motivation
Self-efficacy
Learning style
Emotions
Professional behavior Nature of the behavior
Capacity to plan change
Self-monitoring or feedback
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Domain 3: Patient factors
n/a Patient needs
Patient beliefs and knowledge
Patient preferences
Patient motivation
Patient behavior
Domain 4: Professional interactions
n/a Communication and influence
Team processes
Referral processes
Domain 5: Incentives and resources
n/a Availability of necessary resources
Financial incentives and disincentives
Nonfinancial incentives and disincentives
Information system
Quality assurance and patient safety systems
Continuing education system
Assistance for clinicians
Domain 6: Capacity for organizational change
n/a Mandate, authority, accountability
Capable leadership
Relative strength of supporters and opponents
Regulations, rules, policies
Priority of necessary change
Monitoring and feedback
Assistance for organizational changes
Domain 7: Social, political and legal factors
n/a Economic constraints on the health care budget
Contracts
Legislation
Payer or funder policies
Malpractice liability
Influential people
Corruption
Political stability
As described in table 2, many factors can influence the translation of research into practice, 
with the diffusion and dissemination of innovations facilitated or hindered by these factors. 
The TICD provides a comprehensive overview of these factors, but for the practicing 
rheumatologist in search of feasible tools to improve his own practice, this checklist can 
be difficult to apply. In our opinion, and partly based on own experience, we would suggest 
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that successful implementation of change in daily practice relies mainly on three domains: 
1) knowledge about the desired change, 2) motivation to realize the change and 3) being 
able to apply the new behavior. 
Potential interventions to improve care
Recommendations or guidelines can assist rheumatologists in providing optimal clinical care 
to RA patients, but we have also seen that implementation of guidelines is often difficult 
(1, 14, 24, 25). In the previous section we have discussed studies that have identified many 
factors that may influence the successful implementation of change. Now the question 
remains what types of interventions could be applied to improve care and how effective 
they are.
Before answering this question we will first summarize the types of interventions that do 
exist. The Effective Practice and Organization of Care (EPOC) group is a Cochrane review 
group specialized in undertaking reviews on all types of interventions that aim to improve 
health professional practice (http://epoc.cochrane.org). To aid researchers and clinicians 
in classifying their interventions, the EPOC has developed a taxonomy which can be used 
as a framework for characterizing interventions (32). Interventions are first divided into 
three different categories reflecting the healthcare system: interventions targeted at i) 
healthcare organizations; ii) healthcare workers; or iii) specific types of practice. Each 
of these categories can be further divided into different subcategories, but since this 
review focuses specifically on rheumatologists we will only discuss the second category: 
interventions targeted at healthcare workers. Audit and feedback, educational meetings 
and reminders are a few examples of these interventions (31). A full overview of the EPOC 
taxonomy on interventions targeted at healthcare workers can be found in table 3.
As can be seen in table 3, many different types of interventions could be used when 
implementing, for example, a new RA treatment guideline. As a consequence, many studies 
have been done on the effectiveness of these interventions. An in depth discussion regarding 
all these studies is beyond the scope of this article. But in a systematic review from 2004 
the available evidence was summarized (32). This review concluded that the overall quality 
of the studies was poor and that the intervention effects varied considerably both across 
and within interventions, making it impossible to give evidence-based recommendations 
on when to use which type of intervention (33). Since the publication of this review, many 
additional studies have been conducted and new systematic reviews were published as well. 
We will describe the results of the reviews on the three most performed interventions: 
educational meetings, audit and feedback, and reminders.
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Table 3: EPOC taxonomy of interventions targeted at healthcare workers
Intervention Description*
Audit and feedback A written, electronic or verbal summary given to healthcare 
providers, regarding their performance over a specified period 
of time
Clinical incident reporting A system where critical incidents can be reported
Monitoring the performance of the 
delivery of healthcare
Monitoring of services provided by individuals/healthcare 
organizations
Communities of practice A group with common interest who aim at to increase  
knowledge in this area by interacting on an ongoing basis
Continuous quality improvement An ongoing process to review and improve care including: 
involvement of healthcare teams, analysis of a process or 
system, a structured process improvement method or problem 
solving approach, and use of data analysis to assess changes. 
Educational games In order to improve standards of care, games can be used as an 
educational strategy. 
Educational materials Distribution of educational materials to support clinical care. 
Educational meetings Educational meetings such as courses, conferences or workshops
Educational outreach visits, or 
academic detailing
Providing information by a trained person, during personal 
visits, with the aim of changing practice
Clinical practice guidelines Systematically developed statements to assist healthcare 
providers and patients
Inter-professional education Continuing education for health professionals, involving 
participants from different professions. 
Local consensus processes Formal or informal consensus processes, for example; agreeing 
to a clinical protocol or promoting the implementation of 
guidelines. 
Local opinion leaders Promoting good clinical care by identifying and using local 
opinion leaders
Managerial supervision Routine supervision visits by health staff
Patient-mediated interventions Engage input from patients, to change professional practice
Public release of performance data Release of performance data, to inform the public about the 
practice of healthcare providers 
Reminders Manual of computerized reminders prompting healthcare 
providers to perform an action
Routine patient-reported outcome 
measures
Reporting and administration of patient reported outcomes 
measures
Tailored interventions Development of interventions to change practice, based on 
assessment of barriers for a specific clinical setting
*The description is derived from the EPOC taxonomy of interventions targeted at healthcare workers.
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Educational meetings
The EPOC systematic review on educational meetings was published in 2006 and included 81 
trials with over 11,000 included health professionals (34). When the researchers compared 
‘no intervention’ with ‘any intervention including educational meetings as a component’, 
the risk difference (RD) for compliance with the desired practice was 6% (interquartile 
range 1.8 to 15.9). For interventions with educational meetings alone, similar results were 
obtained. In addition, analyses were done on determinants of success. It was observed 
that higher attendance and a mix between interactive and didactic educational meetings 
were associated with a higher RD. In contrast, educational meetings targeted at complex 
behavior or at perceived less serious outcomes seemed to be less effective (34). 
Audit and feedback
Another EPOC review focused on audit and feedback and this review included 140 different 
studies (35). Comparing ‘interventions with audit and feedback’ as an essential component 
to ‘no intervention’ resulted in an increase of 4.3% of the desired behavior (interquartile 
range 0.5% to 16%). Determinants of success were; low baseline performance; the audit and 
feedback being provided by a colleague, being provided more than once (“booster” session, 
or regular feedback), or being delivered in verbal and written format; and finally when it 
includes specific targets or action plans (35). 
Reminders
On-screen computer reminders are often used as an intervention and their effectiveness 
has also been evaluated by EPOC (36). Reminders resulted in a median improvement of 
4.2% (interquartile range 0.8% to 18.8%) when all process outcomes were taken together. 
When looking at the separate outcomes, the median improvement in adherence was 3.3% 
for medication ordering, 3.8% for vaccinations and 3.8% for test ordering. A few studies 
also reported clinical outcomes (for example blood pressure) and the median absolute 
improvement for these outcomes was 2.5%. In this review none of the specific reminders or 
contextual factors were significantly associated with the magnitude of the observed effects 
(36).
Tailored interventions
When looking at the results from the above mentioned reviews and keeping the previous 
section in mind (determinants of successful implementation), one might wonder if 
interventions specifically tailored to facilitators or barriers of implementation are more 
effective than non-tailored interventions. The EPOC tried to answer this question as well, 
but studies directly comparing ‘tailored interventions’ to ‘non-tailored interventions’ or ‘no 
intervention at all’ were scarce, and a definitive conclusion was not possible. In spite of 
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this scarcity the conclusion was that tailored interventions can be effective, but that their 
effect is variable and tends to be small to moderate at best (37). 
In summary, this section described different interventions that could be used when trying 
to improve quality in clinical practice. The effects of any single one of these different 
interventions are often small to modest at best, but some evidence exist that a combination 
of different interventions is more effective (33). Despite the lack of evidence on which 
specific intervention should be used in which situation, the reviews may provide some 
guidance as to how to choose an intervention for a desired change in daily practice. Based 
on the information in this section we would advise to practicing rheumatologists willing 
to change their practice that, after measuring a chosen indicator set, a simple barrier 
analysis is done using the before mentioned themes (knowledge, motivation and being able 
to change) followed by a intervention tailored to these barriers. If possible, a combination 
of different intervention types is preferred above a single component intervention. 
F. WHAT INITIATIVES EXIST TO SPECIFICALLY IMPROVE RHEUMATOID 
ARTHRITIS CARE?
Several studies have tried to specifically improve RA care by introducing different types of 
interventions. To our knowledge there is no complete overview of these studies available, 
so we will discuss three different studies that describe some kind of intervention designed 
to improve care.
The first example is a pilot study aiming at improvement of disease activity and medication 
prescription in RA patients by implementing nurse-led DAS-28 measurements (38). As stated 
in this study, the assessment of a combined disease activity index like the DAS-28 is often 
perceived as too complex to regularly collect and calculate in a busy day to day clinical 
practice. Therefore, the researchers hypothesized that delegating DAS-28 measurement 
to a well-trained specialized nurse could be of value, since this would save time for the 
rheumatologist and enhances adherence (38). In this study three rheumatologists were 
randomized to the control group and four to the intervention group. In both groups the 
DAS-28 was performed and calculated by a specialized nurse, but only in the intervention 
group the DAS-28 score was provided to the rheumatologist (before the patient visited 
the rheumatologist). This was combined with a general advice to the rheumatologists 
to adjust DMARD therapy in case of active disease (DAS-28 ≥3.2). In order to investigate 
whether this intervention was effective, the change in DAS-28 score and the number of 
medication changes were used as primary outcome measures. After 18 months, a decrease 
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of 0.66 and 0.69 DAS28-points was found in the usual care group and in the intervention 
group respectively (p=0.7). In addition, no significant differences in number of medication 
changes were observed between the two groups (33% in the usual care group vs 35% in 
the intervention group; p=0.99) (38). According to the authors, one of the reasons for the 
failure of this intervention was the absence of a strict treatment protocol. Therefore they 
concluded that nurse-led care may be useful in making DAS28 assessments more feasible for 
use in daily practice, but that rheumatologists should be encouraged to change medication 
when necessary, using the individual DAS-28 values provided to them (38). 
Another example of an attempt to change clinical practice is the Metrix study (39). This 
study assessed the effect of an educational intervention on rheumatologists’ practice 
behavior in RA patients. In this study 20 rheumatologists participated, and they all had to 
perform a prospective chart audit of 50 consecutive RA patients at study start. During this 
chart audit they had to collect information on patient demographics, current and previous 
DMARD use and measurements done during the visit such as tender and swollen joint counts. 
After the chart audit the rheumatologists were randomized in an intervention group and a 
control group (10 in both groups) (39). Rheumatologists in the control group received no 
further interventions and also did not receive their results from the chart audit. In contrast, 
the rheumatologists in the intervention group received the chart audit results as feedback, 
had to attend monthly web-based conferences and a journal club. During the web-based 
conferences and journal club sessions, topics such as the value of systematic assessment 
in RA and the value of using tight control strategies were discussed. After 6 months the 
intervention group collected more global assessments (a 13% increase post-intervention for 
patient global and an increase of 9% in the physician global; p < 0.05) and Health Assessment 
Questionnaires (increase of 5%, p < 0.05), whereas the control group did not show any 
changes. Furthermore, a significant increase of 32% was seen in presence of calculable 
composite scores (any version of CDAI, SDAI or DAS), again no change in the control group 
was observed (39). In patients with active disease (either defined by SDAI or by DAS) therapy 
was changed more often in the intervention group than in the control group (66% vs 36% for 
patients with SDAI between 3.3 and 11; 57% vs 38% for patients with a DAS between 2.4 and 
3.6 respectively) (39). The results of this study show that the combination of feedback and 
educational meetings can improve daily clinical practice. Interestingly, the rheumatologists 
in the control group who also reviewed 50 of their own charts did not change at all. This 
implies that in order to change practice, only reviewing your own work, without receiving 
its results and additional education, is not enough (39). 
In the third and final study Ledwich and colleagues determined the effects of an Electronic 
Health Record (EHR) best practice alert (BPA) on vaccination rates in patients with 
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a rheumatic disease using an immunosuppressive drug (40). In this study the BPA was a 
clinical reminder on influenza and pneumococcal vaccinations. When an adult patient using 
immunosuppressive drugs visited the clinic during the influenza season, the BPA appeared 
prominently on screen to remind the rheumatologist about an influenza vaccination. For 
pneumococcal vaccinations the BPA only appeared in patients using an immunosuppressive 
drug if the patient did not received a vaccination before. With both BPAs rheumatologists 
were also able to document why a vaccination was not given. After implementation of 
the BPA vaccination rates increased significantly with influenza vaccination rates increasing 
from 47% to 65%, and pneumococcal vaccinations increasing from 19% to 41%. Based on 
these results the authors stated that the BPA is an effective tool for improving quality of 
care for patients receiving immunosuppressive drugs (40). 
 
Together these three studies show that initiatives are started within rheumatology evaluating 
strategies to improve quality of care for patients with RA or rheumatic diseases in general. 
Of these three studies, the latter two have demonstrated beneficial effects with regard 
to improving care, whereas the first study suggests that monitoring alone without a strict 
treatment protocol is not effective enough to truly change practice behavior. Overseeing 
these studies we can say that small steps are taken to improve the quality of RA care, but 
we have not reached our goal yet. 
Our conclusions from the previous paragraph are based on results of published studies. 
However, it is likely that many initiatives made to improve quality of care, never appear in 
international peer reviewed journals (publication bias). We have information on two of such 
quality improvement initiatives, only previously described in the Dutch literature. 
Both of the described initiatives come from the Sint Maartenskliniek (SMK) in the Netherlands. 
In this specialized clinic for rheumatology, orthopedic surgery and rehabilitation medicine, 
the rheumatology department has implemented nurse-led DAS-28 assessments for all RA 
patients visiting the outpatient clinic, starting in 2010. Since then, RA patients arrive at the 
clinic one hour before their visit with the rheumatologist. Upon arrival, blood is drawn for 
routine laboratory testing and the patient is seen by a specialized nurse. During this visit 
the DAS-28 and HAQ are performed and the current medication of the patient is discussed in 
order to identify any side effects or changes that have occurred since the last visit. All the 
information gathered during the visit with the nurse is provided to the rheumatologist prior 
to his or her consultation with the patient, increasing the efficiency (41). At the same time a 
locally developed RA treatment protocol also became available to the rheumatologists. This 
protocol included a strict, tight control-based, set of treatment recommendations, explicitly 
stating which DMARD should be given in what order and when. For example, according to 
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this protocol, patients with newly diagnosed RA treatment should start with methotrexate 
and hydroxychloroquine combination therapy. When this first combination fails, etanercept 
and methotrexate should be given. To date, 82% of the RA patients combine their visit 
with the rheumatologist with a nurse-led DAS-28 assessment. This has resulted in DAS-28 
measurements being available in 85% of the visits. Most importantly, 72% of all RA patients 
(irrespective of disease duration) have a DAS-28-CRP below 2.9, and 60% below 2.4..
After the implementation of nurse-led DAS-28 assessments in the department, it became 
clear that to obtain reliable DAS-28 scores across the different health care professionals 
(nurses, physician assistants, residents and rheumatologists) who performed the DAS-
28, an acceptable level of agreement in the DAS-28 scores is mandatory. Furthermore, 
since rheumatologists did not perform the DAS-28 themselves anymore, they had to learn 
to rely on the nurses. Therefore, an interactive and competitive DAS-28 training was 
designed to increase inter-observer agreement and to improve mutual confidence between 
rheumatologists and nurses. In this so called ‘DAS-28 battle’ – using elements of serious 
gaming - rheumatologists and nurses were first trained by an experienced rheumatologist 
to perform the joint counts needed to calculate the DAS-28. Next, the participants were 
divided into small groups and were asked to perform a tender and swollen joint count in 
4 different patients. In every group of patients, one ‘fake patient’ was present (usually 
a partner of a real RA patient) and these persons served as ‘healthy controls’. This extra 
twist was added to assess the number of false positive joints (joint scored as swollen 
in a healthy control). Blood tests were available, so DAS-28 scores could be calculated 
and compared immediately. Measurement error and number of false positive joints were 
calculated per team, and the team with the best score on both items was awarded the 
‘Golden Hand’ (42). Since 2009 two DAS-28 battles have been organized, and during the 
first battle the measurement error ranged from 0.16 to 0.44 (mean of 0.31) and the number 
of false positive joints varied between 0 and 4 per team. Three years later the battle was 
repeated, giving a similar mean measurement error but the variation between the teams 
had decreased (measurement error between 0.29 and 0.36). Due to changes in the health 
care professionals working at the SMK, the positive effects of the battle on both inter-
observer agreement and trust, and the enthusiasm of the participants, the DAS-28 battle 
will be organized again in the near future.
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G. PRACTICAL IMPLICATIONS
In this review we have provided an overview of the current status of quality of care in RA. 
In the first section we saw that defining and measuring quality of care can be challenging 
and that different types of quality indicators exist. Next, we described current treatment 
strategies used in RA, which are based on tight control. Different sets of indicators to 
measure RA care were discussed thereafter, which was followed by describing different 
studies assessing adherence to tight control recommendations. Unfortunately, adherence 
turned out to be suboptimal in most cases. In the subsequent section we have introduced 
the field of implementation science that has addressed this issue before, and examples of 
effective interventions were given. Finally, some of these interventions that are already 
applied in RA and have led to improvements in care provided to patients were described. 
In our opinion, these data show that evidence for the most effective RA treatment is available 
and that rheumatologists are willing to use this evidence in order to treat their patients to 
the best they can, but they need to be assisted in doing so. So, how could rheumatologists 
be assisted in improving their own RAcare? In this final section we will address this theme 
from two different points of view: the researcher’s view and the practicing rheumatologist’s 
view.  
The researcher’s view
We have seen that different groups around the world have developed RA quality indicators. 
However, none of these indicators sets are universally accepted, making it difficult to use 
them in research. While the indicator set formed by the international taskforce of METEOR 
attempts a more international approach, we are still not there (23). Therefore, we need 
a set of clear and internationally accepted indicators to gain more insight in the processes 
and outcomes of RA care. In addition, this indicator set should also incorporate outcome 
indicators next to process indicators. For the development of a universally applicable 
indicator set, based on international consensus, a joint, international taskforce under the 
auspices of international societies (such as ACR and EULAR) is needed. This indicator set 
may not only help in measuring care, but also in improving care and in the evaluation of 
improvement interventions.
In addition, far more attention should be given to the translation of evidence into practice. 
Here we refer to Buchbinder et al, who have recently stated that ‘investment in discovery 
research is essentially wasted if implementation research is ignored’(1). Therefore we 
would make an urgent call to all stakeholders involved in rheumatology research to invest 
in studies trying to find effective interventions that improve the quality of care for RA 
patients. 
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Finally, policy makers and developers of guidelines or practice recommendations should 
be more aware of the fact that only disseminating guidelines does not suffice to ensure 
uptake of recommendations in clinical practice. Therefore, any new or updated version 
of a guideline should be accompanied by an implementation plan or at least some 
recommendations on how to implement the guideline in daily clinical practice. The AGREE 
(Appraisal of Guidelines Research & Evaluation) tool is a helpful aid when developing a 
guideline as the AGREE gives recommendations to develop a high quality guideline. Besides 
recommendations on topics such as clarity and presentation of the guideline, AGREE also 
stresses the need for an implementation plan as a supplement with a guideline. In addition, 
additional materials could be useful, such as a summary document, educational tools or 
computer support. These additional materials should be provided with the guidelines in 
order to enhance their use (43). Furthermore, it might be needed that financial incentives 
are available to facilitate implementation of change. 
The rheumatologist’s view 
In this review we have tried to answer the question ‘how can a rheumatologist improve 
his or her own practice’. Unfortunately the literature is inconclusive and research in 
rheumatology is scarce. This problem has been addressed in the previous paragraphs and 
we will now propose some simple steps that rheumatology practices could use to improve 
their quality of care. 
When changing current practice, a first step would be to define a manageable goal. For 
example: ‘treat your RA patients in such a way that you achieve low disease activity in 60% 
of all your RA patients after one year’. Of note, the goal of 60% in this example is arbitrary 
and not based on evidence. Unfortunately, we do not know what such a percentage should 
be, but based on clinical trials this could be a feasible goal to start implementation with.
Next, it is necessary to check if have enough resources are available to reach the pre-set goal. 
For example, see if an up to date local RA treatment guideline is available and if not, try to 
see that such a guideline will become available. In our experience, guidelines are easier to 
use in daily practice if they include brief and specific descriptions of what to do in specific 
situations rather than elaborating on the underlying evidence. For example, providing a 
step-by-step description on what to do in a patient with active disease. When such a new or 
updated guideline is finished, all relevant stakeholders (nurses, residents, rheumatologists, 
pharmacists, etcetera) should be informed about this. If necessary, additional actions such 
as an educational meeting may be needed to improve implementation of the guideline. 
Apart from a clear treatment guideline, additional resources might be needed. As we saw 
in the TICD checklist by Flottorp, many potential barriers to adherence exist (31). However, 
for daily practice it is not feasible to do a full barrier analysis. Therefore we recommend 
to only focus on issues that have a potentially large impact on the results and that can 
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relatively easy be implemented. For example, if a specialized nurse or physician assistant is 
available, ‘shared care’ between them and the rheumatologists might be an option. 
After all necessary actions are implemented the next step would be to check at specified 
intervals if the pre-set goal has been met. Often, appropriate information for this check 
is not readily available from existing systems such as the EHR. One solution could be to 
conduct a chart review after, for example, six months (medical audit) and collecting data 
on disease activity and on what has been done in response. Such a chart review can be 
very labor intensive if done in many patients, but for feedback purposes a sample from the 
total patient population is often enough. Using the local treatment protocol, a few aspects 
of RA care could be checked for (‘Is disease activity measured during every routine visit?’; 
‘Is DMARD medication changed in response to active disease?’ and ‘Is low disease activity 
present?’). Individual data from the patient’s charts can then be aggregated in order to see 
if the pre-set goal has been reached. This chart review would probably most useful if all 
rheumatologists in one practice are involved and individual results are compared. Of note, a 
safe learning environment is critical when comparing non-anonymized performances among 
rheumatologists.
Nearly always such a chart review will reveal that not all the care is in accordance with 
the guidelines or the pre-set goal. Additional measures may be needed to further improve 
the quality of care and reach the pre-set goal. When finally those additional measures 
have resulted in meeting your goal, a new cycle starts and continuous evaluation will be 
necessary to maintain quality improvement. 
The above mentioned steps are also known as the Plan, Do, Check, Act (PDCA)-cycle or 
the Define, Measure, Analyse, Improve, Control (DMAIC) cycle (44) and closely resemble 
the tight control strategy used in RA treatment itself, as this cycle also involves goal 
setting, measuring and acting if the goals has not yet been reached. The application of 
such strategies in both patients and rheumatologists may result in a better translation of 
evidence into practice, and consequently guarantee the best possible care we could provide 
to our patients.
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ABSTRACT
Objectives
To assess variation in, and determinants of rheumatologist guideline adherence in 
patients with rheumatoid arthritis (RA) in daily practice. 
Methods
In this retrospective observational study, guideline adherence in the first year of 
treatment was assessed for seven pre-defined parameters on diagnostics, treatment 
and follow-up in all adult RA patients with a first outpatient clinic visit at the study 
centre between September 2009 and March 2011. Variation in guideline adherence was 
assessed on parameter and rheumatologist level. Determinants for guideline adherence 
were assessed in patients (demographic characteristics, rheumatoid factor (RF) and/
or anti-cyclic citrullinated (aCCP) peptide antibody positivity, ESR, erosive disease, 
comorbidity and the number of available DMARD treatment options) and rheumatologists 
(demographic and practice characteristics, guideline knowledge and agreement, 
outcome expectancy, cognitive bias, thinking style, numeracy and personality).
Results 
A total of 994 visits in 137 RA patients were reviewed. Variation in guideline adherence 
between parameters was present (adherence between 21% and 72%), with referral to 
the physician assistant as lowest scoring parameter and referral to a specialized nurse 
as highest scoring one. Variation in guideline adherence between rheumatologists was 
also present (adherence between 22% and 100%). Patient sex, the number of DMARD 
options, presence of erosions, comorbidity, RF/aCCP positivity, type of patient and the 
rheumatologists’ scientific education status were associated with adherence to one or 
more guideline parameters.
Conclusions
Guideline adherence varied considerably between the guideline parameters and 
rheumatologists, showing that there is room for improvement. Guideline adherence in 
our sample was related to several patient- and rheumatologist determinants.
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INTRODUCTION
Many guidelines and recommendations on optimal care for patients with rheumatoid arthritis 
(RA) have been developed to help clinicians choosing the best diagnostic and therapeutic 
strategies for their RA patients. All major RA treatment guidelines are now based on tight 
control principles, where monitoring of disease activity and changing treatment if a pre-
set target is not reached are essential.[1-3] Adherence to these tight control principles, 
preferably combined with the use of a specific treatment guideline, results in lower disease 
activity and less functional damage compared to usual care.[4-6] 
In view of the evidence supporting the benefit of adhering to protocolized tight control 
strategies, it is disappointing that current guideline adherence is still suboptimal as observed 
in multiple studies on this topic.[7-13] Unfortunately, these studies focus on DMARD-related 
treatment recommendations only, disregarding the fact that other aspects of RA care are 
also important. Furthermore, these studies are not performed in daily practice, but in pre-
defined cohorts using subsets of RA patients. Therefore, the first aim of this study is to gain 
more insight in guideline adherence of rheumatologists in daily practice, using a broader set 
of guideline adherence parameters than before.
Our second study aim is to gain insight into determinants of guideline adherence. In order 
to improve guideline adherence, it is first necessary to understand the determinants that 
influence adherence. Knowledge on these determinants could then be used to develop 
targeted interventions as evidence suggests that this leads to better intervention effects.
[14] Although knowledge on determinants of guideline adherence is not yet available from 
studies within rheumatology, studies outside rheumatology suggest the importance of 
various determinants, explaining the observed variation in guideline adherence between 
both hospitals and physicians.[15] Examples of such determinants are knowledge and 
cognitions of individual health care professionals and patient factors.[15]
All in all, data on RA guideline adherence in daily routine and its association with potential 
determinants is still lacking. Therefore, we aimed to 1) assess RA guideline adherence 
in daily clinical practice, 2) assess variation in guideline adherence on parameter and 
rheumatologist level, and 3) explore the impact of rheumatologist- and patient-related 
determinants on guideline adherence. 
MATERIAL AND METHODS
Study design
An explorative, retrospective observational multi-level cohort study was performed. 
Guideline adherence is behaviour executed by a rheumatologist, but it is measured in patients 
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who visit the hospital. Hence this study has three different levels: outpatient clinic visits 
(level 1) are nested within patients (level 2), who are in turn nested within rheumatologists 
(level 3). This is also reflected in the data collection and measurement: guideline adherence 
is measured on patient- or visit level (data collection on visit level), whereas the possible 
determinants of guideline adherence were measured either on rheumatologist- or patient-
level.
Setting 
This study was conducted at the rheumatology department of the Sint Maartenskliniek, a 
large clinic specialized in rheumatology, rehabilitation medicine and orthopaedics in the 
Netherlands. In this centre a local, tight control based, RA treatment guideline was put into 
use in 2007. At the same time supportive actions were undertaken to aid rheumatologists 
in following the new guideline. Firstly, specialized nurses were available to provide patient 
education, discuss disease coping and to assess disease activity before the visit with the 
rheumatologist (nurse led assessment of the Disease Activity Score in 28 joints (DAS28)). 
Secondly, after a referral to the physician assistant (PA) by the rheumatologist, patients 
were seen in an alternating fashion by the PA and rheumatologist in order to share care 
between them. The PAs can independently make treatment decisions, but they work under 
the supervision of a rheumatologist and, at the time of this study, were not allowed to 
prescribe medication. 
Participants
All 14 rheumatologists working at the study centre between September 2009 and July 2012 
were eligible for participation. Rheumatologists who did not work the full period were 
excluded; no other exclusion criteria were set. Consent from all participants was sought by 
explaining the study during a regular staff meeting.
We included all patients of 18 years and older diagnosed with RA (ICD-9 code 714.0), treated 
by one of the included rheumatologists and having had a first outpatient clinic visit at 
the study centre between September 2009 and March 2011. Patients with both new and 
established RA could be included, as long as their first visit to the study centre took place 
during the given time period. If patients were seen as second opinions, they were only 
included if treatment was fully taken over by the study centre. After inclusion, all visits 
in the first year of treatment at the study clinic were used to assess guideline adherence 
(figure 1). This means that the follow-up period lasted until March 2012. 
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Figure 1 Study time frame
Guideline adherence measures & data collection
As guideline adherence is multidimensional and cannot be expressed by a single outcome 
measure, we defined a set of seven different parameters to measure various quality aspects 
of RA care. These parameters are based on the quality indicators stated in the Dutch national 
RA treatment guideline.[16] As the local RA guideline used in the study centre is an adapted 
version of the Dutch national guideline, the selected parameters were adapted accordingly. 
This resulted in a set of seven guideline adherence parameters concerning three main 
themes (diagnostics, treatment and follow-up & shared care). All parameters are reported 
as dichotomous outcomes (‘yes’ or ‘no’), but depending on the type of parameter this is 
done at either visit- or patient level. All guideline adherence parameters are described 
in table 1. Online supplement 1 provides a more extensive version of this table, including 
corresponding treatment recommendations.
As mentioned before, all parameters were measured during the first year of treatment at 
the study centre. So, after a patient was included (between September 2009 and March 
2011), all visits in the next year were used to measure guideline adherence. 
Table 1 Guideline adherence parameters 
Guideline adherence parameter Level of 
measurement
Radiographs of hands, feet and thorax ordered within the first three visits, in 
patients with a disease duration ≤1 year
Patients
Prescription of conventional and biological DMARDs in agreement with the local 
preferential sequence
Patients
Referral to a specialized nurse within the first three visits Patients
Referral to a PA or NP within the first year of treatment Patients
Therapy changeΞ in case of moderate to high disease activity* Visits
Regular outpatient clinic visits combined with a nurse led DAS28 assessment Visits
Correct intervals between regular outpatient clinic visits Visits
DMARD: Disease Modifying Anti-Rheumatic Drug; DAS28: Disease Activity Score in 28 joints; PA: physician 
assistant; NP: nurse practitioner. ΞTherapy change included the intensification of DMARD therapy (dosage 
increase, shortening of the interval, adding a new DMARD and/or biological, switching to another 
DMARD and/or biological), starting or increasing corticosteroids (dose), local corticosteroid injections. 
*DAS28 >3.2 or corresponding judgement from the rheumatologist if a DAS28 was not available.
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To calculate the different parameters, the following data from every visit in the first year 
of treatment was collected: date and type of the visit, name of treating rheumatologist, 
presence of a nurse led DAS28 assessment, DAS28 score (using erythrocyte sedimentation 
rate (ESR)), functional status by Health Assessment Questionnaire (HAQ), clinical judgement 
of disease activity, radiographs that were ordered, current medication use (conventional 
and biologic Disease Modifying Anti-rheumatic Drugs (DMARD), glucocorticoids and/or Non-
Steroidal Anti Inflammatory Drugs (NSAIDs)), referral to a specialized nurse and referral to 
a PA. Using pre-defined algorithms, the seven guideline parameters were calculated using 
the above mentioned data.
Determinants of guideline adherence & data collection
Determinants of guideline adherence were assessed on two different levels: patient and 
rheumatologist level. On patient level, eight determinants were collected at baseline: age, 
gender, type of patient (new or second opinion), rheumatoid factor (RF) and/or anti-cyclic 
citrullinated peptide antibody (aCCP) positivity, ESR, presence of erosive disease, relevant 
comorbidity and the number of available DMARD treatment options. The last determinant 
provides the number of conventional and biological DMARDs that the patients has not yet 
used, but could be prescribed in the future in case of treatment failure on the current 
DMARD.
On rheumatologist level, information on five demographic and practice determinants was 
collected (age, gender, PhD, years of work experience as a rheumatologist and percentage 
of direct patient contact per week at the outpatient clinic). Furthermore, all participating 
rheumatologists were asked to complete self-developed questionnaires on guideline 
knowledge and agreement, and outcome expectancy. In addition, existing and validated 
questionnaires on cognitive bias, thinking styles, numeracy and personality traits were 
administered.[17-20] Some of the included questionnaires expressed their score on ≥1 
subscale, resulting in 14 determinants being calculated from seven questionnaires (table 
2 and online supplement 2). All questionnaires were web-based, of which the invitation 
was send to the rheumatologists in July 2012. After two weeks reminders were sent to all 
rheumatologist who had not yet completed the questionnaires. 
Data sources
All data needed to calculate the guideline adherence parameters were retrospectively 
retrieved from paper hospital charts, using a patient list generated from the administrative 
hospital database. During this chart review, the patient-related determinants were 
also collected. All data collected during chart review was written on paper case report 
forms, after which the data was entered in an electronic database and anonymized. All 
rheumatologist-related determinants were collected using the questionnaires mentioned 
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in the previous section and scores were also entered in an electronic database. For the 
purpose of the study, anonymizing the rheumatologist data was not possible. 
Table 2 Questionnaires used to measure rheumatologist-level determinants
Determinant Questionnaire Number of scales Score range
Cognitive 
bias
Inventory for Cognitive 
Bias in Medicine 
(ICBM)[17]
1 0 to 22 
(higher scores indicating less 
cognitive bias)
Personality Big Five Inventory 
(BFI; Dutch version)
[19]
5 
(extraversion, 
neuroticism, openness, 
conscientiousness and 
agreeableness)
1 to 5 on every subscale (higher 
scores indicating a stronger 
personality trait on the specific 
subscale)
Thinking 
styles
Rational Experiential 
Inventory (REI; Dutch 
version)[18]
2 
(rationality and 
experientality)
20 to 100 on every subscale (higher 
scores indicating a more rational/
experiential thinking style)
Numeracy Berlin Numeracy Test 
(BNT; Dutch version)
[20]
1 0 to 7 (a higher score indicating a 
higher level of numeracy) 
Knowledge Self-developed 
questionnaire
2 
(general and specific 
knowledge)
General knowledge: 0 to 10. Specific 
knowledge: -5.2 to 10* (higher scores 
indicating more guideline knowledge)
Guideline 
agreement
Self-developed 
statements
2 
(general and specific 
agreement with the 
guideline)
1 to 5 on every subscale (a higher 
score indicating a higher level of 
agreement)
Outcome 
expectancy
Self-developed 
statement
1 1 to 5 (a higher score indicating a 
higher level of outcome expectancy)
*Negative scores possible due to correction for guessing
Statistical analysis
Results on primary outcome measures (guideline adherence parameters) are reported as 
percentages with the accompanying absolute numbers. For the questionnaire scores and 
remaining variables means and SD or medians and interquartile ranges (IQR) are provided, 
as appropriate. 
Because of the hierarchical structure of our study (repeated measures on the same patient 
and patient nested within rheumatologists) we performed linear or logistic multilevel 
regression analysis when analysing the relation between the guideline adherence parameters 
and determinants. Depending on the type of parameter (outcomes on patient or visit level), 
two or three levels were included in the analyses. For the parameters radiographs ordered, 
preferential DMARD order, referral to a specialized nurse and referral to a PA (patient level), 
the parameter had the same score for every visit within one patient. For example, patients 
should be referred to a PA within the first year of treatment, meaning that this parameter is 
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scored only once per patient taking into account all visits during the study period. Multilevel 
analysis for these parameters only accounted for clustering within rheumatologists (two 
level model). For the other parameters (therapy change, nurse led DAS28 assessments and 
correct visit intervals; visit level) multilevel analysis also accounted for clustering within 
patients. This extra level was added because the parameter score per visit could differ 
within patients. For example, nurse led DAS28 assessments were either done or not done 
during the various visits.
Multilevel analysis started with adding all patient determinants to the model. Then, one 
by one the least significant determinant was deleted from the model until all remaining 
determinants were significant (p < 0.05). Next, the rheumatologist determinant with the 
highest correlation was added to the multilevel regression model, and if significant, included 
in the final regression model. This process was repeated with the rheumatologist determinant 
with the second highest correlation. Depending of the p-value of this determinant in the 
model, the analysis stopped (final model) or another determinant was added. This method 
was chosen because the number of rheumatologists was relatively small compared to the 
numbers of rheumatologist determinants.
Only parameters and determinants with enough variation between rheumatologists were 
analysed for associations between them. In case of floor or ceiling effects a determinant 
was omitted from further analysis. Results are presented as odds ratios (OR) with the 
corresponding 95% confidence interval (95%-CI), p-value and explained variation (%). 
Explained variation was calculated using the method described by Snijders and Bosker.[21] 
Statistical analyses were performed using STATA version 13.0, except the multilevel analysis, 
this was done using SAS version 9.2.
Ethical approval
This study was approved by the local research committee at the study centre (RR-105-PP). 
Although no written informed consent was obtained from the rheumatologists, they were 
informed beforehand about this study and asked if they would participate. It was made 
clear to them that they could stop with this study at any time, without providing a reason.
As this was a quality assessment performed in the hospital where the first two authors of 
this study worked, no written informed consent was needed from the patients. In addition, 
data collection was done by the first author and directly after chart review all patient data 
was anonymized. 
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RESULTS
Rheumatologist and patient characteristics
All 14 eligible rheumatologists (46.2% female; mean age 47.6 ± 10.0 years) participated 
in this study. All questionnaires were returned by all rheumatologists, except for the 
questionnaires on guideline knowledge & agreement and outcome expectancy, which were 
not completed by one rheumatologist.
According to the hospital database 241 patients with an ICD-code of RA were seen for 
the first time at the study clinic between September 2009 and March 2011. 61 patients 
were excluded because they turned out to be second opinion patients of which treatment 
was not taken over by the study centre. An additional 43 patients were excluded because 
charts were missing (n= 9), patients were not seen by an included rheumatologist (n= 11), 
chart review revealed another diagnosis than RA (n= 16) or they had deceased (n= 7). 
The remaining 137 RA patients (67.2% female; mean age 58.9 ± 14.1 year),with a total 
of 994 visits, were included in this study. Roughly half of the patients had not been seen 
by a rheumatologist before (46%), the remaining patients had been treated before by a 
rheumatologist outside the study centre, and visited the study centre for a second opinion. 
This led to a combination of new and established RA, as reflected in the median disease 
duration (0; IQR 0 to 7 years). In table 3 the baseline characteristics of both rheumatologists 
and patients are stated. 
Guideline adherence parameters
Adherence to the different guideline adherence parameters varied between 21% and 72% 
(table 4). The best scoring indicator was ‘referral to a specialized nurse’, with 72% of 
the patients being referred to such a nurse. Ordering of radiographs and changing therapy 
in case of active disease was done in approximately two thirds of the patients or visits 
respectively. The remaining parameters had adherence percentages between 20% and 40% 
(PA referral, DMARD prescription, intervals between visits and nurse led DAS28 assessment). 
As described in table 4, not all guideline parameters apply to all patients or visits. This 
applies for example to the parameter ‘therapy change in case of active RA’. A DAS28 and/or 
clinical judgment was available in 622 visits (63%) and in 285 of these visits active disease 
(DAS28 >3.2 or a corresponding judgment from the treating rheumatologist) was present 
(46%). In 191 of those visits (67%) the rheumatologists decided to change medication 
(parameter therapy change in case of active disease). 
In addition to the aforementioned variation between guideline adherence parameters, 
variation was also observed between rheumatologists. The largest difference between the 
rheumatologists was seen in the parameter concerning radiograph ordering, with adherence 
percentage of individual rheumatologists between 22% and 100%. The least variation was 
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seen in the parameter on correct intervals between visits, with adherence percentages 
varying between 11% and 43%.
Table 3 Baseline characteristics of included rheumatologists and patients 
Characteristic Results
Rheumatologists (n = 14)
Age, in years† 45.2 (39.5 to 56.7)
Female gender (%) 46.2
PhD degree or pursuing a PhD (%) 69.2
Experience as rheumatologist, in years† 6.9 (3.6 to 19.9)
Patient contact per week† (%) 60.0 (45.0 to 70.0)
Guideline knowledge* [0-10]; [-5.2 to 10]
General 8.1 (1.0)
Specific 6.2 (1.8)
Guideline agreement* [0-5]
General 4.8 (0.5)
Specific 4.5 (0.5)
Outcome expectancy* [0-5] 3.9 (0.8)
Cognitive bias* [0-22] 12.5 (4.2)
Thinking styles* [0-100]
Rational 79.5 (9.2)
Experiential 63.7 (7.5)
Numeracy* [0-7] 6.6 (1.1)
Personality* [0-5]
Extraversion 3.4 (0.7)
Neuroticism 2.8 (0.4)
Openness to experience 3.7 (0.6)
Consciousness 3.7 (0.4)
Agreeableness 3.8 (0.3)
Patients (n = 137)
Age, in years* 58.9 (14.1)
Female gender (%) 67.2
Disease duration, in years† 0 (0 to 7)
RF and/or aCCP positive (%) 85.4
Erosions (%) 38.3
ESR† (mm/h) 25 (12 to 36)
Comorbidity (%) 66.4
Number of available DMARD treatment options†‡ 15 (14 to 15)
*Mean (standard deviation). †Median (interquartile range). RF: rheumatoid factor; aCCP: anti-cyclic 
citrullinated peptide antibody; ESR: erythrocyte sedimentation rate; DMARD: Disease Modifying Anti-
Rheumatic Drug. ‡Includes both conventional and biological DMARD treatment options.
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Table 4 Guideline adherence percentages
Guideline adherence parameter Adherence percentage
Patient level (n= 137)
Radiographs of hands, feet and thorax ordered within the first three 
visits, in patients with a disease duration ≤1 year
66 (53/80)
Prescription of DMARDs* in agreement with the local preferential 
sequence 23 (29/126)
Referral to a specialized nurse within the first three visits 72 (98/137)
Referral to a PA or NP within the first year of treatment 21 (29/137)
Visit level (n= 994)
Therapy changeΞ in case of moderate to high disease activity 67 (191/285)
Regular outpatient clinic visits combined a nurse led DAS28 assessment 37 (253/690)
Correct intervals between regular outpatient clinic visits 32 (160/502)
DMARD: Disease Modifying Anti-Rheumatic Drug; DAS28: Disease Activity Score in 28 joints; PA: physician 
assistant; NP: nurse practitioner. *conventional and biological DMARDs. ΞTherapy change include starting 
or increasing dosage of a conventional DMARD or oral corticosteroids, starting a biological DMARD and 
intramuscular or -articular injections with corticosteroids.
Determinants of guideline adherence
All guideline adherence parameters showed enough variation and no floor/celling effects 
were present, therefore all parameters were included in the multilevel analyses. However, 
five determinants (general guideline knowledge, general guideline agreement, specific 
guideline agreement, outcome expectancy and numeracy) were not included in the analyses 
due to lack of variation in the scores and/or ceiling effects (table 3). 
For the remaining determinants eight associations with five different parameters were 
found (table 5). The preferential order of DMARD prescriptions was adhered less to in case 
of more available treatment options. Furthermore, referral to the specialized nurse was 
less likely if patients had erosive disease and comorbidity at baseline. Females, aCCP and/
or RF positive patients and second opinions had less visits combined with a nurse led DAS28 
assessment. Correct intervals between visits were also less likely if a patient was seen as a 
second opinion.
Only one parameter was associated with a rheumatologist-related determinant: 
rheumatologists with a PhD degree or pursuing a PhD were more likely to refer their patients 
to a PA. Personality, thinking styles and cognitive bias did not impact rheumatologists 
adherence to any of the guideline adherence parameters. 
The explained variance of the models was low to moderate. The lowest explained variance 
(2.5%) was seen in the model on correct intervals between visits, and the highest (12.0%) in 
the model on PA referral. 
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Table 5 Multivariate associations between guideline adherence parameters and patient- (P) and 
rheumatologist (R) related determinants
Guideline adherence parameter Odds ratio (95% CI) P-value
Prescription of DMARDs in agreement with the local preferential sequence
P Number of treatment options 0.78 (0.63 to 0.97) 0.03
Explained variance (%) 5.2
Referral to a specialized nurse within the first three visits
P Presence of erosive disease 0.68 (0.16 to 0.93) 0.03
P Comorbidity 0.68 (0.13 to 1.00) 0.05
Explained variance (%) 9.8
Referral to a PA or NP within the first year of treatment
R PhD degree or pursuing a PhD 4.14 (1.33 to 12.86) 0.01
Explained variance (%) 12.0
Regular outpatient clinic visits combined a nurse led DAS28 assessment
P Female gender 0.63 (0.41 to 0.97) 0.04
P RF and/or aCCP positivity 0.43 (0.28 to 0.66) <0.01
P Seen by a rheumatologist before (second opinion) 0.41 (0.22 to 0.77) 0.01
Explained variance (%) 7.9
Correct intervals between regular outpatient clinic visits
P Seen by a rheumatologist before (second opinion) 0.56 (0.37 to 0.85) 0.01
Explained variance (%) 2.5
RF: rheumatoid factor; aCCP: anti-cyclic citrullinated peptide antibody; ESR: erythrocyte sedimentation 
rate; DMARD: Disease Modifying Anti-Rheumatic Drug.
DISCUSSION
Our results show that guideline adherence percentages varied considerably between 
parameters, suggesting suboptimal guideline adherence on at least some guideline 
recommendations. Furthermore, adherence also varied between rheumatologists and a 
part of this variation could be explained by several rheumatologist- and patient-related 
determinants.
Besides being one of the first studies in rheumatology assessing guideline adherence in 
daily practice, other strengths of this study are the inclusion of a wide range of guideline 
adherence parameters and the multi-level association analyses between these parameters 
and determinants. However, our study has some limitations. First, being a retrospective 
study with chart review as the main data source, it is possible that information has been 
missed due to the fact that not everything was well documented in the charts. However, 
the advantage of our retrospective design is that guideline adherence could not have been 
influenced by the study itself. Secondly, the sample size was, with only 14 participating 
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rheumatologists, relatively small. Nonetheless, if we have missed associations due to a lack 
of power, these associations are probably not very strong. Thirdly, this study was conducted 
in only one centre in the Netherlands, probably hampering generalizability. Nevertheless, 
our observation that guideline adherence is suboptimal is most likely to be generalizable 
as other groups before concluded the same. Only our estimates on the degree of guideline 
adherence might be less generalizable. Furthermore, due to the single centre design we 
were not able to assess the influence of organizational factors on guideline adherence. 
As the study centre already implemented some supportive actions to increase adherence, 
results in a centre without these actions might be different. Lastly, the single-centre design 
and the homogeneous population within this centre might have attributed to the fact that 
we had to exclude some of our determinants due to ceiling effects or lack of variation. 
In our study, guideline adherence varied between 21% and 72% and as no absolute norms 
on optimal guideline adherence exist, we can only use relative norms to judge if guideline 
adherence in this study was optimal. Firstly, the adherence percentages of our best scoring 
parameters can be used as a relative norm. So, the observed level of adherence to the three 
highest scoring indicators (radiograph ordering, specialized nurse referral, therapy change; 
adherence 66% to 72%) was probably optimal. Furthermore, aiming for 100% adherence is 
not feasible due to for example patient comorbidity or medication side effects. 
Secondly, we can compare our results with other studies. However, since previous studies 
have primarily focused on therapy recommendations (DMARD prescription and therapy 
change in case of active disease), this makes comparison with existing data impossible 
for all our parameters. With regard to DMARD prescriptions, the 23% guideline adherence 
we found seems to be on the lower end of the spectrum. Another study on this subject 
observed adherence percentages to the American College of Rheumatology (ACR) DMARD 
treatment guidelines of 24% to 90%, depending on the type of DMARD used, disease activity 
and prognosis.[11] However, the lower adherence percentages in our study could probably 
be explained by the more strict definition we used. For example, the ACR guideline names 
methotrexate the first choice DMARD, with combination therapy depending on disease 
activity, prognosis and disease duration. In contrast, according to our local guideline all new 
patients should be started on methotrexate and hydroxycloroquine combination therapy.
With regard to therapy change in case of active disease we can compare our results with 
two previous studies. One study by Fransen et al in patients with established RA used the 
same DAS28 threshold (3.2) at which therapy should be changed as our study, observing 
an adherence percentage of 20%.[9] Although Fransen et al only looked at DMARD therapy 
change whereas we included also corticosteroid use, the adherence of 67% we found is 
substantially higher. The result of the second study by Vermeer et al with an adherence 
of 58%, is more in line with our results, although it only included DMARD therapy change 
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and was limited to early RA.[13] Concerning therapy change, it should be mentioned that 
our centre has participated in a guideline adherence study before. In that particular study, 
therapy was changed in 33% of the visits with active disease, compared to 67% now.[22] This 
large improvement in guideline adherence is most likely caused by the introduction of the 
local RA guideline and the supportive actions afterwards. 
Besides the assessment of guideline adherence we also looked if patient- and rheumatologist 
related determinants were associated with guideline adherence. Despite the low to moderate 
explained variance, some interesting observations can be made. For example, in qualitative 
studies factors like erosive disease, comorbidity and RF/aCCP status are often mentioned by 
rheumatologists as important reasons to intensify or not intensify treatment.[23] Therefore, 
we expected to find associations between these determinants and the guideline parameter 
on therapy change in case of active disease. Although we did not observe this association, we 
observed associations between number of treatment options, erosive disease, comorbidity 
and RF/aCCP status and the parameters on DMARD prescription, referral to a specialized 
nurse and nurse led DAS28 assessments. This implies that patient factors could, justly or 
unjustly, influence more decisions than treatment intensification only.
With regard to the rheumatologist related determinants, it is notable that only one association 
between a rheumatologist determinant (PhD) and a guideline adherence parameter 
(PA referral) was found. This was especially surprising as factors such as knowledge are 
frequently mentioned as a potential determinant of guideline adherence.[15, 24] This might 
imply that rheumatologist related determinants did not play a large role in our sample, but 
further studies on this subject are needed as guideline adherence is probably determined by 
a complex interplay of facilitators and barriers which makes it hard to capture. 
Due to the explorative design of our study, replication of our results is warranted in other 
settings both inside and outside the Netherlands. However, the suggestion from our results 
that rheumatologists do not always practice what is preached, can be used more widely. 
It seems that despite the current focus on treat to target principles in RA literature, these 
principles are not automatically applied in daily practice. 
This study provides an example for other centres to measure their quality of care and the 
determinants found in our sample might be reckoned with in future interventions. Recent 
developments around nationwide registries, such as the RISE (Rheumatology Informatics 
System for Effectiveness) registry, can facilitate measurements by providing real-time 
feedback on important aspects of quality of care.[25] Information gained from quality of 
care studies or registries can than serve as benchmark information for hospitals or individual 
physicians.[26] Furthermore, we would advocate for more attention of researchers and policy 
makers towards implementation of RA guidelines and quality of care. Besides replicating our 
results in larger studies, future research should focus on the identification of determinants 
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influencing adherence. This is crucial to gain insight into the most effective and feasible 
interventions to help rheumatologists adhere better to RA management guidelines and to 
improve patient outcomes in daily practice. Only then can patients benefit from the large 
body of evidence that already exists. 
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 h
an
d 
an
d 
fe
et
 a
t 
m
om
en
t 
of
 
di
ag
no
si
s 
an
d 
on
e 
ye
ar
 t
he
re
af
te
r 
(y
ea
r 
0 
an
d 
1)
.[
16
]
In
 c
as
e 
of
 c
lin
ic
al
 s
us
pi
ci
on
 f
or
 R
A,
 r
ad
io
gr
ap
hs
 
of
 h
an
ds
, 
fe
et
 a
nd
 t
ho
ra
x 
sh
ou
ld
 b
e 
m
ad
e.
Pa
ti
en
ts
Pr
es
cr
ip
ti
on
 o
f 
co
nv
en
ti
on
al
 a
nd
 
bi
ol
og
ic
al
 D
M
A
RD
s 
in
 a
gr
ee
m
en
t 
w
it
h 
th
e 
lo
ca
l p
re
fe
re
nt
ia
l s
eq
ue
nc
e*
RA
 t
re
at
m
en
t 
sh
ou
ld
 s
ta
rt
 w
it
h 
m
et
ho
tr
ex
at
e.
 
Co
m
bi
na
ti
on
 t
he
ra
py
 w
it
h 
an
ot
he
r 
co
nv
en
ti
on
al
 
DM
AR
D 
or
 T
N
F-
in
hi
bi
to
r 
sh
ou
ld
 b
e 
gi
ve
n 
if
 d
is
ea
se
 a
ct
iv
it
y 
re
m
ai
ns
 h
ig
h 
de
sp
it
e 
m
et
ho
tr
ex
at
e 
in
 a
de
qu
at
e 
do
sa
ge
.[
16
]
Al
l c
on
ve
nt
io
na
l a
nd
 b
io
lo
gi
ca
l D
M
AR
Ds
 s
ho
ul
d 
be
 p
re
sc
ri
be
d 
in
 a
 p
re
-d
efi
ne
d 
or
de
r 
w
hi
ch
 is
 
st
at
ed
 in
 t
he
 lo
ca
l R
A 
gu
id
el
in
e.
 
Pa
ti
en
ts
Re
fe
rr
al
 t
o 
a 
sp
ec
ia
liz
ed
 n
ur
se
 
w
it
hi
n 
th
e 
fi
rs
t 
th
re
e 
vi
si
ts
Co
ns
ul
ta
ti
on
 w
it
h 
a 
sp
ec
ia
liz
ed
 r
he
um
at
ol
og
y 
nu
rs
e 
w
it
hi
n 
on
e 
ye
ar
 a
ft
er
 d
ia
gn
os
is
.[
16
]]
Al
l n
ew
ly
 d
ia
gn
os
ed
 R
A 
pa
ti
en
ts
 s
ho
ul
d 
be
 
re
fe
rr
ed
 t
o 
a 
sp
ec
ia
liz
ed
 n
ur
se
 a
t 
th
e 
m
om
en
t 
of
 d
ia
gn
os
is
 in
 o
rd
er
 t
o 
ge
t 
m
or
e 
in
fo
rm
at
io
n 
on
 
RA
 a
nd
 d
is
cu
ss
 c
op
in
g.
Pa
ti
en
ts
Re
fe
rr
al
 t
o 
a 
PA
 o
r 
N
P 
w
it
hi
n 
th
e 
fi
rs
t 
ye
ar
 o
f 
tr
ea
tm
en
t
N
ot
 a
pp
lic
ab
le
Al
l R
A 
pa
ti
en
ts
 s
ho
ul
d 
be
 r
ef
er
re
d 
to
 a
 P
A 
or
 N
P 
w
it
hi
n 
th
e 
fir
st
 y
ea
r 
of
 t
re
at
m
en
t.
 A
ft
er
 r
ef
er
ra
l 
pa
ti
en
ts
 a
re
 a
lt
er
na
te
ly
 s
ee
n 
by
 a
 P
A/
N
P 
an
d 
rh
eu
m
at
ol
og
is
t,
 in
 o
rd
er
 t
o 
sh
ar
e 
ca
re
 b
et
w
ee
n 
th
em
. 
Pa
ti
en
ts
Th
er
ap
y 
ch
an
ge
Ξ  
in
 c
as
e 
of
 m
od
er
at
e 
to
 h
ig
h 
di
se
as
e 
ac
ti
vi
ty
∏
In
te
ns
ifi
ca
ti
on
 o
f 
m
ed
ic
at
io
n 
by
 a
 
rh
eu
m
at
ol
og
is
t 
in
 c
as
e 
of
 a
 D
AS
28
>3
.2
 a
nd
 a
n 
ad
eq
ua
te
 p
er
io
d 
of
 p
re
vi
ou
s 
th
er
ap
y.
 A
da
pt
at
io
n 
of
 t
re
at
m
en
t 
ba
se
d 
on
 D
AS
28
 s
co
re
s 
un
le
ss
 c
o-
m
or
bi
di
ty
, 
ex
tr
a-
ar
ti
cu
la
r 
di
se
as
e 
an
d/
or
 s
id
e-
ef
fe
ct
s 
pr
ev
en
t 
th
is
.[
16
]
In
 c
as
e 
of
 a
ct
iv
e 
di
se
as
e 
(D
AS
28
 >
3.
2)
 t
he
ra
py
 
sh
ou
ld
 b
e 
ch
an
ge
d 
in
 o
rd
er
 t
o 
re
ac
h 
lo
w
 d
is
ea
se
 
ac
ti
vi
ty
/r
em
is
si
on
 a
ga
in
.
Vi
si
ts
Re
gu
la
r 
ou
tp
at
ie
nt
 c
lin
ic
 v
is
it
s 
co
m
bi
ne
d 
a 
nu
rs
e 
le
d 
D
A
S2
8 
as
se
ss
m
en
t
Fr
eq
ue
nt
 m
on
it
or
in
g 
of
 d
is
ea
se
 a
ct
iv
it
y,
 f
or
 
ex
am
pl
e 
us
in
g 
th
e 
DA
S2
8.
[1
6]
Al
l r
eg
ul
ar
 v
is
it
s 
at
 t
he
 o
ut
pa
ti
en
t 
cl
in
ic
 f
or
 R
A 
pa
ti
en
ts
 s
ho
ul
d 
be
 c
om
bi
ne
d 
w
it
h 
a 
vi
si
t 
to
 a
 
sp
ec
ia
liz
ed
 n
ur
se
 in
 o
rd
er
 t
o 
as
se
ss
 t
he
 D
AS
28
, 
w
hi
ch
 is
 a
va
ila
bl
e 
fo
r 
th
e 
rh
eu
m
at
ol
og
is
t 
w
ho
 
se
es
 t
he
 p
at
ie
nt
 n
ex
t
Vi
si
ts
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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Co
rr
ec
t 
in
te
rv
al
s 
be
tw
ee
n 
re
gu
la
r 
ou
tp
at
ie
nt
 c
lin
ic
 v
is
it
s
Pl
an
ne
d 
vi
si
t 
w
it
h 
a 
rh
eu
m
at
ol
og
is
t 
w
it
hi
n 
3 
m
on
th
s 
of
 t
he
 la
st
 v
is
it
 if
 D
AS
28
 >
 2
.6
. 
Pl
an
ne
d 
vi
si
t 
w
it
h 
a 
rh
eu
m
at
ol
og
is
t 
w
it
hi
n 
6 
m
on
th
s 
of
 
th
e 
la
st
 v
is
it
 if
 D
AS
28
 <
 2
.6
. 
Pl
an
ne
d 
vi
si
t 
w
it
h 
a 
rh
eu
m
at
ol
og
is
t 
w
it
hi
n 
on
e 
ye
ar
 a
ft
er
 t
he
 la
st
 
vi
si
t 
if
 D
AS
28
 <
 2
.6
.[
16
]
In
 t
he
 fi
rs
t 
ye
ar
 o
f 
tr
ea
tm
en
t 
RA
 p
at
ie
nt
s 
sh
ou
ld
 b
e 
se
en
 e
ve
ry
 t
hr
ee
 m
on
th
s,
 t
he
re
af
te
r 
it
 d
ep
en
ds
 o
n 
di
se
as
e 
ac
ti
vi
ty
 a
nd
 m
ed
ic
at
io
n 
us
e 
(3
-m
on
tl
y 
vi
si
ts
 in
 c
as
e 
of
 fi
rs
t 
ye
ar
 D
M
AR
D 
or
 b
io
lo
gi
ca
l u
se
 o
r 
ac
ti
ve
 d
is
ea
se
; 
ot
he
rw
is
e 
6-
m
on
tl
y 
vi
si
ts
).
Vi
si
ts
DM
AR
D:
 D
is
ea
se
 M
od
if
yi
ng
 A
nt
i-
Rh
eu
m
at
ic
 D
ru
g;
 D
AS
28
: D
is
ea
se
 A
ct
iv
it
y 
Sc
or
e 
in
 2
8 
jo
in
ts
; P
A:
 p
hy
si
ci
an
 a
ss
is
ta
nt
; N
P:
 n
ur
se
 p
ra
ct
it
io
ne
r.
 *T
he
 p
re
fe
re
nt
ia
l 
or
de
r 
st
ar
ts
 w
it
h 
m
et
ho
tr
ex
at
e 
an
d 
hy
dr
ox
yc
hl
oq
ui
ne
 c
om
bi
na
ti
on
 t
he
ra
py
. A
ft
er
 t
hr
ee
 m
on
th
s 
tr
ea
tm
en
t 
is
 e
va
lu
at
ed
 a
nd
 if
, 
de
sp
it
e 
ad
eq
ua
te
 d
os
ag
e,
 
di
se
as
e 
ac
ti
vi
ty
 r
em
ai
ns
 h
ig
h 
(D
AS
28
 >
3.
2)
 h
yd
ro
xy
ch
lo
ro
qu
in
e 
w
ill
 b
e 
ex
ch
an
ge
d 
fo
r 
et
an
er
ce
pt
. T
re
at
m
en
t 
ef
fe
ct
s 
w
ill
 b
e 
ev
al
ua
te
d 
ev
er
y 
th
re
e 
m
on
th
s 
an
d 
in
 c
as
e 
of
 p
er
si
st
en
t 
hi
gh
 d
is
ea
se
 a
ct
iv
it
y,
 t
he
 b
io
lo
gi
ca
l D
M
AR
D 
w
ill
 b
e 
sw
it
ch
ed
 w
hi
le
 t
he
 u
se
 o
f 
m
et
ho
tr
ex
at
e 
re
m
ai
ns
 s
ta
bl
e.
 In
 c
as
e 
of
 in
to
le
ra
nc
e 
of
 c
on
tr
ai
nd
ic
at
io
ns
 f
or
 m
et
ho
tr
ex
at
e,
 o
th
er
 c
on
ve
nt
io
na
l 
DM
AR
Ds
 c
an
 b
e 
ch
os
en
. 
Ξ T
he
ra
py
 c
ha
ng
e 
in
cl
ud
ed
 t
he
 i
nt
en
si
fic
at
io
n 
of
 D
M
AR
D 
th
er
ap
y 
(d
os
ag
e 
in
cr
ea
se
, s
ho
rt
en
in
g 
of
 t
he
 in
te
rv
al
, a
dd
in
g 
a 
ne
w
 D
M
AR
D 
an
d/
or
 b
io
lo
gi
ca
l,
 s
w
it
ch
in
g 
to
 a
no
th
er
 D
M
AR
D 
an
d/
or
 b
io
lo
gi
ca
l)
, s
ta
rt
in
g 
or
 in
cr
ea
si
ng
 
co
rt
ic
os
te
ro
id
s 
(d
os
e)
, 
lo
ca
l c
or
ti
co
st
er
oi
d 
in
je
ct
io
ns
. 
∏
DA
S2
8 
>3
.2
 o
r 
co
rr
es
po
nd
in
g 
ju
dg
em
en
t 
fr
om
 t
he
 r
he
um
at
ol
og
is
t 
if
 a
 D
AS
28
 w
as
 n
ot
 a
va
ila
bl
e.
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O
nl
in
e 
su
pp
le
m
en
t 
2:
 Q
ue
st
io
nn
ai
re
s 
us
ed
 t
o 
m
ea
su
re
 r
he
um
at
ol
og
is
t-
le
ve
l 
de
te
rm
in
an
ts
D
et
er
m
in
an
t 
m
ea
su
re
d
Ex
pl
an
at
io
n 
of
 t
he
 d
et
er
m
in
an
t 
&
 r
el
at
io
n 
w
it
h 
gu
id
el
in
e 
ad
he
re
nc
e
Q
ue
st
io
nn
ai
re
 u
se
d
N
um
be
r 
of
 s
ca
le
s 
Sc
or
e 
ra
ng
e
Co
gn
it
iv
e 
bi
as
Co
gn
it
iv
e 
bi
as
 is
 a
n 
er
ro
r 
in
 o
ur
 t
hi
nk
in
g 
th
at
 
oc
cu
rs
 w
he
n 
pe
op
le
 p
ro
ce
ss
 a
nd
 in
te
rp
re
t 
in
fo
rm
at
io
n,
 t
ry
in
g 
to
 s
im
pl
if
y 
in
fo
rm
at
io
n.
 
M
an
y 
di
ff
er
en
t 
ty
pe
s 
of
 c
og
ni
ti
ve
 b
ia
se
s 
ar
e 
kn
ow
n 
an
d 
th
ey
 c
an
 in
flu
en
ce
 m
ed
ic
al
 
de
ci
si
on
 m
ak
in
g.
[2
7]
In
ve
nt
or
y 
fo
r 
Co
gn
it
iv
e 
Bi
as
 in
 
M
ed
ic
in
e 
(I
CB
M
):
 2
2 
sh
or
t 
ca
se
 
de
sc
ri
pt
io
ns
 f
ol
lo
w
ed
 b
y 
a 
m
ul
ti
pl
e 
ch
oi
ce
 q
ue
st
io
n.
[1
7]
1
0 
to
 2
2 
(h
ig
he
r 
sc
or
e 
in
di
ca
te
s 
le
ss
 
co
gn
it
iv
e 
bi
as
) 
Pe
rs
on
al
it
y
Pe
rs
on
al
it
y 
tr
ai
ts
 p
la
y 
an
 im
po
rt
an
t 
pa
rt
 in
 
ou
r 
be
ha
vi
ou
r 
an
d 
ca
n 
al
so
 in
flu
en
ce
 m
ed
ic
al
 
de
ci
si
on
 m
ak
in
g.
[2
8,
 2
9]
Bi
g 
Fi
ve
 In
ve
nt
or
y 
(B
FI
; 
Du
tc
h 
ve
rs
io
n)
: 
44
 s
ta
te
m
en
ts
 
an
sw
er
ed
 o
n 
a 
5-
po
in
t 
lik
er
t 
sc
al
e 
(c
om
pl
et
el
y 
di
sa
gr
ee
 t
o 
co
m
pl
et
el
y 
ag
re
e)
.[
19
]
5 (e
xt
ra
ve
rs
io
n,
 
ne
ur
ot
ic
is
m
, 
op
en
ne
ss
, 
co
ns
ci
en
ti
ou
sn
es
s 
an
d 
ag
re
ea
bl
en
es
s)
1 
to
 5
 o
n 
ev
er
y 
su
bs
ca
le
 (
a 
hi
gh
er
 
sc
or
e 
in
di
ca
ti
ng
 a
 m
or
e 
ex
tr
av
er
t,
 
ne
ur
ot
ic
, 
op
en
, 
co
ns
ci
en
ce
 o
r 
ag
re
ea
bl
e 
pe
rs
on
al
it
y)
Th
in
ki
ng
 
st
yl
es
Th
in
ki
ng
 s
ty
le
s 
ar
e 
re
la
ti
ve
ly
 s
ta
bl
e 
pe
rs
on
al
it
y 
tr
ai
ts
 w
hi
ch
 a
dd
re
ss
 h
ow
 p
eo
pl
e 
th
in
k.
 T
w
o 
di
ff
er
en
t 
th
in
ki
ng
 s
ty
le
s 
ar
e 
di
st
in
gu
is
he
d:
 t
he
 r
at
io
na
l (
‘d
el
ib
er
at
e’
 o
r 
‘c
on
sc
io
us
’)
 a
nd
 t
he
 e
xp
er
ie
nt
ia
l (
‘a
ut
om
at
ic
’ 
or
 ‘
un
co
ns
ci
ou
s’
) 
th
in
ki
ng
 s
ty
le
. 
Th
es
e 
st
yl
es
 h
av
e 
be
en
 li
nk
ed
 b
ef
or
e 
to
 g
ui
de
lin
e 
ad
he
re
nc
e.
[3
0,
 3
1]
Ra
ti
on
al
 E
xp
er
ie
nt
ia
l 
In
ve
nt
or
y 
(R
EI
; 
Du
tc
h 
ve
rs
io
n)
: 
40
 s
ta
te
m
en
ts
 a
ns
w
er
ed
 
on
 a
 5
-p
oi
nt
 li
ke
rt
 s
ca
le
 
(c
om
pl
et
el
y 
di
sa
gr
ee
 t
o 
co
m
pl
et
el
y 
ag
re
e)
.[
18
]
2 (r
at
io
na
lit
y 
an
d 
ex
pe
ri
en
ta
lit
y)
20
 t
o 
10
0 
on
 e
ve
ry
 s
ub
sc
al
e 
(a
 
hi
gh
er
 s
co
re
 in
di
ca
ti
ng
 a
 m
or
e 
ra
ti
on
al
/e
xp
er
ie
nt
ia
l t
hi
nk
in
g 
st
yl
e)
N
um
er
ac
y
N
um
er
ac
y 
an
d 
ri
sk
 li
te
ra
cy
 a
re
 im
po
rt
an
t 
w
he
n 
in
te
rp
re
ti
ng
 a
nd
 a
ct
in
g 
on
 r
is
k 
in
fo
rm
at
io
n.
 T
he
se
 s
ki
lls
 a
re
 im
po
rt
an
t 
in
 
m
an
y 
he
al
th
 d
ec
is
io
ns
 b
ut
 p
hy
si
ci
an
s 
se
em
 
to
 s
tr
ug
gl
e 
w
it
h 
nu
m
er
ac
y.
[3
2]
 A
s 
gu
id
el
in
e 
ad
he
re
nc
e 
al
so
 in
vo
lv
es
 m
ed
ic
al
 d
ec
is
io
n 
m
ak
in
g 
an
d 
ri
sk
 in
te
rp
re
ta
ti
on
, 
th
is
 m
ea
su
re
 
w
as
 in
cl
ud
ed
.
Be
rl
in
 N
um
er
ac
y 
Te
st
 (
BN
T;
 
Du
tc
h 
ve
rs
io
n)
: 
se
ve
n 
op
en
 
qu
es
ti
on
s 
1
0 
to
 7
 (
a 
hi
gh
er
 s
co
re
 in
di
ca
ti
ng
 a
 
hi
gh
er
 le
ve
l o
f 
nu
m
er
ac
y)
 
Kn
ow
le
dg
e 
G
ui
de
lin
e 
kn
ow
le
dg
e 
is
 o
ft
en
 m
en
ti
on
ed
 
as
 a
n 
im
po
rt
an
t 
de
te
rm
in
an
t 
of
 g
ui
de
lin
e 
ad
he
re
nc
e.
[1
5,
 2
4]
A 
se
lf
-d
ev
el
op
ed
 q
ue
st
io
nn
ai
re
 
w
it
h 
2x
10
 m
ul
ti
pl
e 
ch
oi
ce
 
qu
es
ti
on
s 
on
 g
en
er
al
 g
ui
de
lin
e 
kn
ow
le
dg
e 
an
d 
sp
ec
ifi
c 
RA
 
gu
id
el
in
e 
kn
ow
le
dg
e
2 (g
en
er
al
 a
nd
 s
pe
ci
fic
 
kn
ow
le
dg
e)
G
en
er
al
 k
no
w
le
dg
e:
 0
 t
o 
10
Sp
ec
ifi
c 
kn
ow
le
dg
e:
 -
5.
2 
to
 1
0 
(n
eg
at
iv
e 
sc
or
es
 d
ue
 t
o 
co
rr
ec
ti
on
 
fo
r 
gu
es
si
ng
).
 O
n 
bo
th
 s
ca
le
s 
a 
hi
gh
er
 s
co
re
s 
in
di
ca
te
s 
m
or
e 
kn
ow
le
dg
e.
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ve
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de
te
rm
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ts
D
et
er
m
in
an
t 
m
ea
su
re
d
Ex
pl
an
at
io
n 
of
 t
he
 d
et
er
m
in
an
t 
&
 r
el
at
io
n 
w
it
h 
gu
id
el
in
e 
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he
re
nc
e
Q
ue
st
io
nn
ai
re
 u
se
d
N
um
be
r 
of
 s
ca
le
s 
Sc
or
e 
ra
ng
e
Co
gn
it
iv
e 
bi
as
Co
gn
it
iv
e 
bi
as
 is
 a
n 
er
ro
r 
in
 o
ur
 t
hi
nk
in
g 
th
at
 
oc
cu
rs
 w
he
n 
pe
op
le
 p
ro
ce
ss
 a
nd
 in
te
rp
re
t 
in
fo
rm
at
io
n,
 t
ry
in
g 
to
 s
im
pl
if
y 
in
fo
rm
at
io
n.
 
M
an
y 
di
ff
er
en
t 
ty
pe
s 
of
 c
og
ni
ti
ve
 b
ia
se
s 
ar
e 
kn
ow
n 
an
d 
th
ey
 c
an
 in
flu
en
ce
 m
ed
ic
al
 
de
ci
si
on
 m
ak
in
g.
[2
7]
In
ve
nt
or
y 
fo
r 
Co
gn
it
iv
e 
Bi
as
 in
 
M
ed
ic
in
e 
(I
CB
M
):
 2
2 
sh
or
t 
ca
se
 
de
sc
ri
pt
io
ns
 f
ol
lo
w
ed
 b
y 
a 
m
ul
ti
pl
e 
ch
oi
ce
 q
ue
st
io
n.
[1
7]
1
0 
to
 2
2 
(h
ig
he
r 
sc
or
e 
in
di
ca
te
s 
le
ss
 
co
gn
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ABSTRACT
Objectives
To assess the effects of education, feedback and a computerized decision support 
system (CDSS) versus education and feedback alone on rheumatologists’ rheumatoid 
arthritis (RA) guideline adherence.
Methods
A single center, randomized controlled pilot study was performed among clinicians 
(rheumatologists, residents and physician assistants; n = 20) working at the study 
center, with a 1:1 randomization of included clinicians. A standardized sum score (SSS) 
on guideline adherence was used as the primary outcome (patient level). The SSS was 
calculated from 13 dichotomous indicators on quality of RA monitoring, treatment and 
follow-up. 
The randomized controlled design was combined with a before-after design in the 
control group to assess the effect education and feedback alone. 
Results
20 clinicians (mean age 44.3 ± 10.9 years; 55% female) and 990 patients (mean age 62 ± 
13 years; 69% female; 72% rheumatoid factor and/or anti-CCP positive) were included. 
Addition of CDSS to education and feedback did not result in significant better quality of 
RA care than education and feedback alone (SSS difference 0.02; 95%-CI -0.04 to 0.08;  
p = 0.60). However, before/after comparison showed that education and feedback 
alone resulted in a significant increase in the SSS from 0.58 to 0.64 (difference 0.06; 
95%-CI 0.02 to 0.11; p <0.01). 
Conclusions
Our results suggest that CDSS did not have added value with regard to guideline 
adherence, whereas education and feedback can lead to a small but significant 
improvement of guideline adherence.
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INTRODUCTION
Treatment of rheumatoid arthritis (RA) is based on the tight control principle in which 
disease activity monitoring and treatment changes if a pre-set target is not reached, is 
essential. Treating patients using a tight control strategy, especially in combination with a 
specified treatment protocol, results in lower disease activity and less functional damage 
compared to usual care.(1-5) In order to help practicing clinicians using a tight control 
strategy, many tight control based guidelines are available.(6-8) Next to the tight control 
based treatment guidelines, separate recommendations exist on topics such as shared care 
or risk management.(9;10)
Unfortunately, adherence to these guidelines is often suboptimal. For example, treatment is 
not changed on time in case of active disease or patients do not receive appropriate Disease 
Modifying Anti-Rheumatic Drug (DMARD) therapy.(11-13) For patients, the lack of adherence 
to tight control recommendations by rheumatologists can have severe consequences as 
non-adherence has been associated with more radiographic progression and functional 
impairment.(5) 
Despite these observations on suboptimal guideline adherence and its consequences for 
patients, implementation research in rheumatology is scarce and almost no trials on 
improving rheumatologist guideline adherence exist (14). However, Cochrane reviews and 
two RA studies on often performed interventions (educational meetings, audit and feedback, 
and reminders) conclude that they all can improve care provided to patients.(15-17)
Based on the lack of intervention studies within rheumatology and the existence of 
effective interventions outside rheumatology, we aim to improve RA care by increasing 
rheumatologists’ guideline adherence using education, feedback and Computerized Decision 
Support System (CDSS). 
METHODS
Study design and participants
A single center, randomized controlled pilot study was performed to assess the effects of an 
extended intervention strategy including education, feedback and CDSS versus a standard 
strategy with education and feedback alone. In addition, the randomized controlled design 
was combined with a before-after design in the control group to assess the effect of the 
standard intervention strategy alone (figure 1). 
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Figure 1 study design
The study was conducted at the department of rheumatology at the Sint Maartenskliniek 
(specialized clinic in rheumatology, orthopedics and rehabilitation medicine, the 
Netherlands). All clinicians prescribing rheumatologic medication (rheumatologists, 
residents and physician assistants (PA)), working at this center between July 2013 and May 
2014 were eligible. Only clinicians that were not willing to sign informed consent were 
excluded. 
Although the interventions were aimed at clinicians, outcomes were measured in patients 
(provided care in accordance with the guideline ‘yes’ or ‘no’). All adult patients with an ICD-
9 code of RA (714.x) with a visit to an included clinician during the pre- or post-intervention 
period were eligible for inclusion. Participation in a biological DMARD (bDMARD) dose 
tapering trial, being held at the study center in the same period, was the only exclusion 
criterion as this trial could influence treatment decisions made during our study.
A random sample of all eligible patients was drawn both before- and after the intervention. 
This because approximately 2250 unique RA patients are treated at the study center and 
data collection for all those patients was deemed too labor intensive. Thus, patients were 
identified from two different time periods: July 2013 to December 2013 (pre-intervention) 
and January 2014 to April 2014 (post- intervention). Balancing precision and feasibility of 
data collection, we included 30 RA patients per clinician in both time periods. For those 
patients, only the first visit in the pre- or post-intervention period was used to assess 
guideline adherence, meaning that in this study the number of visits and patients is equal, 
and that the before after comparison is done between two unpaired groups.
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Randomization
Included clinicians were randomized in a 1:1 ratio of intervention versus control group 
using two blocks (block size 10). A research physician allocated clinicians using a computer 
generated randomization list. After signing informed consent, the clinician received a 
sealed opaque envelope that contained the randomly assigned allocation. Due to the nature 
of the interventions, blinding of participants or researchers was not possible.
Interventions
The standard intervention was provided to all clinicians in the intervention- and control 
group, and comprised a one-hour group session combining education with feedback. The 
first part of the session focused on the importance of tight control and guideline adherence 
in RA patients (education). Next, feedback was given on group level and where possible on 
individual level (non-anonymous). The whole session was developed and provided by NL 
(PhD student) and AdB (rheumatologist), both working at the study center. 
In the intervention group, CDSS was added to the previous intervention (extended 
intervention strategy). The CDSS was linked to the Electronic Health Record (EHR) used 
at the study center (EZIS version 5.2, Chipsoft). The CDSS was incorporated into the 
Computerized Physician Order Entry (CPOE) which was already integrated in the EHR and 
used by all clinicians. The CDSS worked with algorithms, using clinical information from the 
EHR, to automatically complete CPOE orders and to send reminders to the clinician about 
routine care. A week before the CDSS became available to the intervention group, they 
received 1.5 hour training and until the CDSS was released into the EHR, clinicians could 
practice with the CDSS in a special training version of the EHR. After implementation of the 
CDSS into the EHR, assistance from the developers was available for additional explanation 
of the system. The CDSS was designed in such a way that it could be specifically linked to 
the Chipsoft account of intervention group clinicians, making it impossible for control group 
clinicians to access the CDSS thereby preventing contamination between groups. The CDSS 
development was a close collaboration between clinicians (NL and AdB) and the Information 
Technology department of the study center. 
During the intervention development, we took into account determinants of success as 
described in relevant reviews on this topic.(15;16;18-20) A more extensive explanation of 
both interventions can be found in supplement 1, with the PowerPoint slides used during the 
educational meeting provided in supplement 2. 
Outcome measures
As no standard indicator set for quality of care in RA is available (21), we had to develop our 
own indicator set. We chose to base our set on the indicators stated in the Dutch national 
RA guideline (6) as this guideline most closely matches the situation at the study center. 
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As mentioned in the introduction, other recommendations besides tight control treatment 
are available to rheumatologists. Therefore, we chose to incorporate a broader set of 
indicators than in previous RA guideline adherence studies. This resulted in the selection 
of 13 indicators on treatment & monitoring, follow-up & shared care, and administration 
(table 1). In supplement 3 the development process is described in more detail. 
Using the 13 indicators as separate primary outcomes would have resulted in multiple testing 
problems during the analysis. The primary outcome was therefore the mean difference 
in a standardized guideline adherence sum score (SSS) between the intervention and 
control group (i.e the primary analysis was conducted on pre-post intervention differences 
between education alone versus education and CDSS). The 13 separate indicators all had 
dichotomous outcomes (1 for ‘yes’ and 0 for ‘no’). In this way the SSS could be calculated 
for every patient by totaling the score of the individual guideline adherence indicators and 
dividing this by the number of indicators that applied to this patient (score range 0 to 1, 
higher scores indicating more guideline adherence). Both the adherence percentages of the 
separate guideline indicators and the mean difference in SSS before and after the standard 
intervention in the control group are reported as secondary outcomes. 
Data collection
As no real time feedback on all indicators was available at the study center and not all 
data could be automatically extracted from the EHR, we had to rely on manual EHR review 
for data collection. For every included patient, data from one visit was collected in either 
the pre- or post-intervention period. If the patient had visited the clinic more than once 
during the pre- or post-intervention period, only the first visit in this period was taken into 
account. Using pre-defined algorithms, the 13 guideline indicators could be calculated from 
visit data on demographics, disease characteristics, disease activity, functional status and 
current medication use.
Of note, during data collection we mainly relied on the CPOE orders done by included 
clinicians. For example, in case of indicator 11 (interval to the next visit) we looked at 
the corresponding CPOE order and noted the interval that the clinician had entered (i.e. 
three months, six months, etc.). In reality this follow-up visit could be planned a few weeks 
before or after the proposed interval due to organizational issues or patient factors. By 
using the CPOE orders, we were sure that the clinicians’ decision had been noted and not 
organizational or other issues. 
Blinded data collection was not possible as it could be directly seen from the EHR whether 
the patients’ treating clinician used the CDSS (intervention group) or not (control group). 
However, double data extraction and entry was performed on two different random samples 
of patients in order to achieve high-quality data collection.
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Table 1 Guideline adherence indicators and the relation between indicators and interventions
Guideline adherence indicator Topic covered during 
interventions
Education & 
feedback
CDSS
Treatment & 
monitoring
1. DAS28 measurement performed during the outpatient 
clinic visit
 
2. Radiographs of hands, feet and thorax made at the 
moment of diagnosis and radiographs of hands and feet 
repeated 1 and 3 years thereafter

3. Yearly assessment of functional status using the HAQ  
4. Prescription of conventional and biological DMARDs 
according to the preferential order1 when initiating a 
new DMARD
 
5. Use or prescription of a concomitant conventional 
DMARD in case of biological use
 
6. Therapy change2 in case of active disease as measured 
with the DAS283

7. Dose reduction or interval lengthening (dose 
optimization) of biological DMARDs in case of low 
disease activity and stable biological use for the 
previous six months

Follow-up & 
shared care
8. Referral of new RA patients to a specialized nurse 
within the two weeks after diagnosis4 
 
9. Planned nurse led DAS28 assessment during the next 
regular outpatient clinic visit 5
 
10. Referral to a PA6  
11. Correct interval between the visit in the study period 
and the next planned regular outpatient clinic visit
 
Administration 12. A letter to the general practitioner, sent within two 
weeks after diagnosis in case of a new RA patient (new 
patient letter)

13. A letter to the general practitioner, sent once every 18 
months (control patient letter)

DAS28, Disease Activity Measurement in 28 joints; HAQ, Health Assessment Questionnaire; DMARD, 
Disease Modifying Anti-Rheumatic Drug; PA, Physician Assistant. 1Preferred order in which conventional 
and biological DMARDs should be prescribed, the exact order is described in the local RA guideline used 
at the study center. 2Therapy change included intensifying DMARD therapy, initiating or increasing the 
dose of oral corticosteroids and the use of corticosteroid injections (either intra-articular or intra-
muscular).3Active disease as measured with the DAS28 depended on disease duration (disease duration 
≤3 years active disease if DAS28 ≥2.6; disease duration >3 years active disease if DAS28 ≥3.2) 4At the 
study center all patients should be seen by a specialized nurse in their first year of disease in order 
to receive more information on RA and discuss coping with the disease. 5At the study center all RA 
patients should be seen by a nurse before their visit to the rheumatologist, in order to have the 
DAS28 measured. 6At the study center rheumatologists and PA share care for RA patients, meaning that 
patients are alternatingly seen by a rheumatologist and PA. According to Dutch law PAs are allowed to 
prescribe DMARDs, but work always under supervision of a rheumatologist.
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Ethical approval
This study was presented to the local ethics committee (CMO; Commissie Mensgebonden 
Onderzoek region Arnhem-Nijmegen), but according to Dutch Act on Medical Research 
Involving Human Subjects, the study did not need ethical approval (CMO reference number 
2013/529). Written informed consent from all participating clinicians was obtained before 
study start.
All patient data were collected within the study hospital from the local EHR, after which 
the data was anonymized. As this data cannot be traced back to an individual patient, no 
written informed consent was needed from the patients according to Dutch Data Protection 
Act. 
The study was registered with the Dutch trial register (www.trialregister.nl, NTR 4449). 
When reporting this study we followed the CONSORT and SQUIRE guidelines.(22;23)
Statistical analysis & reporting of results
All analyses were done using STATA version 13. Depending on the type of variable, descriptive 
statistics are presented as absolute numbers with the accompanying percentages, as means 
with standard deviations (SD) or as median with the interquartile range (IQR).
Based on an earlier retrospective study (24) we expected a mean SSS of 0.27±0.13 in both 
the intervention and control group before the intervention, increasing to 0.45 in the control 
group and 0.72 in the intervention group (mean SSS difference: 0.27). With one sided testing 
(α=0.05, 1−β=0.8) and a randomization ratio of 1:1, we calculated that 18 subjects would be 
needed for the before/after controlled design and 8 in the randomized controlled design. 
Potential clustering of patients within a clinician was already accounted for in the sample 
size calculation by taking the SSS as the primary outcome measure.
To assess our primary outcome, taking the hierarchical structure of our data into account 
(clustering of patients within clinicians), multilevel linear regression analysis was 
performed. In the regression model, the SSS was added as the dependent variable with study 
period, group allocation and the interaction between group allocation and study period as 
independent variables. By adding the interaction term we tested whether a baseline to 
post-treatment change in the dependent variable was greater for the intervention group 
than for the control group. The effect of the standard intervention alone was assessed with 
a multilevel linear regression model with study period as the independent variable, only 
using the data from the control group. Results from both multilevel regression analyses are 
reported as regression coefficients with the corresponding 95% confidence interval (95% CI) 
and p-value. 
Secondary analyses were performed with the thirteen separate guideline indicators using 
multilevel logistic regression models assessing the added effect of the extended intervention 
and the separate effect of the standard intervention. Results from these analyses are 
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reported as odds ratios (OR) with the corresponding 95% confidence interval (95% CI) and 
p-value.
As not all 13 guideline adherence indicators could be covered with CDSS (table 1), a post-
hoc sensitivity analysis was done in order to see if a SSS excluding the indicators not covered 
in the CDSS yielded different results than the SSS including all indicators. 
A second post-hoc sensitivity analysis was performed to assess if SSS results were different 
when only rheumatologists were included. This was done because clinician randomization 
resulted in more PAs and residents being allocated to the control group.
Finally, the SSS was also calculated and analyzed for all three groups of indicators separately 
(treatment & monitoring, follow-up & shared care, administration) whether to see if this 
made a difference.
RESULTS
Participants
At study start 25 clinicians were assessed for eligibility and 20 fulfilled the inclusion criteria. 
All eligible clinicians signed informed consent and attended the allocated interventions. No 
loss to follow-up occurred. Table 2 shows the baseline clinician and patient characteristics. 
Altogether, 4648 unique adult patients with an ICD-9 code of RA visited the study clinic 
during the study period (pre- and post-intervention) and after drawing the random sample, 
1102 of those patients were selected for participation. Of those, 60 had to be excluded 
due to participation in the dose tapering study. In addition, during the EHR review a small 
proportion of patients turned out not to fulfil the inclusion criteria (n= 52). For example, due 
to rescheduling of visits, no visit in the intervention period was available. This resulted in 
990 patients being included in the final analysis (control group n= 508 patients; intervention 
group n= 482).
Intervention effects on the standardized sum score
Both the standard and extended intervention resulted in an increase of the SSS, with the 
mean SSS increasing from 0.58 to 0.64 for the standard intervention and from 0.55 to 0.63 
for the extended intervention (mean SSS difference 0.02; 95%-CI -0.04 to 0.08; p = 0.60). 
In the before/after analysis in the control group, the increase in SSS after the standard 
intervention was statistically significant (mean difference 0.06; 95%-CI 0.02 to 0.11; p 
<0.01). All post-hoc sensitivity analyses yielded similar results to the primary analysis (table 
3).
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Table 2 Clinician and patient characteristics at baseline
Control group Intervention group
Clinician characteristics n= 10 n= 10
Age, years (SD) 42.4 (11.1) 46.0 (11.0)
Female sex, n (%) 5 (50) 6 (60)
Rheumatologist, n (%) 9 (90) 6 (60)
Work experience, years (IQR) 5.0 (3.0 to 7.0) 8.0 (8.0 to 14.0)
Patient characteristics N= 508 N= 482
Age, years (SD) 62.1 (12.5) 62.0 (12.6)
Female sex, n (%) 340 (66.9) 346 (71.8)
Disease duration, years (IQR) 8.0 (3.0 to 14.0) 7.0 (2.0 to 12.0)
Rheumatoid factor and/or anti-CCP positivity, n (%) 338 (76.5) 257 (67.5)
Erosive disease, n (%) 225 (47.3) 189 (44.0)
SD: standard deviation, IQR: interquartile range
Intervention effects on the individual indicators
The secondary analyses on the individual indicators yielded similar results to the primary 
analysis with no difference between the standard and extended intervention for any of 
the indicators. In the before/after comparison four out of thirteen indicators changed 
significantly after the standard intervention (table 4). Of those four, three improved after 
the intervention (DAS28 measurements, yearly HAQ assessment and PA referral) and one 
worsened (radiographs of hands, feet and thorax). 
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DISCUSSION
To our knowledge this is one of the first randomized controlled trials within rheumatology 
trying to improve guideline adherence of clinicians. Our results show that CDSS has no 
added value in this context, whereas education and feedback did lead to a significant 
improvement in guideline adherence.
The strengths of this study are the use of a randomized design, a broad set of indicators, 
inclusion of different types of clinicians involved in RA care, inclusion of a large sample of 
both early and established RA patients reflecting daily clinical practice and the use of two 
different interventions. 
However, this study has some limitations related to the internal validity and generalizability. 
Firstly, not all desired changes could be implemented in the CDSS. As a result, the SSS 
included indicators not covered with this intervention (table 1). This concerned indicator 
2 (radiographs), 6 (therapy change) and 7 (biological dose optimization). Nevertheless, 
sensitivity analyses yielded no different results when excluding these indicators from the SSS 
calculation. Secondly, after randomization the control group included more rheumatologists 
than the intervention group (90% vs 60%), but this did not seem to have influenced our 
results as sensitivity analyses excluding non-rheumatologists gave similar results as the 
original analysis. Thirdly, due to our study design we are not able to infer a causal relation 
between the standard intervention and guideline adherence afterwards as other events in 
the same time period might have attributed to the observed results. However, we are not 
aware of any events during the study that could have influenced our results and during the 
study special attention was paid not to start other quality improvement projects. Fourthly, 
as this was a single center study the generalizability may be hampered due to differences 
on patient-, hospital-, or societal level. However, the RA population treated in the study 
center seems to represent a normal RA population, thus not hampering generalizability. Of 
course, the study center being a specialized clinic and the study only being performed in 
the Netherlands might have influenced our results, which stresses the need for replication 
of our study in other settings. Finally, the use of a broad set of indicators in combination 
with the sample size can also be seen as a disadvantage as not all patients could be included 
in all indicators. However, by using this set of indicators for the first time we were able to 
gain more insight into the broad concept of quality of care in rheumatology. However, future 
studies, preferably multi-centre, should use a larger sample in order to be able to confirm 
our results when using multiple indicators. 
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Being one of the first intervention studies to improve clinicians’ RA guideline adherence 
also has a downside, as we cannot directly compare all of our results with other groups. 
With regard to our standard intervention we are aware of one other study using education 
and feedback to improve RA care (Metrix study). In this randomized controlled trial, 
rheumatologists receiving education and feedback (n= 10) collected more global assessments 
and HAQs than their colleagues not receiving these interventions (n=10). Furthermore, the 
researchers could calculate more composite scores in the intervention group (increase from 
43% to 57%), whereas the control group did not show any change. Finally, the intervention 
group did change therapy in 57% of the patients with a high DAS compared to 38% of the 
rheumatologists in the control group.(25) Our results from the standard intervention on 
comparable topics are similar (therapy change in active disease) or better (HAQ and DAS28 
measurement). However, the Metrix study did not measure if composite scores were actually 
calculated by the rheumatologists themselves and if they were used to guide treatment 
decisions. This makes our study probably more useful in judging the effect of education and 
feedback on the use of composite measures such as the DAS28 in daily practice. 
With regard to CDSS, parallels can be drawn with other studies within rheumatology but of 
the four studies we are aware of, only one focuses on RA.(26-29) In this study a template, 
integrating information from different sources (i.e. physician itself, patients and/or EHR), 
was implemented. Following implementation of this system, a strong correlation was found 
between use of the system by rheumatologists and disease control, and more patients were 
in a state of low disease activity.(28) Although both the intervention and study population 
are not fully comparable with ours, these results imply that care for patients with rheumatic 
diseases could benefit from EHR changes. 
Outside rheumatology far more studies have been performed on the effect of education 
and feedback. Two Cochrane reviews on this subject conclude that both educational 
meetings and feedback can improve clinical practice, although the effects are often small 
to moderate which resembles the effects found in this study.(15;16;30) Similarly, different 
reviews on CDSS have been performed outside rheumatology concluding that CDSS results 
are not always consistent but can improve practitioner performance. However, patient 
outcomes such as morbidity and mortality are at best moderately improved.(17;31-34)
Finally, it is interesting to notice that not all indicators did show an improvement after 
the intervention. For example, the indicators on ordering of radiographs and correct 
DMARD prescriptions worsened after the intervention in both the standard and extended 
intervention group. For both observations we do not have a good explanation. However, in 
the light of these results and the previously mentioned reviews, our results emphasize the 
need for better understanding why interventions work in one setting and not in another. 
Several reviews have addressed this issue and many factors could possibly influence 
successful uptake of the interventions. We have tried to take these factors into account 
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during the development and execution of our interventions, for example by making sure 
CDSS was integrated into the workflow and the messages were timely and relevant. Also, 
attendance during the educational meeting was high and feedback was provided by a direct 
colleague. However, it was not possible to incorporate all the potential factors for success, 
which might explain the small effects observed. In addition, guideline adherence might be 
classified as complex behavior due the many, and often interconnected, recommendations 
that have to be followed. This could have led to the small effect of education and feedback, 
with our CDSS not being adequate enough to fill in the gap between knowing about the 
recommendations and actually practicing them. 
Despite the small effects observed, we feel that our study has important practical 
implications, especially within rheumatology. First of all, the results of this study confirm 
that improving guideline adherence is a challenge. However, the improvement resulting 
from our standard intervention is a first step in the right direction and again stresses the 
importance of more attention towards the implementation of guidelines. Secondly, this 
study probably could have benefited from a more formal barrier analysis before study start, 
in order to develop an even more targeted intervention. Although a Cochrane review on this 
subject is not conclusive, future studies should certainly consider such an approach.(35) 
Lastly, our study is an example of implementation research where we tried to bridge the gap 
between evidence and practice. So far, this type of research is scarce within rheumatology 
which was recently recognized by Buchbinder et al. We agree with these authors that only 
performing clinical research is not enough to improve care if no attention is given to the 
implementation of new findings in clinical practice.(14) Therefore, we would strongly 
advocate for more attention towards implementation science within rheumatology in order 
to let more patients benefit from optimal RA care. 
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SUPPLEMENT 1: INTERVENTION DESCRIPTION
Intervention choice
The interventions used in this study were education combined with feedback, and a 
Computerized Decision Support System (CDSS). These specific interventions were chosen 
based on an informal barrier analyses at the study center, using the framework proposed 
by Cochrane et al.(36) This framework groups determinants of guideline adherence into 
different themes such as cognitive-behavioral barriers, barriers embedded in the guideline 
or evidence, and barriers related to support or resources. In the years before this study 
started, the study center already invested in improving knowledge and attitudes concerning 
RA treatment. As a result, amongst others, up to date RA treatment guidelines were available 
and a safe learning environment was created. Looking at the Cochrane framework, we 
concluded that the theme ‘barriers related to support or resources’ was not yet optimally 
covered at the study center. Therefore, we decided to develop our own CDSS to aid 
rheumatologists in their daily practice. As the latest updates from the local RA guideline 
(2013) had not been presented in an educational session before, we decided to also include 
education and feedback in our intervention strategy. This resulted in a standard intervention 
strategy (education and feedback) being tested against an extended intervention strategy 
(education, feedback and CDSS). 
When developing both interventions we took into account existing reviews on factors of 
success for education, feedback and CDSS. For example, CDSS uptake was found to be more 
successful if adequate technical support and training were present, CDSS was integrated 
into the workflow and the messages were relevant and on time.(18-20) For education and 
feedback factors like attendance, the source of feedback and the complexity of the targeted 
behavior influence intervention effects.(15;16) Modifiable factors from these reviews were 
reckoned with during the development process. 
 
Education & feedback
All included clinicians attended a one-hour group session, combining an educational 
meeting with feedback. During this meeting clinicians received background information 
on the effectiveness of tight control treatment strategies in RA treatment, the importance 
of guideline adherence for RA patients and the content of existing local RA treatment 
guidelines. With regard to the latter, extra attention was given to the local guideline on 
biological dose optimization, which was disseminated just before this study started. The 
session finished with feedback on current guideline adherence of the clinicians, using results 
from a previous study on guideline adherence in this center (manuscript under review) and 
existing feedback systems in the study hospital. Due to this combination we could give 
feedback on all but two indicators (concomitant cDMARD use and bDMARD dose reduction) 
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included in this study. The PowerPoint slides used during this intervention can be found in 
supplement 2. 
Computerized Decision Support System
Background on the Computerized Physician Order Entry System used at the study clinic 
In order to fully understand the CDSS used as an intervention in our study, it is first necessary 
to know how the EHR at the study clinic worked before the study. At the study center EZIS 
version 5.2 (Chipsoft) is used by all physicians and a Computerized Physician Order Entry 
(CPOE) system was already integrated in this EHR. As the CDSS intervention in this study 
focused at the CPOE, a description of the different CPOE categories before the intervention 
is given in table 1.
Description of the Computerized Decision Support System
The main aim of the changes made to the CPOE was to facilitate guideline adherence by 
clinicians working at the outpatient clinic of the rheumatology department. By reorganizing 
the CPOE and including CDSS it should be less easy for clinicians to accidently forget about 
important recommendations from the local RA guidelines. To achieve this goal, four changes 
were made to the CPOE.
The first of four changes included a reorganization of the CPOE system. As can be seen in 
table 1, the organization of the CPOE categories was mainly receiver-based and not very 
practical for clinicians. In the new version grouping of CPOE orders was done in a sender-
based way, with four main categories: diagnostics, treatment, follow-up and administration. 
All orders from the old system were placed into the new categories and some orders were 
adapted to make the other changes possible. 
With the next change we included hyperlinks to local guidelines in the CPOE system. For 
example, the order on DMARD initiation now included a hyperlink to the guidelines on the 
DMARD preferential order and DMARD toxicity follow-up. 
The third change comprised the development of an algorithm which automatically completed 
some of the CPOE orders, based on patient-specific information from the EHR and the local 
RA guideline. An example of this change was the follow-up order with the algorithm using 
clinical information from the EHR, user login and local guidelines to complete the three 
main components of the order. These components were: 1) follow-up duration (3 or 6 
months based on disease duration, disease activity and DMARD use), 2) preferred provider 
of care (PA or rheumatologist based on provider of the current visit), and 3) referral to a 
specialized nurse for routine DAS28 and HAQ assessments. Clinicians not agreeing with the 
suggestions done by the CDSS could always change the answers on all components of the 
order before sending the order away. 
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Table 1 Main order categories within the pre-intervention Computerized Physician Order Entry system
Order category Suborders included into the category Receiver
Clinical 
admissions
Clinical admissions and surgery Surgery and clinical 
admission planner
Multidisciplinary 
treatments
No suborders were included in this category, although 
the choices following this order also included ordering of 
infusion therapies such as rituximab or infliximab.
Multidisciplinary 
treatment planner
Order to 
rheumatologist
No suborders were included in this category. This order 
only contained a text field in which a remark or question 
to another rheumatologist could be entered (limited 
number of characters). 
Rheumatologist as 
chosen by the sender of 
the order
Order to front 
office
15 suborders were included in this category, ranging from 
orders on follow-up appointments to routine laboratory 
checks in DMARD users. This order could only be used if a 
patient was present at the outpatient clinic.
Nurses or supportive 
staff at the front office 
at the rheumatology 
outpatient clinic
Order to 
outpatient clinic 
nurse
15 suborders were included in this category, ranging from 
blood pressure measurement to the preparation of intra-
articular injections.
Nurse at the 
rheumatology 
outpatient clinic
Order to 
secretary
Several suborders were included in this category such as 
retrieving patient information from other hospitals.
Secretary of the 
rheumatology 
department
Correspondence No suborders were included in this category. This order 
only included a choice on what of letter should be 
made (new or control patient) and a few text fields 
were additional information on the receiver (general 
practitioner, other specialist) or letter (attachments) 
could be entered.
Secretary of the 
rheumatology 
department
Order to archive No suborders were included in this category. This order 
could only be used to retrieve old paper chart from the 
archive.
Archive
Order to myself No suborders were included in this category. This order 
only included a text field were a remark or question 
could be entered. This order often acted as a reminder 
for the sender to perform certain actions for the patient 
in question (for example calling the GP to discuss the 
patient).
Sender of the order
Order to back 
office
No suborders were included in this category. This order 
only included a text field were a remark or question 
could be entered. This order served as a substitute for 
the ‘front office order’ if a patient was not present at 
the outpatient clinic. For example, if after a telephone 
call with a patient, a follow-up visit should be planned, 
this order had to be used.
Nurses or supportive 
staff at the back office 
at the rheumatology 
outpatient clinic
Consulting other 
specialists
No suborders were included in this category. This order 
only included text fields in which clinical information 
about the patient and questions for the consulting 
specialist could be entered. This order only applied to 
clinically admitted patients. 
Internal medicine or 
gerontology specialist
Laboratory tests No suborders were included in this category. All available 
laboratory tests at the study center were included in this 
order and could be selected by clinicians. 
Nurse at the 
rheumatology 
outpatient clinic
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
 Improving rheumatoid arthritis guideline adherence  |  191
9
The final change included the development of a reminder system to assist clinicians in 
keeping their correspondence with the general physician up to date. With this system a 
reminder was created every time a new visit was entered into the EHR by a rheumatologist, 
PA or resident. This reminder consisted of an order stating that a letter to the GP should be 
created. However, this reminder only became visible to the clinician after a certain period 
of time (2 weeks or 18 months depending on the type of letter needed) if the clinician had 
not created a GP letter himself in the meantime. In this way we prevented unnecessary 
reminders for rheumatologists who did not need them.
In table 2 the relation between the CDSS changes and the guideline adherence indicators 
used in this study is stated.
Table 2 CDSS changes in relation to the guideline adherence indicators
Guideline adherence indicator Topic covered with CDSS
Regrouping 
CPOE
Hyperlink to 
guideline
Pre-fill 
orders
Reminders
DAS28 measurement  
Radiographs of hands, feet and thorax 
Yearly assessment of functional status using the HAQ  
Prescription of conventional and biological DMARDs 
according to the preferential order
 
Concomitant conventional DMARD in case of 
biological use
 
Therapy change in case of active disease as 
measured with the DAS28
 
Dose reduction or interval lengthening (dose 
optimization) of biological DMARDs
 
Referral of new RA patients to a specialized nurse  
Planned nurse led DAS28 assessment during the next 
regular outpatient clinic visit
 
Referral to a PA  
Correct interval between the visit in the study 
period and the next planned regular outpatient 
clinic visit
 
A letter to the general practitioner, sent within two 
weeks after diagnosis in case of a new RA patient 
 
A letter to the general practitioner, sent once every 
18 months (control patients)
 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
192  |  Chapter 9
Supplement 2: PowerPoint slides used 
during the educational meeting
Treatment principles in 
rheumatoid arthritis
A translation of the PowerPoint slides used during the educational meeting
Authors: Nienke Lesuis (resident of rheumatology; MD) and Alfons A den Broeder (rheumatologist-epidemiologist; MD, PhD) 
Sint Maartenskliniek, Nijmegen, the Netherlands
Content
• Background
• Treatment principles in RA
• Current situation at our hospital
• Summary
Content
• Background
• Treatment principles in RA
• Current situation at our hospital
• Summary
Background
We would rather prevent than treat these hands, but…
treatment guidelines are not always followed optimally
Content
• Background
• Treatment principles in RA
• Current situation at our hospital
• Summary
Treatment principles in RA
• Many publications on effective RA treatments
• ‘Treat to target’, ‘tight control’ & ‘hit hard, hit 
early’ often mentioned
 Cornerstone of ACR & EULAR RA guidelines
Tight control: ‘frequent assessment of disease activity combined with an 
objective structured protocol to make treatment changes that maintain low 
disease activity or remission at an agreed target’ (Kiely et al, Rheumatology 2009)
Treat to target: ‘the treatment aim was defined as remission with low 
disease activity being an alternative in patients with long-standing disease. 
Regular follow-up with appropriate therapeutic adaptation to reach the 
desired state within 3-6 months. Follow-up examinations ought to employ 
composite measures of disease activity which include joint counts. (Smolen et al, Ann Rheum 
Dis 2010)
Hit hard, hit early: ‘early institution of DMARDs.’ ‘Window of opportunity’
Treatment principles in RA
Tight control: ‘frequent assessment of disease activity combined with an 
objective structured protocol to make treatment changes that maintain low 
disease activity or remission at an agreed target’ (Kiely et al, Rheumatology 2009)
Treat to target: ‘the treatment aim was defined as remission with low 
disease activity being an alternative in patients with long-standing disease. 
Regular follow-up with appropriate therapeutic adaptation to reach the 
desired state within 3-6 months. Follow-up examinations ought to employ 
composite measures of disease activity which include joint counts. (Smolen et al, Ann Rheum 
Dis 2010)
Hit hard, hit early: ‘early institution of DMARDs.’ ‘Window of opportunity’
Treatment principles in RA
“Yes, I agree with the general principle but….”
‘A number says nothing! I always look and listen to
the patient, order a ESR and feel the joints’
‘Patients don’t want all those pills’
‘My judgement is better than a composite measure, 
these numbers mean nothing to a patient’
DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(sw llen28) + 0.70 * 
ln(ESR) + 0.014 * VAS (http://www.das-score.nl/das28/nl/uitleg-das28/de-das28-score.html)
In case of active disease, patients just want to get better. They only 
get worried about the number of pills later on. (van Tuyl, Rheumatology 2008)
A DAS28 <3.2 is associated with 50% less progression of radiographic 
damage and functional status (HAQ) is influenced by both active 
inflammation and radiographic damage. (Fransen et al, Ann Rheum Dis 2005)
Treatment principles in RA
• Intensive management:
– Monthly visits including DAS measurement
– Corticosteroid injection of any swollen joint or depomedrol
120mg i.m. if DAS >2.4
– Strict medication protocol: dose increase or cDMARD switch 
every 1-3 month if DAS >2.4
• Routine care:
– 3-montly visits
– No routine DAS measurement or strict medication protocol
Treatment principles in RA
Treatment principles in RA
SUPPLEMENT 2: POWERPOINT SLIDES USED DURING THE EDUCATIONAL 
MEETING
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Treatment principles in 
rheumatoid arthritis
A translation of the PowerPoint slides used during the educational meeting
Authors: Nienke Lesuis (resident of rheumatology; MD) and Alfons A den Broeder (rheumatologist-epidemiologist; MD, PhD) 
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Tight control: ‘frequent assessment of disease activity combined with an 
objective structured protocol to make treatment changes that maintain low 
disease activity or remission at an agreed target’ (Kiely et al, Rheumatology 2009)
Treat to target: ‘the treatment aim was defined as remission with low 
disease activity being an alternative in patients with long-standing disease. 
Regular follow-up with appropriate therapeutic adaptation to reach the 
desired state within 3-6 months. Follow-up examinations ought to employ 
composite measures of disease activity which include joint counts. (Smolen et al, Ann Rheum 
Dis 2010)
Hit hard, hit early: ‘early institution of DMARDs.’ ‘Window of opportunity’
Treatment principles in RA
Tight control: ‘frequent assessment of disease activity combined with an 
objective structured protocol to make treatment changes that maintain low 
disease activity or remission at an agreed target’ (Kiely et al, Rheumatology 2009)
Treat to target: ‘the treatment aim was defined as remission with low 
disease activity being an alternative in patients with long-standing disease. 
Regular follow-up with appropriate therapeutic adaptation to reach the 
desired state within 3-6 months. Follow-up examinations ought to employ 
composite measures of disease activity which include joint counts. (Smolen et al, Ann Rheum 
Dis 2010)
Hit hard, hit early: ‘early institution of DMARDs.’ ‘Window of opportunity’
Treatment principles in RA
“Yes, I agree with the general principle but….”
‘A number says nothing! I always look and listen to 
the patient, order an ESR and feel the joints’
‘Patients don’t want all those pills’
‘My judgement is better than a composite 
measure, these numbers mean nothing to a 
patient’
Treatment principles in RA
“Yes, I agree with the general principle but….”
‘A number says nothing! I always look and listen to
the patient, order a ESR and feel the joints’
‘Patients don’t want all those pills’
‘My judgement is better than a composite measure, 
these numbers mean nothing to a patient’
DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(sw llen28) + 0.70 * 
ln(ESR) + 0.014 * VAS (http://www.das-score.nl/das28/nl/uitleg-das28/de-das28-score.html)
In case of active disease, patients just want to get better. They only 
get worried about the number of pills later on. (van Tuyl, Rheumatology 2008)
A DAS28 <3.2 is associated with 50% less progression of radiographic 
damage and functional status (HAQ) is influenced by both active 
inflammation and radiographic damage. (Fransen et al, Ann Rheum Dis 2005)
Treatment principles in RA
• RCT: routine vs intensive management
• Inclusion criteria: diagnosis of RA <5 years; DAS 
>2.4
• Study assessment 1x/3 months (DAS etc) by blinded 
assessor
• Primary endpoints:
– Mean fall in disease activity
– % patients with an EULAR good response
Treatment principles in RA
• Intensive management:
– Monthly visits including DAS measurement
– Corticosteroid injection of any swollen joint or depomedrol
120mg i.m. if DAS >2.4
– Strict medication protocol: dose increase or cDMARD switch 
every 1-3 month if DAS >2.4
• Routine care:
– 3-montly visits
– No routine DAS measurement or strict medication protocol
Treatment principles in RA Treatment principles in RA
Treatment principles in RA
• Intensive management:
– More corticosteroid injections (i.m./i.a.)
– Higher doses of MTX
– More frequent start of a new DMARD
– Higher drug survival
– Less medication side-effects
Conclusion: intensive treatment gives substantial 
improvement of disease activity
Treatment principles in RA
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• Cluster RCT: monitoring DAS28 (12 centers) vs 
routine care (12 centers)
• DAS28 assessment by research nurse at 0 & 24 
weeks
• Primary outcomes
– % patients with DAS28 <3.2 (subgroup analysis due to 
organizational issues)
– Changes in DMARD treatment (all patients)
Treatment principles in RA
• Intervention centers
– DAS28 measurement for clinical use at 0,4,12 & 24 weeks by 
treating rheumatologist
– Study advice: change medication if DAS28 >3.2
• Control centers
– Visit at week 0,4,12 & 24
– No systematic monitoring or treatment advices
Treatment principles in RA
• Baseline data
– ± 70% women; 58 years; ± 80% RF positivity; disease duration 6 
years
– DAS28 4.5; 13% low disease activity 
Of note, DAS28 only measured by research nurse in 142 
patients (61 intervention group; 81 control group)
Treatment principles in RA Treatment principles in RA
Treatment principles in RA
• No significant differences in mean MTX, sasp and prednisone 
dose
• No differences in side-effects
• Intervention group
– DAS28 measured in 99% of the visits
– 98% of patients in which medication was changed had a DAS28 >3.2
– 20% of patients with a DAS28 >3.2 had their medication changed
Conclusion: standard monitoring of disease activity in daily 
practice, can lead to more DMARD-changes compared to usual 
care
Treatment principles in RA
• PubMed & Cochrane library 1995 – 2009: monitoring of 
disease activity combined with treatment protocols vs 
monitoring alone
• Inclusion: studies on routine care vs tight control
• Primary outcome
– Mean change in DAS28 (year 0 vs 1)
Treatment principles in RA
• Included studies (n= 6)
– 4 RCT, 2 CCT; study duration between 12 and 24 months
– 3 studies monitoring + treatment protocol, 3 studies 
monitoring alone
– 2 studies in early, DMARD-naive RA; others in early & late 
RA
• Baseline data
– 110 to 435 pt per study; 60% to 70% female; 42% to 80% 
RF positive; DAS28 >3.2
Treatment principles in RA
Treatment principles in RA
• Results clinical effectiveness tight control
– In 5 studies tight control better than routine care
– More medication changes, better physical functioning and less 
radiographic damage with tight control
– Toxicity similar
• Results meta-analysis
– Tight control vs usual care: tight control is more effective, 0.6 
DAS28-point more decrease in DAS28
– Within tight control studies, monitoring + protocol is more 
effective than monitoring alone: 0.66 DAS28-point more decrease 
in DAS28
Treatment principles in RA
Conclusion: the use of tight control strategies in RA is more 
effective than routine care. The use of protocols is more 
effective than monitoring alone.
Treatment principles in RA
“Yes, but these are clinical trials. The effect in 
daily practice has not been proven.”
Treatment principles in RA
Summary: 
Tight control gives better results and guideline 
adherence makes a difference to patients. 
However…
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• Intervention centers
– DAS28 measurement for clinical use at 0,4,12 & 24 weeks by 
treating rheumatologist
– Study advice: change medication if DAS28 >3.2
• Control centers
– Visit at week 0,4,12 & 24
– No systematic monitoring or treatment advices
Treatment principles in RA
Treatment principles in RA
• No significant differences in mean MTX, sasp and prednisone 
dose
• No differences in side-effects
• Intervention group
– DAS28 measured in 99% of the visits
– 98% of patients in which medication was changed had a DAS28 >3.2
– 20% of patients with a DAS28 >3.2 had their medication changed
Conclusion: standard monitoring of disease activity in daily 
practice, can lead to more DMARD-changes compared to usual 
care
Treatment principles in RA
• Included studies (n= 6)
– 4 RCT, 2 CCT; study duration between 12 and 24 months
– 3 studies monitoring + treatment protocol, 3 studies 
monitoring alone
– 2 studies in early, DMARD-naive RA; others in early & late 
RA
• Baseline data
– 110 to 435 pt per study; 60% to 70% female; 42% to 80% 
RF positive; DAS28 >3.2
Treatment principles in RA
Treatment principles in RA
• Results clinical effectiveness tight control
– In 5 studies tight control better than routine care
– More medication changes, better physical functioning and less 
radiographic damage with tight control
– Toxicity similar
• Results meta-analysis
– Tight control vs usual care: tight control is more effective, 0.6 
DAS28-point more decrease in DAS28
– Within tight control studies, monitoring + protocol is more 
effective than monitoring alone: 0.66 DAS28-point more decrease 
in DAS28
Treatment principles in RA
Treatment principles in RA
Conclusion: the use of tight control strategies in RA is more 
effective than routine care. The use of protocols is more 
effective than monitoring alone.
Treatment principles in RA
“Yes, but these are clinical trials. The effect in 
daily practice has not been proven.”
Treatment principles in RA
“Yes, but these are clinical trials. The effect in 
daily practice has not been proven.”
Treatment principles in RA
“Yes, but these are clinical trials. The effect in 
daily practice has not been proven.”
ESPOIR study: less radiographic damage  after 1 year and 
functional deterioration after 2 years (early RA).
MTX study: larger decrease in DAS28 after 48 weeks 
(established RA)
Treatment principles in RA
Summary: 
Tight control gives better results and guideline 
adherence makes a difference to patients. 
However…
Treatment principles in RA
Summary: tight control gives better results 
and guideline adherence makes a 
difference to patients. However…
Cohort Recommendation Guideline adherence
ESPOIR (2002-2005) First DMARD in early RA 
(EULAR)
54% 
ERAN (2002-2007) DMARD i  early RA Median time to DMARD 
start: 8 months
(97% DMARD; 67% after 3 years 
DAS28 >3,2)
North-America (2002-
2009)
DMARD in case of active 
RA (ACR)
25-50%
(publication of updated ACR 
guideline no difference)
DREAM remission 
induction (2006)
DMARD in case of active 
RA 
70%
(98% DAS28 available)
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Treatment principles in RA
Summary: tight control gives better results 
and guideline adherence makes a 
difference to patients. However…
Cohort Recommendation Guideline adherence
ESPOIR (2002-2005) First DMARD in early RA 
(EULAR)
54% 
ERAN (2002-2007) DMARD i  early RA Median time to DMARD 
start: 8 months
(97% DMARD; 67% after 3 years 
DAS28 >3,2)
North-America (2002-
2009)
DMARD in case of active 
RA (ACR)
25-50%
(publication of updated ACR 
guideline no difference)
DREAM remission 
induction (2006)
DMARD in case of active 
RA 
70%
(98% DAS28 available)
Guideline adherence is not always optimal…
But how are things in our hospital?
Content
• Background
• Treatment principles in RA
• Current situation at our hospital
• Summary
Current situation at our hospital
• Local RA treatment guideline available
– Based on tight control: measuring DAS28, target 
based on disease duration, changing treatment if 
target is not reached, adequate follow-up
• Also in the guideline:
– Shared care (nurses, PA)
– Monitoring of functional damage
– Other treatment modalities (physical therapy)
– Risk management
Current situation at our hospital
• Other guidelines on related themes also 
available
– Preferential order of c/bDMARDs and NSAIDs
– bDMARD dose optimization
Optimal RA care is more than tight control alone
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• Guideline adherence not always optimal
• Guideline adherence does not need to be 100%: 
deviations are allowed, but explain them!
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Content
• Background
• Treatment principles in RA
• Current situation at our hospital
• Summary
Current situation at our hospital
• Other guidelines on related themes also 
available
– Preferential order of c/bDMARDs and NSAIDs
– bDMARD dose optimization
Optimal RA care is more than tight control alone
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• Guideline adherence not always optimal
• Guideline adherence does not need to be 100%: 
deviations are allowed, but explain them!
Content
• Background
• Treatment principles in RA
• Current situation at our hospital
• Summary
Summary
• Treatment principles in RA
– Tight control: important strategy that 
benefits our patients
– Application in daily practice not yet optimal, 
but seems feasible
• RA treatment in this hospital
– Improvement possible on many indicators
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SUPPLEMENT 3: DEVELOPMENT OF GUIDELINE INDICATORS 
Knowing how to describe quality of care is a prerequisite for its measurement. Often quality 
indicators are used to assess quality of care. A quality indicator is ‘a measurable element of 
practice performance for which there is evidence or consensus that it can be used to assess 
the quality, and hence change the quality of care provided’.(37) Quality indicators are often 
grouped into structure-, process- and outcome indicators. Outcome indicators reflect the 
result of the care that was provided by the healthcare provider, while process indicators 
reflect the actual care given to patients (‘what is done’). Structure indicators, on the other 
hand, describe organizational aspects (‘what is available’).(38)
Different groups and organizations have developed indicator sets and for the purpose of 
this study we used the process indicators covering monitoring, drug treatment, follow-
up and documentation from the Dutch national RA guideline (CBO indicators).(6) The 
Dutch set is selected because it bests reflects care provided at the study center. Structure 
indicators are not taken into account because this will be a single center study and as a 
consequence all structure indicators will be the same for all clinicians. The CBO indicators 
are not always very specific, therefore some indicators are modified as to better reflect 
the recommendations from the local RA guideline at the study center. An overview of all 
indicators is given in table 1.
Besides adaptations of existing CBO indicators, extra indicators were added to the set used 
in our study. This concerned two indicators in the follow-up & referral domain (PA referral 
and nurse-led DAS28 assessments) and the two indicators in the domain on administration 
(new and control patient letters to the general physician). 
The indicators on PA referral and nurse-led DAS28 assessments were added to cover specific 
shared care practices at the study center. In this center all RA patients should be seen by 
a nurse prior to the visit with the rheumatologist (nurse led DAS28 assessment). During 
this visit the DAS28 is done by a specialized rheumatology nurse, together with routine 
laboratory tests and assessment of current medication use. All information is provided to the 
rheumatologist. Furthermore RA patients can be treated by both a physician assistant (PA) 
and rheumatologist, with alternating visits between them. The PA is allowed to prescribe 
rheumatologic medication and make treatment decisions, but the final responsibility always 
lies with the rheumatologist. 
Finally, a new group of indicators concerning administration was added. In the Dutch RA 
guideline no recommendations were given on correspondence with other relevant clinicians, 
especially the general physician (GP). We chose to add these indicators as it is of crucial 
importance that the GP knows if a patient uses DMARD or biological therapy because of 
potentially severe side effects or interactions with other commonly prescribed medication.
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ABSTRACT
Objectives
Assess the effects of education, guideline development and individualised treatment 
advices on rheumatologist adherence to tight control based treatment and biological 
dose optimization in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and 
spondyloarthropathy (SpA) patients.
Methods
This pilot study, among two rheumatologists and two specialized nurses in a 
general hospital, combined education, feedback, local guideline development and 
individualized treatment advices. Outcomes (baseline and 1 year post-intervention) 
were the percentage of patients with a Disease Activity Score in 28 joints (DAS28) 
or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) measured during the 
visit, mean DAS28/ BASDAI and the percentage of patients using a reduced biological 
dose. DAS28 outcomes only apply to RA and PsA patients, BASDAI outcomes only to SpA 
patients, and outcomes on biological dose apply to all patients.
Results
232 patients were included (67% RA, 58% female, mean age 56 ± 15 years).The percentage 
of DAS28 and BASDAI measurements performed increased after the intervention (DAS28: 
15% to 51%, OR 3.3, 95% CI 2.1 to 5.5; BASDAI 23% to 50%, OR 2.2, 95% CI 1.0 to 5.5), 
with mean DAS28 and BASDAI scores remaining similar (DAS28: mean difference 0.1, 
95% CI -0.3 to 0.5; BASDAI: mean difference 0.03, 95% CI -1.8 to 1.9). Use of reduced 
biological dose increased from 10% to 61% (OR 3.9, 95% CI 2.4 to 6.5).
Conclusions
A multi-component intervention strategy aimed at rheumatologists can lead to improved 
adherence to tight control based treatment and a reduction in biological use in RA, SpA 
and PsA patients.
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INTRODUCTION
Treatment of rheumatoid arthritis (RA) is based on tight control principles: setting a target, 
frequent assessment of disease activity and a structured protocol to make treatment 
changes. This strategy leads to lower disease activity and less functional damage compared 
to usual care.[1, 2] Unfortunately, the dissemination of tight control based guidelines 
does not seem to influence the daily practice of rheumatologists enough.[3] For example, 
treatment is not always changed on time in case of active disease or patients are not 
receiving correct Disease Modifying Anti-Rheumatic Drugs (DMARDs).[3] 
According to the 2014 treat-to-target recommendations “maintenance of the treatment 
target does not in itself imply maintenance of treatment”; this refers towards dose reduction 
or stopping of biological DMARDs (bDMARDs; bDMARD dose optimization).[4] In recent years, 
several studies have shown that this strategy can be successful in patients while preserving 
low disease activity.[5, 6] The high costs and dose-related side effects of bDMARDs make 
dose optimization a desirable goal for implementation in daily practice. Despite this, actual 
adherence seems to be not optimal.[7] 
So far tight control based treatment and biological dose optimization have mainly been 
studied in RA. However, slowly evidence is gained that for PsA and SpA the same principles 
might apply [8, 9] and treat to target recommendations have been recently published.[10] 
Combing all the existing evidence, we conducted a pilot study to improve RA, PsA and SpA 
tight control treatment and bDMARD optimization using a multi-component intervention 
strategy.
METHODS
This pilot study was conducted in a general hospital in the Netherlands with two 
rheumatologists and two specialized nurses between May and October 2014. Although the 
intervention was aimed at clinicians, outcomes were measured in patients. All adult patients 
with an ICD-9 code of RA (714.0), psoriatic arthritis (PsA; 696) and axial spondyloarthropathy 
(SpA; 720), using a bDMARD at study start and having visited their rheumatologist during the 
pre- and post-intervention period were eligible for inclusion.
The intervention strategy consisted of: 1) an educational meeting combined with 
feedback and local guideline development (bDMARD dose optimization and tight control 
based treatment of RA, PsA and SpA), 2) individualized treatment advices in all bDMARDs 
users, written in their electronic health record (EHR), and 3) feedback after three and six 
months. An example of the PowerPoint slides used during the educational meeting can be 
found in supplement 1. This strategy was developed and provided by a rheumatologist-
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epidemiologist, a rheumatology PhD student and an administrative assistant (AdB, NL and 
LN) from the Sint Maartenskliniek, a specialized rheumatology clinic in the Netherlands, 
with experience in using tight control based guidelines and dose optimization. The choice 
of the different steps was based on Cochrane reviews on effective interventions [11, 12] 
and previous experience of the authors. The different steps of the intervention took place 
between May and October 2014.
The outcome measures used in this study are stated in table 1. All outcomes were compared 
between the pre- and post-intervention period. As the intervention took place between 
May and October 2014, the patients’ visits most closely situated before and after this time 
period were used as pre and post-intervention visits respectively. For all patients a single 
visit per period was used for data collection (data as recorded in the EHR).
Table 1 Outcome measures
Outcome measure Patient population
Percentage of patients with a disease activity measure 
DAS28
BASDAI
RA and PsA patients
SpA patients
Mean score of the disease activity measures
DAS28
BASDAI
RA and PsA patients
SpA patients 
Percentage of patients using a reduced dose of their bDMARD All patients using a bDMARD
Percentage of patients using a concomitant cDMARD All RA patients using a bDMARD
DAS28, Disease Activity Score in 28 joints; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 
bDMARD, biological Disease Modifying Anti-Rheumatic Drug; cDMARD, conventional Disease Modifying 
Anti-Rheumatic Drug.
The study hospital approved this study; the rheumatologists were informed beforehand 
about this study and asked if they would participate. As this was a quality assessment 
performed in the hospital where two authors of this study worked, no written informed 
consent was asked from the patients. In addition, data collection was done within the study 
hospital and directly afterwards all patient data was anonymized. 
Depending on the type of variable, descriptive statistics are presented as percentages 
with the accompanying absolute numbers or as means with standard deviations. Outcome 
comparison between the two time periods was done using appropriate statistics (t-test 
or McNemar; two-sided, α = 0.05). As bDMARD dose optimization, according to the local 
guideline, should only be done in patients with low disease activity (DAS28 <3.2/BASDAI 
<4 or, if not available, the judgement of the rheumatologist) and bDMARD use of minimally 
6 months, a post-hoc sensitivity analysis was done on the percentage of patients using a 
reduced bDMARD dose, only including patients fulfilling both criteria. All analyses were done 
using STATA version 13.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Improving tight control based treatment and bDMARD dose optimization  |  207
10
RESULTS
All rheumatologists and nurses (n= 4) participated in this study and in all intervention steps. 
At study start, 258 RA, SpA and PsA patients were using a bDMARD. Of those patients, 24 
were lost to follow-up (n= 8: moving to another city; n= 16: not visited the study clinic 
during the post-intervention period). The remaining 232 patients were included in the final 
analysis (table 2).
Table 2 Description of the patient population
Variable Result (n= 232)
Females, % (n) 58% (131)
Age, in years 56 ± 16
Disease duration, in years 9 ± 8
Diagnosis, % (n)
RA
PsA
SpA
67% (153)
15% (34)
18% (40)
Type of bDMARD, % (n)
Adalimumab
Etanercept
Tocilizumab
Other
42% (98)
22% (50)
13% (30)
23% (54)
After the intervention more disease activity measurements (DAS28 and BASDAI) were done 
and more patients used a concomitant DMARD (table 3). Similarly, after the intervention 
more patients used a reduced biological dose while disease remained stable (table 3 and 
supplemental file 2). 
Of note, after the intervention 20 of the 232 included patients (9%) stopped their bDMARD. 
Nine of them stopped for other reasons than dose optimization (pregnancy, infection, 
ineffectiveness), leaving 11 patients who successfully stopped their bDMARD after dose 
optimization (5%). 
Finally, the sensitivity analysis on reduced bDMARD use, including only patients with data 
on disease activity and duration of bDMARD use (71% available), yielded no different results 
from the primary analysis.
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Table 3 Outcomes on DAS28, BASDAI and bDMARD use
Outcome Pre-intervention
(n= 232)
Post-intervention
(n= 232)
Mean difference (MD) or 
odds ratio (OR) 
(95% confidence interval) 
P-value
DAS28 performed*, % (n) 15% (29) 51% (97) OR 3.3 (2.1 to 5.2) <0.01
BASDAI performedΞ, % (n) 23% (9) 50% (20) OR 2.2 (1.0 to 5.5) 0.04
Mean DAS28* 2.2 ± 0.9 2.1 ± 0.9 MD 0.1 (-0.3 to 0.5) 0.51
Mean BASDAIΞ 4.4 ± 2.5 4.3 ± 2.1 MD 0.03 (-1.8 to 1.9) 0.97
Patients using a reduced 
bDMARD dose†, % (n)
10% (21) 61% (124) OR 3.9 (2.4 to 6.5) <0.01
Patients using a concomitant 
cDMARD∏, % (n)
42% (63) 52% (72) OR 1.1 (0.7 to 1.5) 0.79
*Outcome only assessed in RA and PsA patients. ΞOutcome only assessed in SpA patients. †Outcome 
assessed in all bDMARD users. ∏Outcome only assessed in RA patients using a bDMARD.
DISCUSSION
To our knowledge this is one of the first studies within rheumatology describing an improvement 
strategy on tight control based bDMARD dose optimization combining education, feedback 
and individualized treatment advices. Our results suggest that implementation of relatively 
new treatment principles in daily practice is feasible, resulting in increased adherence to 
tight control based treatment and a sizable reduction in bDMARD use. 
The main strengths of this study are the short time between the publication of positive trial 
results on bDMARD dose reduction and the conduct of this pilot study, the combined focus 
on tight control and dose optimization (with tight control being a necessary prerequisite 
for safe and patient friendly tapering), and the inclusion of RA, PsA and SpA patients to 
aid generalizability. On the other hand, the main limitation of our study is its small scale, 
stressing the need to replicate our trial in a larger sample of rheumatologists. Also, due to 
our uncontrolled study design we are not able to comment on which part of our strategy was 
most effective or to infer a definite causal relation between the intervention strategy and 
the results afterwards as other events in the same time period might have attributed to the 
observed results. However, we are not aware of any external factors during the study that 
could have influenced our results.
Within rheumatology not many comparable intervention studies on tight control 
implementation exist. However, one Canadian study also used education and feedback to 
improve daily practice.[13] In this study, education and feedback resulted in more disease 
activity measures being collected by the rheumatologists (DAS28 measurement from 43% 
to 57%). These results are somewhat in line with our study, although the increase of DAS28 
measurements was higher in our study and mean DAS28 lower (2.1 versus 3.05).[13] 
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Interestingly, with our intervention strategy we were able to replicate the results from the 
only two randomized controlled trials on bDMARD dose optimization (DRESS and STRASS 
study).[5, 14] For example, in the DRESS study 43% of the RA patient could taper their 
adalimumab or etanercept dose and 20% could stop their bDMARD.[5] In our pilot study 
even more patients used a reduced bDMARD dose (61%), however fewer patients completely 
stopped their bDMARD (9%). This might be explained by a shorter follow up in our study 
(12 versus 18 months) and inclusion of SpA patients, in whom stopping is probably less 
successful.[15] Nevertheless, our study shows that replication of trial results in daily 
practice is possible, if, however enough attention is given to optimal implementation of the 
required changes.
In other settings the separate components of our strategy have shown to be effective before 
[11, 12], but we cannot discriminate between the effects of the different components of our 
intervention strategy. In order to gain some insight in this topic, a short interview with the 
participating rheumatologists and nurses was done after the study. During this evaluation 
it was suggested that the individual treatment advices in the EHR of included patients 
were of crucial importance because they acted as a reminder. In addition, the educational 
session and development of local guidelines were seen as necessary prerequisites to change 
behavior. Finally, the feedback acted as a trigger to improve their practice and the close 
contact with the research team was positively evaluated. 
Despite the use of our strategy in only one centre, we feel that our study has important 
practical implications as it shows that implementation of tight control and bDMARD dose 
optimization in daily practice is feasible. The enthusiasm of the rheumatologists and nurses 
at the study centre has strengthened our view that rheumatologists are able to apply new 
treatment strategies if they are assisted in doing so. In our opinion, this study stresses the 
fact that implementation research is of crucial importance for the field of rheumatology 
in order to bridge the gap between theory and practice. Therefore, we are planning a 
randomized controlled trial to assess the effectiveness of our intervention strategy in a 
multi-centre study aimed at tight control based bDMARD dose optimization (Rheumatoid 
Arthritis ImplemeNtation of Biological dose Optimization in real World; RAINBOW). 
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SUPPLEMENTAL FILE 1: POWERPOINT SLIDES USED DURING THE 
EDUCATIONAL MEETING
Supplement 1: PowerPoint slides used 
during the educational meetings
Treatment principles in 
rheumatoid arthritis
A translation of the PowerPoint slides used during the first educational 
meeting
Authors: Nienke Lesuis (resident of rheumatology; MD) and Alfons A den Broeder (rheumatologist-epidemiologist; MD, PhD) 
Sint Maartenskliniek, Nijmegen, the Netherlands
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• Background
• Treatment principles in RA
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• Summary
• How to continue?
Treatment principles in RA
• Many publications on effective RA treatments
• ‘Treat to target’, ‘tight control’ & ‘hit hard, hit 
early’ often mentioned
 Cornerstone of ACR & EULAR RA guidelines
Tight control: ‘frequent assessment of disease activity combined with an 
objective structured protocol to make treatment changes that maintain low 
disease activity or remission at an agreed target’ (Kiely et al, Rheumatology 2009)
Treat to target: ‘the treatment aim was defined as remission with low 
disease activity being an alternative in patients with long-standing disease. 
Regular follow-up with appropriate therapeutic adaptation to reach the 
desired state within 3-6 months. Follow-up examinations ought to employ 
composite measures of disease activity which include joint counts. (Smolen et al, Ann Rheum 
Dis 2010)
Hit hard, hit early: ‘early institution of DMARDs.’ ‘Window of opportunity’
Treatment principles in RA
Tight control: ‘frequent assessment of disease activity combined with an 
objective structured protocol to make treatment changes that maintain low 
disease activity or remission at an agreed target’ (Kiely et al, Rheumatology 2009)
Treat to target: ‘the treatment aim was defined as remission with low 
disease activity being an alternative in patients with long-standing disease. 
Regular follow-up with appropriate therapeutic adaptation to reach the 
desired state within 3-6 months. Follow-up examinations ought to employ 
composite measures of disease activity which include joint counts. (Smolen et al, Ann Rheum 
Dis 2010)
Hit hard, hit early: ‘early institution of DMARDs.’ ‘Window of opportunity’
Treatment principles in RA
“Yes, I agree with the general principle but….”
‘A number says nothing! I always look and listen to 
the patient, order an ESR and feel the joints’
‘Patients don’t want all those pills’
‘My judgement is better than a composite 
measure, these numbers mean nothing to a 
patient’
Treatment principles in RA
“Yes, I agree with the general principle but….”
‘A number says nothing! I always look and listen to
the patient, order a ESR and feel the joints’
‘Patients don’t want all those pills’
‘My judgement is better than a composite measure, 
these numbers mean nothing to a patient’
DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(sw llen28) + 0.70 * 
ln(ESR) + 0.014 * VAS (http://www.das-score.nl/das28/nl/uitleg-das28/de-das28-score.html)
In case of active disease, patients just want to get better. They only 
get worried about the number of pills later on. (van Tuyl, Rheumatology 2008)
A DAS28 <3.2 is associated with 50% less progression of radiographic 
damage and functional status (HAQ) is influenced by both active 
inflammation and radiographic damage. (Fransen et al, Ann Rheum Dis 2005)
Treatment principles in RA
• RCT: routine vs intensive management
• Inclusion criteria: diagnosis of RA <5 years; DAS 
>2.4
• Study assessment 1x/3 months (DAS etc) by blinded 
assessor
• Primary endpoints:
– Mean fall in disease activity
– % patients with an EULAR good response
Treatment principles in RA
• Intensive management:
– Monthly visits including DAS measurement
– Corticosteroid injection of any swollen joint or depomedrol
120mg i.m. if DAS >2.4
– Strict medication protocol: dose increase or cDMARD switch 
every 1-3 month if DAS >2.4
• Routine care:
– 3-montly visits
– No routine DAS measurement or strict medication protocol
Treatment principles in RA
Treatment principles in RA
• Intensive management:
– More corticosteroid injections (i.m./i.a.)
– Higher doses of MTX
– More frequent start of a new DMARD
– Higher drug survival
– Less medication side-effects
Conclusion: intensive treatment gives substantial 
improvement of disease activity
Treatment principles in RA
• Intervention centers
– DAS28 measurement for clinical use at 0,4,12 & 24 weeks by 
treating rheumatologist
– Study advice: change medication if DAS28 >3.2
• Control centers
– Visit at week 0,4,12 & 24
– No systematic monitoring or treatment advices
Treatment principles in RA
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Treatment principles in RA
• Many publications on effective RA treatments
• ‘Treat to target’, ‘tight control’ & ‘hit hard, hit 
early’ often mentioned
 Cornerstone of ACR & EULAR RA guidelines
Tight control: ‘frequent assessment of disease activity combined with an 
objective structured protocol to make treatment changes that maintain low 
disease activity or remission at an agreed target’ (Kiely et al, Rheumatology 2009)
Treat to target: ‘the treatment aim was defined as remission with low 
disease activity being an alternative in patients with long-standing disease. 
Regular follow-up with appropriate therapeutic adaptation to reach the 
desired state within 3-6 months. Follow-up examinations ought to employ 
composite measures of disease activity which include joint counts. (Smolen et al, Ann Rheum 
Dis 2010)
Hit hard, hit early: ‘early institution of DMARDs.’ ‘Window of opportunity’
Treatment principles in RA
“Yes, I agree with the general principle but….”
‘A number says nothing! I always look and listen to
the patient, order a ESR and feel the joints’
‘Patients don’t want all those pills’
‘My judgement is better than a composite measure, 
these numbers mean nothing to a patient’
DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(sw llen28) + 0.70 * 
ln(ESR) + 0.014 * VAS (http://www.das-score.nl/das28/nl/uitleg-das28/de-das28-score.html)
In case of active disease, patients just want to get better. They only 
get worried about the number of pills later on. (van Tuyl, Rheumatology 2008)
A DAS28 <3.2 is associated with 50% less progression of radiographic 
damage and functional status (HAQ) is influenced by both active 
inflammation and radiographic damage. (Fransen et al, Ann Rheum Dis 2005)
Treatment principles in RA
• Intensive management:
– Monthly visits including DAS measurement
– Corticosteroid injection of any swollen joint or depomedrol
120mg i.m. if DAS >2.4
– Strict medication protocol: dose increase or cDMARD switch 
every 1-3 month if DAS >2.4
• Routine care:
– 3-montly visits
– No routine DAS measurement or strict medication protocol
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Treatment principles in RA Treatment principles in RA
• Intensive management:
– More corticosteroid injections (i.m./i.a.)
– Higher doses of MTX
– More frequent start of a new DMARD
– Higher drug survival
– Less medication side-effects
Conclusion: intensive treatment gives substantial 
improvement of disease activity
Treatment principles in RA
• Cluster RCT: monitoring DAS28 (12 centers) vs 
routine care (12 centers)
• DAS28 assessment by research nurse at 0 & 24 
weeks
• Primary outcomes
– % patients with DAS28 <3.2 (subgroup analysis due to 
organizational issues)
– Changes in DMARD treatment (all patients)
Treatment principles in RA
• Intervention centers
– DAS28 measurement for clinical use at 0,4,12 & 24 weeks by 
treating rheumatologist
– Study advice: change medication if DAS28 >3.2
• Control centers
– Visit at week 0,4,12 & 24
– No systematic monitoring or treatment advices
Treatment principles in RA
• Baseline data
– ± 70% women; 58 years; ± 80% RF positivity; disease duration 6 
years
– DAS28 4.5; 13% low disease activity 
Of note, DAS28 only measured by research nurse in 142 
patients (61 intervention group; 81 control group)
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• No significant differences in mean MTX, sasp and prednisone 
dose
• No differences in side-effects
• Intervention group
– DAS28 measured in 99% of the visits
– 98% of patients in which medication was changed had a DAS28 >3.2
– 20% of patients with a DAS28 >3.2 had their medication changed
Conclusion: standard monitoring of disease activity in daily 
practice, can lead to more DMARD-changes compared to usual 
care
Treatment principles in RA
• PubMed & Cochrane library 1995 – 2009: monitoring of 
disease activity combined with treatment protocols vs 
monitoring alone
• Inclusion: studies on routine care vs tight control
• Primary outcome
– Mean change in DAS28 (year 0 vs 1)
Treatment principles in RA
• Included studies (n= 6)
– 4 RCT, 2 CCT; study duration between 12 and 24 months
– 3 studies monitoring + treatment protocol, 3 studies 
monitoring alone
– 2 studies in early, DMARD-naive RA; others in early & late 
RA
• Baseline data
– 110 to 435 pt per study; 60% to 70% female; 42% to 80% 
RF positive; DAS28 >3.2
Treatment principles in RA Treatment principles in RA
• Results clinical effectiveness tight control
– In 5 studies tight control better than routine care
– More medication changes, better physical functioning and less 
radiographic damage with tight control
– Toxicity similar
• Results meta-analysis
– Tight control vs usual care: tight control is more effective, 0.6 
DAS28-point more decrease in DAS28
– Within tight control studies, monitoring + protocol is more 
effective than monitoring alone: 0.66 DAS28-point more decrease 
in DAS28
Treatment principles in RA Treatment principles in RA
Conclusion: the use of tight control strategies in RA is more 
effective than routine care. The use of protocols is more 
effective than monitoring alone.
Treatment principles in RA
“Yes, but these are clinical trials. The effect in 
daily practice has not been proven.”
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Treatment principles in RA
“Yes, but these are clinical trials. The effect in 
daily practice has not been proven.”
ESPOIR study: less radiographic damage  after 1 year and 
functional deterioration after 2 years (early RA).
MTX study: larger decrease in DAS28 after 48 weeks 
(established RA)
Treatment principles in RA
Summary: tight control gives better results 
and guideline adherence makes a 
difference to patients. However…
Cohort Recommendation Guideline adherence
ESPOIR (2002-2005) First DMARD in early RA 
(EULAR)
54% 
ERAN (2002-2007) DMARD i  early RA Median time to DMARD 
start: 8 months
(97% DMARD; 67% after 3 years 
DAS28 >3,2)
North-America (2002-
2009)
DMARD in case of active 
RA (ACR)
25-50%
(publication of updated ACR 
guideline no difference)
DREAM remission 
induction (2006)
DMARD in case of active 
RA 
70%
(98% DAS28 available)
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• PubMed & Cochrane library 1995 – 2009: monitoring of 
disease activity combined with treatment protocols vs 
monitoring alone
• Inclusion: studies on routine care vs tight control
• Primary outcome
– Mean change in DAS28 (year 0 vs 1)
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• Results clinical effectiveness tight control
– In 5 studies tight control better than routine care
– More medication changes, better physical functioning and less 
radiographic damage with tight control
– Toxicity similar
• Results meta-analysis
– Tight control vs usual care: tight control is more effective, 0.6 
DAS28-point more decrease in DAS28
– Within tight control studies, monitoring + protocol is more 
effective than monitoring alone: 0.66 DAS28-point more decrease 
in DAS28
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effective than monitoring alone.
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difference to patients. However…
Cohort Recommendation Guideline adherence
ESPOIR (2002-2005) First DMARD in early RA 
(EULAR)
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ERAN (2002-2007) DMARD i  early RA Median time to DMARD 
start: 8 months
(97% DMARD; 67% after 3 years 
DAS28 >3,2)
North-America (2002-
2009)
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DREAM remission 
induction (2006)
DMARD in case of active 
RA 
70%
(98% DAS28 available)
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Summary: tight control gives better results 
and guideline adherence makes a 
difference to patients. However…
Cohort Recommendation Guideline adherence
ESPOIR (2002-2005) First DMARD in early RA 
(EULAR)
54% 
ERAN (2002-2007) DMARD i  early RA Median time to DMARD 
start: 8 months
(97% DMARD; 67% after 3 years 
DAS28 >3,2)
North-America (2002-
2009)
DMARD in case of active 
RA (ACR)
25-50%
(publication of updated ACR 
guideline no difference)
DREAM remission 
induction (2006)
DMARD in case of active 
RA 
70%
(98% DAS28 available)
Guideline adherence is not always optimal…
But how are things in our hospital?
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Current situation at this hospital
This hospital Reference hospital
%DAS28 measured (all RA) ? 84%
Mean DAS28 (all RA) ? 2,58
%DAS28 <3.2 (all RA) ? 79%
%DAS28 <2.6 (all RA) ? 66%
%Biological users RA              (35%)
SpA            (37%)
PsA             (12%)  
RA              (28%)
SpA            (59%)
PsA (3%)  
Diagnosis amon biological users(%) 1.
2.
3.
RA              (57%)
SpA (20%)
PsA             (16%)
RA                (66%) 
SpA (30%)
PsA               (3%)
Most used biological 1.
2.
3.
Adalimumab (96%)
Etanercept   (86%)
Tocilizumab (102%)
Adalimumab (87%)
Etanercept   (92%)
Rituximab (43%)
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Summary
• Treatment principles in RA
– Tight control: important strategy that 
benefits our patients
– Application in daily practice not yet optimal, 
but seems feasible
• RA treatment in this hospital
– Improvement possible on many indicators
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Goals
To optimize biological use of rheumatologists in 
this hospital
What do we need for rational use of biologicals?
STRASS study DRESS study= Treat to Target & tight control
(=plan, do, check, act)
= developing a local guideline and adhering to it
How to continue?
1. Development of local guidelines
2. Optimizing work flow where necessary         
(for example implementation of standard monitoring 
of disease activity)
3. Individualized treatment advices in the 
medical charts of all biological users
4. Feedback after 3 & 6 months
Treatment principles in 
rheumatoid arthritis & feedback
A translation of the PowerPoint slides used during the second educational 
meeting
Authors: Nienke Lesuis (resident of rheumatology; MD) and Alfons A den Broeder (rheumatologist-epidemiologist; MD, PhD) 
Sint Maartenskliniek, Nijmegen, the Netherlands
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• How to continue?
Tight control: ‘frequent assessment of disease activity combined with an 
objective structured protocol to make treatment changes that maintain low 
disease activity or remission at an agreed target’ (Kiely et al, Rheumatology 2009)
Treat to target: ‘the treatment aim was defined as remission with low 
disease activity being an alternative in patients with long-standing disease. 
Regular follow-up with appropriate therapeutic adaptation to reach the 
desired state within 3-6 months. Follow-up examinations ought to employ 
composite measures of disease activity which include joint counts. (Smolen et al, Ann Rheum 
Dis 2010)
Hit hard, hit early: ‘early institution of DMARDs.’ ‘Window of opportunity’
Treatment principles in RA
“Yes, I agree with the general principle but….”
‘A number says nothing! I always look and listen to 
the patient, order an ESR and feel the joints’
‘Patients don’t want all those pills’
‘My judgement is better than a composite 
measure, these numbers mean nothing to a 
patient’
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Goals
To optimize biological use of rheumatologists in 
this hospital
What do we need for rational use of biologicals?
STRASS study DRESS study= Treat to Target & tight control
(=plan, do, check, act)
= developing a local guideline and adhering to it
Treatment principles in 
rheumatoid arthritis & feedback
A translation of the PowerPoint slides used during the second educational 
meeting
Authors: Nienke Lesuis (resident of rheumatology; MD) and Alfons A den Broeder (rheumatologist-epidemiologist; MD, PhD) 
Sint Maartenskliniek, Nijmegen, the Netherlands
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• How to continue?
Background
We would rather prevent than treat these hands, but…
treatment guidelines are not always followed optimally
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Treatment principles in RA
• Many publications on effective RA treatments
• ‘Treat to target’, ‘tight control’ & ‘hit hard, hit 
early’ often mentioned
 Cornerstone of ACR & EULAR RA guidelines
Tight control: ‘frequent assessment of disease activity combined with an 
objective structured protocol to make treatment changes that maintain low 
disease activity or remission at an agreed target’ (Kiely et al, Rheumatology 2009)
Treat to target: ‘the treatment aim was defined as remission with low 
disease activity being an alternative in patients with long-standing disease. 
Regular follow-up with appropriate therapeutic adaptation to reach the 
desired state within 3-6 months. Follow-up examinations ought to employ 
composite measures of disease activity which include joint counts. (Smolen et al, Ann Rheum 
Dis 2010)
Hit hard, hit early: ‘early institution of DMARDs.’ ‘Window of opportunity’
Treatment principles in RA
Tight control: ‘frequent assessment of disease activity combined with an 
objective structured protocol to make treatment changes that maintain low 
disease activity or remission at an agreed target’ (Kiely et al, Rheumatology 2009)
Treat to target: ‘the treatment aim was defined as remission with low 
disease activity being an alternative in patients with long-standing disease. 
Regular follow-up with appropriate therapeutic adaptation to reach the 
desired state within 3-6 months. Follow-up examinations ought to employ 
composite measures of disease activity which include joint counts. (Smolen et al, Ann Rheum 
Dis 2010)
Hit hard, hit early: ‘early institution of DMARDs.’ ‘Window of opportunity’
Treatment principles in RA
“Yes, I agree with the general principle but….”
‘A number says nothing! I always look and listen to 
the patient, order an ESR and feel the joints’
‘Patients don’t want all those pills’
‘My judgement is better than a composite 
measure, these numbers mean nothing to a 
patient’
Treatment principles in RA
“Yes, I agree with the general principle but….”
‘A number says nothing! I always look and listen to
the patient, order a ESR and feel the joints’
‘Patients don’t want all those pills’
‘My judgement is better than a composite measure, 
these numbers mean nothing to a patient’
DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(sw llen28) + 0.70 * 
ln(ESR) + 0.014 * VAS (http://www.das-score.nl/das28/nl/uitleg-das28/de-das28-score.html)
In case of active disease, patients just want to get better. They only 
get worried about the number of pills later on. (van Tuyl, Rheumatology 2008)
A DAS28 <3.2 is associated with 50% less progression of radiographic 
damage and functional status (HAQ) is influenced by both active 
inflammation and radiographic damage. (Fransen et al, Ann Rheum Dis 2005)
Treatment principles in RA
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• RCT: routine vs intensive management
• Inclusion criteria: diagnosis of RA <5 years; DAS 
>2.4
• Study assessment 1x/3 months (DAS etc) by blinded 
assessor
• Primary endpoints:
– Mean fall in disease activity
– % patients with an EULAR good response
Treatment principles in RA
• Intensive management:
– Monthly visits including DAS measurement
– Corticosteroid injection of any swollen joint or depomedrol
120mg i.m. if DAS >2.4
– Strict medication protocol: dose increase or cDMARD switch 
every 1-3 month if DAS >2.4
• Routine care:
– 3-montly visits
– No routine DAS measurement or strict medication protocol
Treatment principles in RA
Treatment principles in RA Treatment principles in RA
• Intensive management:
– More corticosteroid injections (i.m./i.a.)
– Higher doses of MTX
– More frequent start of a new DMARD
– Higher drug survival
– Less medication side-effects
Conclusion: intensive treatment gives substantial 
improvement of disease activity
Treatment principles in RA
• Cluster RCT: monitoring DAS28 (12 centers) vs 
routine care (12 centers)
• DAS28 assessment by research nurse at 0 & 24 
weeks
• Primary outcomes
– % patients with DAS28 <3.2 (subgroup analysis due to 
organizational issues)
– Changes in DMARD treatment (all patients)
Treatment principles in RA
• Intervention centers
– DAS28 measurement for clinical use at 0,4,12 & 24 weeks by 
treating rheumatologist
– Study advice: change medication if DAS28 >3.2
• Control centers
– Visit at week 0,4,12 & 24
– No systematic monitoring or treatment advices
Treatment principles in RA
• Baseline data
– ± 70% women; 58 years; ± 80% RF positivity; disease duration 6 
years
– DAS28 4.5; 13% low disease activity 
Of note, DAS28 only measured by research nurse in 142 
patients (61 intervention group; 81 control group)
Treatment principles in RA
Treatment principles in RA
• No significant differences in mean MTX, sasp and prednisone 
dose
• No differences in side-effects
• Intervention group
– DAS28 measured in 99% of the visits
– 98% of patients in which medication was changed had a DAS28 >3.2
– 20% of patients with a DAS28 >3.2 had their medication changed
Conclusion: standard monitoring of disease activity in daily 
practice, can lead to more DMARD-changes compared to usual 
care
Treatment principles in RA
• Included studies (n= 6)
– 4 RCT, 2 CCT; study duration between 12 and 24 months
– 3 studies monitoring + treatment protocol, 3 studies 
monitoring alone
– 2 studies in early, DMARD-naive RA; others in early & late 
RA
• Baseline data
– 110 to 435 pt per study; 60% to 70% female; 42% to 80% 
RF positive; DAS28 >3.2
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• Intensive management:
– Monthly visits including DAS measurement
– Corticosteroid injection of any swollen joint or depomedrol
120mg i.m. if DAS >2.4
– Strict medication protocol: dose increase or cDMARD switch 
every 1-3 month if DAS >2.4
• Routine care:
– 3-montly visits
– No routine DAS measurement or strict medication protocol
Treatment principles in RA
Treatment principles in RA
• Cluster RCT: monitoring DAS28 (12 centers) vs 
routine care (12 centers)
• DAS28 assessment by research nurse at 0 & 24 
weeks
• Primary outcomes
– % patients with DAS28 <3.2 (subgroup analysis due to 
organizational issues)
– Changes in DMARD treatment (all patients)
Treatment principles in RA
• Baseline data
– ± 70% women; 58 years; ± 80% RF positivity; disease duration 6 
years
– DAS28 4.5; 13% low disease activity 
Of note, DAS28 only measured by research nurse in 142 
patients (61 intervention group; 81 control group)
Treatment principles in RA
Treatment principles in RA Treatment principles in RA
• No significant differences in mean MTX, sasp and prednisone 
dose
• No differences in side-effects
• Intervention group
– DAS28 measured in 99% of the visits
– 98% of patients in which medication was changed had a DAS28 >3.2
– 20% of patients with a DAS28 >3.2 had their medication changed
Conclusion: standard monitoring of disease activity in daily 
practice, can lead to more DMARD-changes compared to usual 
care
Treatment principles in RA
• PubMed & Cochrane library 1995 – 2009: monitoring of 
disease activity combined with treatment protocols vs 
monitoring alone
• Inclusion: studies on routine care vs tight control
• Primary outcome
– Mean change in DAS28 (year 0 vs 1)
Treatment principles in RA
• Included studies (n= 6)
– 4 RCT, 2 CCT; study duration between 12 and 24 months
– 3 studies monitoring + treatment protocol, 3 studies 
monitoring alone
– 2 studies in early, DMARD-naive RA; others in early & late 
RA
• Baseline data
– 110 to 435 pt per study; 60% to 70% female; 42% to 80% 
RF positive; DAS28 >3.2
Treatment principles in RA Treatment principles in RA
• Results clinical effectiveness tight control
– In 5 studies tight control better than routine care
– More medication changes, better physical functioning and less 
radiographic damage with tight control
– Toxicity similar
• Results meta-analysis
– Tight control vs usual care: tight control is more effective, 0.6 
DAS28-point more decrease in DAS28
– Within tight control studies, monitoring + protocol is more 
effective than monitoring alone: 0.66 DAS28-point more decrease 
in DAS28
Treatment principles in RA Treatment principles in RA
Conclusion: the use of tight control strategies in RA is more 
effective than routine care. The use of protocols is more 
effective than monitoring alone.
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Treatment principles in RA
“Yes, but these are clinical trials. The effect in 
daily practice has not been proven.”
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“Yes, but these are clinical trials. The effect in 
daily practice has not been proven.”
ESPOIR study: less radiographic damage  after 1 year and 
functional deterioration after 2 years (early RA).
MTX study: larger decrease in DAS28 after 48 weeks 
(established RA)
Treatment principles in RA
Summary: 
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adherence makes a difference to patients. 
However…
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ESPOIR (2002-2005) First DMARD in early RA 
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start: 8 months
(97% DMARD; 67% after 3 years 
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North-America (2002-
2009)
DMARD in case of active 
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25-50%
(publication of updated ACR 
guideline no difference)
DREAM remission 
induction (2006)
DMARD in case of active 
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70%
(98% DAS28 available)
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Treatment principles in RA
“Yes, but these are clinical trials. The effect in 
daily practice has not been proven.”
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Current situation at this hospital
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• More DAS28 and BASDAI measurements done
• More patients using a reduced biological dose
• Mean disease activity unchanged
• Slight improvement in concomitant DMARD use
However...
• Individual differences in results on disease 
activity measurements and concomitant DMARD 
use
Summary SUPPLEMENTAL FILE 2: DETAILED OUTCOMES ON bDMARD USE
Table 1 Outcomes on bDMARD use per patient category
Outcome Pre-intervention
(n= 232)
Post-intervention
(n= 232)
Odds ratio 
(95% confidence interval) 
P-value
Patients using a reduced 
bDMARD dose†, % (n)
RA 12% (18) 67% (89) 2.4 (1.3 to 4.4) <0.01
PsA 5% (2) 50% (16) 8.0 (1.9 to 71.7) <0.01
SpA 2% (1) 42% (15) 21 (3.4 to 868.5) <0.01
Table 2 Outcomes on bDMARD use per bDMARD
Outcome Pre-intervention
(n= 232)
Post-intervention
(n= 232)
Odds ratio 
(95% confidence interval) 
P-value
Patients using a reduced 
bDMARD dose†, % (n)
Abatacept 0% (0) 25% (1) - -
Adalimumab 11% (11) 78% (66) 1.7 (0.8 to 4.0) 0.20
Certolizumab 0% (0) 40% (2) - -
Etanercept 8% (4) 60% (28) 4.8 (1.6 to 19.2) <0.01
Golimumab 0% (0) 15% (2) - -
Infliximab 0% (0) 28% (5) - -
Rituximab 0% (0) 0% (0) - -
Tociluzimab
Ustekinumab
25% (6)
-
77% (20)
0% (0)
1.0 (0.3 to 3.7)
-
1.00
-
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11.1 SUMMARY
GENERAL INTRODUCTION
Quality of care is the overarching theme of this thesis and can be described as ‘the 
degree to which health services for individuals and populations increase the likelihood of 
desired health outcomes and are consistent with current professional knowledge’. In this 
thesis we look at quality of care within rheumatology, focusing on two different themes: 
the use of diagnostic laboratory tests in rheumatic diseases and guideline adherence of 
rheumatologists in the treatment of rheumatoid arthritis. These topics are not extensively 
studied within rheumatology. This thesis aims to fill this gap by exploring the following 
questions: ‘Do rheumatologists provide evidence-based care in their daily practice?’, ‘What 
factors influence whether evidence-based care is provided?’ and ‘How can the provision of 
evidence-based care be improved?’.
THEME 1: USE OF DIAGNOSTIC LABORATORY TESTS IN RHEUMATIC 
DISEASES
Chapter 1: Introduction
In this chapter an introduction to the first theme (use of diagnostic laboratory tests) is 
provided. The topic of this theme was chosen because ordering laboratory tests is daily 
routine for many rheumatologists. This chapter starts with describing the relation between 
sensitivity, specificity, pre-test probability on disease and the positive- and negative 
predictive value (PPV and NPV respectively) of a test. For clinicians it is of crucial importance 
to realise that even a good test (high sensitivity and specificity) can have a low PPV or NPV 
if the pre-test probability on disease is either too low or too high. Despite this knowledge 
on optimal test use, many laboratory tests are ordered inappropriately, leading to overuse 
of these tests. Consequently, this leads to a higher rate of false-positives, a higher patient 
burden due to uncertainty and additional testing, and higher costs. This makes overuse of 
laboratory test an important problem in medicine and chapter 2 to 6 will explore this topic 
within rheumatology.
Chapter 2: Use of ANA testing
Here we focus on Antinuclear Antibody (ANA) testing since this test is often used by 
rheumatologists as a screening test for rheumatic diseases although this practice is not 
supported by evidence. In this study we assessed ANA use by rheumatologists in three 
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different hospitals before and after a targeted intervention. This intervention consisted 
of education and feedback, incorporating a short guideline on when (not) to order an ANA 
test. Before the intervention, ANA use was high (ANA/new patient ratio (APR) 0.37) but 
it decreased significantly afterwards (APR 0.11; odds ratio 0.19, 95% confidence interval 
(95%-CI) 0.17 to 0.22, p <0.01). Furthermore, the percentage of repeated ANA tests and 
the variation between rheumatologists also decreased significantly. Only the percentages 
of positive ANA tests and the percentage of patients with an ANA-associated disease did not 
change after the intervention. Based on these results we concluded that it is possible to 
decrease ANA overuse by rheumatologists through a relatively simple intervention. 
Chapter 3: Determinants of ANA testing
This study is an extension of the previous chapter and explores determinants of ANA 
overuse both before and after the intervention. In this study we found associations between 
rheumatologist gender, years of work experience, personality and several ANA outcomes 
before and after the intervention. For example, rheumatologist with more work experience 
and a less extravert personality ordered more ANA tests before the intervention (β 0.01, 
95%-CI 0.003 to 0.02, p= 0.01; β -0.11, -0.21 to -0.01, p= 0.04 respectively; R2 47%). After the 
intervention, female rheumatologists changed less than their male colleagues with regard 
to the number of ordered ANA tests (β 0.15, 95%-CI 0.03 to 0.26, p= 0.02; R2 25%). Besides 
these quantitative analyses we also conducted focus group meetings with rheumatologists 
after the intervention. Eight rheumatologists participated and they identified seven themes 
that influenced improvement in ANA overuse: determinants related to the intervention and 
study; individual health professionals; patients; professional interactions; incentives and 
resources; capacity for organizational change; and social, political and legal factors. 
Chapter 4: Choosing Wisely
In this chapter we describe a ‘Top 5 list of things rheumatologists and patients should 
question’, which is part of the Dutch Choosing Wisely campaign. This campaign originates 
from the United States and aims to ‘advance a national dialogue on avoiding wasteful 
or unnecessary medical tests, treatments and procedures’ by publishing top five lists of 
‘things that physicians and patients should question’. On behalf of the Dutch Society for 
Rheumatology such a list was developed and the final version includes five statements on 
diagnostic tests and treatment that should not be done routinely. One of these statements 
concerns ANA testing and advices only to use ANA testing in patients with a reasonable pre-
test probability on ANA-associated diseases such as systemic sclerosis. 
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Chapter 5: CK and TSH testing in fibromyalgia
Chapter 5 again concerns tests much used in daily rheumatology practice but for which the 
evidence of this use is scarce. Both creatine kinase (CK) and thyroid stimulating hormone 
(TSH) are frequently used tests in the routine diagnostic work-up of fibromyalgia (FMS), 
due to the presumed similarities between FMS and myopathies or hypothyroidism. As the 
diagnostic value of CK and TSH testing in the context of FMS has not been assessed before, 
we aimed to study this in 373 patients with suspected FMS. In those patients only 0.5% 
(95%-CI 0.2% to 1.9%) had an abnormal CK test and none of them was diagnosed with a 
disease related to elevated CK. For TSH similar results were found: 3.5% (95%-CI 2.1% to 
5.9%) of the patients had an elevated TSH and 1.4% (95-CI 0.6% to 3.1%) a lowered TSH but 
the final diagnosis was FMS in all these patients. Based on these results we concluded that 
abnormal CK and TSH values are rare in patients with suspected FMS and do not result in 
an alternative diagnosis. Therefore it seems that routine testing of CK and TSH levels, in 
patients with suspected FMS referred to secondary care, is not useful.
Chapter 6: Effect of computer reminders on laboratory testing
In the final chapter of theme 1 we examined the effects of two different interventions on the 
use of rarely indicated tests in rheumatology (complement, immunoglobulins, cryoglobulins 
and M-protein). Again, these tests were relatively frequently ordered by rheumatologists at 
the study centre, despite negative evidence for this practice. In this trial, using interrupted 
time series analysis, we assessed whether trends in the number of laboratory tests ordered 
by rheumatologists changed following an educational meeting and introduction of computer 
reminders. The analyses were done for the set of tests on which both interventions had 
focused (intervention tests; complement, cryoglobulins, immunoglobins, M protein) and a 
set of tests unrelated to the interventions. After the educational meeting both the level 
and trend of ordered intervention and control tests did not change significantly. After 
implementation of the reminders the level of ordered intervention tests decreased with 
85.0 tests (95%-CI -133.3 to -36.8, p <0.01). The level of control tests did not change 
following the introduction of reminders. In this study we concluded that the educational 
meeting alone was not effective in decreasing the number of ordered intervention tests but 
in combination with computer reminders it did result in a large decrease of those tests.
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THEME 2: GUIDELINE ADHERENCE IN THE TREATMENT OF RHEUMATOID 
ARTHRITIS
Chapter 7: Introduction
The second theme of this thesis, guideline adherence of rheumatologists in the treatment of 
rheumatoid arthritis (RA), is introduced in this chapter. RA is a chronic inflammation of the 
synovial joints, leading to pain, swelling and stiffness, giving limited function of the affected 
joints. Furthermore, ongoing inflammation can give bone and cartilage destruction, leading 
to progressive joint damage and consequently loss of function. This irreversible damage can 
be prevented by adequate and timely treatment with Disease Modifying Anti-Rheumatic 
Drugs (DMARDs). Besides this ‘hit hard, hit early’ principle, it is of equal importance to 
use a ‘tight control’ based treatment strategy. This means that disease activity should be 
measured regularly and treatment changed accordingly. Use of tight control strategies 
leads to lower disease activity, better functional status and less radiographic damage when 
compared to usual care. As adherence of rheumatologists to tight control principles is not 
yet optimal, the chapters in this theme all relate to rheumatologists’ guideline adherence 
in the treatment of RA.
Chapter 8: Guideline adherence of rheumatologists
Here we describe the results of an observational study on rheumatologists’ adherence to 
seven different recommendations from the local RA guideline. These recommendations 
concerned RA diagnostics, treatment and follow-up. Guideline adherence was assessed in 
994 visits from the first year of treatment in 137 RA patients. Guideline adherence to the 
different recommendations varied between 21% and 72%, with referral to the physician 
assistant as the lowest scoring parameter and referral to a specialized nurse as the highest 
scoring one. Variation in guideline adherence between rheumatologists was also present, 
with the parameter on ordering of radiographs showing the highest variation (adherence 
between 29% and 100%). Furthermore, patient sex, the number of DMARD options, presence 
of erosions, comorbidity, RF/aCCP positivity, type of patient and the rheumatologists’ 
scientific education status were associated with adherence to one or more guideline 
parameters. Based on these results we concluded that guideline adherence varied between 
recommendations and rheumatologists, showing that there is room for improvement.
Chapter 9: Improving rheumatologists guideline adherence
Next we conducted a randomised controlled trial to assess the effects of two different 
interventions on rheumatologists RA guideline adherence. In this study 20 clinicians 
(rheumatologists, residents and physician assistants) were randomized in two groups, 
with the control group receiving the standard intervention (education and feedback) 
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and the intervention group receiving an extended intervention (education, feedback and 
a Computerized Decision Support System (CDSS)). Guideline adherence to 13 different 
indicators (RA treatment, follow-up and administration) was assessed in 990 RA patients 
visiting the study clinic. A standardized sum score (SSS) on guideline adherence was used 
as the primary outcome (patient level). The SSS was calculated from the 13 dichotomous 
indicators. Addition of CDSS to education and feedback did not result in significant better 
quality of RA care than education and feedback alone (SSS difference 0.02; 95%-CI -0.04 to 
0.08; p = 0.60). However, a before/after comparison showed that education and feedback 
alone resulted in a significant increase in the SSS from 0.58 to 0.64 (difference 0.06; 95%-CI 
0.02 to 0.11; p <0.01). So, our results suggest that CDSS did not have an added value with 
regard to guideline adherence, whereas education and feedback can lead to a small but 
significant improvement of guideline adherence.
Chapter 10: Implementation of tight control care and biological dose optimisation in a 
general hospital
The final chapter of this thesis again describes an intervention study to improve RA 
treatment provided by rheumatologists. At the Sint Maartenskliniek much attention is given 
to the translation of evidence into practice, and the majority of the studies described in this 
thesis are conducted at the Sint Maartenskliniek. However, other rheumatology practices 
are also experiencing that RA treatment is not always optimally executed. Therefore, 
we conducted a pilot study in another hospital than the Sint Maartenskliniek to improve 
tight control based care and biological DMARD (bDMARD) dose optimization using a multi-
component intervention strategy. As bDMARD dose optimization was an important aspect of 
this study, not only RA patients were included but also patients with psoriatic arthritis (PsA) 
and spondyloarthropathy (SpA). Rheumatologists and specialized nurses (n=4) working at 
the study centre received three consecutive interventions, being: 1) education, feedback 
and local guideline development, 2) individualised treatment advices written down in the 
medical charts of patients using a bDMARD, and 3) repeated feedback after three and six 
months. After these interventions we observed an increase in the percentage of disease 
activity measures (DAS28: 15% to 51%, OR 3.3, 95% CI 2.1 to 5.5; BASDAI 23% to 50%, OR 2.2, 
95% CI 1.0 to 5.5). Furthermore, the percentage of patients using a reduced dose of their 
bDMARD increased from 10% before the interventions to 61% afterwards (OR 3.9, 95% CI 2.4 
to 6.5) while disease activity remained the same (DAS28: mean difference 0.1, 95% CI -0.3 
to 0.5; BASDAI: mean difference 0.03, 95% CI -1.8 to 1.9). Based on these results it seems 
possible to improve tight control based treatment and bDMARD dose optimization in daily 
practice. 
 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
General discussion  |  235
11
CHAPTER 11.2 GENERAL DISCUSSION
In this chapter we discuss the main findings of this thesis in more detail, followed by 
some methodological considerations. This chapter finishes with practical implications for 
rheumatologists and with recommendations for future research.
1. MAIN FINDINGS
The common thread running through this thesis is the behaviour of rheumatologists 
with regard to daily patient care. In the introduction three questions were formulated 
that reappeared in both subthemes described in this thesis: ‘do rheumatologists provide 
evidence-based care in daily practice?’, ‘what factors influence whether evidence-based 
care is provided?’ and ‘how can the provision of evidence-based care be improved?’. These 
questions are used to group the main findings of this thesis and to compare results across 
studies.
Do rheumatologists provide evidence-based care in daily practice?
1. Overuse of ANA, complement, cryoglobuline, gammaglobuline and M-protein 
testing by rheumatologists is present in daily practice as compared to optimal test 
use for various diagnostic tests within rheumatology (chapter 2 and 6)
2. Adherence to existing local rheumatoid arthritis (RA) treatment guidelines by 
rheumatologists is often suboptimal and varies between recommendations and 
between rheumatologists (chapter 8, 9 and 10)
What factors influence whether evidence-based care is provided?
1. Variation in outcomes between rheumatologists could be better explained for ANA 
overuse than for RA guideline adherence, as observed by the explained variance of 
the different models (chapter 3 and 8)
2. Determinant analysis using quantitative methods mainly yielded relations 
between outcomes and non-modifiable determinants (e.g. personality, scientific 
education status), whereas qualitative methods also revealed potential modifiable 
determinants (e.g. knowledge, awareness) (chapter 3 and 8)
3. Frequently mentioned or promising potential determinants of behaviour or 
behavioural change were not associated with any outcome on ANA use or RA 
guideline adherence (chapter 3 and 8)
How can the provision of evidence-based care be improved?
1. Both improvement studies on laboratory tests overuse showed the same pattern: 
the number of tests was vastly reduced, whereas the percentage of abnormal lab 
results did not change (chapter 2 and 6)
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2. The interventions aimed to reduce laboratory test overuse all resulted in a 
significant reduction of overuse, whereas the interventions aimed to improve 
guideline adherence gave less consistent results (chapter 2, 6, 9 and 10)
2. DISCUSSION OF MAIN FINDINGS
2.1 Do rheumatologists provide evidence-based care in their daily practice?
1. Overuse of ANA, complement, cryoglobuline, gammaglobuline and M-protein testing 
by rheumatologists is present in daily practice as compared to optimal test use for 
various diagnostic tests within rheumatology (chapter 2 and 6)
2. Adherence to existing local rheumatoid arthritis (RA) treatment guidelines by 
rheumatologists is often suboptimal and varies between recommendations and 
between rheumatologists (chapter 8, 9 and 10)
Both main findings are not surprising as previous literature on laboratory test use and 
guideline adherence have found similar results1-3. Although these conclusions seem relatively 
straightforward, it is important to note that no absolute norm on optimal adherence to 
evidence-based practices exists. However, other methods can be used to judge quality of 
care.
For example, in the ANA intervention study (chapter 2) Bayes theorem was used to show 
that the number of ANA tests ordered was substantially higher than could be expected based 
on the population at risk of an ANA associated disease. The observation that the percentages 
of positive ANA tests were low and repeated ANA tests were relatively high supported this 
conclusion. So, in case of laboratory test use it is possible to detect overuse on group level 
without the use of an absolute norm on the correct number of laboratory tests that should 
be done. 
With regard to guideline adherence it is important to note that indicators used to 
measure adherence are derived from specific guideline recommendations. This implies 
that adherence to these indicators should be as high as possible while taking for example 
patient co morbidity or medication side-effects into account. No absolute norms on optimal 
guideline adherence exist as we do not know what the cut-off value for ‘optimal’ should 
be. For that reason, relative norms are often used to judge optimal guideline adherence. 
Benchmarking, i.e. comparing individual data with adherence data from one or more peers 
(e.g. similar hospitals or professionals), is an example of a using such a relative norm. 
This comparison shows whether and what improvements are necessary. In addition a ‘best 
practice’ is identified which can serve as an example for other hospitals and individuals. The 
latter implies that the norm on optimal guideline adherence is subject to change as best 
practices might keep on improving. 
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Inter-rheumatologists variation in the degree of ANA overuse and RA guideline adherence 
was observed in this thesis. Again this has been described before, similar to variation in 
adherence between recommendations as observed in chapter 84. As these observations 
closely relate to the question ‘What factors influence whether evidence-based care is 
provided?’ this topic will be described in more detail in the section on this question.
Overall, our results on laboratory test use and guideline adherence are in line with the 
literature. It is striking, however, that in this thesis laboratory tests are mainly associated 
with overuse and not underuse, whereas the pattern is the other way around in guideline 
adherence. Making a comparison to the governance of states, a physician can be seen as 
a state were the legislative, executive and judiciary functions are fused into one system. 
Similar to state governance, this system carries the risk of conflicts of interest between 
the different functions. It could be argued that in guideline adherence a physician 
needs to combine all functions (legislative: indicating treatment; executive: prescribing 
medication; judiciary: evaluating treatment effects), whereas ordering laboratory tests only 
includes two functions (legislative: indicating a test; judiciary: interpreting test result). 
Consequently, this could lead to different forms of conflicting interests between the two 
behaviours. In case of guideline adherence the workload of performing the indicated actions 
directly comes to the physician. This probably results in, consciously or unconsciously, not 
performing some of the guideline recommendations to prevent further workload (conflict 
between executive and legislative function). In contrast, ordering a laboratory test does not 
have this conflict as the test is performed by laboratory personal. When the combination of 
legislative, executive and evaluating functions would be reversed between ordering tests 
and prescribing treatments, it is possible that then laboratory tests would be underused and 
treatments overused. 
2.2 What factors influence whether evidence-based care is provided?
1. Variation in outcomes between rheumatologists could be better explained for ANA 
overuse than for guideline adherence, as observed by the explained variance of the 
different models (chapter 3 and 8)
Several explanations can be given for this observation. Firstly, the literature on laboratory 
test use shows that some determinants -such as work experience- are not consistently 
related with overuse of laboratory tests5;6. The same may hold true for the relative impact of 
those determinants on either test overuse or guideline adherence, although no comparisons 
exist between overuse and guideline adherence determinants. In addition, laboratory test 
use and guideline adherence are different sorts of behaviours. Consequently, different 
determinants might be associated with both behaviours, or similar determinants might 
not have the same impact on rheumatologists’ behaviour. Finally, the sample size in the 
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ANA study was somewhat higher than in the guideline adherence study (20 vs 14 included 
clinicians), which might also have influenced our results. 
2. Determinant analysis using quantitative methods mainly yielded relations between 
outcomes and non-modifiable determinants (e.g. personality, scientific education 
status), whereas qualitative methods also revealed potential modifiable determinants 
(e.g. knowledge, awareness) (chapter 3 and 8)
This main finding relates to differences in determinants resulting from the quantitative 
and qualitative analyses, with the first only finding non-modifiable determinants (gender, 
rheumatoid factor positivity, etc), whereas qualitative analysis in chapter 3 also yielded 
many modifiable determinants such as knowledge. Although the self-reported determinants 
generated from the qualitative analysis might provide new clues to the selection of 
effective interventions, we have to keep in mind that physicians are not always capable 
of judging their own behaviour7;8. In addition, the association of these determinants with 
actual behaviour is not proven by quantitative analysis. Furthermore, determinants such 
as knowledge might be hard to catch with questionnaires, making that no association was 
found with behaviour in the quantitative analysis. This issue is described in more detail in 
the next paragraph. 
3. Frequently mentioned or promising potential determinants of behaviour or behavioural 
change were not associated with any outcome on ANA use or RA guideline adherence 
(chapter 3 and 8)
In this thesis we did not observe any relation between frequently mentioned determinants 
(e.g. knowledge) or promising determinants (e.g. cognitive bias) and outcomes on both 
ANA overuse and guideline adherence, despite inter-clinician variation in determinants and 
outcomes.
Firstly, the absence of an association between knowledge and outcomes in this thesis is 
surprising as knowledge is frequently mentioned in reviews, is a target for many interventions, 
and was also extensively discussed during the focus group meetings where it seemed to 
be an important driver of behaviour change. This discrepancy has been described more 
often5;6, but in our case a suboptimal measurement instrument might also have attributed 
to the discrepancy with previous literature. For example, in our ANA study we wanted to 
assess if knowledge about ANA testing was related to ANA overuse but no ANA knowledge 
questionnaire was already available. Therefore we developed such a questionnaire ourselves 
to at least have some form of objective measurement of ANA knowledge. As this was a non-
validated questionnaire it might not have been adequate enough to capture ANA knowledge.
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Secondly, we also noticed that promising determinants selected from the literature were 
not always related to our outcomes. In this thesis, this issue was predominantly present 
for the determinant ‘cognitive bias’. Multiple studies suggest that cognitive bias influences 
medical decision making, but we could not confirm this relationship 9. If our findings are 
true, the difference with the literature might have to do with differences in study design. 
Unfortunately no systematic review is available, but when looking at individual studies 
they either merely describe potential biases9-12 or they use fictive scenarios to assess the 
influence of cognitive biases on decision making13-16. By linking cognitive bias to actual 
behaviour we are probably the first group to have studied cognitive bias in daily practice, 
explaining the discrepancy. 
Besides being a true finding, we could also have missed associations due to our measurement 
method of cognitive bias. We used the validated Inventory of Cognitive Biases in Medicine 
(ICBM) questionnaire, which is specifically aimed at physicians and addresses multiple 
types of cognitive biases17. However, ANA overuse and RA guideline adherence might be 
linked to specific forms of cognitive bias only, making the ICBM not suitable to detect these 
associations. Therefore, it might be useful to assess cognitive bias in a more indirect way as 
no other measurement instrument exists. For example, if availability bias (judging things to 
be more likely if they readily come to mind) plays a role in ANA testing, one would expect 
rheumatologists to order more ANA tests directly after they have encountered a patient 
with a positive ANA and a related disease. Unfortunately, practical constraints prevented us 
from doing this analysis with our ANA data, but it might be an interesting future direction. 
In summary, based on the findings related to the question ‘What factors influence whether 
evidence-based care is provided?’ we conclude that (1) rheumatologists behaviour is 
probably determined by a complex interplay of different factors and (2) self-reported 
determinants or determinants described in the literature are not always linked to actual 
behaviour in daily practice. 
2.3 How can the provision of evidence-based care be improved?
1. Both improvement studies on laboratory tests overuse showed the same pattern: the 
number of tests was vastly reduced, whereas the percentage of abnormal lab results 
did not change (chapter 2 and 6)
This observation contradicts Bayes theorem as one would expect a rise in the percentage 
of related diagnoses and positive test results if test overuse decreases. This discrepancy 
can be explained by the presumption that rheumatologists have not sufficiently applied 
Bayesian reasoning yet, resulting in test orders in patients in whom pre-test probability is 
too low for the test to be helpful. In other words: although test overuse has decreased, the 
decrease was not large enough yet to overcome the drowning of true positive test results 
into all false positive results.
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Linked to this topic might be the degree of numeracy of the rheumatologists, as it has 
been shown before in other settings that low numeracy might hamper rational decision 
making on for example the value of cancer screening18. However, the rheumatologists 
in our studies were all highly numerate (95% scored a 6 or 7 out of 7 on the numeracy 
questionnaire; chapter 2), which makes numeracy an unlikely explanation for suboptimal 
Bayesian reasoning. On the other hand, Bayesian reasoning is more than understanding 
numbers alone, so numeracy might not capture the broader concept of Bayesian reasoning. 
Moreover, the numeracy questionnaire used was not specifically developed for physicians 
or medical decisions, so the questionnaire might not be suited for use in a medical setting. 
2. The interventions aimed to reduce laboratory test overuse all resulted in a significant 
reduction of overuse, whereas the interventions aimed to improve guideline adherence 
gave less consistent results (chapter 2, 6, 9 and 10)
In this thesis the four intervention studies (chapter 2, 6, 9 and 10) used four different types 
of interventions (education, feedback, computerized decision support (CDSS) and tailored 
treatment advices) in various combinations (table 1). 
Table 1 Interventions used in this thesis
Study topic
Intervention
Laboratory test overuse Guideline adherence
Chapter 2 Chapter 6 Chapter 9 Chapter 10
Education 
Education & feedback  ±
Education & CDSS  
Education, feedback & tailored 
treatment advices

: no (additional) effect, ±: small positive effect, : positive effect
As can be seen in table 1, similar interventions gave different results across studies. Of the 
four studies mentioned in table 1 three were performed in the same hospital. This rules out 
differences in setting as an explanation for differences in results, leaving the intervention 
itself or the targeted behaviour as potential explanations. These factors will be described 
below in more detail, followed by a short notice on the differences in setting for chapter 
2, 6 and 9 versus chapter 10.
Firstly, it is known from various Cochrane reviews on the improvement interventions used 
in this thesis that in general these are effective, but the amount of improvement differs 
between studies19-22. Probably, one of the main reasons for this observation is the notion that 
interventions should be as closely linked as possible to relevant determinants of the targeted 
behaviour. Such tailored interventions are more effective than non-tailored interventions; 
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the most effective method of tailoring is, however, not yet clear23. During the preparation 
of the intervention studies in this thesis, we discussed potential barriers and facilitators 
of the targeted behaviour within the study team, taking into account our own experiences 
and literature on the specific topics. For example, before the ANA intervention study we 
noticed that rheumatologists were not aware of the correct indications for ANA testing and 
did not know whether they ordered few or many ANA tests. To address these barriers, the 
combination of education and feedback was used as the intervention in this study. In the 
case of ANA testing, this informal barrier analysis resulted in the selection of an effective 
intervention. However, the same method did not result in an effective intervention in our 
intervention study on RA guideline adherence (chapter 9). Here education and feedback 
only had a small positive effect on the final outcome and CDSS was not effective at all. In 
hindsight, our studies might have benefitted from a systematic diagnostic analysis assessing 
the specific barriers and facilitators to the targeted behaviour. 
Secondly, similar to education and feedback, education and CDSS were effective in the 
overuse study (chapter 6), but not in the guideline adherence study (chapter 9). With 
regard to the studies including CDSS as an intervention (chapter 6 and 9), the complexity 
of the intervention might have played an additional role besides the aforementioned 
suboptimal barrier analysis at study start. In the overuse study CDSS consisted of one simple 
reminder stating that a particular test should not be done, after which a reason had to 
be given if the rheumatologists wanted to continue the order. So, the CDSS reminder was 
only a small addition to an existing system. In contrast, CDSS in the guideline adherence 
study had multiple different components and included a complete make-over of the existing 
computerized ordering system. This difference in complexity of the intervention might have 
contributed to the differences in intervention effects between the studies. 
Thirdly, differences in targeted behaviour might explain the differences in results in the 
overuse and guideline adherence studies. For example, decreasing one’s ANA overuse can 
be seen as a less complex behavioural change than improving one’s guideline adherence. As 
complexity of the targeted behaviour is associated with the success of an intervention4;24, 
this might partly explain the difference in effectiveness between the studies. 
In addition, the complexity of a guideline itself is also known to influence guideline 
adherence25. Again, following one relatively simple recommendation (‘no ANA unless 
reasonable clinical suspicion on a related disease is present’) is probably less complicated 
than following 13 different recommendations which also interact with each other and might 
all have specific exceptions. Furthermore, the ANA advice was a negative advice stating 
that something should not be done (“don’t”), while in contrast the RA recommendations 
all stated that something should be done in a certain situation (“do”; for example, change 
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therapy if RA is active). There is some evidence from a previous study that “do’s” are less 
frequently adhered to than “don’ts”4, being in line with our observation. 
Fourthly, although not directly supported by other studies, it might also be that the targeted 
behaviour and the interventions were viewed differently by the rheumatologists in the 
various studies, especially with regard to professional autonomy. It might be that in the 
guideline adherence study –as compared to the laboratory overuse study- the intervention 
was felt as a larger breach of professional autonomy as application of the new behaviour 
would influence a greater part of daily patient care than the application of the ANA advice. 
Similarly, the complex CDSS used in the RA guideline adherence study might have felt as a 
larger breach on professional autonomy than the simple CDSS (single reminder) used in the 
overuse study. 
Finally, the study described in chapter 10 is the only study in this thesis not executed 
at the Sint Maartenskliniek. As the studies in chapter 9 and chapter 10 both aimed to 
improve RA guideline adherence, but within a different setting we want to comment on 
the difference in effects between the two studies (small effect in chapter 9, substantial 
effect in chapter 10). Firstly, the intervention strategies differed between the studies with 
education and feedback being the only overlap. Secondly, the baseline values were different 
in both studies with much lower values in chapter 10 compared to chapter 9, giving the 
rheumatologists in chapter 10 more room for improvement. Finally, the study in chapter 10 
was performed in another hospital than most of the studies in this thesis. Therefore setting 
and organizational issues might have played a role. But probably more important was the 
fact that the rheumatologists in chapter 10 had an additional financial incentive to improve 
their practice: if they did not reduce their biological costs, insurance companies would not 
fully pay for these costs. 
All in all it can be concluded that changing rheumatologists’ behaviour is a challenge that can 
be achieved. Various determinants of success probably play a role, including hospital setting, 
complexity of the intervention, targeted behaviour and recommendations. Incorporating all 
these factors in a formal diagnostic analysis before selecting the interventions probably 
would have enhanced the effects of our interventions.
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3. METHODOLOGICAL CONSIDERATIONS
In an ideal situation clinical trials include a control group, are double-blinded, and have 
enough follow-up time and subjects to adequately measure relevant and validated outcomes. 
When performing implementation studies with clinicians as the main study population, 
adherence to the standard of clinical trials can be difficult as implementation studies 
have additional methodological issues. These methodological issues were also encountered 
during the execution of the studies described in this thesis and will therefore be discussed 
in more detail below.
3.1 Inclusion of participants in implementation studies
Inclusion of sufficient participants can be a challenge in any type of trial, but implementation 
trials pose some specific problems as participants are often clinicians instead of patients. 
Firstly, by default less clinicians than patients are available, leading to smaller target 
populations in implementation trials. Secondly, inclusion in implementation trials often 
needs to be done on hospital or ward level as it would otherwise lead to problems with 
contamination between groups or patient clustering. This results in a group of physicians 
needing to be included as a whole instead of including physicians on individual basis, meaning 
that group processes are very likely to influence successful inclusion. In addition, in a group 
of physicians the motivation to change behaviour -or not- might differ between individuals. 
Many different psychological models describe different steps of behaviour change, for 
example distinguishing an orientation, insight, acceptance, change and preservation 
phase26. These phases of behaviour change influence the willingness of physicians to take 
part in implementation studies and can therefore aid or hamper inclusion.
In this thesis we also struggled with the inclusion of participants in our studies, especially 
during our multi-centre trial (chapter 2, intervention to decrease ANA overuse). Only 3 
out of 7 hospitals participated and in hindsight this might have been caused by differences 
in behaviour change phase the rheumatologists in those hospitals were in. Therefore, our 
study could have benefitted from a more extensive target group analysis aiming to gain 
more insight into which phase of behaviour change rheumatologists were in before study 
start and to adapt our inclusion strategy accordingly26. 
3.2 Use of a control group and blinding of participants in implementation studies
In a classic medication trial, the effectiveness of a medicine is tested using a control and 
intervention group with participants and researchers blinded for group allocation. Using 
this design it is relatively easy to assess the effectiveness of the new medicine, but with 
implementation trials two problems arise.
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Firstly, contamination between intervention- and control group poses a real problem if the 
trial is a single-centre study. In such a trial clinicians might talk about the intervention with 
their control-group colleagues thus influencing those clinicians as well. Furthermore, patients 
can be treated by more than one clinician which further increases the risk of contamination 
between groups as outcomes are often measured on patient level. Randomizing on hospital 
or ward level rather than on clinician level (cluster randomization) prevents this problem 
but also requires multi-centre rather than single-centre studies. This again poses an extra 
challenge to the researchers regarding the inclusion of multiple sites. In this thesis the 
control group issue was encountered multiple times and for pragmatic reasons we often 
chose not to use a randomized controlled study design. However, were possible we tried to 
find other solutions to overcome this problem. For example, we decided to use the number 
of routine laboratory tests as a control group in combination with an interrupted time series 
design (chapter 6) or to randomize only one of two interventions (chapter 10). 
Secondly, in an implementation trial behaviour change of physicians is almost always the 
primary aim. Reaching this aim often requires multi-component interventions such as the 
combination of education and feedback. This can make it difficult to separate intervention 
effects of the individual components of a multi-modal intervention strategy. This problem 
was for example encountered in chapter 10 (pilot study on education, feedback and 
tailored treatment advices) of this thesis, warranting the need for replication of our results 
in a randomized controlled setting.
Finally, due to the type of interventions performed in implementation trials it is virtually 
impossible to blind participants for group allocation. For example, providing a ‘placebo 
educational meeting’ with non-relevant or even incorrect information to a control group 
would most probably be immediately noticed by the participants and if not, could lead 
to non-desired behaviour. On the other hand, blinding of researchers is possible but in 
our randomized controlled trial this could not be done as the researcher performing data 
analysis was also the researcher performing the interventions.
3.3 The selection of outcome measures in implementation studies
The selection of validated outcome measures can be another major issue in implementation 
trials. In general, quality of care is measured using quality indicators. These indicators can 
be further divided into structure (organizational aspects of care), process (provided care to 
a patient), and outcome (result of provided care) indicators27. Compared to outcomes used 
in clinical trials, use of indicators poses several specific problems.
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Firstly, quality of care is a broad concept and often a set of multiple indicators is used to 
measure several important aspects of care. Especially in combination with a small number 
of study participants this method can easily lead to multiple testing problems as the number 
of outcome measures is too high for the number of study subjects. To overcome this issue a 
sum score can be calculated from individual indicators if those indicators are dichotomous 
variables. This method has disadvantages as well. For example, if a sum score is used, the 
scores for indicators not directly related to each other end up in one score. In addition, 
the relative impact of the intervention on the separate indicators cannot be seen and 
comparison with other studies might me hampered if different indicators or sum scores 
are used. In our guideline adherence intervention trial (chapter 9) we encountered the 
multiple-testing issue, and weighing this against the potential disadvantages of sum scores, 
we chose to use an indicator sum score as the primary outcome measure, reporting the 
separate indicator scores as secondary outcomes.
Secondly, in an ideal situation indicator sets used in implementation studies should be 
validated and widely accepted, similar to outcome measures in clinical trials. As for the last 
criterion: widely accepted indicator sets are virtually non-existing within rheumatology. For 
example, during the literature search for our RA quality review (chapter 7) we encountered 
seven different RA indicator sets. Although their content overlapped, the number and 
type (structure, process or outcome) of indicators included in the sets varied28-34. None 
of these sets is internationally accepted, hampering comparison of quality of care studies 
within RA. In clinical trials the quality of outcome measures used can be assessed using 
the COSMIN checklist, which comprises aspects on reliability, responsiveness and validity 
of outcome measure35. Although some of those aspects (internal consistency, face validity) 
can be applied to quality indicators, others are more difficult as for example often no 
golden standard is available for quality indicators (criterion validity). However, a recent 
review from the Guidelines International Network describes nine reporting standards for 
guideline indicators including standards such as measure specification and measure testing/
validating36. In addition to this review, other tools are available to judge the quality of 
indicators. The Appraisal of Indicators through Research and Evaluation (AIRE) is such a 
tool using 20 statements on four themes to assess the quality of an indicator37. The issue 
of indicator selection was encountered during the preparation of the studies in this thesis, 
especially those on guideline adherence. In these studies we chose to be pragmatic by 
selecting indicators from the set stated in the Dutch national RA guideline, as this most 
closely resembled the local situation at the study hospital.
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Thirdly, outcomes in implementation trials are often process indicators, thus reflecting care 
that is provided to a patient but not the outcomes of that care. Thus, process indicators 
are essentially surrogate markers for the real outcome in patients. The same can also be 
seen in clinical trials were for example high cholesterol is a surrogate marker for risk of 
subsequent myocardial infarction. Often such surrogate markers are easier to measure than 
the real outcome. However, they carry the risk that results on surrogate markers do not 
translate into results for hard outcomes. In contrast, for quality of care research process 
indicators can be used as real outcomes and indeed should be considered the desired 
outcome measure, when in other types of studies a clear causal relation between provided 
care and patient outcome has been established. For example, different trials have proven 
that strict use of tight control strategies benefits RA patient outcomes such as disease 
activity and functional status38;39. Therefore, process indicators on the provision of tight 
control care by rheumatologists could be used as an outcome measure to judge quality and 
quality improvement of RA care. In this thesis we mainly used process indicators to assess 
quality of care, but we are aware of the fact that not for all indicators used a strong relation 
between process and outcomes of care is established, leaving an issue for future research. 
3.4 Measuring outcomes in implementation studies
When measuring outcomes in any type of study it is important to have sufficient study 
participants to ensure adequate precision of the results. However, due to aforementioned 
difficulties with participant inclusion this can be a challenge in implementation studies. In 
chapter 8 and 9 (RA guideline adherence) of this thesis this issue was encountered during 
study preparation. In both studies the number of clinicians that could be included was 
relatively low (14 and 20 respectively), so we needed to include as many patients per 
clinician as possible in order to ensure adequate precision. However, in chapter 8 the 
number of eligible patients was limited due to our in- and exclusion criteria (first year of 
treatment, second opinion partly excluded). This might have hampered the precision of our 
results. In contrast, in chapter 9 our patient inclusion criteria were less strict, leading to 
large numbers of eligible patients. However, due to manual data collection (chart review) 
we had to balance precision with feasibility of data collection.
Besides the number of participants, results can also be influenced by other events that take 
place during follow-up. Especially in uncontrolled studies embedded in daily practice this 
can be a real issue. Our overuse intervention studies (chapter 2 and 6) are examples of 
these kinds of studies. However, in none of those studies we are aware of any event that 
could have given the same effect size. Nevertheless, we did learn from the ANA intervention 
study (chapter 2) and in our next overuse intervention study (chapter 6) we choose to 
strengthen the study design by using a control group and an interrupted time series design.
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Secondly, the measurement of outcomes in implementation studies can also be complicated 
by multilevel issues. Interventions in those studies are often aimed at clinicians, leading 
to behaviour change with regard to care provided to their patients. This means that 
the intervention and outcome measurement takes place on different levels (clinician vs 
patient), and in case of multi-centre studies a third level is added (hospital). This calls for 
more advanced statistical techniques and less power when analysing study results. 
Finally, when measuring quality indicators it is also important to consider how they are 
measured, especially if this concerns process indicators on guideline adherence. In general 
the two most used methods are: self-reported guideline adherence by the study population or 
registered behaviour, as measured by medical chart review of patients treated by the study 
population. The latter method is more labour intensive, but judged to be more objective. 
In the only review on this subject, comparing self-reported adherence with medical chart 
review, self-reported adherence exceeded more objective methods in almost all instances 
and a median over-estimation of adherence of 27% was observed7. Therefore, we chose to 
only measure guideline adherence using medical chart review (chapter 9 to 11). This still 
had some practical issues as there can be a difference between what a rheumatologists 
decided to do and what is actually done (visit interval of 3 months as decided by the 
rheumatologist vs actual interval of 4 months due to holiday of the patient). As we were 
mainly interested in the decisions made by rheumatologists, we chose to rely on the written 
instructions of the rheumatologists as entered in the chart or orders. 
3.5 Generalizability of results
As a final part of this section on methodological issues we comment on the generalizability 
of results from implementation studies. In order to be able to generalize results outside 
the specific study setting, it is important to include a sample representative of the target 
population in daily practice. One way to do this in implementation studies is by running a 
multi-centre trial including different types of centres, preferably in different settings. In this 
thesis only one multi-centre trial was performed and even within this trial (ANA intervention 
study, chapter 2) generalizability might be hampered as all participating centres were 
located in the Netherlands and only 3 out of 7 hospitals participated. However, we did 
include various types of hospital (general, academic and specialized), aiding generalisation 
of our results. For our guideline adherence studies, this issue is probably more profound 
as all were single-centre studies mainly conducted in one specialized rheumatology clinic. 
Nevertheless, due to the scarcity of quality of care research in rheumatology, our studies 
provide a first valuable insight into daily rheumatology practice. However, multi-centre 
studies should be the goal of future research. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
248  |  Chapter 11
Secondly, generalizability of results from implementation studies might be hampered by 
the fact that interventions are often not similar between studies. Using the intervention 
taxonomy proposed by the EPOC group40 can counter this to some extent by at least using 
the same terminology to describe interventions. 
All in all, the preparation and execution of implementation trials has some major challenges 
compared to clinical trials, especially regarding participant inclusion and outcome measures. 
Nevertheless, the standards of clinical trials also apply to implementation research. 
4. IMPLICATIONS OF THIS THESIS FOR PRACTICING RHEUMATOLOGISTS 
With this thesis we have tried to provide more insight into different aspects of quality 
of rheumatologic care, but above all we hope that our studies will encourage other 
rheumatologists to assess and improve their quality of care. Therefore, the practical 
implication of this thesis described below specifically focus on rheumatologists, providing a 
stepwise approach to improve quality of care. 
4.1 How to choose a topic for improvement?
As ‘quality of rheumatic care’ is a far too broad topic to cover with a single improvement 
project, specific topics must be chosen. The two most common ways are to act on signals 
coming either from daily practice (e.g. the observation of large differences in the number 
of laboratory tests ordered between rheumatologists) or from evidence (e.g. publication 
of a new RA treatment guideline). To identify areas with room for improvement, a more 
systematic and continuous approach to quality improvement can also be used by applying a 
risk matrix often used in safety procedures. These matrixes use the frequency and severity 
of the consequences of an event to assess the risk level. For example, applying this to the 
treatment of patients with a rheumatic disease, one can chose to focus on RA patients with 
high disease activity as this constitutes a large patient population (frequency) and high 
disease activity has a potentially large impact on patients live (consequences). Depending 
on the level on which this matrix is applied (patient, hospital, society) factors such as 
costs could also be taken into account when selecting a topic for improvement. A similar 
method is proposed by Flottorp et al. In their manuscript they provide useful worksheets to 
facilitate the selection of a topic for improvement41. 
4.2 How to engage rheumatologists in implementation research?
As described in the previous section inclusion of participants in quality or implementation 
projects can be difficult. Moreover, due to differences in behaviour change motivation, it 
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might be necessary to apply different strategies in different groups of rheumatologists. 
For those reasons, we recommend rheumatologists who aim to improve quality of care to 
first estimate the level of motivation of the targeted colleagues. If they are already aware 
of the quality of care being suboptimal and are in principle willing to change, the focus 
can be directed towards the intervention and how this can help them improve the quality 
of care. However, if the target population is still in an early phase of behaviour change 
(orientation or insight), this method will not work. In this situation it is first necessary to 
create awareness about the proposed change and provide insight into the current situation. 
Most probably the targeted rheumatologists do not exactly know their own performance 
on the selected topic, so the first step would be to offer rheumatologists a non-committal 
assessment of their own quality of care. When quality of care proves to be suboptimal after 
the analysis, the focus can change to the proposed intervention and how this can improve 
quality of care. In addition, the rheumatologists probably feel bad about their suboptimal 
quality of care, aiding internal motivation and increasing the likelihood that they accept the 
intervention as a ‘way out’ of this feeling. 
4.3 How to select outcomes measure for improvement?
As often no widely accepted indicator set is available, the choice of quality measurements 
used in daily practice should be pragmatic. This means that if indicator sets for the chosen 
topic are available, the set best reflecting care for that specific setting should be chosen. 
Such an indicator set can slightly be adapted, for example when the indicators are not defined 
specific enough (i.e. changing ‘regular DAS28 measurements’ to ‘DAS28 measurements 
every 3 months’). If no indicator set is available, own indicators should be developed. When 
developing new indicators it is of crucial importance to be very specific and careful about 
the choice of denominator and numerator as this greatly influences interpretation of the 
result. During the process of indicator selection and/or development it is also valuable to 
use tools such as the AIRE instrument37.
This topic also relates to another aspect of quality improvement projects: goal setting. In 
order to easily judge current quality of care or improvement after an intervention it can 
be helpful to set a goal (‘70% of all RA patients should have a DAS28 measured every 3 
months’). Furthermore, there are suggestions from previous literature that goal setting aids 
guideline adherence19. However, as mentioned before it is often not known what such a goal 
should be. Another option is to choose a relative instead of an absolute goal. For example, 
if after a first measurement of the indicator adherence percentages vary between 20% and 
40%, a reasonable goal in this setting could be 50% adherence.
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4.4 How to choose an intervention?
Many different types of interventions are available and, as also shown in this thesis, results 
are not consistent across different studies and different settings, making it impossible to 
know exactly when to use what intervention. However, in general interventions selected 
or developed to address barriers specific to the target population are more successful 
than interventions which are not targeted to barriers23;26;42. Therefore, the choice of an 
intervention starts with a ‘diagnostic analysis’ to assess which determinants (both barriers 
and facilitators) drive current practices. Based on this analysis, an intervention can be 
chosen that specifically targets the observed barriers. During this process worksheets 
developed by Flottorp et al. can be helpful as they provide help to prioritize determinants 
and select interventions41. In addition, the reviews from the Cochrane Effective Practice 
and Organization of Care (EPOC) group provide up to date evidence for the effectiveness of 
various types of interventions (http://epoc.cochrane.org).
4.5 How to retain change?
If after the selected interventions rheumatologists’ behaviour has improved, it is important 
that results are sustained. Additional actions are probably necessary to prevent that the 
effect wears off. An important element in this seems to be the continuation of regular 
monitoring of the desired behaviour. So, the chosen set of indicators could be used to 
regularly measure adherence. This information can then be used to guide additional 
interventions to sustain or improve achieved results. In addition, topics generated from the 
first, or a new, barrier analysis not yet covered could also be targeted in this phase. Regular 
monitoring and a new barrier analysis are also important if the intervention did not give the 
desired result, further stressing the need for additional actions to reach the goal. Of note, 
in a busy day to day practice attention for these kind of projects may also wear off after a 
certain time, so it might be helpful to make somebody responsible for quality of care (not 
necessarily being a rheumatologist) in order to ensure long-term attention to the topic.
5. IMPLICATIONS OF THIS THESIS FOR FURTHER RESEARCH
Research almost always raises more questions than it answers. This thesis also raised 
several interesting directions for further research. Based on our results we propose that it 
is important to:
- Assess whether incorrect use of diagnostic tests is also present in other areas than 
laboratory tests. Based on the frequency of use, imaging techniques such as plain 
X-ray’s or Magnetic Resonance Imaging could be relevant targets for rheumatology
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- Assess the added value of general history taking and/or physical examinations 
in the diagnostic work-up of rheumatic diseases. Both are used to base further 
clinical decisions upon and incorrect or non-relevant findings may cause incorrect 
use of diagnostic modalities later on in the diagnostic process
- Develop a set of internationally accepted indicators for the diagnosis, treatment 
and follow-up of RA patients. Such a set should preferably be developed and 
endorsed by both the American College of Rheumatology (ACR) and the European 
League Against Rheumatism (EULAR)
- Establish strong causal relations between proposed process indicators and relevant 
outcome indicators 
- Assess the relation between complexity and workload of guideline recommendations 
and targeted behaviour in the setting of rheumatology
- Assess the influence of cognitive bias and/or numeracy on actual physician 
behaviour using indirect measures of bias or better suited questionnaires
- Make a head-to-head comparison of different multi-modal intervention strategies 
in order to identify the most (cost) effective combination in a certain setting
- Explore the link between rheumatologists’ behaviour and what patients do with 
the advices and treatments provided to them, for example the influence of the 
way rheumatologists communicate about risks of treatment or rheumatologists’ 
own beliefs about medication 
- Systematically explore the reasons for non-participation in implementation trials 
and consequently develop strategies to enhance participation
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INLEIDING
Kwaliteit van zorg is een breed begrip. Een veel gebruikte Engelse definitie is ‘the degree 
to which health services for individuals and populations increase the likelihood of desired 
health outcomes and are consistent with current professional knowledge’. Vrij vertaald naar 
het Nederlands is kwaliteit van zorg ‘de mate waarin de zorg voor individuen en populaties 
de kans vergroot dat de gewenste gezondheidsresultaten behaald worden en de mate waarin 
de zorg consistent is met de huidige kennis van de professionals’. In dit proefschrift staat 
kwaliteit van zorg binnen de reumatologie centraal waarbij de focus ligt op twee thema’s: 
het gebruik van diagnostische testen en de behandeling van reumatoïde artritis.
THEMA 1: HET GEBRUIK VAN DIAGNOSTISCHE TESTEN BIJ REUMATISCHE 
AANDOENINGEN
Hoofdstuk 1: Inleiding
Voor het eerste thema is gekozen omdat diagnostische testen veel gebruikt worden door 
reumatologen om te kijken of een patiënt een bepaalde ziekte wel (aantonen van ziekte) of 
juist niet (uitsluiten van ziekte) heeft. Dit wordt vaak gedaan met behulp van bloedtesten. 
Helaas is geen enkele test perfect en worden mensen soms onterecht als ziek of gezond 
aangemerkt. Hoe goed of slecht een test dit onderscheid kan maken wordt aangegeven met 
de sensitiviteit en specificiteit van een test (de kans op een positieve test bij zieken en 
de kans op een negatieve test bij gezonden). Dit zijn belangrijke kenmerken van een test, 
maar voor een reumatoloog is de omgekeerde vraag veel belangrijker: wat is de kans dat 
mijn patiënt ziek is nu de testuitslag positief is of juist gezond nu de test negatief is? Wat 
de kansen hierop zijn, wordt uitgedrukt met de positief en negatief voorspellende waarde. 
Met deze twee kansen is wel iets bijzonders aan de hand: ze hangen niet alleen af van hoe 
goed de test is, maar ook van het vóórkomen van de ziekte. In de praktijk betekent dit dat 
een bijna perfecte test voor een zeldzame ziekte nog steeds een lage positief voorspellende 
waarde kan hebben. Hoe lager de kans op de ziekte is en hoe vaker een dergelijke test 
wordt aangevraagd, hoe sterker dit effect is. Reumatologen die voor hun patiënten een test 
aanvragen moeten dus van te voren bedenken hoe groot de kans op een bepaalde ziekte 
is zodat ze achteraf de testuitslag kunnen vertrouwen. In de dagelijkse praktijk blijkt dit 
echter lastig te zijn en worden er vaak teveel testen aangevraagd (ook wel overdiagnostiek 
genoemd). In hoofdstuk 2 tot 6 brengen we voor een aantal veel gebruikte testen deze 
overdiagnostiek in kaart en beschrijven we hoe we het gebruik hebben proberen terug te 
dringen.
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Hoofdstuk 2 en 3: Het gebruik van de ANA-test
In deze twee hoofdstukken richten we ons op een veelgebruikte test binnen de reumatologie: 
de Antinuclear Antibody (ANA) test. Deze test is eigenlijk bedoeld voor een aantal zeldzame 
reumatische ziekten en zou daarom ook niet vaak aangevraagd moeten worden. Desondanks 
wordt deze test toch veel gebruikt door reumatologen. Daarom hebben we, door middel van 
een training, geprobeerd 29 reumatologen in drie verschillende Nederlandse ziekenhuizen 
minder ANA-testen te laten aanvragen. Tijdens deze training kregen de artsen informatie 
over de ANA-test en hoe deze te gebruiken. Ook kregen ze een spiegel voorgehouden over 
het aantal testen dat ze zelf aanvroegen, waarbij ze zichzelf met directe collega’s konden 
vergelijken. Na een jaar bleek deze interventie zeer succesvol te zijn geweest aangezien het 
aantal aangevraagde ANA-testen in alle deelnemende ziekenhuizen sterk gedaald was (ANA/
nieuwe patiëntratio van 0,37 naar 0,11; odds ratio 0,19, 95%-betrouwbaarheidsinterval 
0,17 tot 0,22, p-waarde <0,001). Dit onderzoek staat beschreven in hoofdstuk 2. Het 
volgende hoofdstuk, hoofdstuk 3, is een verdieping van het ANA-onderzoek en probeert 
te achterhalen welke factoren bij de reumatologen hebben bijgedragen aan het succes 
van de interventie. Uiteindelijk bleken artseigenschappen zoals geslacht, werkervaring en 
persoonlijkheid gerelateerd te zijn aan het aantal ANA-aanvragen voor de interventie en de 
verandering in het aantal aanvragen daarna. Zo bleek bijvoorbeeld dat reumatologen met 
meer werkervaring en een minder extraverte persoonlijkheid meer ANA-testen aanvroegen 
(respectievelijk regressiecoëfficiënten van 0,01 en -0,11 met 95%-BI van 0,003 tot 0,02 
en -0,21 tot -0,01). Verder werden door de reumatologen zelf nog vele andere factoren 
genoemd die hebben bijgedragen aan het succes, zoals de kwaliteit van de interventie en 
het enthousiasme van het onderzoeksteam.
Hoofdstuk 4: Verstandig Kiezen
In dit hoofdstuk beschrijven we een ‘Top 5 van Verstandige Keuzen’, zoals opgesteld door 
de Nederlandse Vereniging voor Reumatologie (NVR) en wat onderdeel uitmaakt van de 
Nederlandse campagne ‘Verstandig Kiezen’. Dit project is geïnspireerd op de Amerikaanse 
campagne ‘Choosing Wisely’ en heeft als doel om medische specialisten en patiënten 
te ondersteunen bij beslissingen over gepaste zorg. De ‘Top 5 van Verstandige Keuzen’ 
is bedoeld als praktisch handvat hierbij. Namens de NVR hebben wij deze top 5 voor de 
reumatologie opgesteld. Deze bevat stellingen over diagnostische tests en behandelingen 
die niet routinematig gedaan zouden moeten worden. Een van deze stellingen is: ‘Vraag niet 
standaard een ANA aan, maar alleen bij patiënten die op basis van anamnese en lichamelijk 
onderzoek een redelijke kans hebben op een zeldzame reumatische ziekte’.
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Hoofdstuk 5: Schildklier- en spiertesten bij fibromyalgie
In dit hoofdstuk gaan we in op twee andere veelgebruikte testen binnen de reumatologie: 
de testen op het schildklierhormoon TSH en op het spierenzym CK. Deze laboratoriumtesten 
worden regelmatig gebruikt in de diagnostiek rondom het pijnsyndroom fibromyalgie om 
schildklier- of spierziekten uit te sluiten. Dit wordt gedaan omdat de symptomen van 
fibromyalgie soms kunnen lijken op die van schildklier- of spierziekten. Maar aan het nut 
van deze testen kan sterk getwijfeld worden en bovendien is dit nooit goed uitgezocht. 
Daarom hebben wij bij 373 patiënten met fibromyalgiesymptomen het TSH en CK geprikt 
en gekeken hoeveel van de testuitslagen afwijkend waren. Vervolgens is er ook gekeken of 
er bij mensen met een dergelijke afwijkende testuitslag uiteindelijk ook een schildklier- 
of spierziekte vastgesteld werd. Uit dit onderzoek bleek dat maar 5% van de mensen met 
mogelijke fibromyalgie een afwijkend TSH had en bij CK was dit zelfs nog lager (0,5%). Na 
verder onderzoek bleek er bij geen van deze mensen een schildklier- of spierziekte aanwezig 
te zijn en een dergelijke ziekte was dus ook niet de verklaring van de fibromyalgieklachten. 
Op basis van deze resultaten lijkt het er dus op dat het niet zinvol is om bij alle mensen met 
een mogelijk fibromyalgiesyndroom het TSH en CK te testen.
Hoofdstuk 6: Het effect van pop-ups op het aanvraaggedrag van reumatologen
Naast de ANA-test zijn er binnen de reumatologie nog meer testen die, ondanks de 
zeldzaamheid van gerelateerde ziekten, toch regelmatig worden gebruikt. Ook voor deze 
testen (complement, gammaglobulines, cryoglobulines, M-proteïne) wilden we het gebruik 
terugdringen. Net als bij het ANA-onderzoek kregen de reumatologen scholing over het 
gebruik van deze testen (deze keer zonder feedback over hoe vaak ze zelf de testen 
aanvroegen). Ook werd hen geadviseerd om de testen minder vaak aan te vragen. Acht 
maanden na deze scholing werd er nog een aanvullende maatregel genomen: wanneer een 
reumatoloog een van de betreffende testen wilde aanvragen in het Elektronisch Patiënten 
Dossier (EPD), verscheen er eerst een mededeling (‘pop-up’). Deze bestond uit één zin over 
de (on)zin van de test binnen reumatologie en het advies om nog een keer goed over de 
aanvraag na te denken. Wilde de reumatoloog de test toch aanvragen, dan moest er een 
reden ingevuld worden voor de aanvraag. Uit de resultaten van dit onderzoek bleek dat de 
scholing weinig effect had op het aantal aanvragen, maar dat na de invoering van de pop-
ups het aantal aanvragen flink daalde (-85,0 testen; 95%-BI -133,3 tot -36,8, p <0.01). Ter 
controle is er gekeken naar een groep andere testen waarover geen scholing was gegeven 
en waarbij geen pop-up verscheen tijdens de aanvraag. Bij deze testen veranderde er in 
de gehele studieperiode van drie jaar weinig aan het aantal aangevraagde testen. Hierdoor 
kunnen we dus concluderen dat het instellen van een pop-up kan leiden tot een forse daling 
in het aantal aangevraagde laboratoriumtesten.
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THEMA 2: DE BEHANDELING VAN REUMATOIDE ARTRITIS – 
PROTOCOLADHERENTIE
Hoofdstuk 7: Inleiding
In het tweede thema gaan we in op de behandeling van een van de meest voorkomende 
vormen van ontstekingsreuma: reumatoïde artritis (RA). Patiënten met RA hebben meestal 
een symmetrische ontsteking van de gewrichten aan de handen en voeten. Deze ontstekingen 
geven pijn, stijfheid en zwelling waardoor deze gewrichten minder goed functioneren. 
Uiteindelijk kan door de ontsteking ook onherstelbare schade aan de gewrichten ontstaan. 
Reumatologen proberen deze schade te voorkomen door al snel na het begin van de RA 
te starten met reumaremmers (Disease Modifying Anti-Rheumatic Drugs, DMARDs). Naast 
het snel starten van DMARDs is het volgens de laatste wetenschappelijke inzichten ook 
belangrijk om patiënten te behandelen volgens het ‘tight control’-principe. Dit betekent 
dat regelmatig de ziekteactiviteit gemeten moet worden, er een behandeldoel gesteld moet 
worden (bijvoorbeeld het volledig rustig zijn van de RA) en dat de behandeling aangepast 
moet worden als dit doel niet gehaald wordt. Patiënten die strikt volgens dit principe 
behandeld worden hebben uiteindelijk een lagere ziekteactiviteit, functioneren beter 
en lijken ook minder onherstelbare gewrichtsschade te hebben. Vanwege deze gunstige 
resultaten zijn (inter)nationale behandelrichtlijnen voor RA gebaseerd op het tight control-
principe. Helaas is dit nog niet genoeg om ervoor te zorgen dat alle reumatologen zich altijd 
aan dit principe, en dus de richtlijnen, houden (ook wel protocoladherentie genoemd). 
Daarom richten de hoofdstukken 8, 9 en 10 zich op protocoladherentie van reumatologen 
bij de behandeling van RA-patiënten. 
Hoofdstuk 8: Protocoladherentie van reumatologen
In het eerste onderzoek van dit thema hebben we gekeken naar de protocoladherentie 
van reumatologen in de Sint Maartenskliniek. Hiervoor hebben we in de medische status 
van 137 RA-patiënten gekeken die net begonnen waren met hun behandeling in de Sint 
Maartenskliniek. Bij al deze patiënten hebben we bij alle visites in het eerste jaar van hun 
behandeling gekeken of de reumatoloog zich aan zeven belangrijke adviezen uit het RA-
protocol hield. Zo keken we bijvoorbeeld of de ziekteactiviteit werd gemeten, of de medicatie 
op tijd werd aangepast en of patiënten gezien werden door een reumaverpleegkundige. Het 
bleek dat de ene aanbeveling beter werd gevolgd dan de andere, met protocoladherentie 
die varieerde tussen de 21% en 72%. Daarnaast verschilde de protocoladherentie ook nog 
tussen de reumatologen onderling. In het onderzoek hebben we ook gekeken naar redenen 
voor deze variatie. Het bleek dat verschillende kenmerken van patiënten geassocieerd 
waren met de protocoladherentie van artsen. Zo werd er bijvoorbeeld gevonden dat 
patiënten met gewrichtsschade en bijkomende ziekten (co-morbiditeit) minder vaak naar 
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de reumaverpleegkundige verwezen werden (respectievelijk odds ratio 0,68, 95%-BI 0,16 
tot 0,93 en odds ratio 0,68, 95%-BI 0,13 tot 1,00). Daarnaast verwezen gepromoveerde 
artsen hun patiënten vaker naar de physician assistant dan niet gepromoveerde artsen (odds 
ratio 4,14, 95%-BI 1,33 tot 12,86). Al met al concludeerden wij uit deze resultaten dat de 
protocoladherentie van reumatologen nog niet optimaal is en dat verschillende arts- en 
patiëntkenmerken geassocieerd kunnen zijn met protocoladherentie. 
Hoofdstuk 9: Interventie ter verbetering van protocoladherentie reumatologen 
Uit de vorige studie kwam naar voren dat protocoladherentie van reumatologen in de Sint 
Maartenskliniek nog niet op alle onderdelen optimaal was. Daarom is er een vervolgonderzoek 
gedaan waarbij we geprobeerd hebben deze protocoladherentie te verbeteren. Hiervoor 
werden de 20 deelnemers (reumatologen, arts-assistenten en physician assistants) 
ingedeeld in een controle- en interventiegroep. Vervolgens kregen alle deelnemers 
onderwijs over optimale RA-zorg en het belang van protocoladherentie. Ook kregen ze de 
resultaten van de vorige studie te horen (feedback). Daarna kreeg de interventiegroep 
nog een extra maatregel: bij hen werd het EPD zo aangepast dat het makkelijker moest 
worden om het RA-protocol op te volgen. Zo deed het EPD bijvoorbeeld al een voorstel 
over het juiste aantal maanden tot de volgende afspraak met de patiënt. Om het effect 
van beide interventies te testen is er gekeken naar de adherentie van reumatologen aan 
13 verschillende aanbevelingen, waarbij er zowel voor als na de interventie bijna 500 
patiënten gescoord zijn. Na vergelijking tussen de interventie- en controlegroep bleek dat 
de gemiddelde protocoladherentie over die 13 punten gelijk was (gemiddelde verschil tussen 
de groepen: 0.02, 95%-betrouwbaarheidsinterval -0,04 tot 0,08, p-waarde = 0,60). Wel bleek 
dat het onderwijs voor een kleine, maar significante, stijging van de protocoladherentie had 
gezorgd (gemiddelde verschil: 0,06, 95%-BI 0,02 tot 0,11, p-waarde <0,01). Deze resultaten 
betekenen dat in dit geval de computeraanpassingen geen extra effect hebben gehad 
bovenop het onderwijs, maar dat het onderwijs wel effectief is geweest in het verbeteren 
van de protocoladherentie van reumatologen.
Hoofdstuk 10: Invoering van optimale reumazorg in een praktijk buiten de Sint 
Maartenskliniek
Binnen de Sint Maartenskliniek is er veel ervaring opgedaan met het uitvoeren van 
tightcontrol-reumazorg. Omdat dit principe in andere ziekenhuizen nog niet altijd optimaal 
gevolgd wordt, hebben we er in dit onderzoek voor gekozen om te proberen of we het 
tight control-principe ook konden invoeren in een ander ziekenhuis. Daarnaast werd er 
in dezelfde periode bekend dat het mogelijk was om dure reumaremmers (‘biologicals’) 
– mits patiënten goed werden gecontroleerd - ook in lagere doseringen aan patiënten 
voor te schrijven zonder nadelige gevolgen voor patiënten. Het ziekenhuis in Lelystad was 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
264  |  Chapter 12
bereid om mee te werken aan dit project en in verschillende stappen werden zowel tight 
contol-reumazorg als biological dosisoptimalisatie ingevoerd. Als eerste kregen de twee 
reumatologen en twee reumaverpleegkundigen onderwijs over optimale reumazorg en 
werd er feedback gegeven op de huidige situatie. Daarna werden er protocollen opgesteld 
die, onder andere, de behandeling van RA en biological dosisoptimalisatie beschreven. 
Vervolgens heeft een team van de Sint Maartenskliniek de medische statussen bekeken van 
alle reumapatiënten die een biological gebruikten. Indien deze patiënten nog niet volledig 
volgens het nieuwe protocol behandeld werden, werd in de status opgeschreven wat er nog 
beter kon (bijvoorbeeld: ‘denk aan het doen van regelmatige ziekteactiviteitsmetingen’). 
Tot slot werd er na drie en zes maanden feedback gegeven aan de reumatologen over de 
huidige situatie. Dit alles resulteerde in een sterke toename van het aantal uitgevoerde 
ziektemetingen (DAS28 van 15% naar 51%; oddsratio 3,3, 95%-BI 2,1 tot 5,5), toename van 
het gebruik van een gereduceerde biological dosis (van 10% naar 61%; oddsratio 3,9, 95%-BI 
2,4 tot 6,5). Ondanks het verlagen van de biological dosering bleef de ziekteactiviteit gelijk 
(gemiddelde verschil DAS28 0,1, 95%-BI -0.3 tot 0.5). Uit de resultaten van deze pilot studie 
blijkt dat het mogelijk is om ook in andere ziekenhuizen de reumazorg te verbeteren.
Hoofdstuk 11: Algemene discussie
In dit hoofdstuk worden de bevindingen uit dit proefschrift samengevat en in meer detail 
besproken. De belangrijkste bevindingen zijn als volgt:
- Zowel wat betreft het aanvragen van laboratoriumtesten als het volgen van 
behandelprotocollen is er een gat tussen theorie en praktijk (hoofdstuk 2, 6, 8, 9 
en 10)
- Variatie tussen reumatologen kan beter verklaard worden voor ANA-overdiagnostiek 
dan voor RA-protocoladherentie (hoofdstuk 3 en 8)
- De determinanten gevonden in de studies verschillen op een aantal punten van 
andere bestaande studies en hangen daarnaast af van de gekozen analysemethode 
(hoofdstuk 3 en 8)
- De verbetering in het aanvraaggedrag van artsen vertoont hetzelfde patroon in 
beide overdiagnostiekstudies: het aantal testen daalt sterk terwijl het percentage 
abnormale testresultaten niet verandert (hoofdstuk 2 en 6)
- Gelijksoortige interventies geven niet altijd dezelfde resultaten (hoofdstuk 2, 6, 
9 en 10)
In het vervolg van hoofdstuk 11 wordt er vooral ingegaan op de tegenstellingen binnen en 
tussen de onderzoeken. Het is bijvoorbeeld opvallend dat gelijksoortige interventies niet 
altijd dezelfde effecten geven. Zo is de combinatie van onderwijs en feedback gebruikt 
in twee studies (ANA-overdiagnostiek in hoofdstuk 2 en verbeteren protocoladherentie in 
hoofdstuk 9), maar in de ANA-studie was het effect van deze interventie veel groter dan 
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in de protocoladherentie-studie. Dit verschil zou mogelijk te maken kunnen hebben met 
verschillen in het aangepakte gedrag tussen beide studies. Zo ging het in de ANA-studie 
bijvoorbeeld maar om één opdracht die opgevolgd moest worden (‘minder ANA’s aanvragen’), 
terwijl bij de protocoladherentie studie zeven verschillende adviezen opgevolgd moesten 
worden. Hierdoor zou het voor de reumatologen makkelijker kunnen zijn om het ANA-
advies op te volgen, wat heeft geleid tot de betere interventie-effecten in hoofdstuk 2 
vergeleken met hoofdstuk 9. Naast dit soort verschillen wordt ook de praktische betekenis 
van de resultaten uit dit proefschrift besproken en worden er aanbevelingen gedaan voor 
vervolgstudies. Onder andere de volgende aanbevelingen worden gedaan:
- Nagaan of het incorrect gebruiken van diagnostische testen ook voorkomt bij 
bijvoorbeeld het aanvragen van röntgenfoto’s of scans
- Ontwikkeling van een algemeen geaccepteerde set van indicatoren voor de 
diagnostiek, behandeling en follow-up van reumatoïde artritis. Bij voorkeur wordt 
zo’n set door de American College of Rheumatology (ACR) en de European League 
Against Rheumatism (EULAR) opgesteld
- Uitgebreidere analyse van factoren die mogelijk het gedrag van artsen beïnvloeden
- Het direct vergelijken van verschillende multimodale interventiestrategieën zodat 
de meest effectieve combinatie van interventies vastgesteld kan worden
- Nagaan wat de redenen zijn voor ziekenhuizen om niet deel te nemen aan 
implementatieonderzoek en deze informatie gebruiken om effectieve strategieën 
te ontwikkelen die deelname bevorderen
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DANKWOORD
Na alle wetenschappelijke inhoud van dit boekje is het nu tijd voor een wat luchtiger, maar 
niet minder belangrijk hoofdstuk: het dankwoord. Dit boekje was er niet geweest zonder de 
praktische, maar vooral ook morele steun van heel veel mensen. 
Als eerste wil ik mijn co-promotor dr. A.A. den Broeder bedanken. Beste Alfons, zonder 
één bepaald diner onder aan de berg in Tante Koosje had dit boekje er waarschijnlijk niet 
gelegen en had ik misschien niet eens gekozen voor de reumatologie. Met je enthousiasme, 
maar ook begrip voor mijn twijfels, wist je me toen toch om te praten. Ook daarna heb 
je dit goed weten vol te houden en heb ik een fantastische onderzoekstijd gehad. Dank 
voor het delen van je bijna oneindige hoeveelheid (onderzoeks)kennis en optimisme over 
het doen van onderzoek, ook als het met mede-auteurs even niet opschoot of een artikel 
wéér werd afgewezen. Maar ik wil je vooral bedanken voor alles buiten het promoveren: 
de gezellige theemomenten, goede gespreken over het leven, maffe (metaaldetector)-
verhalen, interessante boekentips en natuurlijk de gesprekken over onze gedeelde liefde: 
cognitieve bias en alles wat daarmee maar enigszins samenhangt!
Prof. M.E.J.L. Hulscher, beste Marlies, het duurde even voordat je we jou als eerste 
promotor hadden gevonden. En ondanks dat je in een al (vrij hard?) rijdende trein stapte, 
heb ik ontzettend veel aan je begeleiding gehad. Jij zorgde voor de broodnodige ‘kwaliteit 
van zorg’ input en zorgde ervoor dat ik & Alfons niet met te wilde ideeën aan kwamen 
zetten. Daarnaast heb ik altijd heel veel plezier gehad tijdens onze overleggen, zelfs als 
je mijn artikelen weer eens helemaal had omgeschreven (en ik al je pijlen en commentaar 
op commentaar moest ontcijferen). Dank voor je enthousiasme, positieve houding en 
vertrouwen in een goede afloop van de studies in dit boekje.
Prof. R.F. van Vollenhoven, mijn tweede promotor, beste Ronald, ook jij hebt letterlijk 
aan de wieg gestaan van dit boekje. Als begeleider van mijn onderzoeksstage als student 
geneeskunde liet je me voor het eerst zien dat onderzoek doen in de eerste plaats leuk 
is en pas in de tweede plaats (soms) ook lastig. Tijdens mijn promotie was je opeens een 
begeleider op afstand, maar desondanks kon je ook zo prima de grote lijn bewaken en mij 
met ogenschijnlijk simpele commentaren weer op het juiste pad brengen. Dank ook voor 
de gastvrijheid tijdens onze bezoeken aan Stockholm (een leuke bonus van een Zweedse 
promotor), maar ook voor je bezoekjes aan ons plekje op de berg.
De Sint Maartenskliniek is tijdens mijn promotie mijn tweede ‘thuis’ geweest, niet in de 
laatste plaats vanwege de erg fijne werksfeer op de afdeling reumatologie. Daarom wil ik 
ook graag prof. F.H.J. van den Hoogen bedanken. Beste Frank, dank voor je interesse in mijn 
projecten en het mogelijk maken van mijn promotietraject.
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Geen enkel onderzoek is mogelijk zonder de deelname en inzet van de proefpersonen, 
daarom een speciaal woord van dank aan alle reumatologen, arts-assistenten, physician 
assistants en verpleegkundigen die op een of andere manier hebben deelgenomen aan een 
(of meerdere) van de onderzoeken uit dit boekje. Jullie waren een geweldige groep om mee 
te werken en ondanks de soms ‘spannende’ onderwerpen van de studies lieten jullie je niet 
kennen en deden jullie met veel enthousiasme mee. Heel veel dank daarvoor! 
Achter alle onderzoeken uit dit boekje gaat een grote hoeveelheid werk schuil wat mij niet 
was gelukt zonder de hulp van allerlei mensen. Michiel, in je eerste periode hier had je 
nog tijd om Acces databases voor anderen te bouwen en daarvan heb ik dankbaar gebruik 
gemaakt. Verder wil ik je bedanken voor je hulp als ik er met STATA net niet helemaal uit 
kwam. 
Joke, naast de directe bijdrage aan hoofdstuk 3 uit dit boekje heb je ook heel veel praktische 
& morele steun geboden toen ik als neventaak ‘even’ de JAK-trial erbij moest doen, dank 
hiervoor. 
Niet alle onderzoeken uit de afgelopen jaren zijn in dit boekje gekomen, maar desondanks 
wil ik jou, Hanneke, bedanken voor de ontzettend leuke & bij vlagen hilarische samenwerking 
tijdens het artsenbeliefsproject. 
Van alle onderzoeken in dit boekje heeft de voorbereiding van hoofdstuk 9 het meeste tijd 
& moeite gekost. Ilse, onder jouw strakke leiding liep ‘project checklist aka ITS BETTER’ 
op rolletjes en heb ik ook nog eens wat geleerd over projectmanagement (die nobelprijs is 
helaas nog niet gelukt, maar leuk was het wel!). Ik hoop in de toekomst opnieuw met je te 
kunnen samenwerken. Marc, zonder jou was de hele interventie er niet geweest en ik wil 
je ontzettend bedanken voor je inzet, geduld en enthousiasme tijdens dit project. De vele 
uren bij jou op de kamer maakten me duidelijk dat ik het goede beroep heb gekozen maar 
dat een inkijk achter de EPD-schermen wel erg nuttig is, bedankt hiervoor. Isabelle & Margo, 
ook jullie wil ik even noemen en bedanken voor alle input om de EPD wijzigingen ook voor 
de poli in goede banen te leiden. Lieke Nieboer, ook jij was onmisbaar tijdens dit project: 
bedankt voor de berg werk die je hebt verzet door van 1000 patiënten de status door te 
nemen en de info in te voeren. Na dit project ging je gelukkig nog niet weg en konden we 
samen op pad naar Lelystad om daar de data voor hoofdstuk 10 te verzamelen. Toen ook Lise 
hierbij aansloot werd het helemaal leuk, dank dames voor de hulp & gezellige autoritjes van 
en naar de polder. Lise, je bent qua onderwerp toch wel een beetje mijn ‘opvolgster’, dus 
bij deze wil ik je heel veel succes wensen met je promotie en ik hoop dat ik in de toekomst 
toch nog verder kan helpen met de RAINBOW. 
Nathan & Nadine, jullie kwamen in het laatste jaar van mijn promotie om de hoek kijken en 
jullie hebben er, met veel enthousiasme, voor gezorgd dat er opeens nog 2 hoofdstukken in 
het boekje bij konden. Dankjewel hiervoor. 
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Reinier, jou wil ik bedanken voor al je hulp bij de statistische kant van veel van de 
onderzoeken in dit proefschrift. Je uitleg en adviezen waren altijd de moeite van het heen 
en weer fietsen waard. 
Tot slot mogen ook Majella en de andere dames van het secretariaat hier niet ontbreken. 
Bedankt dames voor alle administratieve ondersteuning en de gezellige praatjes tussen de 
bedrijven door. 
Het ‘thuisgevoel’ bij de Sint Maartenskliniek heeft alles te maken met de ontzettend fijne 
(ex-)collega’s terplekke. Daarom, Alfons, Karen, Henk, Joost van Zadelhoff, Aatke, Hans, 
Marcel Flendrie, Marcel Franssen, Maartje, Annemiek, Hatice, Agnes, Frank, Elien, Maurice, 
Esther, Joost Huijs, Vincent, Susan, Regina, Iris, Anne Wennemers, Calin, Gijs, Anne Cremers, 
Sandra, Delia & Fleur: ontzettend bedankt voor de enorm gezellige, fijne & leerzame tijd 
die ik bij/met jullie heb gehad. 
Ook alle andere reumaonderzoekers (‘uit het W-gebouw’) wil ik bedanken voor de afgelopen 
tijd. Buiten de onderzoeksoverleggen zagen we elkaar niet altijd veel, maar dankzij de 
jaarlijkse schrijfdagen is er toch een band gesmeed. De ‘Ski-radio’ en andere maffe 
uitspraken tijdens 30 seconds (of andere spelletjes) zal ik niet snel vergeten. 
In de rijtjes hierboven missen bewust 3 mensen, want mijn (ex-)kamergenootjes Noortje, 
Chantal & Lieke wil ik graag speciaal bedanken. Als eerstje Noortje: vanaf het eerste moment 
dat ik als co-assistent bij de reuma begon, was jij altijd in de buurt. Naast de medisch/
onderzoeks-inhoudelijke kant konden we op persoonlijk gebied ook veel met elkaar delen. 
Ik vond het ontzettend fijn om jou zo lang als collega te hebben gehad en gelukkig hebben 
we tijdens de opleiding tot reumatoloog nog genoeg momenten waarop we elkaar weer 
tegen kunnen komen. Chantal, ook met jou heb ik bijna vanaf het begin samen gewerkt. 
Vanaf het begin konden we het goed met elkaar vinden en hebben we ondertussen heel wat 
af gekletst. Dit laatste kwam ook goed van pas tijdens de vele 4Daagse trainingen als we 
uren over saaie wegen door de regen moesten lopen, gelukkig bezorgden vissers langs de 
route ons altijd genoeg afleiding. Ik vind het dan ook erg leuk dat ik je straks als directe 
collega weer in Rijnstate tegen kom. Lieke, je theebeker was vaak nog halfvol als we alweer 
voor de volgende ronde gingen, maar hierdoor hadden we wel weer even tijd om te kletsen 
over vanalles en nog wat. Ook met jou heb ik een hele gezellige tijd gehad en totdat ook jij 
in opleiding gaat, hoop ik je nog op andere momenten te treffen.
Gelukkig hebben er in de afgelopen jaren ook mensen gezorgd voor afleiding buiten het 
werk om. Annemiek, sinds groep 3 ben je een constante factor in mijn leven en hoewel 
je mijn promotie vooral vanuit andere landen dan Nederland hebt meegekregen wil 
ik je toch bedanken voor de gezellige, fijne en mooie gesprekken via alle mogelijke 
communicatiemanieren. Lieke, ook onze geschiedenis gaat terug tot op de basisschool en in 
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de afgelopen jaren heb ik je oprechte interesse in mij enorm gewaardeerd. Wat mij betreft 
mag je nog wel even in Arnhem blijven wonen zodat we nog vaak kunnen bijkletsen bij een 
kopje thee.
Wienke, Maaike, Joep, Ramon, Lyvonne, Lianne, Monique, Nicky en Yara, ook jullie mogen 
in dit dankwoord niet ontbreken. Na een zeer geslaagde gezamenlijke studietijd ben ik 
heel blij dat jullie in de afgelopen jaren nog steeds voor de broodnodige afleiding zorgen 
met alle gezellige eetafspraken, musicalbezoeken, schaatstrainingen, spelletjesavonden en 
natuurlijk het jaarlijkse weekendje-weg. 
Sybilla, als ex-co-groepgenootje hebben we tijdens de laatste fase van onze studie veel 
lief & leed gedeeld. Ik ben erg blij dat het contact ook hierna is gebleven en de bezoekjes 
aan jou en Rick in het Zuid-Limburgse Mechelen zijn altijd een feest. Bedankt voor deze 
bijzondere vriendschap en ik loop graag nog een keer het Pieterpad met jullie mee.
Katerina, a special word of thanks is for you. I would never have thought that I would get 
a Greek friend living in Sweden, who I can meet most easily at international conferences 
in Chicago, Boston or San Francisco. I hope we can keep this up, but for now you deserve a 
big ‘thank you’ for the cartoon on the front of this thesis. Tack så mycket, dankjewel, σας 
ευχαριστώ! 
Met familie verspreid over bijna het hele land is afspreken niet altijd makkelijk, maar 
toch wil ik Oma Lesuis en alle ooms, tantes, neven & nichten Lesuis en Olthof bedanken 
voor de gezellige familiebijeenkomsten en de altijd aanwezige interesse in mijn doen & 
laten. In 2013 werd hier ook nog een schoonfamilie aan toegevoegd: Jan, Janneke & Karen, 
dankjewel voor het warme welkom in jullie gezin. Ditzelfde geldt ook voor de hele familie 
Ligtenberg, en al zal ik nooit een echte Toeteboer worden, Roode Klif heb ik door jullie toch 
maar mooi gezien!
Lieve papa, mama en Jasper, de goede basis die ik bij jullie heb meegekregen heeft er zeker 
voor gezorgd dat dit boekje nu voor jullie ligt. Mama, ondanks al je eigen drukte rondom 
de naailes & tig andere bezigheden wil je altijd heel graag weten hoe het mij gaat. De hele 
wetenschappelijke inhoud van mijn promotie is volgens mij wat meer langs je heen gegaan, 
maar ik ben je enorm dankbaar voor alle gezellige momenten in de afgelopen jaren én 
natuurlijk je praktische hulp (potjes jam aanleveren, naaivragen oplossen, verhuishulp…). 
Papa, tijdens onze gesprekken over ons beider werk kwam ik er al snel achter dat het weinig 
uitmaakt of je nu fabrieksmedewerkers betere buizen wilt laten maken of artsen betere 
zorg wil laten leveren. Dit maakte dat ik jou interesse in mij & dit boekje steeds meer ben 
gaan waarderen, en net als mama ben je nooit te beroerd om ook op andere gebieden hulp 
te leveren (taxi spelen, helpen in de tuin, rommel naar de stort brengen…). Dankjewel 
hiervoor! Jasper, als mijn ‘kleine grote’ broer neem je voor mij een bijzondere plek in. 
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Niemand kan met zoveel oprechte interesse de meest directe & persoonlijke vragen stellen 
op een moment dat je dit totaal niet verwacht. Ik ben heel blij dat we nog steeds aardig 
dicht bij elkaar wonen want onze (eet)afspraken wil ik zeker niet missen!
Lieve, lieve Rob, dit keer is het laatste woord niet aan jou maar voor jou. Je bent het 
liefste, leukste en grappigste vriendje dat ik me kan wensen en vanaf het eerste begin ben 
je een grote steun voor mij geweest. Als nuchtere Twentenaar weet je me altijd weer tot 
rust te brengen als ik te snel wil of vrolijk je me met maffe woordgrapjes weer op als ik 
iets teveel stress heb. En nu we ook echt samen in 1 huis wonen weet ik het zeker: ik wil 
je nooit meer kwijt!
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